Identifying novel genes that cause congenital heart disease by Wilsdon, Anna
Identifying Novel Genes that cause Congenital Heart Disease  1 
 





Identifying Novel Genes that cause 
Congenital Heart Disease 
 
 
Anna Wilsdon; B Med Sci, BM BS 
School of Life Sciences 





Thesis submitted to the University of Nottingham for the 




Main supervisor – Prof. J David Brook 
 
 





I hereby declare that this thesis is the result of my own work, which has 
been undertaken during my period of registration for the PhD degree at 
The University of Nottingham, and that it has not been presented to this 
or any other university for the award for any degree or diploma other 





















Thank you to my family for supporting me through my PhD, it has been a busy 
few years. I could not have written this up if my second child had not been such 
a good napper. 
Thank you to my supervisor David Brook who has guided me through this work, 
and continues to support my future plans for research. Thank you to my second 
supervisor Siobhan Loughna for all the hard work setting up the HREM. A huge 
thanks to all of the staff and students in their labs including A Ketley, S Buxton, 
K Setchfield, T Ghosh, J Aparicio Sanchez, S Rochette and all the technical staff. 
Thank you also to the staff in the Biosupport Unit, especially S Ecob. 
Thank you also to all the collaborators who were part of the Sifrim et al. 
publication, and especially M Hitz who I continue to work with, A Sifrim who 
attempted to teach me to code, and M Hurles.  
Thank you to M Prior, who devised the MRI protocol with me. 
Thank you to the BHF for awarding me a Clinical Fellowship to allow me to carry 
out this work. 
This study makes use of data generated by the DECIPHER community. A full list 
of centres who contributed to the generation of the data is available from 
https://decipher.sanger.ac.uk and via email from decipher@sanger.ac.uk. 
Funding for the project was provided by Wellcome. As per the Decipher citation 











Index of Figures .................................................................................................. 11 
Index of Tables ................................................................................................... 14 
Abstract ............................................................................................................. 16 
List of Abbreviations ............................................................................................ 17 
Chapter 1 Introduction ......................................................................................... 22 
1.1 Overview of Congenital Heart Disease .............................................................. 22 
1.2 Heart development ........................................................................................ 24 
1.2.1 Human Heart Development ..................................................................... 25 
1.3 Pathophysiology of CHD ................................................................................. 61 
1.4 The Mouse as a model for CHD ........................................................................ 62 
1.5 Imaging the Mouse Heart ............................................................................... 65 
1.6 Aetiology of CHD ........................................................................................... 66 
1.6.1 Genetic Causes of CHD .......................................................................... 67 
1.6.2 Evidence for Oligogenic inheritance of CHD ............................................... 78 
1.7 Recurrence Risk ............................................................................................. 80 
1.8 Classification of CHD ...................................................................................... 82 
1.8.1 Anatomical Based Classification Systems .................................................. 82 
1.8.2 Clinical Classification Systems ................................................................. 83 
1.9 Diagnosis of CHD ........................................................................................... 83 
1.10 Treatment of CHD ........................................................................................ 85 
1.11 Prognosis and Complications ......................................................................... 85 
1.11.1 Increased mortality .............................................................................. 86 
1.11.2 Association with Neurodevelopmental Disability ....................................... 86 
1.11.3 Association with Respiratory Disease ...................................................... 87 
1.11.4 Association with Myocardial Dysfunction ................................................. 87 
1.12 Current Recommendations for Genetic Testing in CHD ...................................... 88 
1.13 Hypothesis and aims .................................................................................... 90 
Chapter 2 Methods .............................................................................................. 91 
2.1 Methods Relating to the Whole Exome Sequencing Analysis ................................ 91 
2.1.1 Sample Collection for WES project ........................................................... 91 
2.1.2 Bioinformatic Analysis ............................................................................ 91 
2.1.3 Characterising the de novo mutation burden in CHD .................................. 92 
2.1.4 Characterising the burden of inherited mutations in CHD ............................ 92 
2.1.5 Comparison with other disease models ..................................................... 92 
Identifying Novel Genes that cause Congenital Heart Disease  5 
 
2.1.6 Evaluation of individual Genes ................................................................ 92 
2.1.7 Gene Function and pathway analysis........................................................ 93 
2.1.8 Copy number variation analysis ............................................................... 94 
2.2 Laboratory Methods ....................................................................................... 94 
2.2.1 PCR ..................................................................................................... 94 
2.2.2 Agarose Gel Production .......................................................................... 97 
2.2.3 Running an agarose gel .......................................................................... 97 
2.2.4 Reading an agarose gel .......................................................................... 97 
2.2.5 Gel Extraction ....................................................................................... 97 
2.2.6 PCR clean up ........................................................................................ 97 
2.2.7 Sanger Sequencing ................................................................................ 98 
2.2.8 Nanodrop ............................................................................................. 98 
2.2.9 Preparation of Phosphate Buffered Saline (PBS) ........................................ 98 
2.2.10 4% PFA Production .............................................................................. 98 
2.3 Mouse Work .................................................................................................. 99 
2.3.1 General husbandry ................................................................................ 99 
2.3.2 Mouse strains studied and genotyping protocols ........................................ 99 
2.3.3. Timed Matings ................................................................................... 105 
2.3.4 DNA extraction .................................................................................... 105 
2.3.5 Culling methods used ........................................................................... 106 
2.3.6 Embryo harvests for lethality assessment ............................................... 106 
2.4 High Resolution Episcopic Microscopy ............................................................. 108 
2.4.1 Collection of E15.5 hearts for HREM ....................................................... 108 
2.4.2 Tissue Dehydration .............................................................................. 110 
2.4.3 Infiltration .......................................................................................... 110 
2.4.4 Embedding ......................................................................................... 110 
2.4.5 Preparing blocks for imaging ................................................................. 112 
2.4.6 Harvesting and preparing Adult hearts for HREM ..................................... 114 
2.4.7 Sectioning HREM blocks ....................................................................... 115 
2.4.8 HREM Image processing ....................................................................... 117 
2.5 Mouse Phenotyping ...................................................................................... 119 
2.5.1 Embryo Phenotyping ............................................................................ 120 
2.5.2 Adult Phenotyping ............................................................................... 120 
2.6 MRI Imaging of Adult Mice ............................................................................ 121 
2.6.1 Harvesting and preparing Adult hearts for MRI ........................................ 121 
2.6.2 MRI Protocol ....................................................................................... 121 
2.6.3 Cardiac Assessment of MRI Scans ......................................................... 122 
Identifying Novel Genes that cause Congenital Heart Disease  6 
 
2.7 Disposal of Mice and Tissue ........................................................................... 126 
2.8 Identifying Pathogenic CHD Mutations for Feedback ......................................... 126 
Chapter 3 Using Whole Exome Sequencing to discover novel CHD genes .................. 128 
3.1 Whole Exome Sequencing in Congenital Heart Disease ..................................... 129 
3.1.1 De novo mutations in histone-modifying genes cause congenital heart disease.
 ................................................................................................................. 129 
3.1.2 The role of De novo mutations in Congenital Heart Disease with 
Neurodevelopmental and other Congenital Abnormalities. ................................. 132 
3.1.2 Current use of WES in CHD ................................................................... 137 
3.2 Aims 138 
3.3 Results and Discussion ................................................................................. 138 
3.3.1 Phenotyping the Cohort for Analysis ...................................................... 138 
3.3.2 Defining the High Confidence CHD Gene List ........................................... 142 
3.3.3 De novo Mutations are an important cause of S-CHD, and NS-CHD to a lesser 
extent ........................................................................................................ 143 
3.3.4 Inherited mutations may contribute to the pathogenesis of NS-CHD. ......... 145 
3.3.5 Comparison with other disease models ................................................... 152 
3.3.6 Gene Function and Pathway Analysis ..................................................... 152 
3.3.7 Expanding the phenotype of known genes; wider phenotype associated CHD 
and NDD genes ........................................................................................... 154 
3.3.8 The potential shared genetic aetiology between CHD and NDD .................. 155 
3.3.9 Individual Gene Analysis ...................................................................... 156 
3.3.10 CDK13 ............................................................................................. 160 
3.3.11 PRKD1 ............................................................................................. 160 
3.3.12 CHD4 ............................................................................................... 160 
3.3.12.6 Function of CHD4 ............................................................................ 175 
3.3.13 Copy Number Variation Analysis .......................................................... 189 
3.3.14 Finding further novel CHD genes will require much larger cohorts ............ 190 
3.4 Challenges, Limitations and Future Work ........................................................ 192 
3.4.1. Defining S-CHD and NS-CHD ............................................................... 193 
3.4.2 Parental Phenotyping ........................................................................... 193 
3.4.3 Sample Size ....................................................................................... 194 
3.4.4 Reduced Penetrance and Mechanisms other than Monogenic Inheritance .... 195 
3.4.5 Environmental and Maternal Factors ...................................................... 196 
3.4.6 Whole Genome Sequencing .................................................................. 196 
3.4.7 Further Functional and Animal work ....................................................... 197 
3.5 Conclusions ................................................................................................. 197 
Chapter 4 The role of PRKD1 in CHD .................................................................... 199 
Identifying Novel Genes that cause Congenital Heart Disease  7 
 
4.1.1 An introduction to the Structure and Function of PRKD1 ................................. 199 
4.1.2 Movement of PRKD1 within the cell ............................................................. 202 
4.1.3 PRKD1 expression ..................................................................................... 204 
4.1.4 Functional redundancy ............................................................................... 206 
4.1.5 Mechanism of action .................................................................................. 207 
4.1.5.1 Role of PRKD1 In cardiogenesis .......................................................... 208 
4.1.5.2 Role of PRKD1 in Cardiac Hypertrophy and Heart Failure ....................... 209 
4.1.5.3 Role of PRKD1 in Angiogenesis and ischaemia ...................................... 209 
4.1.6 Existing Prkd1 Mouse Models ...................................................................... 210 
4.2Aims 211 
4.3 Results and Discussion ................................................................................. 212 
4.3.1 Individuals Reported with mutations in PRKD1 .............................................. 212 
4.3.2 Genotype phenotype correlation .......................................................... 215 
4.3.3 Correlation of the clinical features with PRKD1 expression .............................. 216 
4.3.3.1 Limb Abnormalities ........................................................................... 216 
4.3.3.2 Ectodermal Features ......................................................................... 218 
4.3.3.3 The brain ......................................................................................... 219 
4.3.3.4 Other Features ................................................................................. 219 
4.3.4 What is the mechanism causing clinical abnormalities, including CHD? ............. 220 
4.3.4.1 p.G592R in the Protein Kinase Domain ................................................ 220 
4.3.4.2 p.L299W in the Second CRD .............................................................. 221 
4.3.4.3 p.R439Q in the PH Domain ................................................................ 222 
4.3.4.4 Additional information to help determine the pathogenic mechanism of 
PRKD1 mutations ......................................................................................... 223 
4.4 Clinical Recommendations ............................................................................ 228 
4.5 Results from the Prkd1 Mice .......................................................................... 230 
4.5.1 Confirming genotype in a Prkd1Em1(IMPC)Wtsi mouse .................................... 230 
4.5.2 Ratios of Genotypes Produced in the Prkd1Em1(IMPC)Wtsi Mouse ..................... 234 
Embryos ..................................................................................................... 235 
Live born Mice ............................................................................................. 238 
4.5.3 Forelimb Staging of Prkd1Em1(IMPC)Wtsi Mouse Embryos ............................... 239 
4.5.4 Crown Rump Length Measurements of Prkd1Em1(IMPC)Wtsi Mouse Embryos ..... 241 
4.5.4 External Phenotype of Prkd1Em1(IMPC)Wtsi Mouse E15.5 embryos ................... 242 
4.5.5 Phenotype of Adult Prkd1Em1(IMPC)Wtsi Mice ................................................ 245 
4.5.6 HREM cardiac assessment of Prkd1Em1(IMPC)Wtsi Mouse mice ........................ 246 
4.6  Results from the Prkd1Em2(IMPC)Wtsi Mouse ........................................................ 254 
4.6.1 Confirming genotypes in the Prkd1Em2(IMPC)Wtsi Mouse ................................ 254 
Identifying Novel Genes that cause Congenital Heart Disease  8 
 
4.6.2 Ratios of Genotypes Produced in the Prkd1Em2(IMPC)Wtsi Mouse ..................... 256 
Embryos ..................................................................................................... 256 
Live born mouse genotypes .......................................................................... 258 
4.6.3 Forelimb Staging of Prkd1Em2(IMPC)Wtsi E15.5 Embryos ................................ 259 
4.6.4 Crown Rump Length Measurements of Prkd1Em2(IMPC)Wtsi E15.5 Embryos ...... 260 
4.6.5 External Phenotype of Prkd1Em2(IMPC)Wtsi E15.5 embryos ............................. 261 
4.6.6 Phenotype of Adult Prkd1Em2(IMPC)Wtsi Mice ................................................ 264 
4.6.7 HREM cardiac assessment of Prkd1Em2(IMPC)Wtsi mice .................................. 264 
4.7 Comparison of Embryonic Lethality in the the Prkd1Em1(IMPC)Wtsi and Prkd1Em2(IMPC)Wtsi 
lines 269 
4.8 Comparison of Extra cardiac Phenotypic Abnormalities in the the Prkd1Em1(IMPC)Wtsi and 
Prkd1Em2(IMPC)Wtsi lines ......................................................................................... 272 
4.9 Significance of Cardiovascular Abnormalities identified in the the Prkd1Em1(IMPC)Wtsi and 
Prkd1Em2(IMPC)Wtsi lines ......................................................................................... 274 
4.10 Limitations and Future Work ........................................................................ 277 
4.11 Conclusions ............................................................................................... 278 
Chapter 5 Cardiac Findings in the Adult Prkd1 Mouse ............................................. 279 
5.1 Introduction ................................................................................................ 279 
5.1.1 Role of Prkd1 in Cardiac Hypertrophy .......................................................... 279 
5.1.2 Previous relevant Prkd1 mouse models ........................................................ 280 
5.1.3 Imaging Modalities .................................................................................... 281 
5.1.4 The Basis of MRI ....................................................................................... 283 
5.1.5 Previous relevant MRI studies ..................................................................... 284 
5.2 Aims 287 
5.3 Results and Discussion ................................................................................. 287 
5.3.1 Determining the Required Resolution for MRI Scanning .................................. 288 
5.3.2 Preservation of Mice by freezing ................................................................. 290 
5.3.3 Test MRI Scans ......................................................................................... 291 
5.3.4 Structural Cardiac findings in 2 month old Prkd1Em2(IMPC)Wtsi mice ..................... 295 
5.3.5 Ventricular Wall and Septal Thickness in 2 month old Prkd1Em2(IMPC)Wtsi mice ...... 303 
5.4 Challenges, Limitations and Future Work ........................................................ 312 
5.5 Conclusions ................................................................................................. 314 
Chapter 6 The Role of CDK13 in Congenital Heart Disease ...................................... 316 
6.1 Introduction ................................................................................................ 316 
6.1.1 The Structure and Function of CDK13 .......................................................... 316 
6.1.1.1 RNA Polymerase II and the transcription process .................................. 317 
6.1.1.2 Structure of the RPB1 subunit and the Heptad Repeats ......................... 320 
Identifying Novel Genes that cause Congenital Heart Disease  9 
 
6.1.1.3 Structure of CDK13 and binding with Cyclin K ...................................... 321 
6.1.2 Similarities and differences between members of the CDK family .................... 325 
6.1.3 Function of CDK13-Cyclin K Complex in transcription and splicing ................... 328 
6.1.4 Differences in Gene Regulation by CDK12 and CDK13 .................................... 329 
6.1.5 CDK13 Expression ..................................................................................... 331 
6.1.6 Animal Models .......................................................................................... 331 
6.2 Aims 336 
6.3 Results and Discussion ................................................................................. 336 
6.3.1 Individuals reported with mutations in CDK13 .............................................. 336 
6.3.2 The Phenotypic Spectrum of CHDFIDD/CDK13-related disorder ...................... 338 
6.3.3 CHD in CHDFIDD/CDK13-related Disorder .................................................... 340 
6.3.4 Mutational Mechanism causing Clinical Abnormalities ..................................... 345 
6.3.4 Which Individuals develop CHD ................................................................... 353 
6.3.5 Clinical Recommendations .......................................................................... 356 
6.3.6 Results from the Cdk13tm1b(EUCOMM)Hmgu Mouse ............................................... 358 
6.3.6.1 Embryonic lethality in Cdk13tm1b(EUCOMM)Hmgu  mice ................................. 360 
6.3.6.2 Forelimb Staging of Cdk13tm1b(EUCOMM)Hmgu  E15.5 Embryos ...................... 365 
6.3.6.3 Crown Rump Length Measurements of Cdk13tm1b(EUCOMM)Hmgu  E15.5 Embryos
 ................................................................................................................. 366 
6.3.6.4 External Phenotype of Cdk13tm1b(EUCOMM)Hmgu  E15.5 embryos .................. 368 
6.3.6.5 Phenotype of Adult Cdk13tm1b(EUCOMM)Hmgu Mice ...................................... 371 
6.3.6.6 HREM cardiac assessment of E15.5 Cdk13tm1b(EUCOMM)Hmgu Embryos .......... 374 
6.3.6.7 Comparison with Cdk13tm1a/d mouse ........................................... 394 
6.4 Limitations and Future Work ......................................................................... 395 
6.6 Conclusions ................................................................................................. 398 
Chapter 7 Confirmation and Feedback of results to participants and associated ethical 
issues .............................................................................................................. 401 
7.1 Introduction ................................................................................................ 401 
7.1.1 Duties of Clinicians and Researchers............................................................ 401 
7.1.2 Secondary Findings generated by WES ........................................................ 403 
7.1.3 Current guidance regarding secondary findings ............................................. 406 
7.1.3.1 Guidance for Clinicians ...................................................................... 406 
7.1.3.2. Guidance for Research ..................................................................... 406 
7.1.3.3 Current Examples: The 100 000 Genomes Project ................................ 407 
7.2 Aims 408 
7.3 Results and Discussion ................................................................................. 408 
7.3.1 Confirmation of Pathogenic Mutations .......................................................... 408 
Identifying Novel Genes that cause Congenital Heart Disease  10 
 
7.3.1.1 Confirmation of GATA6 mutation ........................................................ 409 
7.3.1.2 Confirmation of PTPN11 mutation p.Asn308Asp .................................... 411 
7.3.1.3 Confirmation of PTPN11 mutation p.Tyr63Cys ...................................... 412 
7.3.2 Consideration of Secondary Findings ........................................................... 412 
7.4 Conclusions ................................................................................................. 416 
Chapter 8 Final Conclusions ................................................................................ 418 
Appendix A. Overview of cardiovascular development in the mouse ......................... 421 
Appendix B. Cdk13tm1b(EUCOMM)Hmgu Mouse Sequence ................................................ 424 
Appendix C. Phenotype of the Wildtype C57BL/6N Mouse ....................................... 426 
Appendix D Embryonic Mouse Phenotyping Protocol ............................................... 429 
Appendix E Adult Mouse Phenotyping Protocol ...................................................... 433 
Appendix F: Sifrim et al. .................................................................................... 435 
Appendix G: Syndromic and Non-Syndromic Cohort Composition ............................ 448 
Appendix H: Cohort Composition ......................................................................... 449 
Appendix I: Cardiac Phenotypes .......................................................................... 450 
Appendix J: CHD gene list criteria ....................................................................... 453 
Appendix K: High Confidence CHD Gene List ......................................................... 454 
Appendix L. Clinical features reported with mutations in CDK13 .............................. 463 
Appendix M: Clinical features seen with mutations in PRKD1 ................................... 465 
Appendix N: Sample size requirements for novel CHD gene detection ...................... 466 








Identifying Novel Genes that cause Congenital Heart Disease  11 
 
Index of Figures 
 
Figure 1.1 Early cardiac development. ................................................................... 26 
Figure 1.2. Steps in cardiogenesis. ........................................................................ 29 
Figure 1.3 Derivation of the heart fields. ................................................................ 31 
Figure 1.4. Genetic controls of cardiogenesis .......................................................... 32 
Figure 1.5 Cell migration in cardiogenesis. ............................................................. 33 
Figure 1.6 The linear heart tube. ........................................................................... 36 
Figure 1.7 Heart tube looping. .............................................................................. 38 
Figure 1.8 Formation of the atrial septum. .............................................................. 41 
Figure 1.9 Development of the ventricular and outflow tract septum. ......................... 44 
Figure 1.10 Septation of the cardiac outflow tract.................................................... 46 
Figure 1.11 Genetic controls of septation. .............................................................. 50 
Figure 1.12 Schematic drawing of the development of the aortic arch and its branches. 52 
Figure 1.13 Formation of the coronary ostia. .......................................................... 55 
Figure 1.14 The fetal circulation. ........................................................................... 60 
Figure 1.15 Prominent transcription factors in cardiogenesis. .................................... 75 
Figure 2.1 Representation of Prkd1em1(IMPC)Wtsi mouse with exon 2 deleted. ................ 101 
Figure 2.2 Relevant sequence for amplification by PCR to genotype the Prkd1Em2(IMPC)Wtsi 
mouse. ............................................................................................................ 103 
Figure 2.3 Primers to genotype the Cdk13tm1b(EUCOMM)Hmgu mouse. ............................. 104 
Figure 2.4 Removal of the gravid uterus. .............................................................. 107 
Figure 2.5 E13.5 mouse embryo. ........................................................................ 108 
Figure 2.6 Example of E15.5 heart after initial dissection........................................ 109 
Figure 2.7 Embedding embryonic hearts. ............................................................. 111 
Figure 2.8 Removal of the block from the mould. .................................................. 112 
Figure 2.9 Trimming the resin blocks. .................................................................. 113 
Figure 2.10 A finished resin block. ....................................................................... 114 
Figure 2.11 Example of an embedded adult heart. ................................................. 115 
Figure 2.12 Set up of the HREM sectioning equipment. .......................................... 116 
Figure 2.13 Orientation of the hearts in the resin block. ......................................... 117 
Figure 2.14 MRI images of adult mice. ................................................................. 123 
Figure 2.15 Aortic measurements using MRI. ........................................................ 125 
Figure 3.1 Protein-protein interactions between high confidence genes. ................... 153 
Figure 3.2 Probands with de novo CHD4 mutations. ............................................... 162 
Figure 3.3 Pictorial representation of CHD4 and reported mutations. ....................... 174 
Figure 3.4 Updated protein-protein interactions. ................................................... 191 
Figure 4.1 Structure of PRKD1. ........................................................................... 201 
Figure 4.2 Mechanism of action of PRKD1. ............................................................ 208 
Figure 4.3 Mutations reported in association with CHD and Ectodermal Defects. ........ 214 
Figure 4.4 Additional variants reported in PRKD1. ................................................. 225 
Figure 4.5 Prkd1+/+ mouse genotype. .................................................................. 231 
Figure 4.6 Prkd1Em1/+ genotype. .......................................................................... 232 
Figure 4.7 Sequence of Prkd1Em1/+ mouse. ............................................................ 233 
Figure 4.8 Deleted sequence in the Prkd1Em1/+ mouse. ........................................... 233 
Figure 4.9 Genotypes from Prkd1Em1/+ crosses. ..................................................... 236 
Figure 4.10 Genotypes from Prkd1Em1/+ WT crosses. .............................................. 237 
Figure 4.11 Forelimb staging. ............................................................................. 239 
Figure 4.12 External view of E15.5 heart. ............................................................. 247 
Figure 4.13 Aorta and aortic valve. ...................................................................... 248 
Identifying Novel Genes that cause Congenital Heart Disease  12 
 
Figure 4.14 Pulmonary artery and ductus arteriosus. ............................................. 250 
Figure 4.15 The heart valves. ............................................................................. 250 
Figure 4.16 Interrupted aortic arch. ..................................................................... 252 
Figure 4.21 Muscular VSD in a Prkd1Em2/+ mouse ................................................... 266 
Figure 4.22 HREM of Prkd1Em2/Em2 mouse. ............................................................. 269 
Figure 5.1 MRI images at differing resolutions. ..................................................... 293 
Figure 5.2 Wrap around artefact. ........................................................................ 294 
Figure 5.3 Wrap around artefact and image shadow. ............................................. 295 
Figure 5.4 Typical images shown in three planes generated in ITK-Snap. ................. 296 
Figure 5.5 Left ventricular outflow tract and aortic valve. ....................................... 297 
Figure 5.6 Great Vessels on MRI sections of a Prkd1Em2/+ mouse. ............................ 298 
Figure 5.7 Right and left outflow tracts in a Prkd1+/+ mouse. .................................. 299 
Figure 5.8 Valves and atrial septum in a normal Prkd1+/+ mouse. ............................ 300 
Figure 5.9 Atrial septum and components of atrioventricular valves in a normal Prkd1+/+ 
mouse. ............................................................................................................ 301 
Figure 5.10 Abnormal cardiac phenotypes detected. .............................................. 302 
Figure 5.11 Representation of the measurements of ventricular wall and septal thickness 
in Prkd1+/+ and Prkd1Em2/+ mice. .......................................................................... 305 
Figure 5.12 Box and whisker plots of ventricular wall thickness. .............................. 306 
Figure 5.13 Box and whisker plots LV diameter. .................................................... 307 
Figure 5.14 Summary of aortic measurements. ..................................................... 309 
Figure 5.15 Box and whisker plots of aortic measurements. .................................... 310 
Figure 6.1 CDK13 Cyclin K complex. .................................................................... 318 
Figure 6.2 RNA polymerase II subunit composition and assembly. ........................... 319 
Figure 6.3 A Schematic of CDK13 structure. ......................................................... 322 
Figure 6.4 Representation of Cyclin K. ................................................................. 324 
Figure 6.5 Mouse allele models. .......................................................................... 332 
Figure 6.6 Clinical features seen with missense mutations in CDK13. ....................... 337 
Figure 6.7 Phenotypes reported in individuals with mutations in CDK13. .................. 339 
Figure 6.8 Representation of the CDK13 protein and reported mutations. ................. 346 
Figure 6.9 Alignment of mouse and human CDK13 proteins. ................................... 359 
Figure 6.10 Average CRL across all Cdk13tm1b(EUCOMM)Hmgu litters harvested at E15.5 by 
developmental stage. ........................................................................................ 368 
Figure 6.11 Large multiloculated cyst found in Cdk13tm1b/+ female mouse abdomen. .. 374 
Figure 6.12 Abnormal position of outflow tract valves. ........................................... 377 
Figure 6.13 Mitral Valve and VSD ........................................................................ 378 
Figure 6.14 Tricuspid valve and VSD. ................................................................... 378 
Figure 6.15 VSD and aortic override. ................................................................... 379 
Figure 6.16 Relationship of aortic valve and VSD. .................................................. 379 
Figure 6.17 Raw HREM images confirming DORV. .................................................. 380 
Figure 6.18 Abnormal origins of the coronary arteries. ........................................... 382 
Figure 6.19 BAV in a Cdk13tm1b/+ embryo. ............................................................ 384 
Figure 6.20 Raw HREM images showing BAV in a Cdk13tm1b/+ embryo. ..................... 384 
Figure 6.21 External view of E15.5 heart. ............................................................. 386 
Figure 6.22 Normal pulmonary and aortic valves in Cdk13tm1b/tm1b heart. .................. 386 
Figure 6.23 Common atrioventricular valve in a Cdk13tm1b/tm1b heart. ....................... 387 
Figure 6.24 Common atrioventricular valve and VSD in a Cdk13tm1b/tm1b heart. .......... 387 
Figure 6.25 Aortic override in a Cdk13tm1b/tm1b heart. ............................................. 388 
Figure 6.26 Raw HREM images of aortic override. .................................................. 389 
Figure 6.27 Raw HREM images of common atrioventricular valve. ........................... 390 
Figure 6.28 Raw images of aortic override with underlysis. ..................................... 391 
Figure 7.1 Examples of secondary findings. .......................................................... 404 
Identifying Novel Genes that cause Congenital Heart Disease  13 
 
Figure 7.2 PCR was carried out to amplify the region of interest in GATA6. ............... 410 
Figure 7.3 Sequence results for the PTPN11 mutation. ........................................... 411 
Figure 7.4 PTPN11 sequence amplifying the region of interest. ................................ 412 
Figure A.1 Overview of mouse heart formation including looping. ............................ 421 
Figure B.1 Sequence of Cdk13 with relevant sites for generating and genotyping the 
Cdk13tm1b(EUCOMM)Hmgu mouse. .............................................................................. 424 
Figure B.2 Wildtype Cdk13 sequence. .................................................................. 425 
Figure M.1 Clinical phenotypes of probands with de novo PRKD1 mutations. ............. 465 























Identifying Novel Genes that cause Congenital Heart Disease  14 
 
Index of Tables 
 
Table 2.1 Primers used to genotype the three mouse strains. ................................... 95 
Table 2.2 Primers required to confirm pathogenic mutations identified. ...................... 96 
Table 2.3 Nomenclature of mice genotypes employed in this thesis. ........................ 100 
Table 3.1 Genes identified with de novo mutations. ............................................... 134 
Table 3.2 S-CHD genes identified in individuals with NS-CHD. ................................. 149 
Table 3.3 Genes containing rare PTVs. ................................................................. 151 
Table 3.4 Significant S-CHD genes identified. ....................................................... 157 
Table 3.5 Likely CHD genes identified. ................................................................. 158 
Table 3.6 Overlapping phenotypes seen in CHARGE, RTS and CHD4 mutations. ........ 165 
Table 3.7 Clinical features of all the individuals reported with mutations in CHD4. ..... 167 
Table 3.8 CHD phenotypes reported with mutations in CHD4. ................................. 172 
Table 3.9 Components of the NuRD complex. ....................................................... 176 
Table 3.10 Proposed mechanism of CHD4 mutations. ............................................. 182 
Table 3.11 Clinical phenotypes associated with variants in the CHD gene family. ....... 186 
Table 4.1 Expression patterns of the Prkd genes. .................................................. 205 
Table 4.2 CHD subtypes in PRKD1. ...................................................................... 212 
Table 4.3 Updated PCR for Prkd1Em1(IMPC)Wtsi mouse. ............................................... 234 
Table 4.4 Prkd1Em1(IMPC)Wtsi embryo genotypes. ...................................................... 235 
Table 4.5 Genotypes of Prkd1Em1(IMPC)Wtsi live born mice. ................................. 238 
Table 4.6 Forelimb stage of all Prkd1Em1(IMPC)Wtsi mouse embryos. ............................. 240 
Table 4.7 Crown rump length of all E15.5 Prkd1Em1(IMPC)Wtsi embryos. ....................... 241 
Table 4.8 Phenotypic analysis of all E15.5 Prkd1Em1(IMPC)Wtsi. .................................... 244 
Table 4.9 Weights and lengths of 7 Prkd1Em1+/- mice at three months old. ............ 245 
Table 4.10 Adult Prkd1Em1(IMPC)Wtsi mice phenotypes. ....................................... 246 
Table 4.11 Summary of phenotypes seen in the Prkd1Em1(IMPC)Wtsi E15.5 embryo 
hearts processed using HREM. ............................................................................ 251 
Table 4.12 Genotypes and expected ratios found in the embryos of Prkd1 Em2(IMPC)Wtsi  mice.
....................................................................................................................... 257 
Table 4.13 Figure 4.21 Genotypes and expected ratios found in the adult Prkd1Em2(IMPC)Wtsi  
mice. ............................................................................................................... 258 
Table 4.14 Forelimb stage of all E15.5 Prkd1Em2(IMPC)Wtsi embryos and their respective 
genotypes. ....................................................................................................... 259 
Table 4.15 CRL (mm) for all Prkd1Em2(IMPC)Wtsi embryos collected at E15.5 and their 
corresponding genotypes. .................................................................................. 260 
Table 4.16 Phenotype of all Prkd1Em2(IMPC)Wtsi embryos collected. .............................. 263 
Table 4.17 Summary of phenotypes seen in the E15.5 embryo hearts processed using 
HREM. ............................................................................................................. 267 
Table 5.1 C57BL6 cardiac measurements found in the literature.............................. 289 
Table 5.2 Ventricular wall thickness in Prkd1+/+ and Prkd1Em2/+ mice. ................. 304 
Table 5.3 Average measurements of the aortic root at the sinus of Valsalva (SoV) and 
ascending aorta. ............................................................................................... 308 
Table 6.1 CDK13 Cyclin K complex. ..................................................................... 325 
Table 6.2 Structure of the CDK family proteins...................................................... 328 
Table 6.3 Effect of Cdk12 and Cdk13 on RNA expression. ....................................... 330 
Table 6.4 All reported mutations and CHD phenotype reported up to November 2019. 344 
Table 6.5 mutations reported in CDK13, with information about their possible functional 
consequences. .................................................................................................. 348 
Table 6.6 Cdk13tm1b(EUCOMM)Hmgu embryo genotypes. ................................................ 361 
Identifying Novel Genes that cause Congenital Heart Disease  15 
 
Table 6.7 Cdk13tm1b(EUCOMM)Hmgu embryo genotypes. ................................................ 362 
Table 6.8 Forelimb staging of all Cdk13tm1b(EUCOMM)Hmgu embryos collected at E15.5, split 
by litter. ........................................................................................................... 365 
Table 6.9 Crown rump length (CRL) of all Cdk13tm1b(EUCOMM)Hmgu embryos. ................. 367 
Table 6.10 Gross external assessment of Cdk13tm1b(EUCOMM)Hmgu embryos based on 
gestation and genotype. ..................................................................................... 370 
Table 6.11 Abnormalities seen in adult Cdk13tm1b(EUCOMM)Hmgu mice. ........................... 372 
Table 6.12 Summary of abnormalities detected in the Cdk13tm1b(EUCOMM)Hmgu  E15.5 
embryos by genotype. ....................................................................................... 375 
Table 7.1 Review of de novo variants for feedback. ............................................... 409 
Table 7.2 Completed table from the MRC guidance.. .............................................. 414 
Table A.1 Overview of some of the main events in mouse heart development. .......... 423 
Table C.1 Characteristics of the C57BL/6 mice. ..................................................... 426 
Table C.2 Cardiovascular development in mouse embryos. ..................................... 428 
Table G.1 Cohort composition: Syndromic and non-syndromic ................................ 449 
Table H.1 Cohort composition: Participating centres. ............................................. 450 
Table I.1 Composition of cohort: CHD phenotype. ................................................. 453 
Table J.1 Criteria for CHD associated genes. ......................................................... 454 
Table K.1 CHD associated genes. ........................................................................ 462 

























Complex genetic networks underlie the development of the heart. Variants in 
some of these genes can lead to congenital heart disease (CHD). Despite the 
hundreds of genes that have been identified as causing CHD in humans, they 
only account for a small proportion of individuals with CHD. We carried out 
whole exome sequencing in the largest cohort of individuals with CHD reported 
at the time of publication, and identified three novel genome wide significant 
syndromic CHD genes; CDK13, PRKD1 and CHD4.  
Individuals with mutations in CHD4 show neurodevelopmental disability, genital 
abnormalities and share some phenotypic overlap with other chromatinopathies. 
Mutations in PRKD1 also cause syndromic CHD, but identification of further 
affected individuals is required to determine if there is a consistent phenotype. 
Prkd1 mouse models do not have a high incidence of CHD, but this gene may be 
important in future work as it plays a role in cardiac hypertrophy.  
Individuals with mutations in CDK13 show a recognisable phenotype and the 
mouse model shows embryonic lethality and atrioventricular canal defects. The 
precise mechanism by which heterozygous mutations cause disease in humans 
remains unclear. The phenotypic and genotypic spectrum has been expanded by 
subsequent reports of individuals with mutations in CKD13.  
We also identify a role for inherited variants with reduced penetrance in 
individuals with non-syndromic CHD. This is significant, as the vast majority of 
individuals with CHD have non-syndromic CHD. It is an important step in 
understanding the potential oligogenic pathogenesis of the majority of CHD. 
Ultimately we aim to increase our knowledge of the genes and networks that 
underlie CHD, to improve diagnostic yield in individuals affected with CHD. I was 
able to feedback pathogenic mutations in CHD genes to participants in this study 
locally. Following this unbiased approach of non-targeted testing in a cohort with 
multiple types of CHD, will improve our knowledge of genotype phenotype 
correlations. We also hope that understanding more about the genes involved in 
cardiogenesis and CHD might have relevance for the failing heart, and 
development of treatments in the future too.  
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Chapter 1 Introduction 
 
1.1 Overview of Congenital Heart Disease 
 
Congenital Heart Disease (or Congenital Heart Disorders/defects, CHD) are 
abnormalities in the structure of the heart or great vessels that are present at 
birth. These terms encompass a wide range of defects that may be mild and 
require no intervention, or may be life-limiting and require complex surgery 
soon after birth.  
 
CHD is important for two reasons. It is the most common congenital 
abnormality, and has a higher mortality that many other birth defects [1, 2]. It 
affects 7-9 babies per 1000 births [1, 3]. If you include milder lesions such as 
bicuspid aortic valve (BAV), the incidence rises to 2-3% [4]. Prevalence has 
been estimated at 13 per 1000 children, and 6 per 1000 adults [5]. Almost 60% 
of individuals with CHD have three common subtypes; atrial septal defect (ASD), 
ventricular septal defect (VSD) or patent ductus arteriosus (PDA) [6]. Tetralogy 
of Fallot (TOF) is the most common cyanotic form of CHD, and affects 
approximately 1 in every 2500-3000 live births [1, 7]. 
 
Given that CHD is a common congenital abnormality, it is an important issue for 
healthcare providers, and the potentially complex needs of this growing group of 
individuals must be considered. Individuals with CHD are living longer due to 
better medical and surgical care, with 95% reaching adulthood [8]. The 
prevalence of both milder and more complex lesions has risen by around 10% 
every 5 years since 1970 [6].  As a result, individuals with CHD now represent a 
considerable cohort of individuals, some of whom require lifelong specialist 
medical care. Their needs range from complicated neonatal and paediatric 
surgery, to lifelong surveillance to monitor for late complications, as some types 
of CHD are associated with high morbidity and mortality in adulthood [9]. In 
addition, given that individuals are now more likely to survive to reproductive 
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age, they may ask about the risks of their children also being affected with CHD. 
Provision for genetic counselling and testing should be provided [10].  
 
There is a significant genetic component and strong heritability to CHD. The 
classical pedigree displaying Mendelian inheritance is uncommon, and in the 
majority of cases there appears to be a complex pattern of inheritance. It has 
become apparent that the mechanisms underlying CHD are complicated, and 
that perturbation of gene expression contributes towards abnormality in the 
developing heart. Transcription factors such as NKX2.5 and the genes they 
regulate, form an important part of these networks. Aberrations in copy number, 
and mutations in many of these genes have been identified as causing CHD [11-
18]. However a single mutation in a specific gene can produce different CHD 
phenotypes and there is now mounting evidence of reduced penetrance with 
seemingly deleterious mutations in CHD causing genes [12, 19]. This and the 
fact that CHD is usually only seen in a single individual within a family, suggests 
that monogenic causes are rare and there are likely to be additional genetic and 
non-genetic factors which contribute.  
 
Whilst a number of genes have been identified previously by investigation of 
families with a Mendelian pattern of CHD, sequencing of large cohorts of affected 
individuals is now at the forefront of research to discover novel CHD genes [12, 
14, 15, 19]. This method has been successful in identifying new CHD genes. 
Close collaboration between clinicians and research groups will be required to 
obtain large enough cohorts to fully understand the genetic basis of this complex 
group of conditions. 
 
Research in the Brook laboratory has focussed on identifying genes essential in 
heart embryogenesis that cause CHD. This thesis aims to identify further genes 
that cause CHD, provide an animal model for support, and consider the 
mechanism by which variants are deleterious. Identification of a genetic cause of 
an individual’s CHD allows accurate genetic counselling, may guide prognosis, 
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medical management and antenatal care. Therefore it is important that we try to 
understand the genetic aberrations that cause CHD. 
 
The heart has no real regenerative power, so damage is cumulative and can 
have long lasting consequences despite remodelling. Understanding the 
pathways involved in successful cardiac development will help us understand 
mechanisms behind CHD, and may also provide opportunities to develop 
treatments for the damaged heart. 
 
1.2 Heart development 
 
CHD results from perturbations in the normal development of the heart. A 
specific structure may fail to develop, or form abnormally due to altered 
haemodynamics within the heart and great vessels. Abnormalities include 
defects of laterality, septation and formation of specific structures such as the 
valves. The consequences depend on the structure affected, and may differ 
between the fetal and postnatal circulation states. Given that the heart is the 
first fully functioning organ in embryogenesis, severe cardiac abnormalities can 
result in embryonic lethality.  
 
This thesis focusses on identifying genetic causes of CHD in humans, but also 
involves the use of both zebrafish and mice. The early stages of development of 
the heart follows a similar path in all three species, with formation of a heart 
tube and subsequent looping. Both the mouse and zebrafish have been used as 
model organisms in cardiac research extensively in the past. Understanding the 
normal development of the human heart can help us understand how and why 
CHD develops. Cardiogenesis in the human is discussed in more detail below. 
This is followed by a discussion of the links between genes known to be 
important in heart development, and those that have subsequently been found 
to play a role in CHD.  
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1.2.1 Human Heart Development 
 
Embryogenesis begins with formation of the zygote, after fusion of the ova and 
sperm. Active circulation of fetal blood is required relatively early on in 
gestation, so that oxygen can be delivered to the growing embryo. Diffusion is 
adequate initially, but cannot maintain fetal growth and development. The heart 
by necessity, is there for the first organ to develop.  
The heart develops from a number of different cell populations or heart fields. 
They contribute to formation of a single tube initially, which then loops to form 
the chambers of the heart. Looping of the heart tube is the first evidence of the 
left-right axis in the body. Formation of the heart tube and its subsequent 
development into the four chambered heart and outflow tract is detailed in 
section 1.2.1.2. The mature heart is formed by day 50 of gestation [20]. 
 
1.2.1.1 The heart fields  
 
The heart is derived from four main sources; the primary and secondary heart 
fields (both from cardiac mesenchymal progenitor cell populations), the cardiac 
neural crest, and the proepicardium (Figure 1.1).  
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Figure 1.1 Early cardiac development. 
Reproduced from Tan et al. [21], with permission from Karger Basel. Early 
cardiac development. a Cardiac cell lineage and specification during 
development demonstrating the commitment of pluripotent cells toward mature 
cardiac cell types within the heart development. b Schematic of cardiac 
morphogenesis in humans. At the second week of gestation, the cardiogenic 
mesodermal cells migrate toward the anterior side of the embryo to form the 
first heart field (FHF) or cardiac crescent and second heart field (SHF) that are 
specified to form specific segments of the primary heart tube (PHT), which is 
patterned along the anteroposterior axis to form the various regions and 
chambers of the looped and mature heart during weeks 3 and 4. The FHF gives 
rise to the beating PHT and will eventually give rise to the left ventricle (LV) and 
parts of the right and left atria (RA and LA, respectively). The SHF, located 
behind the PHT and within the pharyngeal mesoderm by gestational week 3, will 
contribute to the formation of the RV, parts of the atria and outflow tract, and 
later to the base of the aorta and pulmonary artery. At gestational week 3, the 
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cells at the venous pole contribute to the formation of the superior and inferior 
vena cavas (SVC and IVC, respectively). By gestational week 4, the cardiac 
neural crest cells migrate in from the dorsal neural tube, forming smooth muscle 
cells within the aortic and pulmonary arteries. In addition, the proepicardial 
organ formed by the proepicardial progenitor cell clusters later contributes to the 
formation of the epicardium. The 4 chambers form by the end of week 7. Wnt, 
Wingless integrated; FGF, fibroblast growth factor; BMP, bone morphogenetic 
proteins; OFT, outflow tract; PM, pharyngeal mesoderm; VP, venous pole; 
CNCCs, cardiac neural crest cells; LV, left ventricle; RV, right ventricle; PEO, 
proepicardial organ; EPC, epicardium; and PA, pulmonary artery. 
 
Initial development centres on formation of the heart tube. Subsequent 
migration of different cell populations to the arterial (cranial) pole, and the 
venous (caudal) pole, cause elongation of the tube and formation of the 
structures within the heart. 
 The primary (or first) heart field produces the initial heart tube, and later 
primarily the left ventricle (LV) [22]. It also contributes to the atria, part 
of the right ventricle (RV), tricuspid (TV) and mitral valves (MV).  
 The second heart field (SHF) produces the outflow tract, and is split into 
anterior and posterior components. It contributes to all chambers with the 
exception of the LV [23].  
o The anterior SHF moves to the arterial pole of the heart. It 
contributes to the right ventricle (RV) and outflow tract (OFT, conus 
cordis and truncus arteriosus). The mesoderm extends to form the 
myocardium of the RV, and the right side of the interventricular 
septum. The SHF also forms part of the aortic and pulmonary 
(semilunar) valves (AV, PV) and the walls of the great arteries [24, 
25]. Cells in the aorta are added from the right, and cells in the 
pulmonary trunk are added from the left which may contribute to 
the crossing over of the aorta and pulmonary trunk [26].  
o The posterior SHF reaches the venous pole of the heart. It 
contributes to the atrioventricular canal, the atria, the dorsal 
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mesenchymal protrusion, the central chamber of the sinus venosus 
and the outflow tract [22, 27]. The myocardium derived from these 
cells covers the sinus venosus and forms part of the dorsal wall of 
the right and left atrium [24, 28, 29].  
 
 The cardiac neural crest is derived from ectodermal lineage, from the 
neural tube cells near the first three somites. This is in contrast to the rest 
of the heart that is derived from mesoderm [30]. It contributes 
structurally to the outflow tract septum, the endocardial cushions/valves 
and the parasympathetic nervous system [31, 32]. These cells migrate 
from the dorsal neural tube, through the posterior pharyngeal arches to 
the anterior part of the heart tube [31, 32]. The cells then migrate to the 
outflow tract between weeks three and four, and are involved in 
separation of the aorta and pulmonary trunk. They produce myocardium 
for the outflow tract and a small outflow tract septum with the endocardial 
cushions.  
 
 The proepicardium is a transient tissue which derives from the 
proepicardial organ. It is a collection of epithelial cells, with a core of 
mesenchymal cells, within an extracellular matrix in the dorsal mesoderm 
of the septum transversum in mammals [22, 33, 34]. It contributes to the 
epicardium, fibroblasts in the myocardium and the coronary arteries. 
Proepicardial cells are produced from a specific population of cells in the 
splanchnic mesoderm. The cells migrate to the primary heart tube just as 
it begins looping. The cells attach to the AV junction and migrate over the 
myocardium to form the epicardium [33]. A few of the cells undergo EMT 
(epithelial to mesenchymal transition) and with the other mesenchymal 
cells of the proepicardium, form the smooth muscle cells, perivascular 
fibroblasts and endothelial cells of the coronary arteries [35-37]. There is 
also some contribution to the muscular ventricular septum and the atria 
by a small number of proepicardial cell precursors [38, 39].  
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1.2.1.2 Stages of Formation of the heart 
 
Formation of the heart centres on the creation of a single linear heart tube, 
which then loops and forms the chambers of the heart. An overview of the 
elements of cardiogenesis are shown in figure 1.1 and 1.2, and the steps are 
discussed in more detail below.  
 
 
Figure 1.2. Steps in cardiogenesis. 
An overview of the elements of formation of the heart in normal embryogenesis. 
The steps are described in more detail in the following sections. 
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1.2.1.2.1 Gastrulation and formation of the Cardiogenic Mesoderm 
 
Following fertilisation (day 0), the blastocyst develops and implants into the 
uterine lining. Two layers of cells form not long after this; the epiblast and 
hypoblast. This is the bilaminar embryonic disc or germ disc. The primitive 
streak forms within the epiblast of the germ disc [40]. The groove of the 
primitive streak marks out the axis of the embryo.  
 
By day 15, some of the epiblast cells that are located around the primitive 
streak, migrate between the epiblast and hypoblast layers (Figure 1.4). These 
cells become the endoderm and mesoderm. The cells that do not migrate 
become the ectoderm [39]. This produces a trilaminar structure, comprising of 
dorsal ectoderm, mesoderm and ventral endoderm. This is gastrulation. The 
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Figure 1.3 Derivation of the heart fields. 
Representation of formation of the trilaminar structure in gastrulation and 
derivation of the first and second heart fields. The endoderm contributes to the 
epithelium of the respiratory, urogenital and gastrointestinal tract. The ectoderm 
is required for the epidermis and parts of the central nervous system. The 
mesoderm contributes to most other structures.  
 
The cells that produce mesoderm delineate to form four specific mesodermal cell 
populations; the cardiogenic mesoderm, the paraxial mesoderm, the 
intermediate and lateral plate mesoderm. The first and second heart field derive 
from the cardiogenic mesoderm [39].  
 
These early processes in embryogenesis are tightly controlled by a number of 
important gene networks (Figure 1.4). During the process of the epiblast cells 
invaginating through the primitive streak, BMP, NODAL, Wnt/β-catenin and FGF 
control the differentiation of epiblasts to mesodermal cells which express 
Brachyury, a T-box transcription factor [42]. As described already, the cells 
migrate to the lateral splanchnic mesoderm and differentiate into cardiogenic 
mesoderm and then the first and second heart fields. These cardiac precursor 
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cells express Eomesodermin, a T-box transcription factor, which plays a key role 
in formation of the definitive endoderm [43, 44], but which also activates Mesp1 
which is seen in cardiac progenitors as well as other mesodermal lineage cells 
[45-48]. This process is controlled by Wnt/ β-catenin signalling, which 




Figure 1.4. Genetic controls of cardiogenesis 
Representation of gastrulation and the genetic controls guiding mesodermal 
differentiation into the heart fields, which are located within the cardiac 
crescents. Additional information on gene pathways involved from references: 
[50-55]. Flk-1 = vascular endothelial growth factor receptor 2, VEGFR2. 
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1.2.1.2.2 Formation of the First/Primary and Second heart fields 
 
  
Once the cardiac mesodermal cells have differentiated, they migrate in a cranio-
lateral direction to form the primary heart field. This migration pattern results in 
changes to the orientation of the cells from a rostro-caudal pattern in the 
primitive streak, to a medio-lateral formation in the cardiogenic fields (Figure 
1.5). The primary heart field will go on to produce the linear heart tube. 
`
 
Figure 1.5 Cell migration in cardiogenesis. 
A: The cardiogenic precursors migrate through the primitive streak to form the 
intraembryonic mesoderm. These cells then migrate craniolaterally to form the 
cardiogenic fields.  B: The migration pattern results in a change to the 
orientation of the cells from a rostro-caudal pattern in the primitive streak, to a 
medio-lateral formation in the primary heart field.  
 
Medial and caudal to the first heart field, the second heart field forms in the 
pharyngeal mesoderm. The two lie adjacent at day 15, in the cardiac crescent 
[39] (Figures 1.1, 1.4). The second heart field will contribute cells to the arterial 
and venous poles of the heart tube when it has formed [24, 56]. At the stage of 
the cardiac crescent, at day 15 NKX2.5, GATA4, MEF2C, SRF and FOXP1 are 
expressed and the WNT, BMP and FGF pathways are active (Figure 1.4) [51-53, 
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55]. Canonical Wnt/β-catenin signalling inhibits cardiogenesis, whereas non-
canonical Wnt/Calcium and Wnt/polarity signals support cardiogenesis [39]. 
 
1.2.1.2.3 Formation of the Heart Tube and Aorta 
  
The heart tube is derived from cells from the first heart field. However the 
majority of the heart is produced from cells derived from the second heart field 
which are added to and elongate the heart tube [24, 57, 58].  
 
The lateral plate mesoderm (Figure 1.3) of the embryo splits to form the 
intraembryonic space/pericardial coelom on day 18-19 of gestation. This results 
in the formation of the somatic (dorsal or somatopleuric) mesoderm and 
splanchnic (visceral, ventral or splanchnopleuric) mesoderm on either side of the 
pericardial coelom. Cells from the splanchnic mesoderm merge centrally at the 
caudal end of the embryo where the heart will develop. The myocardial and 
endocardial cardiogenic precursors are located here. The angioblastic cords 
develop within the heart field, and these embryonic precursor cells go on to form 
the endocardial heart tubes by day 18. These two heart tubes come together in 
the midline and fuse to become the primordial heart tube. Fusion continues in a 
caudal direction and occurs as the embryo folds to close the ventral foregut.  
 
The differentiation of splanchnic mesoderm, to become cardiogenic mesoderm as 
described above, is influenced by a number of different genes, including BMP2, 
FGF8, SHH [59, 60]. Medial migration of the heart tubes is influenced by the MIL 
gene. Mesp1 and Gata4 are required for the central fusion [61-63]. Impaired 
migration of the bilateral sections of mesoderm towards each other means that 
the midline heart tube fails to form, and cardia bifida results instead. The 
enzyme Furin, is also required for ventral closure. Mouse embryos without Furin 
are embryonic lethal and cardia bifida is often observed [64, 65]. 
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The endocardial tube consists of myocardium and endocardium separated by the 
cardiac jelly, which is an extracellular matrix. The epicardium forms later on 
from the proepicardium [56]. When active blood flow is needed to sustain the 
embryo, precardiomyocytes differentiate and produce a myocardial sleeve 
around the heart tube which begins to contracting by day 21 [66], and possibly 
earlier [67].  
 
The single heart tube is modified further to produce the truncus arteriosus, 
bulbus cordis, primordial ventricle, primordial atrium and sinus venosus. (Figure 
1.6) The sinus venosus receives the blood, which then passes through the tube 
to the bulbus cordis, the aortic sac and then the first aortic arch. The sinus 
venosus includes a left and right horn, which will become the right atrium (RA), 
coronary sinus and vena cava.  
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Figure 1.6 The linear heart tube. 
The linear heart tube and subsections that will go on to form the chambers and 
other important sections of the heart. The ventricles will form from the outer 
curvature of the loop and the venous pole will form the atrial appendages [68].  
 
At the stage of the linear heart tube, at day 20, GATA4/5/6, MESP1/2, TBX5 and 
miles-apart are all expressed, and the BMP and FGF pathways are active and 
control terminal differentiation to myocardiocytes [51-53, 55]. Blood enters the 
heart tube from the cardinal, umbilical and vitelline veins and then passes 
through to the aortic arches and dorsal aorta [66].  
 
The dorsal aortae form separately in the somatic mesoderm, and are separated 
from the heart tube by the primitive foregut [66]. They attach to the heart tubes 
prior to their fusion in the midline and are pulled forwards to make the first 
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aortic arch arteries as the embryo folds. Additional arches form later which 
become the arteries supplying the upper body (e.g. internal and external 
carotids). Below the first arch, the aortae fuse to produce a single vessel to 
supply the rest of the body. 
 
1.2.1.2.4 Heart Tube Looping 
 
Heart tube looping occurs during days 22-28 [66]. Looping of the heart tube is 
the first anatomical evidence of the left-right axis in the body. Its purpose is to 
bring the sections of the heart tube into alignment, to produce the normal 
cardiac anatomy. Growth of the bulbus cordis and primitive ventricle, increases 
the length of the heart tube and causes it to curve towards the left side of the 
embryo. This is the formation of the C shaped loop. Additional pressure from the 
dorsal mesocardium and omphalomesenteric veins help create this C shape. A 
group of myocardial progenitor cells which express Isl1 add myocardium onto 
the loop [69]. The S-shaped loop then forms as a result of caudal migration of 
the ventricle section and positions the atria above the ventricles (Figures 1.1 and 
1.7).  
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Figure 1.7 Heart tube looping. 
Representation of the linear heart tube components and their final position once 
looping has finished.  
 
The left and right horns of the sinus venosus go on to form the coronary sinus 
and the sinoatrial orifice. The sinoatrial orifice has two valves which separate the 
right ventricle and sinus venosus. It is eventually sited in the right atrium and 
will allow blood from the superior and inferior vena cavae into the heart. The 
coronary sinus also forms in the right atrium and drains blood used to oxygenate 
the heart into the right atrium here. The four pulmonary veins become fused 
with the posterior wall of the left atrium to receive oxygenated blood from the 
lungs.   
 
As mentioned previously, looping of the heart tube is the first evidence of 
laterality in the embryo.  This occurs at around three weeks when the cells of 
the primitive streak have established the right/left, medial/lateral and cranio-
caudal axes. The primitive node containing cilia is part of the primitive streak 
and is found at its cranial end. Within the node are the motile cilia centrally and 
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the non-mobile mechanosensory cilia peripherally [70]. Clockwise rotation of the 
angulated cilia results in unidirectional flow towards the left [71]. Additional 
factors such as gradients of signalling molecules, movement of vesicles 
containing signalling modules, and activation of mechano or chemosensory cilia, 
may also contribute to forming a gradient across the embryo [70-72]. 
 
The leftward flow leads to induction of NODAL, one of the TGFβ subfamily, by 
calcium influx [73]. As the expression levels of NODAL increase on the left hand 
side, the levels of transcription factor PITX2 and LEFTY gene expression also 
increase [74]. The LEFTY protein competes for some of the same receptors as 
NODAL, and so acts antagonistically to block NODAL signalling on the right hand 
side [75]. CITED2 is also important in determining the axis and heart 
development. Cited2 is expressed in the lateral mesoderm and acts on Nodal, 
Lefty2/1 and Pitx2 [76]. Cited2 knockout mouse embryos are lethal with severe 
defects including cardiac laterality abnormalities [77].  
 
In addition to NODAL, other members of the TGFβ subfamily including BMP 
(BMP4, BMP2), GDF and WNT also contribute to laterality and associated 
disorders [78]. They interact with cell surface receptors which use SMAD and 
other non-SMAD pathways [78-80]. Fgf expression in the heart fields bring the 
inflow and outflow tracts together in close proximity [24]. FGF8, cSNR (inhibitor 
of Pitx2) and NKX2.5 act on the right side, and Shh, CFC, Nodal, Lefty, BMP2, 
NKX2.5, NKX2.3 and Pitx2 act on the left to establish correct laterality [77, 81-
85]. At day 30, when the heart tube has finished the looping process, NKX2.5, 
SNAI1, PITX2, HAND1/2, XIRP1, LEFTY1/2, FOXH1 and FOXP1 are all expressed, 
and NODAL and Hedgehog pathways are active having helped set the axis [55, 
58, 86].  
 
The determining factors that lead to the differentiation of atrial and ventricular 
cells are not yet fully clear. Possible contributors include COUP-TFII [87], 
localised synthesis of retinoic acid [88], and Irx4 [89]. The left and right atria 
are determined by left sided expression of Pitx2, which supresses the 
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development of pacemaker tissue in the left atrium [90, 91]. Transcription 
factors Tbx5 and Hand1 determine the left and right ventricular myocytes [92, 
93].  
 
Migration of cells from the proepicardial organ onto the heart tube begins just as 
the heart begins to undergo looping to produce the epicardium. This will produce 
the coronary vasculature. In addition, whilst looping and ballooning is taking 
place, the cells in the secondary heart field undergo EMT (epicardial to 
myocardial transformation) and contribute myocardial cells to the outflow tract.  
 
1.2.1.2.5 Formation of the Atrial Septum 
 
 
Septation of the heart occurs after cardiac looping has been completed. In the 
fourth and fifth weeks of gestation, the atrial septum begins to form [20]. Four 
components come together to form the atrial septum [94-97]: 
 The superior atrioventricular cushion from endocardium that has 
undergone epithelial to mesenchymal transition (EMT). 
 The inferior atrioventricular cushion from endocardium that has 
undergone EMT. 
 The primary atrial septum and mesenchymal cap, formed from the 
endocardium that has undergone EMT. 
 The dorsal mesenchymal protrusion. 
The primary atrial septum is formed from the second heart field. It forms at the 
top of the atria, and fuses inferiorly in the atrioventricular canal region with the 
atrioventricular cushions (Figure 1.8) [20]. This divides the cavity into the left 
and right atria.  
 
Cells from the second heart field allow growth of the atrial septum primum 
towards the atrioventricular endocardial cushions. There is a mesenchymal cap 
on the lower end of the myocardial atrial septum primum. The atrioventricular 
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endocardial cushions sit on a bed of myocardial cells which have a unique 
pattern of gene expression that is different to the standard myocardium present 
in the heart chambers. This encourages EMT and suppress the chamber 
myocardium specific gene expression. TBX2, BMP2 and NFATC2/3/4 are all 
required. EMT of these endothelial cells produces the superior and inferior 
atrioventricular cushions and the mesenchymal cap on the primary septum. The 
endocardial cells in the atrioventricular cushions express ALK2/3/5, VEGFR and 
NOTCH1 [94] and Wnt/β-catenin signalling is required for formation of the 
cushions, and their subsequent expansion and remodelling [98]. In addition, a 
non-myocardial second heart field structure called the dorsal mesenchymal 
protrusion, extends towards the cushions with the primary septum myocardial to 
divide the atria [20]. 
 
Figure 1.8 Formation of the atrial septum. 
A: The atrial septum primum (primary atrial septum) grows downwards from the 
top of the atrial cavity (blue arrow) towards the atrioventricular endocardial 
cushions (blue). Attached is the mesenchymal cap (orange) and the dorsal 
mesenchymal protrusion (green) extends downwards with it. This process closes 
the ostium primum. B. The ostium secundum forms caudally as a result of 
breakdown of the atrial septum primum. This produces the ostium secundum. C: 
An additional septum, the atrial septum secundum (secondary atrial septum) 
forms by inward folding of the roof of the atria and extends downwards to form a 
flap that covers the ostium secundum (white arrow). This is the foramen ovale 
which will close at birth, but allows unidirectional flow of blood from right to left 
atrium in the foetus (red arrow). LA: Left atrium, RA: Right atrium. 
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The two atria remain connected by an opening that allows the fetal circulation to 
bypass the lungs. The ostium (foramen) primum is the gap between the septum 
primum and atrioventricular endocardial cushions. This closes when the 
mesenchymal cap fuses anteriorly with the cushions, and posteriorly with the 
dorsal mesenchymal protrusion [20]. The more caudal ostium (foramen) 
secundum results from perforations in the septum primum. These are produced 
by apoptosis as the ostium primum closes. A more muscular septum secundum 
forms around day 33 and extends alongside the septum primum. The septum 
secundum overlaps the ostium secundum during weeks 5-6 of gestation, but 
leaves the ostium secundum open. This is the foramen ovale, which acts as a 
valve that allows flow from right to left across the atrial septum. It does not fuse 
until after birth when pulmonary pressures rise [20]. There is no need for 
circulation through the pulmonary vasculature in the foetus, as the placenta 
contributes all the required diffusion.  
 
Tbx5, Gata4 and Nkx2.5 are required to define the precursors for, and the actual 
process of atrial septum formation [99-101]. Tbx5 is thought to be crucial in 
starting the process of atrial septation and may regulate the effects of Hedgehog 
signalling on the posterior second heart field [102]. Tbx5+/- mice develop atrial 
septal defects (ASD) [103]. Mice with conditional Tbx5 haploinsufficiency in the 
second heart field develop ASDs, due to a lack of atrial septal progenitors [102]. 
Tbx5 regulates Hedgehog binding protein Gas1 and hedgehog transcription 
factor target Osr1, which are expressed in the second heart field, and ASD 
formation could be rescued in these mice by activation of hedgehog signalling 
[104]. 
 
In addition to TBX5, mutations in other transcription factors TBX20, GATA4 and 
NKX2.5 have been established as a cause of ASDs in humans [105]. Structural 
proteins are also important, including the sarcomeric genes ACTC1, MYH6 and 
MYH7 which are also associated with ASDs [106-108]. 
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Defective formation of the dorsal mesenchymal protrusion, produced from the 
second heart field can contribute to atrioventricular canal defects (AVCD) [109] 
and ostium primum ASDs [29]. Conditional deletion of BMP receptor Alk3 from 
the cardiac venous pole, can lead to impaired formation of the dorsal 
mesenchymal protrusion and an ostium primum defect in mice [110]. 
Mechanisms include reduced cell proliferation, abnormal apoptosis and impaired 
migration [29]. 
 
1.2.1.2.6 Division of the Atrioventricular Canal 
 
Division of the atrioventricular canal occurs between weeks four to five. The 
superior and inferior endocardial cushions fuse together and form the 
atrioventricular septum, which splits the atrioventricular canal into the atria and 
ventricles. Two further endocardial cushions will later become the mitral and 
tricuspid valves [20]. Endothelial cells in the endocardial cushions undergo EMT, 
as a result of regulation by TGFβ and NOTCH signalling [68]. The increasing 
numbers of mesenchymal cells this produces allows growth of the endocardial 
cushions.  
 
1.2.1.2.7 Ventricular Septation and the Atrioventricular Canal 
 
A muscular interventricular ridge develops as the medial walls of the growing 
ventricles come together in the midline. This is the muscular ventricular septum. 
It stretches from the apex of the heart, to the atrioventricular endocardial 
cushions. Increasing ventricular trabeculation may also contribute to its 
formation [111] (Figure 1.9). 
 
The interventricular foramen is a small gap that lies above the muscular septum. 
The four endocardial cushions of the atrioventricular canal (superior, inferior and 
two lateral cushions) grow and come together to form a septum which divides 
atrioventricular canal into right and left sides. This process helps close the 
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ostium primum in the atrial septum, as well as the interventricular foramen 
inferiorly by the end of 7 weeks gestation [111, 112].  
 
Figure 1.9 Development of the ventricular and outflow tract septum. 
The muscular septum grows caudally from the floor of the ventricles. The 
atrioventricular cushions and components of the forming outflow tract septum 
(green) contribute to the membranous ventricular septum.  
 
Superiorly, the aorticopulmonary septum rotates and then fuses with the 
muscular ventricular septum. This produces the membranous interventricular 
septum. There is an additional contribution to the membranous septum from the 
atrioventricular endocardial cushions [112-114].  
 
Interestingly, there is evidence from transgenic mouse lines that the left and 
right sides of the septum do not overlap as the septum forms, and there is a 
right and left myocardial identity [115]. Tbx5, Gata4, Nkx2.5, Sall4 and the 
Hand transcription factors contribute to septum formation [116, 117]. However, 
loss of these genes does not result in a completely absent interventricular 
septum, but instead results in a variety of septal defects and wider effects on the 
heart as a whole [50].  
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1.2.1.2.8 Ventricular Trabeculation 
 
Formation of the trabeculae in the ventricles is required for a number of reasons. 
The trabeculae allow increased oxygen diffusion in the heart at a stage when 
coronary circulation is not present, allowing a concurrent increase in myocardial 
mass. They are also needed for formation of the Purkinje fibres and act as an 
anchor for the atrioventricular valves [118]. The trabeculae are highly conserved 
across species [50].  
 
Animal studies suggest that myocardial projections form from the myocardium 
along the outer curve of the looping heart [119, 120]. These “sheets” are the 
beginnings of the trabeculae. They increase the surface area across which 
diffusion can occur, to facilitate gas exchange in the developing heart [118, 121, 
122]. Perfusion is taken over later by the coronary plexus, which forms between 
five to eight weeks of gestation. This will supply blood to the myocardium [118]. 
As the coronary plexus forms, the trabeculae merge with each other at their 
bases. This increases the width of the compact myocardium. The recesses 
between the trabeculae become capillaries which are continuous with the 
coronary arterial system [121].  
 
Neuregulin/ErbB, Notch, Ephrin/Eph, Hand2, YAP, DAAM1, Numb Family Proteins 
and Bmp10 are all involved in the process of trabeculation [123-130]. Failure of 
normal compaction results in Left Ventricular Non Compaction (LVNC) [121]. 
 
1.2.1.2.9 Septation of the Outflow Tract 
 
The outflow tract forms from two adjacent sections of the heart tube; the 
truncus arteriosus and the bulbus cordis sections. Septation of the outflow tract 
is required to form the separate pulmonary artery and aorta. This relies on the 
truncal and bulbar ridges and occurs during the seventh and eighth week of 
gestation [20] (Figure 1.9, Figure 1.10). 
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Figure 1.10 Septation of the cardiac outflow tract. 
Reproduced with permission from Chien-Jung Lin et al. (A) Left lateral view of an 
E10 mouse embryo. The neural crest at rhombomere 6-8 gives rise to cells 
(blue) that migrate to and colonize the distal cardiac outflow tract (OFT). (B) The 
cardiac OFT contains conal (proximal) and truncal (distal) cushions. The 
boundary between the conal and truncal cushions is marked by an outer 
curvature of the OFT (the conotruncal curvature). (C) The conotruncal cushions 
(CTCs) and intercalated cushions (ICCs) develop within the OFT. These cushions 
occupy four quadrants of the OFT (shown in cross-section). The conotruncal 
cushions fuse to septate the OFT, as shown in D. (D) Fusion of the conotruncal 
cushions forms a spiral septum, the truncal part of which divides the OFT into 
aorta and pulmonary trunk, whereas the conal part septates the OFT into left 
and right ventricular outlets (LVOT, RVOT). The aortic valves (AV) and pulmonic 
valves (PV) develop at the conotruncal junction. 
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The bulbar ridges are formed in the bulbus cordis during the fifth week gestation 
from proliferation of mesenchymal cells [20]. The bulbar ridges grow upwards to 
reach into the truncus arteriosus and join the truncal ridges, above the bulbus 
cordis. Cardiac neural crest cells begin their migration from between the first 
and third somites of the neural tube and move through the pharyngeal arches 
into the ridges to help produce the conotruncal septum. The ridges form a helix 
shaped aorticopulmonary septum. The two arteries are completely separated 
during weeks 6-8, after fusion of the ridges in a zipper like fashion from a distal 
to proximal position. The helix shape means that the pulmonary trunk wraps 
around the aorta.  
 
The bulbar ridges also grow inferiorly to fuse with the atrioventricular 
endocardial cushions and the interventricular septum. The conal endocardial 
cushions are the proximal outflow tract cushions which grow and fuse to form 
the outlet septum, as part of ventricular septation and are a necessary part of 
conotruncal septation  [20]. The bulbar ridges also go on to form part of the 
aortic and pulmonary valves with the truncal endocardial cushions. The bulbus 
cordis produces the infundibulum of the right ventricle and aortic vestibule in the 
left ventricle. 
 
Abnormalities of the outflow tract and conotruncal region can lead to double 
outlet right ventricle (DORV), transposition of the great arteries (TGA), TOF, 
VSD, common arterial trunk and interrupted aortic arch (IAA). BMP2, SHH, 
FOXC1/C2, NKX2.5, TBX1, PITX2, FGF8 and FGF10 are all required in septation 
of the outflow tracts [117]. 
 
1.2.1.2.10 Valve Formation 
 
 
EMT in the endocardial cushions is central to the process of valve formation. The 
endocardial cushions are found in the atrioventricular canal (section 1.2.1.2.6) 
and the outflow tract (section 1.2.1.2.9). EMT causes expansion of the 
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endocardial cushions in the areas that will become the valves. EMT is initiated by 
localised expression of genes that support EMT such as Bmp2, which controls 
migration of these transformed cells in the cardiac jelly [131]. The cushions and 
mesenchymal cells then remodel to produce a more elongated valve shape. 
Apoptosis of cells at the base, and proliferation at the tip extend the cushion and 
produce the recognisable shape of the valve leaflet [132].  
 
The mitral and tricuspid valves form between 5-8 weeks gestation [94]. The 
mesenchymal cells generated from the atrioventricular endocardial cushions by 
EMT, divide the canal into left and right atrioventricular canals and form the 
mitral and tricuspid valves. Later migration of the epicardial cells onto the valve 
leaflets and cushions completes the process of valve formation [20]. Both the 
mitral and tricuspid valves become attached to the heart wall by the chordae 
tendinae and papillary muscles. 
 
The semilunar valves form from two conotruncal cushions and two intercalated 
cushions [133-135]. Whilst the atrioventricular valves rely on EMT alone for their 
formation, the outflow tract valves rely on both EMT in the endocardial cushions, 
and an additional contribution from the cardiac neural crest cells [20]. The 
outflow tract forms from the second heart field and neural crest cells join to 
provide the cells for the cushions of the distal outflow tract. The proximal outflow 
tract cushions are derived from the underlying endothelium and EMT [136]. The 
neural crest cells are also required for the formation of the outflow tract septum 
and the ventricular septum (sections 1.2.1.2.7 and 1.2.1.2.9) [20, 137].  
 
Control of growth and formation of the atrioventricular canal and valves requires 
Bmp2, which induces EMT [131]. GATA4 expression in the endocardium also 
activates other factors required for EMT such as ErbB3 [138]. Notch and Bmp2 
signalling are required to control whether EMT in invasive or non-invasive [139]. 
BMP2 supports invasive EMT [131]. In addition, TGFβ is required to induce the 
expression of Snail family of transcription factors (Snai1, Snai2), which causes 
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the cells to become invasive after undergoing EMT [139]. BMP2 inhibits 
endothelial Gsk3β which stabilises Snail1 and also supports invasiveness.  In 
contrast to Bmp2, Notch1 seems to support non-invasiveness. Mouse studies 
show that active Notch1 signalling in the endocardium results in expression of 
Hey1 and Heyl, an activated mesenchyme gene pattern in the ventricles and 
non-invasive EMT [140]. Inhibition of Snail1, TGFβ2 or Notch1 reduced the BMP2 
controlled transformation and invasion.  
 
The signalling pathways supporting the formation of the outflow tract valves 
share many similarities with those that contribute to the atrioventricular valves, 
but there are also a number of differences (Figure 1.11) [50, 94]. Mouse models 
suggest that VEGF signalling through VEGFR1 receptors is required for EMT in 
the outflow tract, but not the atrioventricular canal [136]. VEGFR1 is down 
regulated after EMT has occurred. VEGF then acts via VEGFR2 receptors in the 
atrioventricular cushions to facilitate remodelling into their final valve leaflet 
shape. VEGF expression in myocardium where the valves form, is inhibited by 
the actions of calcineurin/NFAT signalling in mice [141].  
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Figure 1.11 Genetic controls of septation. 
Reproduced with permission from Lin et al [94]. Many of the same genetic 
pathways play a role in both the septation, and formation of valves, in the 
atrioventricular canal and the outflow tract. However, the process is also 
presided over by multiple other genes and networks. 
 
The processes that regulate elongation and maturation of the valves are less 
well understood, in comparison to their formation. Calcineurin and Nfat signalling 
are required for these later stages in the mouse and zebrafish [141]. Sox9 
knockout mouse models are embryonic lethal with hypoplastic endocardial 
cushions and abnormal extracellular matrix suggesting it is required for normal 
valve formation [142]. Conditional deletion of Sox9 causes thickened heart valve 
leaflets and calcium deposits, which are common features of valve disease. This 
suggests that Sox9 is required for early and later processes of valve 
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development. Scx is also expressed form E15.5 onwards, and postnatally in 
remodelling heart valves. Knockout mice develop thickened heart valves [143]. 
 
1.2.1.2.11 The Aorta and Pulmonary Artery 
 
Cells from the primary heart field form cardiac myoblasts which produce the 
endocardial tubes[144]. Initially bilateral ventral and dorsal aortae form, which 
are connected through the first aortic arch[145] (Figure 1.12). The two ventral 
aortae coalesce to form the aortic sac. The aortic sac is superior to the truncus 
arteriosus. It splits to form two horns, the right becomes the brachiocephalic 
artery and the left forms the part of the aorta proximal to the brachiocephalic 
trunk with rest of the aortic sac. The aortic sac also gives rise to the aortic 
arches [146]. Six pairs are produced in total, but they form and regress at 
different times. The two dorsal aortae remain separate at this point and receive 
the aortic arches on each side, from the aortic sac in the midline. 
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Figure 1.12 Schematic drawing of the development of the aortic arch 
and its branches. 
Reproduced with permission from Kau et al (Thieme) [145]. 1, first aortic arch; 
2, second aortic arch; 3, third aortic arch; 4, fourth aortic arch; 5, fifth aortic 
arch; 6, sixth aortic arch; aa, aortic arch; va, ventral aorta; da, dorsal aorta; cc, 
common carotid artery; ic. Internal carotid artery; ec, external carotid artery; 
rs, right subclavian artery; av, vertebral artery; pt, pulmonary trunk; rp, right 
pulmonary artery; lp, left pulmonary artery; db, ductus arteriosus botalli.  
 
The pharyngeal arches start to form from day 28. The aortic arches are the 
vasculature of the pharyngeal arches, and are paired with a cranial nerve. There 
are five paired arches; I, II, III, IV and VI (there is no fifth arch) [145]. These 
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aortic arches form segments of the aortic arch, its branches and the pulmonary 
arteries. 
 
The aortic arch itself forms from the aortic sac, the left forth aortic arch and the 
dorsal aorta [146]. The most proximal branch of the aortic arch, is the 
brachiocephalic trunk on the right hand side. As described already, this is formed 
from the right horn of the aortic sac. It has two branches; the right subclavian 
artery (SCL) which is formed from the 4th right aortic arch and dorsal aorta 
[147], and the right common carotid artery (CCA) formed from the proximal 
segment of the 3rd aortic arch [145]. The second branch of the aortic arch is the 
left CCA, which is also formed from the 3rd aortic arch [145]. The final branch of 
the aortic arch is the left SCL artery, which is formed from the 7th intersegmental 
artery [147]. The descending aorta forms from the dorsal aorta [148]. 
 
The pulmonary trunk and right and left pulmonary arteries are derived from the 
6th aortic arch [147]. The also produces the ductus arteriosus (DA). 
 
1.2.1.2.12 The Coronary Arterial System 
 
At 42 days gestation, the truncus arteriosus is divided into the aorta and 
pulmonary artery. Surrounding the aorta is a capillary ring. CXCL12 and CXCR4 
expression encourages expansion of this ring to form a vascular plexus [149]. As 
the workload of the heart increases, relative hypoxia in the myocardium induces 
HIF-1α and HIF-1β [150] and subsequent expression of angiogenic genes 
including VEGF, FGF2 and PDGF [151-153]. VEGF-A, VEGF-B, and angiopoietin-2 
are also produced in the myocardium in response to Shh signals [154]. These 
gene pathways facilitate formation of the vascular plexus. 
 
Following on from formation of the vascular plexus, apoptosis in the wall of the 
aorta allows endothelial cells from this plexus to create a connection between 
the capillaries and the aorta [155-157] (Figure 1.13). These are the beginnings 
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of the coronary ostia, sited above the right and left aortic cusps. This process 
requires cardiomyocytes and neural crest cells [149]. Blood can now flow into 
the vascular plexus from the aorta. The flow and associated sheer stress, 
induces differentiation and migration of vascular smooth muscles cells and their 
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Figure 1.13 Formation of the coronary ostia. 
Reproduced with permission from Tomanek et al [149]. Fig. 1. A. Formation of 
the coronary ostia and stems is initiated when the capillary ring that encircles 
the aortic root expands and attaches as a vascular plexus (in response to 
CXCL12 + CXCR4). The sites of ostial formation are adjacent to an epicardial 
cusp (Epi-cus), a thickened portion of the subepicardium, which contains 
epicardial derived cells (EPDC) that are rich in VEGF 
receptors and erythroblasts (RBCs). Cardiomyocytes guide the attachment of the 
vascular plexus. FGFs from the myocardium promote Sonic hedgehog (Shh) 
signalling, which together with hypoxia inducible factor-1 (Hif-1) 
stimulates VEGFs and angiopoietin (Ang) 2, thus facilitating angiogenesis of the 
vascular plexus. B. Myocardial-derived cardiomyocytes and neural crest 
cells facilitate the entry of the vascular plexus into an opening in the aortic wall, 
created by apoptosis. An endothelial ingrowth demarcates the pathway of the 
forming ostium. C. The onset of coronary flow and shear stress are key to the 
remodelling of the vascular plexus. Differentiation, migration, and attachment of 
VSMCs are influenced by 1) PDGF-BB activation in endothelial cells and the 
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ligand's interaction with PDGFR-β in VSMC progenitors, and 2) the influence of 
VEGFs and FGFs.  
Vascular smooth muscle cell recruitment requires PDGF-BB, PDGFR-β, VEGFs 
and FGFs [149, 159, 160] (Figure 1.10). The vascular smooth muscle cell 
precursors migrate with the proepicardium before differentiating [35]. Neural 
crest cells also facilitate recruitment of vascular smooth muscle cells [161], as 
well as being required to guide the entry of endocardial cells through the aortic 
wall described above [162]. The Notch pathway is also required for normal 
coronary artery formation [163-168]. 
 
1.2.1.2.13 The Conduction System 
 
A functioning heart is required early on in human embryogenesis to provide an 
adequate supply of oxygen and nutrients to the developing embryo. This 
requires not only correct anatomical development, but also a working and 
coordinated conduction system. Myocardial cells specialise to become the cells of 
the conduction system. The myocardial cells of the primitive heart tube 
spontaneously depolarise allowing conduction of an electrical impulse [169], but 
the ability of the cells to contract at this stage is limited due to their immaturity. 
The impulse is generated in the venous part of the heart tube initially, and 
remains at this site throughout elongation of the tube [170]. 
 
As the heart tube loops and forms chambers, a number of gene programmes 
required for conduction are expressed to create myocardium that has high 
contractility and fast conduction properties [171]. In other sections of 
myocardium, this “working pattern” is supressed, so the cells maintain lower 
rates of proliferation, slow conduction and automaticity [169]. This nodal 
phenotype is retained in the sinus venosus, atrioventricular canal and the inner 
curvature of the tube. The slower conduction in the atrioventricular canal means 
that the myocytes are slow to relax, effectively fulfilling the task of the valves 
and preventing retrograde flow at a point before they are formed.  
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Myocardium from the second heart field is incorporated into the posterior wall of 
the atria [169] and the sinoatrial node (SAN) myocardium forms at the base of 
the cardinal veins, where the right atrium and right sinus horn meet [172]. SAN 
precursor cells form at the same time as the sinus venosus, and have a distinct 
genetic lineage from those cells that form the atria [173]. As development of the 
heart progresses, the SAN takes over the pacemaker activity from the sinus 
venosus pacemaker cells, which become atrialised [169, 174]. 
 
Tbx3 facilitates the formation of conductive tissue by promoting the 
development of ion channels needed for pacemaker activity and spontaneous 
depolarisation [173, 175, 176]. It also represses the normal “working 
myocardium” cell patterning. Its expression contributes to formation of the SAN, 
and the atrioventricular node (AVN) which is described next.  
 
Cells from the left and right posterior second heart field produce the anterior and 
posterior AVN [27].  The atrioventricular canal contains most of the cells 
required to form the AVN [177, 178]. Markers of the canal include Bmp2, Tbx2 
and Tbx3 [175, 179]. In addition to suppression of the “working myocardium” 
gene expression patterns which are associated with rapid conducting cells, the 
slower conduction in the atrioventricular canal is maintained by expansion of the 
cardiac jelly during valve formation, which acts as a physical barrier to 
conduction [180]. The annulus fibrosis then develops from the epicardial 
mesenchyme that reaches the atrioventricular cushions and passes between the 
atrioventricular canals and the ventricles [181-183]. This means that there is no 
myocardial connection between the atria and ventricles, with the exception of 
the atrioventricular bundle attached to the AVN [169]. This ensures that the AVN 
is the singular gateway for impulses to pass through and prevent lethal and re-
entry arrhythmias [177, 184]. Tbx2, Tbx3 and Bmp2, Gata4, Gata6 and Notch 
signalling are essential in formation of the AVN [131, 179, 184-189].  
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Electrical impulses are conducted through the ventricles by the Bundle of His and 
the Purkinje fibres, which are both derived from myocardium [190, 191]. Cells 
expressing G1N2 and Tbx3 within the atrioventricular canal forge a path into the 
ventricular septum and form the interventricular ring, which in turn forms the 
Bundle of His [175, 192]. Subendocardial myocytes in the septal trabeculae form 
the bundle branches and Purkinje fibres [193-195]. The expression of another 
transcription factor Id2 is controlled by upstream Tbx5 and Nkx2.5, and is 
required for formation of the His-Purkinje system [196]. Id2 deficient mice show 
both abnormalities in the structure and function of the conduction system, and 
compound haploinsufficiency with Tbx5 or Nkx2.5 resulted in lack of specification 
of the ventricular conduction system in the embryo. 
 
The ventricular conduction system is designed to enable fast conduction and 
expresses gap junction forming genes Cx40 and Scn5a to facilitate this. This 
gene expression sets the cells apart from both the normal working myocardium, 
and the nodal tissue which has slower conduction properties [169]. Irx3 
represses Connexin 43 (Gja1) and activates Connexin 40 transcription (Gja5) 
[195]. The final step required is repolarisation which is dependent on Irx5 [197]. 
Irx5 maintains a repolarisation gradient by supressing the expression of Kv4.2 
potassium channel genes, by recruiting the cardiac transcription repressor mBop 
to repress Kv4.2. 
 
1.2.1.2.14 Fetal Circulation 
 
In utero, the fetal heart is required to deliver oxygen and nutrients from 4 weeks 
gestation, when passive diffusion becomes insufficient [198, 199]. By week 10, 
the placenta has become the dominant organ for gas exchange, as opposed to 
the passive gas exchange that has occurred through the yolk sac and placenta 
prior to this [199]. The workload of the heart gradually increases throughout 
fetal life, and there is a sudden step up in requirements after birth [21]. This is 
due to the change from the fetal, to neonatal and then postnatal circulation 
(Figure 1.14).   
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The fetal cardiovascular system is designed to funnel oxygenated blood from the 
placenta directly to the brain and organs, bypassing the lungs. There are four 
shunts in place to do this; the ductus venosus, the ductus arteriosus, the 
foramen ovale and the placenta. In addition to the anatomical adaptations, there 
are additional biochemical factors which support this, such as prostaglandin and 
endothelin-1 which increase pulmonary vascular resistance in the fetal 
circulation [21, 200-202]. The reduction in pulmonary vascular pressure after 
birth and release of bradykinin, means that the blood begins to flow through the 
pulmonary circulation, and the ductus begins to close immediately [202-204]. 
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Figure 1.14 The fetal circulation. 
Reproduced with permission Wiley 2006 [205]. Diagram illustrating the serial 
partitioning of nutrient‐ and oxygen‐rich blood reaching the fetus via the 
umbilical vein. The first partition at the level of the ductus venosus distributes 
the majority of umbilical venous blood to the liver. Umbilical venous blood that 
continues towards the heart is partitioned towards the left ventricle (LV) at the 
foramen ovale. This blood supplies the brain and upper part of the body via the 
brachiocephalic circulation and the myocardium via the coronary circulation. A 
minor proportion of blood from the right ventricle (RV) supplies the lungs, while 
the remainder continues through the ductus arteriosus (DA) towards the aorta. 
At the aortic isthmus, bloodstreams directed towards the descending aorta are 
partitioned based on the relationship of blood‐flow resistance in the 
brachiocephalic and subdiaphragmatic circulations. While net forward flow is 
maintained under physiological conditions, diastolic flow reversal occurs when 
brachiocephalic resistance falls and/or subdiaphragmatic (placental) resistance 
rises. Finally, the major proportion of descending aortic blood is partitioned at 
the umbilical arteries, to return to the placenta for respiratory and nutrient 
exchange. 
Identifying Novel Genes that cause Congenital Heart Disease  61 
 
1.3 Pathophysiology of CHD 
 
Understanding the process of formation of the heart, allows us to determine the 
mechanisms by which different types of CHD develop. Defects might arise as a 
result of a structure failing to form, or abnormal apoptosis. This is the case in 
secundum ASDs, where the defect lies within the fossa ovalis. The flap may not 
be sufficiently sized to cover the fossa, or there may be perforations resulting 
from either failure of formation of the floor of the fossa from the primary atrial 
septum, or failure of normal apoptosis [206]. 
 
An ostium primum ASD is a form of atrioventricular defect, rather than atrial 
septal defect. There is an AVSD, but blood is only shunted between the atria as 
the atrioventricular valve leaflets fuse with the crest of the muscular ventricular 
septum, to divide the atria from the ventricles. This and other atrioventricular 
canal defects are a result of failure of normal growth of the vestibular spine 
(mesenchymal cap) [206, 207]. The endocardial cushions may fuse normally. 
Depending on whether the bridging leaflets are fused to the atrial or ventricular 
septum, or neither (floating) determines where shunting can occur.  
 
A key part of normal ventricular septation is transfer of the aorta from over the 
RV to over the LV. This reduces the size of the interventricular foramen by 
bringing the fused outflow tract cushions and the top of the muscular ventricular 
septum into closer proximity. The foramen will then be closed by the 
atrioventricular cushions. Failure of this process will result in a VSD [206]. A 
muscular VSD results from a different mechanism, which is failure of 
trabeculations to come together. This leaves a pathway in the septum between 
the trabeculae, through which blood can flow. 
 
TOF and DORV can be considered part of a spectrum. Abnormalities which 
develop whilst both arterial trunks remain over the RV, when the intermediate 
cushions have already created a separate aorta and pulmonary artery, will result 
Identifying Novel Genes that cause Congenital Heart Disease  62 
 
in DORV [206]. DORV can also result from abnormal development of the 
atrioventricular region of the heart. Abnormal alignment of the tricuspid orifice 
so that it is aligned with the left part of the outflow tract septum has also been 
demonstrated [208]. The proximal cushions should go on to form the 
subpulmonary infundibulum. If they obstruct the pulmonary trunk outlet, TOF 
results. Hypertrophy of the RV then occurs as a consequence of the outflow tract 
obstruction. 
 
Defects can result from a variety of mechanisms which interact. For example, an 
initial event may be precipitated by an environmental change or genetic variant, 
and then be compounded by altered haemodynamics within the heart. 
Hypoplastic left heart can be a consequence of reduced blood flow secondary to 
aortic and mitral valve atresia or stenosis. Hypoplasia of the RV can also occur in 
the setting of an atretic pulmonary valve. The size of the ventricle will vary, 
depending on the point at which blood flow fell too low to allow normal 
development of the ventricle. 
 
Normal blood flow and the ability of cells to respond to changes in flow, are 
required for normal cardiovascular development [209]. Transcription factors 
such as Klf2a show variable expression levels in different flow conditions, and 
control endocardial cell shape and size, and interactions with the myocardial 
cells, to ensure correct chamber formation in the heart [210, 211]. Cilia are also 
important for facilitating response to shear stress and are found on endocardial 
cells. Stimulation of cilia is required to initiate ventricular trabeculation for 
example [212]. Cilia are also important for establishing the left right axis of the 
heart and are implicated in heterotaxy defects [71, 213]. 
 
1.4 The Mouse as a model for CHD 
 
I planned to use mouse models to evaluate the impact of knockout of novel CHD 
genes. The mouse is an excellent cardiovascular model, as its heart closely 
Identifying Novel Genes that cause Congenital Heart Disease  63 
 
resembles the human heart in its embryology and genetics. A vast multitude of 
genetically engineered lines have been produced, along with mouse atlases 
describing their anatomy and standard phenotyping procedures 
(www.mousephenotype.org) [214]. The mouse heart follows a similar course to 
that already described above, with initial formation of a single heart tube which 
loops and expands to form the chambers of the heart. This is described in more 
detail in appendix A. The mouse heart may begin to beat as early as E7.5 [215].   
 
A large proportion of knockout mouse lines are early embryonic lethal, and this 
often results from defective cardiovascular development [216]. This is not 
surprising given that many of the other organ systems are not required prior to 
birth when the placenta is functioning, but the heart is required to sustain the 
embryo. Failure to form the linear heart tube, establish circulation or adequate 
cardiac function can cause death pre E11.0 [217]. Abnormal looping and failure 
of formation of the correct anatomy of the chambers is less likely to cause 
lethality, and can instead result in a different spectrum of cardiac abnormalities 
in the surviving embryo. Death from E11.0 onwards results from a different 
spectrum of abnormalities including persistent truncus arteriosus (PTA), failure 
to separate the atria and ventricles, or failure of the conduction system [216]. 
Thus, lethality itself and the timing of lethality are both important outcomes to 
consider in assessing a mouse model. 
 
1.4.1 Comparison of embryogenesis of the mouse and human heart 
 
The embryology and anatomical structure of both the mouse and human foetus 
follow a similar course [218]. Atrial and ventricular septation and the structures 
present at the heart tube stage are similar in both species. The human heart is 
more pyramidal in shape as it sits on the diaphragm as opposed to the more 
ellipse shaped mouse heart. The atrial appendages are also more prominent in 
the mouse, and are relatively small in the human. Other important differences 
include a single superior vena cava (SVC) in humans and bilateral SVCs in mice 
[218]. In the mouse, the left SVC remains and drains into the atrium via the 
Identifying Novel Genes that cause Congenital Heart Disease  64 
 
coronary sinus, whereas humans have the brachiocephalic vein, which drains 
into the right sided SVC. There are 2-4 pulmonary vein orifices in the human, 
compared with one in the mouse.  
 
There is no delamination of the tricuspid valve (TV) in the mouse in utero, and 
no moderator band [218]. The septal leaflet of the TV may remain attached to 
the septum in the newborn mouse. In both the mouse and human, the tricuspid 
valve is positioned inferior to the mitral valve, and both have chordae in the 
right ventricle between the tricuspid valve and the ventricular septum. Both mice 
and humans have two papillary muscles in the left ventricle. 
 
The atrioventricular septum is thinner in humans than the mouse, and fibrous as 
opposed to the muscular mouse septum [218]. Different ventricular 
trabeculations allow identification of the left and right ventricles in the human. 
The left ventricle has smooth trabeculations compared with the coarser 
trabeculations in the right ventricle. In the mouse the difference is less 
pronounced, but some difference can be seen on the septal surfaces of the 
ventricles, where it is smoother on the right at E14.5 [219]. More subtle 
differences are present, but not apparent without specific detailed quantitative 
analysis, and it is difficult to tell the ventricles apart based on trabeculation 
patterns alone in mice. 
 
Another significant difference between the human and mouse, is the fraction of 
time in utero during which cardiogenesis occurs. The gestational period in the 
mouse is 20 days and cardiogenesis is mainly complete at E15.5, which is 
drastically different to the human foetus which has an extended period between 
the heart being completely formed and birth. This may produce a different 
spectrum of CHD in the human compared to the mouse as there is far more 
potential for morphological changes due to haemodynamic stress in the human 
[218]. Specific examples of CHD that are potentially time dependant include 
HLHS, PS and Ebstein anomaly, which were not seen in 10 000 ENU mutagenic 
mice [220]. HLHS is a prime example of a time dependant form of CHD, which is 
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not present throughout embryogenesis [221]. It can occur as a result of LV 
outflow obstruction, or obstruction of inflow into the LV. Most commonly it 
results from aortic valve defects, which leads to higher afterload in the LV and 
subsequent dilatation. As a result the LV might actually appear normal in size 
initially. Later, reduced blood flow through the LV results in failure of the 
chamber to enlarge and further negative feedback on growth. A similar process 
occurs with MV abnormalities causing reduced preload. 
 
Despite the differences, the mouse is an ideal model to study CHD given the 
anatomical and genetic similarities, possibility for manipulation with CRISPR and 
the extensive phenotype data that has already been collected in knockout mice 
[214].  
 
1.5 Imaging the Mouse Heart 
 
Traditional methods used to phenotype the mouse heart include paraffin 
embedding and sectioning. Newer methods include ultrasound, computed 
tomography (CT), optical projection tomography (OPT), magnetic resonance 
imaging (MRI), episcopic fluorescence image capture (EFIC) and high resolution 
episcopic microscopy (HREM). I had planned to use HREM to determine the 
cardiac anatomy of animal models used in this thesis.  
 
HREM provides exceptionally high resolution imaging of tissue and has the added 
benefit of allowing 3D image reconstruction to study anatomy [222, 223]. Tissue 
specimens are fixed in 4% PBS-buffered formaldehyde, then dehydrated and 
embedded in a JB4 resin. The blocks are then mounted on a microtome for 
sectioning and an image is taken after each slice is removed. The sections can 
be 0.5 to 10μm thick. The digital images captured can then be used to create a 
3D model of the structure. This method also allows study of cell morphology and 
gene expression, in addition to anatomy.  
 
Identifying Novel Genes that cause Congenital Heart Disease  66 
 
HREM has been used extensively to study cardiovascular development in a 
number of animal models including the mouse. The development of the wild type 
(WT) C57BL6 mouse has been characterised using HREM, which provides an 
important control aspect for any other mouse models studied[224]. HREM 
analysis forms an important part of the pipeline in the DMDD Study (Deciphering 
the Mechanisms of Developmental Disorders https://dmdd.org.uk/) and is used 
to image knock out mice.  
 
1.6 Aetiology of CHD 
 
CHD usually occurs as a “one off” in a family, and pedigrees exhibiting Mendelian 
inheritance are rare. Initial research focussed on these rare families to identify 
genes that cause CHD [225]. Despite the apparent scarcity of families with 
monogenic CHD, first degree family members have an increased risk of CHD, 
and this along with concordance in monozygotic twins supports a genetic 
component in the aetiology of CHD [226]. The overall sibling recurrence risk is 
3.1% [227], but more severe types of CHD may have higher rates of recurrence 
(including heterotaxy, right and left ventricular outflow tract obstruction 
(RVOTO/LVOTO)) [3, 228-230]. Ethnic origin does appear to contribute to CHD 
risk also supporting a genetic contribution, although there is often a complex 
relationship with socioeconomic factors which can make this relationship difficult 
to interpret [231, 232].  
 
Recurrence risk in children is twice as high when CHD is present in the mother, 
compared to the father [233]. In addition, around 50% of affected siblings will 
be affected with a different type of CHD confirming variable expressivity [234]. 
Even if the siblings are not affected with CHD, they have a higher chance of 
other congenital abnormalities [227]. It is therefore likely that CHD is oligo or 
polygenic [12, 235]. How exactly each type of CHD occurs and why penetrance 
and expressivity are variable is not known but there are likely to be additional 
maternal and environmental factors involved [236-238]. 
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Despite advances is our knowledge of genes that cause CHD, it can be difficult to 
elucidate the cause of an individual’s CHD. De novo and inherited mutations in 
single genes [12, 14, 16], more complex structural variation [17, 18, 239] and 
epigenetic factors [240] all contribute. At the moment we can identify a genetic 
cause in up to 40% of people with CHD [241-244]; this is much more likely in 
those who have CHD in combination with other medical issues including 
neurodevelopmental disability (NDD) and specific types of [242, 243].  
 
Studies have already begun to look at the potential gains of genetic evaluation in 
certain clinical populations including neurodevelopmental clinics and cardiology 
units [245, 246].  Knowledge of the aetiology of CHD can help guide treatment 
and investigations, provide information about prognosis and allow appropriate 
genetic counselling and advice about recurrence risk. For this reason it is 
beneficial to expand our knowledge of the genetic causes of CHD, which is the 
focus of this thesis. 
 
 1.6.1 Genetic Causes of CHD 
 
Genetic causes of CHD include chromosome aneuploidy, large chromosome 
deletions and duplications, smaller copy number variations and single nucleotide 
variants. Other mechanisms include epigenetic factors and somatic mutations. 
Examples are shown below in table 1.1. The majority of these identified genetic 
causes result in syndromic CHD (S-CHD), that is CHD in combination with other 
congenital abnormalities or neurodevelopmental disability (NDD). This is 
reflected in the higher chance of identifying a genetic cause in individuals with S-
CHD, compared to non-syndromic CHD (NS-CHD, CHD in isolation).  
 
This thesis centres on single gene causes of CHD. Transcription factors and 
genes involved in chromatin modification are important examples of monogenic 
causes of CHD. Many of these genes that cause CHD, are required for normal 
cardiac development in the embryo. Other pathways that have proved important 
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in development of the cardiovascular system, require more evidence of their role 
in causing CHD in humans, such as the SHH pathway [247-249] (Table 1.1). 
 
A genetic variant that causes CHD can be detected in around 15-25% of 
individuals with the use of karyotype, FISH (fluorescent in situ hybridisation) and 
array-CGH (array-comparative genomic hybridisation) [246, 250-253]. 
Nowadays, gene panels and whole exome sequencing (WES) are used in 
addition, and WES may identify a diagnosis in up to 28% of individuals referred 
for clinical testing with CHD and a positive family history [254]. 
     
 
Chromosomal and Structural causes of CHD 
 
Abnormality Phenotype 
Trisomy 21 40-50% have CHD 
ASD, VSD, AVSD, PDA [255-257]  
Trisomy 18 90% have CHD 
ASD, VSD, PDA, AVSD, valvular dysplasia, TOF, DORV 
[258-261]  
  
Trisomy 13 55 - 80% have CHD  





35% have CHD, 22% develop aortic dilatation [265], 
BAV, CoA, PAPVD, HLHS, [266, 267]  
  
 






60-80% have CHD, accounts for 18% of ToF.  
ToF, IAA (type B), VSD, TA, ASD, BAV, CoA, right sided 
aortic arch. The phenotype is variable and include NS-




50-85% have CHD 
Supravalvular AS, supravalvular PS, peripheral 
pulmonary stenosis due to haploinsufficiency of ELN 




<45% have CHD  
ASD, VSD, MVP, PS, PA [274] 
Wolf Hirschhorn 
Syndrome 
50-65% have CHD 
ASD, VSD, PDA, PS [275] 




and duplication  
30% of each CNV have CHD.  
PDA, ASD, VSD, TOF, TA, PS. TGA 26066539 
Candidate genes include deletion of PLXNA2 and 
duplication of GJA5 [276, 277] 
1p36 deletion 70% have CHD 
ASD, VSD, PDA, BAV, TOF, CoA [278] 
1q41q42 deletion 50% have CHD 
BAV, ASD, TGA, VSD [279]  
8p23.1 deletion 50-75% have CHD 
AVSD, ASD, VSD, PS, TOF [280] 
CHD may result from haploinsufficiency of GATA4 
 




Mutations are associated with AD ASD, HLHS, EA, TOF, 
VSD and conduction disorders leading to AV block [281-
283]  
  
Identification of NKX2.5 mutations is important as 
individuals have a higher risk of conduction disease and 
sudden cardiac death [284]. NKX2.5 interacts with 
TBX5 [99, 282] and mouse models suggest CHD results 
from reduced NKX2.5 nuclear import, downregulated 
BMP and Notch signaling and dysregulation of genes 









75% have CHD  
AD VSD, ASD, AVSD, hypoplastic LV, conduction defects 
leading to AV block [99, 286-290]  
Mainly truncating variants, but gain of function 
mutations have also been reported [291-295]  
GATA4 AD ASD, AVSD, PS, TOF VSD [296, 297] 
Non-coding variants in GATA4 have been associated 
with BAV [298] 
Gata4 signalling is required by Hh-responsive 
progenitor cells in the second heart field, which is 
required for development of the outflow tract [299].   
GATA5 AD ASD, BAV, DORV, TOF, VSD [300, 301]  
  
GATA6 
CHD and pancreatic 
agenesis 
AD NS-CHD TA, TOF and ASD and S-CHD with 
pancreatic agenesis [302-304] 
  
TBX1 AD TOF, PA, ASD, aorticopulmonary collateral artery, 
IAA, isolated left pulmonary artery, VSD [305, 306] 
TBX20 ASD, VSD, MS, DCM [307, 308]  
 
HAND1 AD Single Ventricle, VSD [309, 310] 
Identifying Novel Genes that cause Congenital Heart Disease  70 
 
  
HAND2 AD PS, TOF, VSD [311-313]  
  
CITED2 AS, ASD, PS, SIT, dextocardia, TGA, TOF, RVOTO, 
TAPVR, VSD 
[52, 94, 314] 
  
 
Single Gene Disorders: Structural Proteins 
 
MYH6 AD mutations cause ASD, DCM [108, 315]. AR missense 
mutations cause HLHS [316] 
  
MYH7 AD HCM and DCM including LVNC, EA [317] 
  
ACTC1 AD ASD, HCM, DCM, LVNC [106] 
 
MYBPC3 AD ASD, MR, PDA, VSD [318, 319] 
  
 
Single Gene Disorders: Chromatin Modifiers 
 
KMT2D (MLL2)  AD Kabuki Syndrome [320] VSD, ASD, CoA [321] 
H3K4 methyltransferase. 
KDM6A  XLD Kabuki Syndrome [320] CoA, ASD (AVSD, PS, 
hypoplastic RV are rare) [320]. Removes H3K27 
methylation [322]. 
CHD7  AD CHARGE syndrome, 80% have CHD including ToF, 
ASD, VSD, Conotruncal defects, DORV, PS [323, 324]. 
Chromatin remodeller. 
NSD1 Sotos Syndrome, ASD, VSD [325, 326] 
  
CASZ1  A zinc finger transcription factor that interacts with 
histones and is associated with AD VSD [327] 
  
SMYD4 Interacts with HDAC1 and plays a role in histone 
acetylation, linked with DORV and TOF [328] 
  
 
Single Gene Disorders: Specific Pathways 
 
RAS MAPK Signalling 
Pathway  
Noonan Syndrome 






PTPN11, KRAS, SOS1, SOS2, RAF1, BRAF, MEK1, CBL, 
NRAS, NF1, MAP2K1, MAP2K2, RIT1, SHOC2 (mainly 
gain of function mutations)  [329-337] 
 
AD Noonan Syndrome 80-90% have CHD, 50-60% have 
HCM PS, ASD, VSD, AVSD, PDA, HCM [336, 338, 339] 
CFC – 75% have CHD [339, 340]  





NOTCH signalling is involved in controlling neural crest 
cell proliferation/differentiation, AV and left/right 
patterning [341], cell fate, formation of the heart 
chambers, and valves through EMT of the cushion 
progenitor cells [341, 342].  
 
NOTCH1 mutations cause AD CHD; CoA, VSD, HLHS, 
BAV, TOF and may account for 4.5% of NS-TOF [19, 
343, 344]. 
 
NOTCH1 mutations are mainly reported in CHD affecting 
the left side of the heart and mutations in other Notch 
pathways genes also cause LVOT defects (ARHGAP31, 
MAML1, SMARCA4, JARID2) [344, 345].  
 
AD Alagille Syndrome. Caused by LoF mutations and 
deletions of NOTCH ligand JAG1 (90%) and NOTCH2 (1-
2%) [346-348] 90% have CHD. TOF, peripheral PS 
[348-352]  
 
Other genes in this pathway associated with CHD in 
humans include ADAM17 [353], HES1 [354-356] and 
HEY2 [94, 355, 357]   
Wnt/β-Catenin 
Signalling 
This pathway regulates proliferation of SHF cells during 
cardiogenesis [358]. Non-canonical Wnt signalling is 
also involved in the planar cell polarity process which 
regulates chamber remodelling and ciliagenesis [359-
361]. Mutations in Wnt pathway genes are enriched in 
BAV and other types of CHD [12, 14]. Much of the 
evidence comes from mouse models [362-364]. Other 
genes in this pathway associated with CHD in humans 
include APC [365] , BCL9 [16], DCHS1 [366] and EDN1 
[367]. 
 
Bmp Signalling Bmp is required for differentiation of the cardiac 
mesoderm [358]. It regulates Nkx2.5 and Mef2c [123]. 
Common variants in BMP4 are associated with CHD 
[368]. Other genes known to alter BMP signalling are 
also associated with CHD (SMAD6 [369] , SMAD2 [370] 
and GALNT1 [371]). 
   
NODAL Signalling 
 
NODAL is a member of the TGF-β Cytokine Superfamily. 
This includes BMP-2, TGF-β2, TGF-β3. Nodal signalling 
is required to regulate left right patterning in the 
embryo. Mutations in NODAL are associated with AD 
heterotaxy and NS-CHD (TGA, DORV, TOF, VSD) [372, 
373].  
CNVs including NODAL have also been identified in 
individuals with CHD [374]. 
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Mutations in upstream genes such as ZIC3, and 
downstream targets of NODAL including GDF1, CFC1, 
TDGF1, FOXH1, SMAD and PITX2 have been identified 
in individuals with CHD [375, 376]. 
 
VEGF Signalling VEGF is required for the formation of the 
atrioventricular valves [377]. Damaging variants in 
VEGF related genes FLT4, KDR, VEGFA, FGD5 and 
others have been identified in individuals with TOF 
[378], and might contribute to CHD in individuals with 
trisomy 21 [377]. 
 
Table 1.1 Overview of genetic causes of CHD. 
An overview of some of the important genes and pathways involved in CHD. 
Structural genes are often also associated with cardiomyopathy. Additional 
structural genes not included in the table include DCHS1, TTN, ELN and MYH11 
[379]. A more comprehensive review of transcription factors and pathways 
involved in CHD can be found in other dedicated reviews [10, 380]. AD: 
autosomal dominant AS: aortic stenosis, ASD: atrial septal defect, AV: 
atrioventricular, AVSD: atrioventricular septal defect BAV: Bicuspid aortic valve, 
DCM: Dilated Cardiomyopathy, Del: deletion, DORV: Double outlet right 
ventricle, EA: Ebstein anomaly, HCM: hypertrophic cardiomyopathy, HLHS: 
Hypoplastic left heart syndrome, IAA: Interrupted aortic arch, LoF: loss of 
function, LV: Left ventricle, LVNC: Left ventricular non-compaction, LVOT: Left 
ventricular outflow tract, MS: mitral stenosis, MVP: mitral valve prolapse, PA: 
Pulmonary atresia, PAPVD: Partial anomalous pulmonary venous drainage, PDA: 
Patent ductus arteriosus, PS: Pulmonary stenosis, RV: right ventricle, RVOTO: 
Right ventricular outflow tract obstruction, SIT: Situs inversus totalis, TA: 
tricuspid atresia, TAPVR: Total anomalous pulmonary venous return, TGA: 
Transposition of the great arteries, TOF: Tetralogy of Fallot, VSD: ventricular 
septal defect XLD: X linked dominant.  
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1.6.1.1 Chromosomal Aneuploidy 
 
Around 8 -13% of CHD is thought to result from chromosomal abnormalities 
[379, 381, 382]. Trisomy 13, 18 and 21 commonly result in CHD (Table 1.1). 
Both trisomy 13 and trisomy 18 have a poor prognosis, but can survive to term 
and women are offered prenatal testing to quantify the risk to their baby. 
Trisomy 21 is a far more variable condition and does not always include CHD. 
When it does, they are usually defects of the endocardial cushions such as an 
AVSD. Turner Syndrome is the only other chromosome aneuploidy with CHD that 
can survive to term, with the exception of mosaicism for trisomy 8 and 9 [383, 
384]. Turner Syndrome is associated with BAV and CoA [265-267]. 
  
1.6.1.2 Structural Abnormalities including Copy Number Variation 
  
There are a number of well characterised large deletions associated with CHD 
such as 22q11.2 deletion syndrome and Williams-Beuren Syndrome (Table 1.1). 
These large deletions can be detected using fluorescent in situ hybridisation 
(FISH). More recently, an increasing number of sub microscopic microdeletion 
and microduplication syndromes have been brought to our attention as a result 
of increased use of Array-Comparative Genomic Hybridisation (Array-CGH). 
Some of these copy number variations (CNVs) cause CHD.  
 
CNVs are thought to affect over 10% of the genome [385], but estimates vary 
depending on the platform used to detect them.  CNVs found in normal 
individuals are likely to represent benign copy number polymorphisms. Other 
CNVs have been associated with diverse disease processes and cumulative 
reporting of CNVs has allowed us to recognise some common microdeletion and 
microduplication syndromes. Many of these syndromes exhibit variable 
penetrance and expressivity, making it difficult to define the relationship 
between a CNV and disease. It is likely that other genetic, and possibly 
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environmental factors, contribute to the phenotype when these CNVs are 
present.  Even monozygotic twins with 22q11.2 deletion, have been reported 
with discordant phenotypes (although this was an older case report with limited 
tests available at the time). This variability makes it difficult to assess the exact 
contribution of CNVs to CHD [18, 239, 276, 386, 387]. It has been suggested 
that CNVs can be identified in up to 1 in 8 individuals with CHD [388].  However, 
rare, mainly de novo CNVs are thought to contribute to around 15-20% of S-
CHD (mainly 22q11.2 deletions) and 5% of NS-CHD [17, 389].  
 
1.6.1.3 Single Gene Mutations 
 
Around 5%-10% of CHD is thought to result from single gene disorders [244, 
390]. Variants have been associated with both NS-CHD and S-CHD. Given the 
usually simplex nature of CHD and the associated reduced reproductive fitness, 
we might postulate that these mutations are mainly de novo. More recently 
however, inherited single gene variants have been shown to play a role in NS-
CHD [12]. Additional variability of expression and penetrance associated with a 
single gene mutation suggests that there are likely to be other contributing 
genetic and/or environmental factors that modify the phenotype.  
 
Heart development is controlled by complex networks of genes that interact to 
ensure correct development of the heart tube and its asymmetric looping, to 
produce a functioning heart, including transcription factors (Figure 1.15). Many 
additional groups of genes play important roles in this process including 
sarcomeric, signalling and adhesion genes. Variants in some of these genes 
can result in CHD (Table 1.1). Homsy et al. suggested that 20% of S-CHD and 
2% NS-CHD might result from deleterious mutations in genes known to be in 
the top quartile of expression in the mouse heart during embryogenesis [14]. 
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Figure 1.15 Prominent transcription factors in cardiogenesis. 
From Franco et al [391]. Reproduced with permission. Figure 1A. Schematic 
representation of the developing heart delineating distinct developmental stages 
and the most prominent transcription factors involved in these morphogenetic 
processes.  
 
Given that some of these pathways and transcription factors function 
throughout multiple developing organ systems in the embryo, it is not 
surprising that mutations in these genes can result in additional extra-cardiac 
phenotypes. Indeed, S-CHD results from single genes in many cases [392]. 
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1.6.1.4 The Epigenetic contribution to CHD 
 
Epigenetics relates to changes in gene expression, rather than actual changes in 
the genetic code.  Epigenetic processes includes DNA methylation, histone and 
chromatin modification, and regulation of non-coding microRNAs. There is plenty 
of functional evidence and animal models that demonstrate the importance of 
genes involved in epigenetic processes in cardiogenesis. It has also become 
evident that this holds true in human CHD, where de novo mutations in 
chromatin remodelling enzymes are over-represented [12, 14, 16, 393]. 
Importantly, some epigenetic mechanisms are heritable [209]. 
 
Methylation was the first epigenetic mechanism described, and has an 
established role in imprinting and X-inactivation [394]. Mouse studies have 
shown only a small number of differentially methylated sites within a mainly 
consistent methylome, which are enriched for genes known to contribute to 
heart development [395]. Methylation patterns of genes involved in cardiac 
development change throughout development suggesting methylation plays a 
role in control of transcription during cardiogenesis [395]. 
 
Some studies have been carried out comparing methylation patterns in normal 
hearts and those affected with CHD. Abnormal methylation of NKX2-5 and 
HAND1 in individuals with sporadic TOF, [396] and significant differences in 
promotor methylation have been identified in CHD candidate genes in individuals 
with TOF [240]. It is not clear however, whether the altered methylation is an 
association with, or contributes to, the development of TOF. The current 
literature does not provide definitive evidence that methylation abnormalities 
alone cause CHD, but suggests it may contribute in some cases. Larger studies 
are required. 
 
The second epigenetic mechanism that may contribute to CHD is histone 
modification and the resultant changes in chromatin conformation. Subunits of 
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certain chromatin remodelling complexes are expressed during cardiogenesis 
and interact with key cardiac transcription factors such as GATA4, TBX5 and 
NKX2.5 [397, 398]. This include the BAF complex where RNA interference 
mediated knockdown in mice results in abnormal cardiac development [397, 
399].  
 
A number of genes in specific histone modification pathways appear to be 
significant in the aetiology of CHD [12, 14, 16]. This includes de novo mutations 
in genes involved in the modification of histone 3 lysine 4 (H3K4). Several genes 
known to cause S-CHD such as KMT2D, KDM6A (Kabuki Syndrome) and CHD7 
(CHARGE Syndrome) are involved in histone and chromatin modification (Table 
1.1). Histone acetyl transferases such as p300 and CBP are also important in 
cardiac development [400]. p300 deficient mice have cardiac defects including 
reduced ventricular trabeculation and double null p300/CBP mutants were 
embryonic lethal [401]. The role of histone deactelyation is covered further in 
chapter 3 in the discussion of novel CHD gene CHD4.  
 
A third epigenetic mechanism to consider are microRNAs (miRNAs). MiRNAs are 
short (19-22bp) non-coding RNAs. Although the function of most is still 
unknown, it is becoming apparent that they are important in normal heart 
development [402-408]. Studies suggest that non-coding RNAs may support the 
pathogenesis of CHD by influencing gene regulation [409].  
 
1.6.1.5 Somatic Mutations 
 
Less is known about the role of somatic variants in the heart, compared to 
germline variants. 1% of individuals with CHD have mosaic variants identified on 
blood testing which may contribute to their CHD [410]. Cardiac tissue has a 
higher yield (5%). Somatic mutations have been identified in hearts affected by 
sporadic atrial fibrillation and CHD, in GATA6, Cx40 and Cx43 [411, 412]. 
Overall, current evidence suggests that somatic mutations only play a small role 
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in CHD, or are part of a more complex combination of genetic and environmental 
factors. 
 
1.6.2 Evidence for Oligogenic inheritance of CHD 
 
The non-Mendelian nature of CHD in the majority, suggests that there is some 
contribution from either other genetic or environmental causes, or both. It is a 
minority of families where a monogenic cause is identified and there is now 
increasing evidence of non-penetrance and a role of inherited variants to support 
this idea [12]. Supporting evidence is described further in chapter 3, where I 
describe the contribution of inherited deleterious mutations in genes known to 
cause CHD in individuals with NS-CHD. 
 
Evidence of an oligogenic patterns are have also been reported in mice and 
specific human populations. Mutations in NKX2.5 were initially identified as 
causing ASD and conduction abnormalities [13, 413], but it has since been 
shown that the penetrance and expressivity of NKX2.5 mutations are influenced 
by the genetic background in mice [414], as well as other mutations in humans 
[415, 416].  
 
1.6.2.1 Maternal and Environmental contribution to CHD 
 
Additional non-genetic modifiers and contributors to CHD include haemodynamic 
changes during embryogenesis, maternal and environmental factors. 
Epidemiological studies have attempted to pinpoint specific environmental 
factors associated with CHD [238]. Attributable fractions differ between the CHD 
lesions, from 13.6% in HLHS to 30% in TGA with intact ventricular septum 
(IVS). Some suggested associations include exposure to chemicals including 
solvents and pesticides, as well as paternal marijuana use and anaesthesia. 
Other paternal risk factors have been suggested including paternal age, but the 
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evidence is contradictory [417]. Whether these associations prove to be causal 
or not remains to be seen.  
 
There are a number of well described maternal medical conditions and 
medications that can increase the risk of CHD in a pregnancy. Cardiogenesis 
occurs mainly between 2 and 7 weeks of gestation, so maternal factors in this 
period and the three months leading up to conception are usually considered 
[418, 419]. Twins have a higher risk of CHD compared to singletons, most likely 
due to vascular consequences of sharing a single placenta [420-422]. However, 
dizygotic twins also have a higher incidence of CHD than their siblings, 
suggesting that there may be an additional maternal environmental component 
[423]. 
 
Older maternal age increases the risk of CHD [424, 425], as does maternal 
smoking, especially in the first trimester [426, 427]. Alcohol consumption has 
been suggested to increase the risk of CHD, but this was not supported in a 
meta-analysis [428]. Therapeutic medications including anticonvulsants, non-
steroidal anti-inflammatory drugs, trimethoprim, sulfasalazine, retinoids, ACE 
inhibitors and thalidomide are associated with CHD [429-431]. 
 
Maternal obesity has been associated with a number of congenital abnormalities 
including CHD, in an apparent dose response relationship [432-434]. 
Pregestational diabetes (type 1 and 2) is associated with a risk of CHD in the 
foetus (RR=4, 4-5% compared with 1% [236, 237, 435]. Interestingly, the risk 
of CHD in a diabetic mother’s offspring is not significantly different between 
those with type 1 or type 2 diabetes [236]. The type of diabetes may correlate 
with the subtype of CHD seen in the foetus, with AVSD and conotruncal lesions 
being associated with type 1 diabetes, and heterotaxy and LVOTO being mainly 
associated with type 2 [435]. 
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The beginning of fortification of food with folic acid was associated with a trend 
towards a lower incidence of CHD [436, 437]. The exact mechanism by which 
folic acid could influence cardiogenesis is unclear, but it may play a role in 
migration of cardiac neural crest cells [438, 439]. The association remains 
uncertain however.  
 
1.7 Recurrence Risk 
 
Originally CHD was thought to be due to de novo mutations, because of the 
detrimental effect on reproductive fitness and the low risk of developing CHD, 
even if you have an affected first degree relative [3]. However recurrence is 
seen and Ellesoe et al found non-penetrance in apparently obligate carriers in 
32% of families with more than one affected individual [440]. Whilst a minority 
of families have monogenic CHD and a potentially significant recurrence risk 
despite evidence of non-penetrance [13], in the majority of cases, CHD occurs in 
a single individual in the family. Only around 2% have an affected first degree 
relative [3]. Studies have shown however that there is an increased risk to 
relatives, and estimates of recurrence risk fall between 1-9% [3, 233, 441-448]. 
Recurrence risk in siblings is thought to be around 3-4%, and 3-10% if a parent 
is affected [448]. The risk is highest in first degree relatives, and reduces with 
decreased relatedness [440, 449, 450]. The relative risk to a first degree relative 
is 3.21, 1.78 to a second degree relative and 1.1 to a third degree relative [3].  
The recurrence risk varies by CHD subtype, and some types are more heritable 
than others [3, 230, 233, 451-454]. The relative risk (RR) for a first degree 
relative of being affected with the same type of CHD varies considerably. For 
heterotaxy the RR is 79, for RVOTO it is 49, and for AVSD the RR is 25. The RR 
is much lower for septal defects (ASD RR 7, VSD RR is 3) [234]. Risk appears to 
be especially high in left sided lesions. Cardiac screening of relatives of 
individuals with HLHS found that 19 -55% of first degree relatives had a 
cardiovascular malformation [452]. BAV accounted for the majority of 
abnormalities, but other more diverse phenotypes included VSD, AVSD and left 
sided SVC. Family screening has been recommended in those with BAV because 
up to 20% of relatives are affected [453, 455]. For probands with CoA, another 
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left sided defect, 9% of screened relatives were affected as were 3% of relatives 
in families with dTGA [230]. The relatives mainly exhibited left sided lesions 
when the proband was affected with HLHS or CoA (72% and 67% respectively). 
The risk to second and third degree relatives was significantly lower (1% or less, 
and 2% or less respectively).  
 
When recurrence of CHD occurs within a family, the individuals may exhibit the 
same or different CHD lesions. In a study of 1163 families with over 3000 
affected individuals, Ellesoe et al. found that CHD phenotypes in affected family 
members were more likely to be discordant than concordant [440]. This has 
been shown in other cohorts [447, 452, 456]. This might suggest that when a 
particular genetic pathway is affected, it can result in several different defects 
[382, 457]. However Oyen et al found that it was more likely that siblings would 
be affected with the same type of CHD [3]. Ellesoe et al. confirmed that higher 
concordance were seen in more closely related individuals. Higher concordance 
was also seen in some families with larger numbers of affected relatives, in this 
case it is more likely that there was a monogenic cause of CHD. Despite this 
reported discordance, it seems that certain types of CHD are more likely to 
cluster together in families than others. Examples include TGA and right left 
patterning abnormalities, which were more likely to occur together. DORV and 
right left patterning were weakly associated. Whilst there are anatomical 
similarities between DORV and discordant ventriculo-arterial connections, these 
results suggest that different genetic and molecular mechanisms might 
contribute to these two types of CHD. This is supported by the findings of others 
[450].   
 
Possible explanations for both low recurrence risk and discordant phenotypes 
within a family include de novo mutations, reduced penetrance, oligogenic 
mechanisms and influence by additional environmental factors. This makes it 
particularly difficult to determine a recurrence risk for a specific family unless 
there is a clear Mendelian pattern of inheritance. What is clear though, is that 
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there is a risk to close family members of also being affected with CHD with 
variable expressivity, but that this risk is difficult to quantify and may vary 
between subtypes. 
 
1.8 Classification of CHD 
 
The spectrum of CHD is vast and includes abnormalities of position, the great 
arteries, coronary arteries, veins, the valves and connections between the 
chambers. There are a number of ways in which CHD is classified, and there is 
no single system that has a clear advantage over the others. Some are based on 
anatomy, others are based on clinical consequence. Some are useful from a 
clinical and prognostic point of view, some from a genetic or recurrence point of 
view. It is important to consider extra-cardiac features too including 
neurodevelopmental delay. Some of the important classification systems are 
outlined below as correct phenotypic labelling was required for the WES work I 
carried out with collaborators described in chapter 3. 
 
1.8.1 Anatomical Based Classification Systems 
Two of the main classification systems based on anatomy are the IPCC 
(International Society for Nomenclature of Paediatric and Congenital Heart 
Disease) and HPO (Human Phenotype Ontology) systems [458, 459]. Both are 
hierarchical systems and have been adopted by many clinicians and researchers.  
 
This IPCC system was produced by amalgamating the previous two main coding 
systems and it focusses solely on CHD, and does not include any acquired heart 
disease [458]. It has been designed for use in audit and research, by both 
clinicians and administrators. One of the founding principles is that the code 
represents the core of the disease, rather than the variable manifestations and 
consequences of it. It also includes codes for treatments and genetic syndromes 
Identifying Novel Genes that cause Congenital Heart Disease  83 
 
and we used IPCC codes as part of the whole exome sequencing WES project 
described in chapter 3 [12].  
 
The Human Phenotype Ontology (HPO) system is not just focussed on the heart, 
but covers the whole body. It also incorporates genetic syndromes. The 
advantage over the IPCC terms is that it allows coding of extra cardiac 
abnormalities. However it is not as specific when it comes to CHD, and the IPCC 
terms do offer a greater breadth of options. HPO terms were also used in the 
WES work described in chapter 3 to code for extra cardiac features, and in 
development of a list of genes we were highly confident cause CHD in humans 
[12]. 
 
1.8.2 Clinical Classification Systems 
 
CHD can also be classified by clinical consequence [460]. Commonly it is split 
into cyanotic and acyanotic types, and the effect of the anatomical changes on 
pulmonary blood flow. Increased pulmonary blood flow will occur with left to 
right shunts, and septal defects without pulmonary obstruction. Decreased 
pulmonary blood flow occurs with right to left shunts and septal defects with 
pulmonary obstruction. Increased pulmonary blood flow increases the risk of 
developing pulmonary vascular disease, which can reverse the left to right shunt 
resulting in cyanosis (Eisenmenger Syndrome). Treatment is indicated early to 
prevent the complications of pulmonary hypertension. Cyanotic or acyanotic is 
there for an important distinction in guiding management, as is duct 
dependency. 
 
1.9 Diagnosis of CHD  
 
CHD may be diagnosed antenatally, after birth, throughout life or in some cases 
on post mortem. Timing of diagnosis depends on the particular type of CHD. 
Given that CHD tends to occur in a single individual within a family and 
monogenic inheritance with full penetrance seems rare, it is difficult to identify 
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who is at risk of CHD and would benefit from targeted screening. Increasing our 
knowledge of the genetic aetiology of CHD may help clarify this. 
 
Almost 50% of all individuals who required a procedure to treat CHD in the first 
year of life were diagnosed antenatally in the UK, although pick up rates vary 
from region to region (NICOR Report 2012-2015 https://nicor4.nicor.org.uk). 
USS at 18-22 weeks provides the best view of the fetal heart. Structural, 
functional and rhythm disturbances can be detected using USS. CHD tends to be 
picked up incidentally on the 18-20 week fetal anomaly scan, as there is no 
identified high risk obstetric population for targeted CHD screening (with the 
exception of maternal diabetes) 
(https://www.gov.uk/government/uploads/system/uploads/attachment_data/file
/398598/Congenital_heart_disease_-_HP_-_FASP76.pdf).  Antenatal detection 
allows parents to decide whether or not to continue with the pregnancy or to 
come to terms with the diagnosis before the birth. Importantly it can allow the 
medical teams to determine if any special care will be required. Ensuring 
delivery in a hospital is carefully planned with neonatal support available to 
prevent deterioration prior to surgery can improve outcomes [461]. 
 
CHD might be detected in the neonatal period after auscultation of a murmur or 
if the child has symptoms suggestive of CHD. In adulthood, CHD may be 
detected incidentally or symptoms might arise if there is additional stress on the 
heart such as pregnancy, or if decompensation and symptoms of heart failure 
occur. Other sequlae, such as arrhythmias, may become apparent. Some of the 
more common lesions such as BAV may not present until later life with 
symptoms of valve dysfunction, or detection of aortic dilatation. ASD and CoA 
are also sometimes detected in adults for the first time. Later detection can 
mean that person is at an increased risk of complications even after repair. 
Repair of an ASD in later life means that there is often severe enlargement of 
the RA and RV, which may not improve [462]. Therefore, defining a population 
for screening can improve outcomes and may be facilitated by increasing our 
Identifying Novel Genes that cause Congenital Heart Disease  85 
 
knowledge of genetic factors that increase risk, and identifying the genes which 
cause CHD. 
 
1.10 Treatment of CHD 
 
Treatment of CHD is beyond the scope of this thesis and will not be discussed in 
detail. Treatment may be aimed at treating the actual structural lesion, or 
complications of it such as arrhythmias or cardiac failure. Surgical interventions 
can correct some anatomical abnormalities, or provide a functioning heart which 
is not necessarily structurally normal. Some individuals will require multiple 
surgeries, and in some cases a heart transplant may eventually become 
necessary. Percutaneous treatments can be used to treat a variety of lesions, 
including some septal defects. One of the newer areas of development are the 
fetal interventions which include balloon valvuloplasty. Treatment in many 
instances is lifelong with medications to optimise heart function and control 
arrhythmias. 
 
1.11 Prognosis and Complications 
 
Whilst great progress has been made in the treatment of CHD, some individuals 
do have an associated increase in morbidity and mortality. There is emerging 
evidence that the pathways controlling heart and brain development are closely 
linked and genetic variants may potentially affect both organ systems [14]. 
Understanding which genes cause CHD and how they affect the development of 
other organs too, may increase our ability to provide prognostic information. 
Potentially it might help us identify whether non cardiac phenotypes could 
potentially predict the occurrence of CHD. Additionally, we may be able to tailor 
treatments by genotype if there is evidence of pharmacogenetic interactions. 
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1.11.1 Increased mortality  
 
The prognosis for individuals with CHD has improved dramatically over the 
years, with over 90% now surviving to older age [463]. Unfortunately however, 
individuals with CHD still find themselves at higher risk of stroke, heart failure 
and higher mortality overall [8, 464]. Whist this might not be unexpected for 
individuals with severe CHD, it appears that there is also a higher mortality with 
the more simple and common defects, such as ASD and VSD [465, 466]. One of 
the larger studies of adults with CHD has shown those with simple CHD had a 
mortality rate of 0.8% per annum, those with moderate severity CHD had a 
mortality rate of 0.7%, and those with severe defects had a mortality rate of 2% 
(over an 8 year follow up period) [467]. Mortality was lowest in patients who did 
not require any repair. Additional risk was conveyed if the individual has a 
genetic syndrome, subpulmonary ventricular dysfunction, cyanosis, pulmonary 
outflow tract obstruction, pulmonary hypertension, infective endocarditis and 
single ventricle physiology. Reassuringly though, the majority of adult CHD 
patients will have a mortality rate only slightly higher than the general 
population, and many of the complications such as arrhythmias and infective 
endocarditis are treatable and preventable. Increasing our knowledge of S-CHD 
genes may help us identify more individuals who may be at higher risk of 
mortality, and provide an opportunity to optimise their care and organise 
examination of other organs systems if relevant. 
 
1.11.2 Association with Neurodevelopmental Disability 
 
Around 10% of individuals with CHD have additional neurodevelopmental 
disability (NDD). This rises to around 50% when you consider those with severe 
forms of CHD [468]. The aetiology of NDD in CHD is difficult to define given that 
factors such as time on intensive care and in hospital in general, circulatory 
arrest during surgery, and reduced cerebral perfusion may feasibly contribute. 
Clinical factors that identify those at high risk of NDD are those with cyanotic 
lesions, those requiring open heart surgery in the neonatal or infantile period, 
CHD with prematurity, ECMO, heart transplants, CPR or prolonged seizures and 
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abnormal cerebral imaging [392]. However it is becoming apparent that genetic 
influences are also important and there are shared genes in the pathways 
required for both brain and heart development [14]. Features such as 
microcephaly also independently predict NDD in individuals with CHD, which is 
unlikely to be due to the factors mentioned above and supports an additional 
genetic contribution [469].  
 
1.11.3 Association with Respiratory Disease 
 
Respiratory dysfunction is an important cause of morbidity and mortality in 
individuals with CHD. It is also closely tied to the pathogenesis of CHD in cases 
where ciliopathy genes are altered. Cilia help determine the right left axis of the 
body and are involved in development of the heart, renal and neurological 
systems. Primary ciliary dyskinesia results in heterotaxy, CHD and respiratory 
abnormalities [213]. Extra precautions and preoperative optimisation can make 
a difference to outcomes in those undergoing surgery and who experience chest 
infections [470, 471], therefor identifying individuals with ciliopathies is 
important. 
 . 
1.11.4 Association with Myocardial Dysfunction 
 
Individuals with CHD (excluding septal defects) have a 25% chance of 
developing significant cardiac failure by 30 years of age [472]. The risk is related 
to the type of CHD, their age, the number of operations they have had and the 
function of the right ventricle. Interestingly cardiac failure in those with CHD 
may develop by a different mechanism to those who do not have CHD. Norozi et 
al. suggested that the mechanism may be due to chronotropic incompetence, as 
indicated by lower maximum heart rates in those with CHD [472]. This may 
mean that individuals with CHD respond differently to treatments for cardiac 
failure than those without CHD. Evidence for this is provided by some studies 
which have shown that enalapril does not help improve exercise capacity in 
adults who have undergone the Fontan procedure [473], or improve cardiac 
function and somatic growth in infants with a single ventricle [474]. 
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A few studies have already begun to consider the implications of genetic burden 
on the chances of individuals with CHD developing heart failure, by considering 
which pathways are involved and suggesting potential mechanisms [475]. In 
some cases aberrations in monogenic genes can cause both CHD and heart 
failure such as MYH6. In other instances, cardiac failure might result from a 
combination of genetic, cardiac, and haemodynamic stress on the heart [107, 
476]. Identifying links between the genetic aetiology of an individual’s CHD and 
their risk of cardiac failure may help develop tailored treatment pathways. 
 
1.12 Current Recommendations for Genetic Testing in CHD 
 
Identifying the genetic cause of CHD in an individual is important for a number 
of reasons. A genetic test result can guide prognosis and identify whether 
other organ systems should be screened for abnormalities [477]. It can also 
identify if other family members are at risk, provide accurate recurrence risks, 
and allow testing in a pregnancy and preimplantation genetic diagnosis.  
 
European and American guidance on genetic testing in CHD have been 
produced [10, 478]. European guidelines suggest that genetic testing should 
be reviewed at transition clinics in those with a recognisable syndrome, or CHD 
in combination with facial dysmorphism, skeletal defects and visceral organ 
malformations. In addition those with growth delay and NDD including 
behavioural or psychiatric disorders, should be considered for genetic testing. 
Individuals with a family history of one or more affected first degree relatives, 
or multiple miscarriages and/or siblings with birth defects may also benefit 
from testing [10, 235]. Testing should also be considered in the case of an 
affected foetus as this may guide management during the pregnancy, birth 
and neonatal period [235]. Because it may be difficult to ascertain in a 
neonate has S-CHD or not, testing should be considered in those that have 
types of CHD which are commonly associated with a known genetic syndrome 
such as TOF, TA, IAA and left sided obstructive lesions [479]. 
Identifying Novel Genes that cause Congenital Heart Disease  89 
 
 
Generally the guidelines recommend an appropriate targeted test, and if this is 
negative WES with consideration of an array [10, 235, 480-484]. Whole Genome 
Sequencing (WGS) can then be considered on a research basis if no conclusive 
variant is found. Up to 35% of individuals with S-CHD with no known genetic 
diagnosis have a deleterious (usually de novo) variant detected using WES [12, 
14, 15]. 
 
Testing for those with NS-CHD is more limited. The 100 000 Genomes project 
offered a panel of NS-CHD genes, but this was on a research basis and 
recruitment is now closed 
(https://panelapp.genomicsengland.co.uk/panels/212/). The current UK test 
directory from Genomics England only offers a microarray for individuals with 
syndromic CHD (https://www.england.nhs.uk/wp-
content/uploads/2018/08/rare-and-inherited-disease-eligibility-criteria-march-
19.pdf). WES can identify a deleterious mutation in up to 40% with NS-CHD 
with a family history of CHD, [485]. For those with a family history of CHD 
appropriate testing should be offered [10]. For those without a family history 
testing is not recommended unless the affected individual or their first degree 
relative is of reproductive age and wants to find a diagnosis, or the individual 
has a specific type of CHD (TOF, IAA, TA, VSD with ascending aortic 
aneurysm, anomalous branch pulmonary arteries). Unfortunately NS-CHD with 
no family history is the most common presentation of CHD, and monogenic 
causes are only thought to account for around 4% [486]. The European 
guidelines recognise that genetic testing is more common in those with S-
CHD, but that headway is being made in understanding the genetic aetiology 
behind NS-CHD. 
 
Phenotypic variability, reduced penetrance and identification of variants means 
that genetic testing can incredibly complex. Current recommendations suggest 
genetic testing should include pre and post-test genetic counselling and be 
carried out by a genetic counsellor as part of multidisciplinary team [10, 478, 
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479]. An individual’s plans for family and their perception of risk should be 
explored during the discussion [10]. Ideally counselling should be carried out 
prior to conception, but testing during a pregnancy can also be helpful [487]. 
Van Engelen et al. reported that half of the patients they interviewed had 
postponed having children until they had been through genetic counselling for 
CHD, and 13% changed their mind about whether or not to have children based 
on the genetic information provided [488].  
 
1.13 Hypothesis and aims 
 
Whilst significant progress has been made in identifying novel CHD genes, the 
reality is that the majority of individuals with CHD do not receive a genetic 
diagnosis. This thesis concentrates on the identification of novel CHD genes, and 
animal models of some of these new genes. Identifying and providing evidence 
for these new CHD genes, will hopefully translate into benefit for patients by 
increasing diagnostic yield, and by providing a starting point for identifying 
related genes and pathways that might be important in CHD pathogenesis. The 
main aims were as follows: 
 
 To conduct a WES based study to identify novel CHD genes.  
 To identify pathogenic mutations from this WES data, for correlation with 
individual phenotype, validation of the mutation and feedback to the 
individual. 
 To perform a preliminary analysis in mice for newly identified novel CHD 
genes, for embryonic lethality. 
 To perform a preliminary analysis of mouse colonies for newly identified 
novel CHD genes, for cardiac defects using high resolution episcopic 
microscopy (HREM) and Magnetic Resonance Imaging (MRI) analysis. 
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Chapter 2 Methods 
 
 
2.1 Methods Relating to the Whole Exome Sequencing Analysis 
 
2.1.1 Sample Collection for WES project 
 
The study population for this analysis was recruited across a number of centres 
across the world [12]. Local recruitment was through BHF funded research 
nurses, most recently C Thornborough, and paediatric cardiologists lead by Dr F 
Bu’Lock at Leicester Glenfield Hospital. Recruitment was over the preceding 20 
years. DNA extraction was carried out by members of the Brook lab, mainly K 
Setchfield, prior to my arrival in the lab.   
 
2.1.2 Bioinformatic Analysis 
 
WES and bioinformatics analysis was carried out at the WTSI (M Hurles team). 
The pipeline matched that of the DDD project [489]. Samples with a median 
coverage below 29.7X were excluded. Agilent SureSelect V5 and V3 were used 
for exome capture. GATK was used to identify SNPs and indels [490]. 
DeNovoGear was used to call de novo mutations [491]. TADA was used to study 
genes with enrichment of both DNMs and rare inherited variants [492]. 
Denovonear was used to identify mutational clustering 
(https://github.com/jeremymcrae/denovonear). 
 
PCA analysis was used to characterise and define a suitable control population. 
Ensembl Variant Effect Predictor (VEP) was used to classify the mutation 
consequence [493]. Mutations were classified as either protein truncating 
mutations (PTV, nonsense, frameshift, splice site variants), missense variants 
(including in frame indels) and silent (synonymous) mutations. Full methods are 
reported in appendices 3A and 3B of this thesis.  
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2.1.3 Characterising the de novo mutation burden in CHD 
 
The de novo mutation analysis was based on a comparison of the actual rate of 
de novo mutations, with the expected number under a null mutational model 
[494]. It is a statistical model designed to be used for gene discovery in 
disorders that exhibit extensive locus heterogeneity. This method has been used 
by the DDD Study [495] and to investigate autistic spectrum disorders, which 
share a similar polygenic mechanism to CHD, where de novo mutations are 
important contributors [14].  
 
2.1.4 Characterising the burden of inherited mutations in CHD 
 
A case control approach was used to determine the burden of inherited 
mutations. S-CHD and NS-CHD individuals of European ancestry, were compared 
with 12,031 population matched controls. The control group included unaffected 
parents recruited as part of the DDD study [495, 496] and healthy blood donors 
derived from the UK INTERVAL study [497]. This group had had similar exome 
sequencing processed by an identical pipeline. 
 
2.1.5 Comparison with other disease models 
 
The genome wide excess of de novo mutations found in the CHD cohort [12] was 
compared with other studies looking at autism and developmental disability 
without CHD, to compare the relative excess burden of each type of mutation 
[495, 498, 499]. 
 
2.1.6 Evaluation of individual Genes  
 
The same null mutation model was used for this analysis, as was used for the de 
novo mutation analysis [494]. Genome wide significance was set at p<1.3x10-6. 
Analysis considered S-CHD and NS-CHD trios, those with de novo PTVs, and 
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then missense variants. This analysis did not include individuals where we had 
identified a genetic cause of their CHD.  
 
To consider the cohort as a whole, a Bayesian model was used to integrate 
analysis of the trios and singletons, to identify genes which were enriched for 
both de novo and inherited variants [492]. This method was developed to take 
into account de novo mutations with mechanisms other than loss of function and 
include inherited rare variants, in cases and controls. This is the TADA analysis 
(Transmission and De novo Association). It has previously been used in autism 
spectrum disorder analysis [500]. PTVs and missense variants were considered. 
Candidate genes were stratified by false discovery rate (FDR) of strong (FDR 
<0.01/1%), intermediate (FDR >=0,01 and <0.05/>=1% and <5%) and weak 
(>=0.05 and <0.1/ >=5% and <10%). 
 
The evidence for genes identified as possibly significant was reviewed. This 
included whether it was a known CHD gene, animal models, case reports and 
any characteristics of the mutations such as clustering to suggest possible gain 
of function mutations.  
 
2.1.7 Gene Function and pathway analysis 
 
The highest ranked genes from the TADA analysis, with a FDR <50%, were run 
through InnateDB [501] (accessed November 2015). This programme identified 
GO terms and pathways that are represented more than we would expect by 
chance. It uses information from KEGG [502], Reactome NetPath [503], and 
other databases. A term/pathway was considered to be overrepresented if the 
Benjamini-Hochberg corrected FDR was less than 10%. High confidence protein-
protein interactions (confidence >/= 0.9) were ascertained from STRING 
(version 10) PPI database [504] to assess for over-represented combinations. 
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2.1.8 Copy number variation analysis 
 
Copy number variation (CNV) analysis used CoNVex [505]. This analysis is based 
on read depth information and compares the sample of interest with the median 
read depth from a group of highly correlated samples. This produces a log2 ratio 
which is then adjusted using a GC correction. This score is used with the Smith-
Waterman algorithm [506]. CIFER[507] was used to determine inheritance 
pattern. Rare CNVs were identified by comparison with results from other studies 
including the CNV Project Hapmap Study [508] the Wellcome Trust Case Control 
Consortium (WTCCC) [509], the 1000 Genomes Project [510] and the DDD 
normal controls (UKBS and Generation Scotland) [495]. Rare was applied to 
CNVs that overlapped by 80% or less with other reported CNVs that occur at a 
frequency greater than 1%. 
 
2.2 Laboratory Methods  
 
2.2.1 PCR  
 
2.2.1.1 PCR for Mouse Genotyping 
 
PCR protocols were supplied by the WTSI with the mice. Primers were purchased 
from Sigma and diluted to a concentration of 100µM. A full list of all primers 
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Mouse Primer Name Sequence (5’>3’) 
Prkd1em1(IMPC)Wtsi Prkd1_DF1 GGCATGGCTGGACCTAATCT 
Prkd1em1(IMPC)Wtsi Prkd1_ER1 CACCCATGCCCTCAAGTATC 
Prkd1em1(IMPC)Wtsi Prkd1_DR1 GCTTGACACTGGAAATGGAA 
Prkd1em2(IMPC)Wtsi Prkd1_Gly592_F GACTCCGAGACACACAGATTCA 
Prkd1em2(IMPC)Wtsi Prkd1_Gly592_R GCCATTGAAATTTTATCCGACA 
Cdk13tm1b(EUCOMM)Hmgu CAS_R1_Term TCGTGGTATCGTTATGCGCC 
Cdk13tm1b(EUCOMM)Hmgu LacZ_2_small_F ATCACGACGCGCTGTATC 
Cdk13tm1b(EUCOMM)Hmgu LacZ_2_small_R ACATCGGGCAAATAATATCG 
Cdk13tm1b(EUCOMM)Hmgu Cdk13_84881_F GCTCTAAGGGCAACCTTGAA 
Cdk13tm1b(EUCOMM)Hmgu Cdk13_84881_R AGCTGGGAAGATGGTGTTGT 
 
Table 2.1 Primers used to genotype the three mouse strains. 
 
For all PCR reactions, 50-100ng of DNA template was used. The protocol 
supplied by the WTSI used Invitrogen Platinum Taq DNA polymerase. In this 
instance, 2µl of 10x buffer, 0.6µl of MgCl (50mM), 0.2µl of Taq, 0.2µl of DNTPs 
(100mM), 0.4µl of the forward and reverse primers, and 15.2µl SDW were 
combined.  
 
Promega PCR Master Mix (M7501) could also be used. 1µl of forward and reverse 
primers (diluted to 10µM) were added to 11.5 µl of master mix. The reaction 
was made up to 25µl with SDW.   
 
For reactions using NEB LongAmp Taq DNA polymerase, the manufacturer’s 
protocol was followed allowing for the required extension time. 
 
In all cases, amplification was carried out in a 0.2-ml PCR tube, using the T100 
Thermal-Cycler (Bio-Rad). A standard protocol of initial denaturation for 5 
minutes at 94°C, subsequent denaturation at 94°C for 30 seconds, annealing at 
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58°C for 30 seconds, extension at 72°C for 1 minute and 30 seconds, repeated 
34 times was used. This was followed by a final extension at 72°C for 5 minutes, 
and hold at 12°C.  
 
2.2.1.2 PCR to confirm mutations identified in human DNA samples 
 
Primers were designed using Primer 3 and Primer 3 Plus freely available design 
tools on the web (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi) [511]. The relevant gene sequence was 
derived from Ensembl (https://www.ensembl.org/index.html) [512]. NCBI blast 
primer design/primer designing tool was used to check if the primers might 
amplify any other products [513] (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/). PCR protocols were designed using Optimase Protocol Writer 
(http://www.mutationdiscovery.com/md/MD.com/screens/optimase/OptimaseIn
put.html?action=none).  A full list of primers is shown below in table 2.2. 
 
Gene Primer Name Sequence (5’>3’) 
GATA6 GATA6_F GTTGATGACAGGGACAAAATACC 
GATA6 GATA6_R CAAGTGAGCAGAATACATGGCA 
PTPN11 PTPN11_308F ACCAGGGTTGTCCTACACGA 
PTPN11 PTPN11_308R TTTCCTCTCTCCACTTCTTTCG 
PTPN11 PTPN11_63F cttgcctccctttccaatg 
PTPN11 PTPN11_63R ctgacCTTTCAGAGGTAGGATCT 
 
Table 2.2 Primers required to confirm pathogenic mutations identified. 
 
Amplification was carried out in a 0.2-ml PCR tube, using the T100 Thermal-
Cycler (Bio-Rad). PCR required an initial denaturation step of 2 minutes at 95°C, 
subsequent denaturation at 95°C for 30 seconds, annealing at 58.3°C for 30 
seconds, 30 seconds at 72°C to allow extension, and repeated for 29 cycles. The 
final extension time was 5 minutes at 72°C, followed by holding at 12°C. 




2.2.2 Agarose Gel Production 
 
1% agarose gels were made with 1g of Sigma molecular biology grade agarose 
powder, dissolved in 100ml of TAE buffer. 2µl of ethidium bromide (10mg/mL 
Sigma Aldrich) was added. 
 
2.2.3 Running an agarose gel 
 
To visualise the PCR reaction products, x10 loading dye (0.04g bromophenol, 
0.04g Xylene Cyanol, 6.25ml 80% Glycerol and 3.75ml SDW) was added. 10µl of 
Invitrogen 100bp ladder was used to size PCR products. 
 
2.2.4 Reading an agarose gel 
 
Once the electrophoresis was complete, the gel was placed in the Gel 
Documentation reader (Gel Doc XR+, Bio-Rad). Images were captured using the 
Quantity One software (Bio-Rad). 
 
2.2.5 Gel Extraction 
 
Gel extraction was performed using the QIAquick Gel extraction kit (Qiagen). 
The manufacturer’s standard protocol was used.  
 
2.2.6 PCR clean up 
 
PCR clean-up was performed using the QIAquick PCR purification kit (Qiagen) 
and the recommended protocol from the manufacturer.  
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2.2.7 Sanger Sequencing 
 
Sanger sequencing was performed by Source Bioscience 
(https://www.sourcebioscience.com/) and Deep Seq at the University of 
Nottingham (https://www.nottingham.ac.uk/deepseq/). Purified PCR products 
(5µl at a concentration of 100ng/µl) and primers (5µl at a concentration of 
3.2pmol/µl) were supplied for sequencing reactions. 
 





DNA, and RNA concentrations were measured on the Nanodrop 2000 
Spectrophotometer (ThermoFisher Scientific) in accordance with the 
manufacturer’s instructions. 
 
2.2.9 Preparation of Phosphate Buffered Saline (PBS)  
A number of different suppliers of PBS tablets were used, and made up as per 
the manufacturer’s instructions. This was usually dissolution of 1 tablet per 
100ml of distilled water.  
 
2.2.10 4% PFA Production 
400ml of PBS was made using double distilled water. 16g of PFA (Sigma P6148) 
was added to 384g PBS and mixed at 65oC. If necessary, a few drops of sodium 
hydroxide was added to help dissolution and to ensure that the pH is between 
6.9 and 7.3. 10ml aliquots were stored at -20 oC.  
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2.3 Mouse Work  
 
Both Prkd1 mouse models were produced at the Wellcome Trust Sanger Institute 
(WTSI) and the Cdk13 mouse was obtained from Infrafrontier [511].  
 
2.3.1 General husbandry 
 
Mouse husbandry was carried out by the staff in the Bio Support Unit at the 
University of Nottingham, mainly by S. Ecob. This included breeding of the 
mouse pairs to produce a stable colony and to produce pregnant dams for 
sacrifice, under a Home office Breeding Licence held by Anne-Marie Kelly 
initially, and then Ian Devonshire (P375A76FE). 
 
Mice were housed in accordance with UK Home Office legislation in ventilated 
cages with access to food and water ad liberatum. They were fed standard 
laboratory mouse high calorie mouse diet and provided with mash in cases of 
increased stress. Additional tubes were added to the cages to improve their 
environment and to allow handling with minimal stress to the mice. They were 
housed in a maximum of 4 mice per cage. No mice were kept alone where 
possible. A standard 16 hour light, 8 hour dark cycle was followed. 
 
 
2.3.2 Mouse strains studied and genotyping protocols 
 
The background strain used was C57BL/6N. Three mouse lines were studied, two 
Prkd1 lines and a single Cdk13 line. For the purposes of this thesis, the 
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 WT Heterozygous Homozygous 
Prkd1em1(IMPC)Wtsi Prkd1+/+ Prkd1em1/+ Prkd1em1/em1 
Prkd1em2(IMPC)Wtsi Prkd1+/+ Prkd1em2/+ Prkd1em2/em2 
Cdk13tm1b(EUCOMM)Hmgu Cdk13+/+ Cdk13tm1b/+ Cdk13tm1b/tm1b 
 
Table 2.3 Nomenclature of mice genotypes employed in this thesis. 
 
The genotypes of the mice sent to us had been previously confirmed by the 
WTSI. I confirmed the genotypes of the mice we received and optimised the 
genotyping protocols we had been sent. I genotyped approximately the first 100 
mice produced from all three strains. After that I had help from S Buxton, K 




The Prkd1em1(IMPC)Wtsi mouse generated by the WTSI using Crispr/Cas9, deletes 
exon 2 and some of the surrounding intronic sequence (Figure 2.1). Exon 1 is 
the first coding exon. Exon 2 codes for part of the cysteine rich domain of the 
protein. Three primers used for genotyping, they are DF1, DR1 and ER1. 
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Exon 2 and the surrounding intronic sequence are shown. Exons are in capitals 
font, introns are in lowercase. Primer sites are DF1 red text, ER1 yellow text, 
DR1 green text. RNA guide sites for the Crispr/Cas9 work are in pink text. The 
deleted section is italicised. Prkd1 sequence (GRCm38.5) from Ensembl [512]. 
The deletion was confirmed to be smaller (Chapter 4, Figure 4.8). 
Figure 2.1 Representation of Prkd1em1(IMPC)Wtsi mouse with exon 2 
deleted. 
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Two PCR reactions were required to genotype the mouse. The primers are shown 
in table 2.1. In this instance, 1.5μl of 10x Buffer, 0.45μl of MgCl2, 0.15μl of 
Platinum Taq, 0.15μl of dNTPs, 0.3μl Primer and 11.15μl of SDW were used to 
complete the PCR reaction. 
 
The combination of DF1 and ER1 only produced a product if the wild type allele 
was present (233bp). The DF1 DR1 combination produced a short product if the 
deletion is present (212bp). It could also produce a much longer sequence from 
the WT allele (1360bp). A Prkd1em1/em1 mouse should produce a band at 212bp. A 





Genotyping of this mouse was based on a single PCR reaction and the products 
were sent for sequencing (section 2.2.7) after PCR clean-up had been carried 
out (section 2.2.6). The sequence and primers are illustrated in figure 2.2.  
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Figure 2.2 Relevant sequence for amplification by PCR to genotype the 
Prkd1Em2(IMPC)Wtsi mouse. 
Mouse sequence (GRCm38.5) from Ensembl [512]. Exons are in blue capitalised 
font, introns are in lowercase grey letters. Primer sites are highlighted in red and 
green text. The base that is subject to the mutation is highlighted in pink, the 
base change is G/A (reverse complement) or C/T. 
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2.3.2.3 Cdk13tm1b(EUCOMM)Hmgu Mouse 
 
This mouse employed a reporter tagged deletion allele (post-cre). A figure 
illustrating the manufacture of the tm1b allele and a comparison with the tm1a 
and tm1d alleles is shown in chapter 6, figure 6.5. Figure 2.3 below illustrates 
the primers and their position in the Cdk13tm1b(EUCOMM)Hmgu and wildtype mouse. 
The section of genomic sequence in the mouse and the cassette, is included in 
appendix B. 
 
A. Wild type mouse illustrating the position of the CDK13_84881_F and 
CDK13_84881_R primers, just prior to exon 3. B. The Cdk13tm1b(EUCOMM)Hmgu 
mouse illustrating the position of the cassette and other primers. The green box 
illustrates the FRT site and the red box, the LoxP site. The wild type sequence 
finishes just prior to the Cas_R1_Term primer. 
 
The Cdk13tm1b(EUCOMM)Hmgu mouse may be genotyped through a combination of 
separate PCR reactions that detect the cassette (LacZ_2_small_F and 
LacZ_2_small_R, 108bp) , the gene-specific wild type allele (Cdk13_84881_F 
and Cdk13_84881_R, 250bp), and a mutant allele-specific sequence 
Figure 2.3 Primers to genotype the Cdk13tm1b(EUCOMM)Hmgu mouse. 
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(Cdk13_84881_F and CAS_R1_Term, 200bp) using short range PCR. The 
standard PCR protocol was used, with the exception of a slightly shorter 
extension step of 45 seconds at 72°C.  
 
Interpretation of the consolidated results reveals the genotype of the mice. For 
example, cassette positive, mutant positive, wild type positive represents 
Cdk13tm1b/+.  
 
2.3.3. Timed Matings 
 
Timed matings were carried out by introducing a male stud to a new cage in 
advance so he could lay down his scent. Dams were then introduced and each 
morning they were checked for the presence of a cervical plug. If this was 
present, they were considered to be pregnant with a gestation of E0.5 (0.5 days 
post conception). Pregnant dams were then sacrificed on the morning of the 
specific day required. Schedule 1 methods were carried out by the staff in the 
BSU. 
 
2.3.4 DNA extraction 
 
The following DNA extraction protocol was used for ear notches and embryonic 
tissue, such as liver for genotyping. The protocol was supplied to me by Dr Bedford 
at the University of Nottingham.  
 
Mouse tails or ear notches were placed in 700µl (tail) or 500μl (ear) of lysis buffer 
(0.1 M Tris-HCl, 5 mM EDTA, 0.2 % SDS, 0.2 M NaCl). 35µl (tail) or 25μl (ear) of 
10mg/ml proteinase K was added, and the sample was incubated overnight at 
55oC. The sample was then vortexed to ensure the tissue had been lysed. The 
sample was spun down and DNA was precipitated using isopropanol. This was 
followed by a 70% ethanol wash. 
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2.3.5 Culling methods used 
 
Adult mice were sacrificed using the schedule one method of cervical dislocation, 
and death was confirmed by severing the neck vessels to cause exsanguination. 
For mice due to be imaged using MRI, sacrifice was by exposure to high 
concentration of carbon dioxide and confirmation of death was by identification 
of rigor mortis. Embryos in the first two thirds of gestation were sacrificed by 
disruption of the membranes and decapitation, which severs the spinal cord and 
allows exsanguination. Embryos more than two thirds of the way through 
gestation, were sacrificed by cervical dislocation and exsanguination by 
decapitation. No procedures or interventions were carried out on any mice whilst 
alive in accordance with our licence. 
 
2.3.6 Embryo harvests for lethality assessment 
 
Assessment of gestational age was based on detection of a mucous plug by a 
BSU staff member. Gestation was set as 0.5 days on finding a plug. To extract 
embryos, the pregnant female mouse was culled on the required day. The 
abdomen was cleaned with 70% ethanol and opened using a midline or V shaped 
incision. The uterus was isolated in the pelvis and draw upwards out of the body 
cavity (figure 2.4). The uterus was dissected away from the cervix/vagina. Both 
ovaries were identified, and evidence of reabsorbed embryos looked for. Each 
sac was given an identification number and those that had apparently failed to 
progress were recorded. 
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Figure 2.4 Removal of the gravid uterus. 
Six separate sacs are visible in this picture. 
 
Each uterine cavity was opened and each embryo was removed. The embryo 
was culled immediately using an appropriate schedule 1 method. The crown 
rump length (CRL) could be measured at this point by performing the schedule 
one method over a ruler under the transparent container, so it did not delay 
culling. At this point and any gross deformities were noted and tissue was 
removed for genotyping. The heart could be easily dissected out after culling 
(figure 2.5).  
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Figure 2.5 E13.5 mouse embryo. 
An embryo collected as part of lethality assessment and the heart has been 
isolated for further work.  
 
2.4 High Resolution Episcopic Microscopy 
 
Protocols for HREM were obtained from https://dmdd.org.uk/hrem/ and Mohun 
and Weniger [513]. Additional information was added from personal 
communication with T Mohun and his team at the Crick Institute. In addition I 
made several trips to the Crick to learn the techniques in person.  
 
2.4.1 Collection of E15.5 hearts for HREM  
 
Embryo harvest was as described in section 2.3.6. Embryos were removed into 
PBS, which had been maintained at 37°C, and schedule 1 methods applied. CRL 
should be measured at this point. The placenta was detached and 
exsanguination was encouraged by repeatedly cutting a distal section from the 
umbilical vessels to remove clots, and by keeping the embryos in constant 
motion. The embryo was bisected across the region of the liver, to encourage 
further exsanguination. External phenotyping and forelimb staging were 
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performed whilst exsanguination is ongoing (see section 2.5.1). The heart was 
exposed via sternotomy, dissected from the diaphragm and removed (Figure 
2.6). The hearts must remain submerged throughout the whole process, to 
prevent chambers collapse and damage. 
 
Figure 2.6 Example of E15.5 heart after initial dissection. 
Some lung tissue is still attached. Blood is still evident in one of the two atria 
and some is also seen in the ventricles and will require removal by lysis as 
described below. 
 
The hearts were then transferred to 4% PFA and left at room temperature for 
20-30 minutes. Hearts were then washed extensively in tap water to remove the 
PFA. They were then placed in a 15ml falcon tube of water and put on roller 
bars. The water was replaced every 5-10 minutes. This causes lysis of any 
remaining blood in the heart. 
 
Time in water was mimised to prevent blistering of the external walls of the 
heart due to local dissection. The hearts were transferred to 4%PFA for 
overnight fixation, after which additional fine dissection could be carried out. 
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2.4.2 Tissue Dehydration 
 
The hearts were washed in PBS for 30 minutes at a time, for a total of 4 washes. 




The hearts were immersed overnight in a 50:50 mix of methanol and JB-4 dye 
mix (200ml Solution A, 2.5g Catalyst (benzoyl peroxide, plasticised), 0.55g 
Eosin B, 0.113g Acridine Orange stirred overnight and filtered through 0.22 µm 
PES membrane). Samples were briefly rinsed in JB-4 dye mix to remove any 





Samples were embedded in JB4 mix in a custom mould, and a plastic “chuck” 
was placed on top (figure 2.7). Three hearts were embedded in each resin block. 
 
Solution B and JB-4 dye mix were combined (0.6 ml Solution B per 10 ml JB-4 
dye mix) and poured into the mould. 10-30 minutes after mixing, viscosity was 
sufficient to position the hearts apex up.  
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Figure 2.7 Embedding embryonic hearts. 
The 10mm custom made mould required for embedding of embryonic hearts. 
The square wells in the centre are for the heart to sit in. The circular depression 
or “shelf” allows the plastic chuck to sit over the sample and adhere to it. 6 of 
the 8 wells contain embedded hearts in resin, and the plastic white chuck has 
been placed on top.  
 
The exposed surface of JB-4 in and around the chuck was covered with a thin 
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2.4.5 Preparing blocks for imaging 
After embedding, the polymerised blocks were removed from moulds, trimmed 
and baked to harden them for sectioning (Figure 2.8).  
 
 
Figure 2.8 Removal of the block from the mould. 
An adjustable wrench was used, and the mould covered with tissue paper to 
prevent any splashing from liquid JB4 and mineral oil. Care must be taken not to 
damage the chuck, as this is required to fix the block to the sectioning machine. 
 
Excess resin was trimmed from around the circular edge of the chuck with a 
blunt knife or scissors (Figure 2.9). 
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Figure 2.9 Trimming the resin blocks. 
A block that has been trimmed with a blunt knife. The pieces of excess resin can 
be seen on the paper towel. They need to be removed prior to sectioning so that 
the chuck can be securely attached to the HREM machinery. 
 
The resin blocks were baked at 95 – 100°C overnight, to ensure the blocks were 
completely hard before sectioning. They were then stored at 4°C (Figure 4.10). 
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Figure 2.10 A finished resin block. 
Two E15.5 hearts are visible in the resin block, with their apex pointing 
downwards, as the block has been inverted after removal from the mould.  
 
2.4.6 Harvesting and preparing Adult hearts for HREM 
 
This protocol was adapted from the published protocol from 
https://dmdd.org.uk/hrem/, and personal communication with Dr T Mohun. 
 
The adult mouse was transferred into PBS at 37°C after being culled, and the 
thorax opened by sternotomy. The thymus and restrictive attachments, such as 
the diaphragm, were removed. The great vessels were isolated and lifted out of 
the chest cavity with the heart. To aid exsanguination, any clots forming in the 
distal vessels were removed, and the heart was gently agitated whilst 
submerged in the warm PBS. Further excess tissue not required for examination 
was removed before transferring to 4% PFA for 30 minutes. 
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The dissected hearts were washed extensively in tap water to remove the PFA. 
The water was changed every 10-15 minutes until the hearts appeared clear of 
blood, and then transferred to 4% PFA. 
 
The same protocol was used for dehydration, infiltration and embedding as that 
detailed for the embryo hearts (sections 2.4.2, 2.4.3, 2.4.4, 2.4.5), with the 
exception of methanol washes all being one hour steps as opposed to 30 
minutes, and infiltration in JB4-dye mix was for a week. A finished adult heart is 
shown in figure 2.11. 
 
Figure 2.11 Example of an embedded adult heart. 
Due to the larger sized heart, this required a larger 17mm depth custom mould. 
 
2.4.7 Sectioning HREM blocks 
 
Sectioning was carried out at the Crick Institute in T Mohun’s laboratory. The 
setup of equipment is shown in figure 2.12.  
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Figure 2.12 Set up of the HREM sectioning equipment. 
The camera sits directly above the block and the blade moves forwards and 
backwards to cut each slice. A fan is required to ensure that the cut section does 
not remain on the block and obscure the picture. Photograph taken on a visit to 
T Mohun’s laboratory at the Crick Institute. 
 
The top corner of the block was marked to maintain the orientation of the block 
images once they have been sectioned (Figure 2.13). An initial photograph was 
taken of the graticule, to calculate the pixel size for image processing. The block 
was then sectioned (~2 µm thick sections). 
 
Identifying Novel Genes that cause Congenital Heart Disease  117 
 
 
Figure 2.13 Orientation of the hearts in the resin block. 
The blue block represents how the three hearts were orientated in the block in 
relation, to the score mark made in the top right corner. A photograph of a real 
block is shown. Black arrows indicate the scoring visible in the top right hand 
corner of the block made prior to sectioning. This indicates that heart A is in the 
top right hand corner. The blue arrow points to some imperfections on the block 
surface and the green arrow indicates some tissue that is already visible at this 
top level of the unsectioned block. 
 
2.4.8 HREM Image processing 
 
2.4.8.1 Preparation of Images 
 
Processing was carried out using Graphic Converter 9 (free software 
www.lemkesoft.de), Photoshop (Adobe, Knoll and Knoll 1990), ImageJ (free 
software https://imagej.net), Guideliner (free software 
https://www.dsd.net/prod/mac/guideliner.php), Quicktime Player (free 
software[514]) and Osirix ([515]) on a Mac pro. F Prim at the Crick Institute 
taught me how to carry out the image processing. 
 
Graphic Converter 9 was used to create a video from all the section images. Any 
substandard images were identified on the video (viewed in Quicktime) and 
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removed.  The remaining images were then imported into ImageJ, and 
converted to greyscale 8 bit. The proportional scale was then reduced by 50% or 
less to produce a smaller sized data set.  
 
A Photoshop macro was created, to optimise the contrast between the resin and 
tissue. The three stages required in the macro were crop, adjust image levels 
and adjust image curves. The Guideliner app was used to guide image cropping. 
ImageJ was used to invert the images and reduce the final stack size to around 
500-700Mb. 
 
2.4.8.2 Conversion to 3D Model 
 
The ratio of pixels per 1µm was calculated using ImageJ, based on the initial 
image taken of the graticule. This was used to calculate a scaling factor as 
shown below, to ensure that the images remain proportional in 3D. 
 
Measurement from graticule:  
5500 equates to 5235pixels = 1.05062µm per pixel. 
 
Calculation of scale factor: 
 
For a 450Mb file size, the scaling factor is:  
√250/450 
= 0.745 
Scale Factor for 250Mb: 
  √      250 
          
_________ 
      Cubic 
(Mb) 
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Conversion to cubic data: 
The image needs to be reduced to 74.5% of its original size. The x and y axis in 
Osirix was 1, as both were 1 pixel in size. The z axis value, to produce cubic data 
was calculated as below. 
 
Z proportion =   section thickness     x   scaling factor. 
     Resolution in um/pixel 
  = 2.6 x 0.745 
       1.05062 
  = 1.844 
 
This proportions used in Osirix were therefore x = 1, y = 1, z = 1.844 
 
The stack was imported as a DICOM into Osirix. The following setting were 
applied in the 2D viewer; WL/WW = full dynamic, CLUT = No CLUT, Opacity = 
Linear table and BW / RGB = B&W. The x, y and z values were calculated were 
entered to produce a 3D image which could be rotated and cropped as 
necessary. 
 
2.5 Mouse Phenotyping 
 
This section covers phenotyping of both adult mice and embryos, for cardiac and 
extra cardiac features. All phenotyping in embryos was carried out blind to 
genotype. In most cases, I knew the genotype of adult mice because they were 
either heterozygous females being culled to collect embryos, or previously 
genotyped mice that had to be culled because of welfare issues.  
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2.5.1 Embryo Phenotyping 
 
I devised a protocol based on those used by EMPReSS [516] and the IMPC [214] 
for use in the Deciphering Mechanisms of Developmental Disorders (DMDD) 
pipelines [516]. The protocol I constructed included a more detailed analysis of 
the heart, based on the features expected at the specific gestation [224]. The 
expected cardiac development at the stages to be studied are outlined in 
appendix C. A single protocol was used for embryo phenotyping given that there 
are no significant differences between male and female anatomy at E15.5, with 
the exception of the reproductive systems [517]. Embryonic development was 
staged by measurement of the interdigital web [518]. A copy of the protocol can 
be found in appendix D. 
 
Cardiac anatomy was assessed using both the raw axial section images, and the 
3D reconstructions. Abnormalities were confirmed on orthogonal 2D imaging and 
3D reconstructions in Osirix.  
 
2.5.2 Adult Phenotyping 
 
Adult mice were phenotyped to varying degrees. Detailed cardiac assessment 
was carried out on a group of 2 month old Prkd1Em2/+ mice using MRI and a 
single Prkd1Em2/Em2 heart was analysed by HREM.  
 
Mice were examined for gross external malformations as part of normal mouse 
husbandry processes. Brief internal examinations were conducted on any mice 
that were culled for any reason. This consisted of an examination of all organ 
systems with the exception of the brain and spinal cord, by visual inspection 
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2.6 MRI Imaging of Adult Mice 
 
2.6.1 Harvesting and preparing Adult hearts for MRI 
 
Surplus two month old male Prkd1Em2/+ mice were imaged using MRI. Mice were 
sacrificed with overdose of carbon dioxide, and death confirmed by onset of rigor 
mortis. The mouse was then stored at -20°C until required for scanning.  
 
2.6.2 MRI Protocol 
 
The protocol detailed below produced images with a resolution of 50µm. All 
imaging was carried out on a 7 T Bruker Avance III (Ettlingen, Germany) MRI 
system. The protocol was devised by M Prior (Senior Research Fellow, University 
of Nottingham). 
 
Mice were positioned in the scanner on the animal bed and a small, curved 
receive-only coil was placed over the heart area for data acquisition. Signal 
excitation was carried out by a 72 mm internal diameter volume coil. A scout 
image was acquired showing three orthogonal planes through the chest region to 
help align the subsequent scans with the heart. 
 
For cardiac imaging, data were acquired using a 3D fast spin-echo (RARE) 
method with the following parameters: echo spacing of 12 ms, repetition time of 
1000 ms and an echo train length of 8 echoes. The phase encoding start position 
was shifted to allow an effective echo time of 24 ms. Data were acquired with a 
field of view of 26 x 23.3 x 10.5 mm using 520 x 466 x 210 data points, 
respectively, resulting in an isotropic image resolution of 0.05 mm. 
 
The method was reliant on the restricted field of view of the surface coil to limit 
the area that had to be covered by the data acquisition and thereby reduced the 
total acquisition time. However, it was necessary to place a 7 mm thick 
saturation band on the edge of the field of view opposite to the coil to reduce the 
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extent of wrap-around artefacts in the final images. Fat suppression was also 
employed to reduce image artefacts. 
 
The acquisition time was 3 h 54 min for one image volume and a total of five 
image volumes were collected from each mouse. This resulted in a total imaging 
time for each mouse of 19.5 hours. It was anticipated that field drift may occur 
over such a long acquisition time and that image blurring might be apparent in 
such high resolution datasets. To allow for correction of this, the acquisition was 
split up into 5 volumes, so that the acquisition software could recalculate the 
field value at the start of acquisition for each image volume. Data from five 
images volumes were added together following rigid body alignment carried out 
with the FLIRT function in FSL (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki).  
 
 
2.6.3 Cardiac Assessment of MRI Scans 
 
ITK-Snap software was used for analysis http://www.itksnap.org. Review of 
orthogonal imaging (Figure 2.14) was carried out by myself and Dr B Erhayiem. 
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Figure 2.14 MRI images of adult mice. 
ITK-Snap was used to view the MRI images produced. It provides simultaneous 
orientation in axial, sagittal and coronal planes allowing easy identification of 
structures. 
 
In addition to assessment of cardiac morphology, we took the following 
measurements: 
In the short axis, at the mid-ventricular level where the papillary muscles are 
present: 
- RV free wall thickness 
- LV anterior, posterior and lateral wall thickness 
- Diameter of the IVS 
- Internal diameter of the LV, AP and transverse measurements 
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Measurements of the aortic root were taken at the level of the sinus of Valsalva 
(Figure 2.15): 
- Three measurements across the commissures 
- Diameter measure on long axis image (coronal plane). 
- Diameter measure on perpendicular long axis (sagittal plane). 
Measurements of the ascending aorta 
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Figure 2.15 Aortic measurements using MRI. 
Short and long axis views of Prkd1Em2/+ mouse illustrating some of the 
measurements made.  
A. Measurements of the aortic root were taken at the level of the sinus of 
Valsalva. The maximum measurement was taken from the long axis image 
(coronal plane). The aortic root at this level was also assessed in the sagittal 
plane. In addition 3 measurements were taken across the cusps. 
B: Diameter of the ascending aorta. The widest diameter of aorta was measured 
at level of pulmonary artery in the short axis view. 
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2.7 Disposal of Mice and Tissue 
 
Remaining mouse tissue was stored at -20c in the Bio Support Unit and MRI Unit 
and then disposed of by the staff there. Tissue no longer required that had been 
removed from the unit was double bagged and incinerated as per University 
protocol. 
 
2.8 Identifying Pathogenic CHD Mutations for Feedback 
 
Confirmation of pathogenic mutations identified in known CHD genes through 
WES [12] was carried out by PCR. The predicted consequence was confirmed 
using the Ensembl Variant Effect Predictor (VEP) [493]. HGMD [519], the Leiden 
databases (LOVD) [520], ClinVar [521] and Pubmed 
(https://pubmed.ncbi.nlm.nih.gov/) were reviewed for additional information 
about each variant. Clinical records at Glenfield hospital were examined to 
determine if the phenotype and family history were consistent with the 
mutation.  
 
If the individual had not already received a genetic diagnosis since recruitment 
to the study, and if they had consented to receive results, the information was 
relayed by Dr Bu’Lock (Consultant Paediatric Cardiologist) and I together, or by 
Dr Bu’Lock alone. The relevant information required for Clinical Genetics review 
and testing in an NHS laboratory was provided.  
  
PCR was carried out as described in section 2.2.1.2, followed by PCR clean up 
(2.2.6) and sequencing (2.2.7). A higher annealing temperature of 58.7°C and a 
slightly longer extension time of 40 seconds was required for PCR to confirm the 
mutation c.992A>G, (p.Asn308Asp) in PTPN11. 
 
Touchdown PCR was required to confirm PTPN11 mutation c.188A>G, 
(p.Tyr63Cys). An initial denaturation step was carried out at 95°C, for 2 
minutes. Denaturation was for 30 seconds at 95°C, annealing was for 30 sec at 
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62.5ºC, with a decrease of 0.5ºC per cycle, followed by 30 seconds at 72°C. 14 
cycles were required before a further denaturation step for 30 sec at 95ºC. 
Annealing was for 30 sec at 55.5ºC, extension was for 30 seconds at 72°C and 
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This chapter documents my involvement in the following publication: 
 
Exome Sequencing reveals distinct genetic architectures for syndromic 
and non-syndromic congenital heart defects, and three novel disorders 
[12]. 
Alejandro Sifrim, Marc-Phillip Hitz, Anna Wilsdon et al. Nature Genetics 
September 2016. 
 
A copy of this paper can be found in Appendix F. This study makes use of data 
generated by the DECIPHER community. A full list of centres who contributed to 
the generation of the data is available from https://decipher.sanger.ac.uk and 
via email from decipher@sanger.ac.uk. Funding for the project was provided by 
Wellcome. As per the Decipher citation agreement, all recruiting centres for 
individuals identified through DDD were contacted. 
 
My contribution to this paper included phenotyping, method development and 
data analysis and writing. 
 
Through bioinformatic analysis of a large cohort of individuals with CHD, we 
identified three novel CHD genes. This chapter describes my contribution to this 
work, and one of the new genes we described (CHD4). It is included here to 
present a complete story for the following two chapters, which describe the 
experimental work I carried out on two further novel genes we identified 
(Chapters 4 and 5: PRKD1, Chapter 6:CDK13). 
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3.1 Whole Exome Sequencing in Congenital Heart Disease 
 
Traditional gene discovery in CHD relied upon identification of new genes in 
pedigrees with Mendelian patterns of inheritance, followed by targeted 
sequencing in cohorts with an identical phenotype. Whilst this worked well, these 
families are rare in CHD. In most instances, there is only a single individual in 
the family with CHD. This method also predisposes to ascertainment bias, by 
only including individuals with distinct phenotypes. This means we may not 
discover the full spectrum of abnormalities associated with that particular gene.  
 
More recently exome sequencing projects in large cohorts with diverse 
phenotypes, such as the DDD study, have proved successful at identifying novel 
disease genes in neurodevelopmental disability [522].  Prior to the publication of 
Sifrim et al. [12], a similar approach using WES in unselected CHD phenotypes 
to investigate single gene causes of CHD had been tried. Homsy et al. [14] and 
Zaidi et al.[16] demonstrated the contribution of de novo damaging variants to 
syndromic-CHD (S-CHD), an important role for histone modifying genes, and 
identified the novel CHD gene RBFOX2. They found that 20% of S-CHD and 2% 
of NS-CHD could be explained by de novo mutations in genes highly expressed 
in the developing mouse heart. These two studies went some way to explaining 
the low recurrence risk in S-CHD, but did not identify any significant results for 
NS-CHD, which accounts for the majority of people with CHD. These two papers 
are considered further below. 
 
3.1.1 De novo mutations in histone-modifying genes cause congenital 
heart disease. 
 
Zaidi et al. was the first study to use WES in a large cohort of unselected CHD 
and identify that de novo mutations were an important cause of CHD.[16]. They 
studied 362 trios, who were selected based on an index with severe CHD, no 
known genetic diagnosis, and no family history of CHD. The control group 
comprised of trios of parents and unaffected siblings collected as part of an 
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autism study. They compared the mutations found in cases and controls in a 
gene set referred to as the high heart expression (HHE) genes. These 4,169 
genes are mouse genes with human orthologues that were in the top quartile of 
expression in an E14.5 mouse heart based on RNA sequencing. There was a 
significant excess of de novo protein altering mutations in the HHE genes in 
individuals with CHD, compared to controls.  
 
To isolate those mutations that were most likely to be deleterious, they 
increased the stringency of variant filtering which resulted in a higher odds ratio 
(OR) of de novo mutations in these genes in the CHD group, compared with 
controls. Similar increases in the OR were obtained when using in silico 
programmes, such as polyphen2, gene expression levels in the developing heart 
and RNA expression at E9.5 to predict pathogenicity. They also considered CHD 
by subtype. The OR of de novo mutations in CHD compared to controls was 
increased for specific CHD groups including left ventricular obstruction, 
conotruncal defects and heterotaxy. 
 
Evidence that these predicted pathogenic mutations are significant in the CHD 
cohort is supported by the finding that there was no increased burden in the 
number of de novo mutations overall, or in genes in the lower quartile of heart 
expression in the CHD cohort. There was no significant difference in the 
mutation burden in genes expressed in other tissues such as the adult liver, 
brain, heart and lung, when compared with the control cohort.  
 
Zaidi et al. identified that abnormal histone modification is likely to be important 
in the pathogenesis of CHD. This theme has been seen again in subsequent 
studies [12, 14]. Predicted damaging de novo mutations were identified in eight 
genes that play a role in histone modification in the CHD cohort, some of which 
are already linked with CHD. The eight genes were MLL2 (Kabuki Syndrome), 
WDR5, KDM5A, KDM5B (AR mental retardation, including CHD), RNF20, UBE2B, 
CHD7 (CHARGE Syndrome) and USP44. They are involved in production, 
removal or reading of methylation of H3K4 (histone H3, at lysine 4). This is a 
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well-studied acetylation/methylation site on histone 3, which plays an important 
role in transcription [523]. Genes involved in H3K4me modifications, including 
KDM6A (X-linked Kabuki Syndrome) were the only gene set that was 
significantly enriched in the CHD cohort, based on an excess of mutations 
compared to that expected by chance, and absence of mutations in these genes 
in the control population. There was no consistent CHD genotype-phenotype 
association, but the majority had S-CHD. This is not surprising given that several 
of these genes are known to cause S-CHD already.  
 
This study demonstrated the benefits of an untargeted phenotype approach in 
expanding genotype-phenotype correlations. For example, an atypical non-
syndromic phenotype was seen in an individual with a CHD7 mutation, who was 
reported to have none of the significant features of CHARGE Syndrome. They 
were also able to retrospectively diagnose an individual with Kabuki Syndrome, 
who had a mutation in MLL2. This approach may have resulted in an earlier 
diagnosis for this individual.   
 
A number of other genes harboured multiple mutations, and may be significant. 
SMAD2 demonstrated more mutations expected than by chance and compared 
to the control data set, as did SUV420H1, MED20, HUWE1, CUL3, NUB1 and 
NAA15. Both individuals with SMAD2 mutations had dextrocardia, in keeping 
with its known involvement in left-right organisation [524]. The authors felt that 
this could explain the individuals’ phenotypes.  
 
13 further probands were identified with mutations in a predefined set of 277 
genes known CHD genes. This included two genes that had been identified by 
CNV studies (RAB10, BCL6) [18], providing additional evidence of their role in 
CHD. An individual with a severe conotruncal defect was found to have a 
mutation in NF1. Mutations in this gene cause Neurofibromatosis type 1, where 
this type of CHD is unusual. It was not clear from the paper whether the person 
had other signs of neurofibromatosis or not. 
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Overall, Zaidi et al. identified an important contribution of de novo mutations to 
CHD, but the exact contribution to S and NS-CHD was not defined. One 
limitation is that the cohort was made up of individuals with severe CHD only. 
Additionally the HHE gene list was based on mouse expression, and we know 
that mouse genes do not always translate to similar phenotypes in humans.  
 
3.1.2 The role of De novo mutations in Congenital Heart Disease with 
Neurodevelopmental and other Congenital Abnormalities.  
 
The next major publication using WES in CHD came from Homsy et al [14]. This 
WES study includes the 355 trios from the previously described Zaidi et al [16], 
in addition to other CHD trios with no known genetic diagnosis (n=1213). NS-
CHD and S-CHD are considered separately, and are referred to as isolated CHD, 
and CHD with neurodevelopmental disability (NDD) and/or other congenital 
abnormalities. The control population of 900 healthy trios were collected as part 
of a study into the genetics of autism. They compared the actual and expected 
numbers of de novo mutations in each gene by variant class to identify 
significant genes, the same method reported by Samotcha et al. [494] and used 
in our publication described in this chapter [12]. 
 
Like Zaidi et al.[16] before them, they demonstrated an important contribution 
of de novo mutations in CHD. A significant enrichment (1.4 fold) of predicted 
deleterious de novo LoF (loss of function) and missense variants was found in 
the CHD cohort [525]. All phenotype groups except heterotaxy, displayed this 
trend. Heterotaxy is a diverse group and includes a number of known recessive 
causes, so this is perhaps not surprising despite the results from Zaidi et al [16]. 
In addition, there was a 2.4 fold increase in deleterious mutations in 4420 genes 
in the HHE list of genes [16]. This was not seen in controls.  
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Homsy et al. then considered the mutational burden in S-CHD and NS-CHD, to 
see if there was a difference. There was a significant enrichment of de novo 
predicted damaging LoF mutations in S-CHD. Enrichment was higher when they 
considered genes in the HHE list [16] in the most severe phenotypes (CHD with 
both congenital anomalies and neurodevelopmental disability). They did not 
demonstrate any significant enrichment in NS-CHD, so the genetic mechanism 
underlying this group remained unknown. 
 
21 genes were identified with more damaging de novo mutations than expected 
by chance in the CHD cohort only, and not present in controls. These genes are 
thought likely to contribute to the pathogenesis of CHD. In keeping with this 
theory, a number of genes were identified that were already known to cause 
























PTPN11 Noonan Syndrome  Yes 
KMT2D (MLL2) Kabuki Syndrome Yes 
RBFOX2   
KDM5B AR Mental Retardation  
KRT13 White sponge naevus  
MYH6 ASD, Dilated and Hypertrophic 
Cardiomyopathy 
Yes 
CAD AR epileptic encephalopathy  
NAA15 AD mental retardation  
SMAD2 Identified by Zaidi et al as potentially 
pathogenic[16] 
 
RABGAP1L   
POGZ White Sutton Syndrome Possibly 
JAG1 Alagille Syndrome Yes 
GANAB AD polycystic kidney disease  
DTNA LVNC with/without CHD Yes 
PPL   
CHD7 CHARGE Syndrome Yes 
ZEB2 Mowat Wilson Syndrome Yes 
FBN1 Marfan Syndrome Yes 
CHD4 Unknown, but confirmed as CHD gene by 
Sifrim et al.[12] 
Yes 
AHNAK   




Table 3.1 Genes identified with de novo mutations. 
Genes with damaging de novo variants identified in the CHD cohort only, the 
associated syndrome and whether CHD is a feature or not. A number of these 
genes are associated with neurodevelopmental disorders. 
 
PTPN11, KMT2D and RBFOX2 had significantly higher numbers of de novo 
damaging mutations than the others listed in this table. RBFOX2 is the only 
novel gene of the three. Three individuals from this study, and an additional 
patient with a deletion of RBFOX2 [526], all had hypoplastic left heart syndrome 
(HLHS). The authors suggest that given this gene is needed for correct 
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development of the zebrafish heart [527], and is involved in epithelial to 
mesenchymal transformation which is linked to HLHS [528, 529], it is likely to 
be a true CHD causing gene. The mouse model however does not have CHD, 
although Rbfox2 is reported to be expressed in the heart [530]. Further research 
suggests it may play a role in heart failure and [531] and that it is important in 
controlling the transcriptome of HLHS hearts [532]. 
  
Homsy et al. also considered which gene ontology terms were enriched in the 
CHD cohort [14]. A number of categories were identified as significant based on 
an enrichment of damaging de novo variants, and included anatomic structure 
morphogenesis, cardiovascular system development, neurodevelopmental 
abnormality and chromatin modification. Chromatin modification was highlighted 
particularly, as this is in line with the results of Zaidi et al [16]. This group of 
genes were still significant when the previously reported patients from Zaidi et 
al. were removed from the analysis, suggesting this finding is not just associated 
with the initial Zaidi et al. cohort. They suggested these genes can cause a high 
risk of CHD.  
 
More genes were identified as potentially significant based on the number of 
mutations found involving that particular gene. In the CHD only cohort (NS-
CHD), damaging de novo mutations were identified in SMAD2, which has been 
highlighted previously [16]. KANSL1 was also identified. Mutations (and 
deletions) in KANSL1 are known to cause AD Koolen-De Vries Syndrome which 
includes CHD [533]. This expands the phenotype of this syndrome. Both KDM5A 
(demethylase of H3K4me2/3) and HLTF (role in chromatin modification) [534] 
may be significant. HIRA, UBE2B, RNF20 and CTR9 were also highlighted.   
 
In both the CHD and neurodevelopmental disorder cohorts, de novo damaging 
mutations were identified in ARID1B, CHD4, TLK2, KDM5B, KMT2C, KMT2D, 
POGZ, KDM6B, NSD1, WHSC1, ASH1L. Of these genes KANSL1, KMT2D, KDM5B 
and NSD1 are associated with S-CHD. POGZ causes White-Sutton Syndrome and 
a single individual has been reported with CHD [535]. KMT2C and WHSC1 have 
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links with methylation and KDM6B has a role in heart development. A single 
individual has been reported with an abnormality in the SVC and the KDM6B 
monoallelic Neurodevelopmental Disorder with Coarse Facies and mild distal 
Skeletal abnormalities [536]. More individuals with damaging mutations in these 
genes will be required to determine if they definitely cause CHD, as was the case 
with CHD4, which we later showed to be a true CHD gene after it reached 
genome wide significance [12]. 
 
The mutational burden in both S-CHD and NS-CHD was compared by Homsy et 
al, after excluding patients with a known genetic diagnosis identified from the 
sequencing results. There was enrichment of damaging de novo mutations in 
genes from the HHE list in the S-CHD cohort. This was 3 fold in those with CHD 
and NDD or congenital abnormalities, and even higher in those with CHD, NDD 
and other congenital abnormalities (4.7-fold). There was no enrichment in the 
NS-CHD or control groups. This confirms the findings of Zaidi et al.[16], that de 
novo mutations contribute to S-CHD, but also suggests that we are more likely 
to find de novo mutations in those with the more severe presentations of S-CHD. 
Homsy et al. predicted that de novo mutations in these HHE genes contributed 
to CHD in 20% of patients with CHD, NDD and congenital abnormalities, 10% of 
CHD with NDD, 6% of CHD with congenital abnormalities, and only 2% of NS-
CHD. The authors suggested that reduced penetrance in the same genes could 
lead to both S-CHD and NS-CHD.  
 
We have seen a number of known NDD genes being highlighted as potentially 
significant in individuals with CHD (Table 3.1). A number of the genes showing 
enrichment for de novo mutations, were expressed in both the developing heart 
and the developing brain, suggesting a shared underlying genetic pathogenesis 
of CHD and NDD. To assess this possible relationship further, Homsy et al. 
investigated the overlap of genes with de novo damaging mutations in 
individuals with NDD and CHD, and 1161 genes that were identified with 
damaging de novo mutations in a population with NDD, but no CHD [14]. 69 
genes were shared between the two cohorts and were significantly enriched for 
de novo damaging mutations (2.6-fold enrichment). They were also significantly 
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more likely to be in the top quartile of heart and brain development expressed 
genes. A number of these genes are important in cardiac development pathways 
including the WNT and NOTCH pathways. This led to the important suggestion 
that there is a common aetiology for both CHD and neurodevelopmental 
disorders, but with variable expressivity of the genes involved.  
 
This was the first study to really consider the contribution of damaging 
mutations in both S-CHD and NS-CHD, and identify a genome wide significant 
novel CHD gene. The contribution of de novo mutations in S-CHD was 
confirmed, but the genetic mechanism behind NS-CHD remained unexplained. 
They also confirmed the role of chromatin modifying genes in CHD and proposed 
an overlap between the aetiology of CHD and neurodevelopmental disorders.  
 
3.1.2 Current use of WES in CHD 
 
Unfortunately as things stand, the majority of individuals with CHD do not 
receive a genetic diagnosis, but studies such as these suggest that WES may be 
successful in identifying novel CHD genes and diagnoses for patients [537]. 
Testing within the NHS has moved away from single genes, to panels of multiple 
relevant genes. This is likely to move towards WGS in the future. In the 
meantime, it is important that we try and identify novel CHD genes, so that 
more extensive panels can be provided for use on a clinical basis. The NS-CHD 
population is the most underserved; they make up the majority of individuals 
with CHD, but are less likely to receive a genetic diagnosis. Understanding the 










1. To accurately phenotype a cohort of individuals with CHD. 
2. To produce a list of high confidence genes known to cause CHD in humans 
based on evaluation of the current available literature. 
3. To identify novel CHD genes using WES and established statistical models, 
which can be put forward for functional and animal studies. 
4. To identify pathogenic mutations for feedback to individuals involved in 
the study locally. 
 
3.3 Results and Discussion 
 
3.3.1 Phenotyping the Cohort for Analysis 
 
WES results from 1891 individuals (1365 trios) with CHD were analysed in Sifrim 
et al [12]. The majority were NS-CHD (NS-CHD = 1281, S-CHD = 610)) 
(Appendix G, supplementary table 1). Appendix H (Supplementary table 2) 
indicates the number of trios and which centres they were collected from.  
 
The individuals with CHD had been collected by a number of different groups and 
as a result both the cardiac and non-cardiac phenotypes required standardising 
before any analysis could be carried out. A number of phenotyping systems 
already exist. These include the Human Phenotype Ontology (HPO) [538] and 
the European Paediatric Congenital Cardiology Codes (EPCC)[539]. HPO 
classification has been used as part of Online Mendelian Inheritance in Man 
(OMIM)[540] and the DDD project [496] and is familiar to Clinical Geneticists. A 
proportion of the cohort included in this paper are DDD participants, which have 
HPO coding already. Cardiologists however are more familiar with the EPCC 
codes, a system designed for phenotyping only cardiac defects.  
 
We transferred all CHD phenotypes into HPO and EPCC terminology. Extra-
cardiac information was classified using HPO terms. Additionally, all individuals 
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were allocated to either syndromic (S-CHD) or non-syndromic CHD (NS-CHD) 
groups. Additional medical information was gathered from the medical notes 
when there was insufficient detail, or I consulted the recruiting clinician for the 
Glenfield Hospital cohort. Information on other contributing factors, family 
history and other significant information was also coded. We discussed 
classification systems with Dr Bu’Lock. 
 
We categorised the phenotypes using the following guidelines. 
 
1. Classify the type of CHD as accurately as possible. 
Problems arose due to ambiguous cardiac phenotyping in the raw data. For 
example, some individuals were recorded as having an abnormality of the heart 
with no further information. Others were recorded as having pulmonary stenosis, 
which could represent either pulmonary artery stenosis or pulmonary valve 
stenosis. I reviewed the medical records to confirm the specific lesion before 
deciding on a final code.  
 
2. Use the most specific IPCC and HPO term possible 
 
The phenotype codes must match the patient’s phenotype as closely as possible 
to facilitate accurate interpretation of the genotype results. Both the HPO and 
EPCC systems are hierarchical, with a less specific term at the top and an 
increasing number of subdivides to reach a more specific term. We used the 
most specific term possible. We also needed to be able to collect phenotypes 
together in large enough groups to allow a robust and sufficiently powered 
analysis. Highly specific groups containing only a few individuals, or large groups 
of individuals with a non-specific phenotype are not ideal. Grouping defects by 
heart field or lesions with similar developmental mechanisms was thought to be 
too difficult. We therefore assigned each individual with a detailed and a second 
more generalised term, such as secundum ASD and interatrial communication, 
using both HPO and EPCC terminology. 
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Individuals with multiple cardiac defects and complicated defects were difficult to 
categorise. For example, Tetralogy of Fallot (TOF) represents a combination of 
abnormalities. It is broken down into VSD, pulmonary infundibular stenosis, an 
overriding aorta and right ventricular hypertrophy. The primary pathogenesis is 
the septal abnormality and anterocephalad deviation of the outlet septum[541], 
so it may be appropriate to classify it as VSD mainly. However, this is clearly not 
the same as an individual with an isolated VSD. TOF has different developmental 
origins from isolated pulmonary stenosis. We therefore coded this lesion as TOF, 
rather than its separate components. 
 
However, other diagnoses should be categorised as multiple defects to 
distinguish them from each other. For example, transposition of the great 
arteries (TGA) with an intact ventricular septum is more common and less likely 
to be inherited than TGA with a VSD. It would be appropriate to classify these 
two subtypes of TGA separately as they do appear to be two separate entities. 
Supplementary table 3 in Sifrim et al [12]. Details the results of the phenotyping 
we carried out. 
 
3. Classify the individual as either S-CHD or NS CHD 
S-CHD was defined as individuals with CHD, who in addition had a distinct facial 
gestalt and/or at least one extra-cardiac abnormality and/or developmental 
delay/disability. NS-CHD was those individuals with CHD and no other 
abnormalities.  
 
Heterotaxia could be classified as either S-CHD or NS-CHD. Ciliopathies are a 
known cause of heterotaxy and result in a range of abnormalities including 
retinal degeneration, bronchiectasis, polydactyly, renal and hepatic 
abnormalities. A transient node in the embryo is responsible for left right 
patterning and contains motile cilia, therefore a defect in a single cilia gene can 
result in multiple abnormalities including situs abnormalities in the heart [542]. 
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It was decided to classify heterotaxy malformations as NS-CHD as these 
malformations can all be accounted for by one well established mechanism. Both 
isolated dextrocardia and dextrocardia with full situs inversus would both be 
classified as just heterotaxy.  Laterality disorders are less common in our cohort 
overall. 
 
The cohort comprised of 1365 trios, 518 were S-CHD and 847 were NS-CHD. 
The most common type of CHD was VSDs (19.4%), followed by aortic valve 
abnormalities (17.72%) and ASDs (14.86%). CoA, TOF, AVCD accounted for 
10% of individuals or more each. Please see appendix I (supplementary table 3) 
for the full table of results of the phenotyping using HPO codes. 
 
To facilitate discovery of novel CHD genes, phenotypes that might represent 
different genetic and non-genetic processes were removed from further analysis. 
This included patent ductus arteriosus (PDA), a common occurrence in preterm 
births. Often gestation at birth has not been recorded, so it is difficult to 
interpret if this is a normal finding or not. In addition, patent foramen ovale 
(PFO) was excluded. The foramen ovale normally closes soon after birth, but is 
found to be still patent in 20-35% of adults of different age groups [543]. 
Isolated arterial tortuosity, non-congenital aortopathies and cardiomyopathy 
were also excluded. In the main these are separate entities to CHD, although 
there is some overlap with CHD.  
 
Although the Nottingham cohort had some information on maternal diabetes, 
medications and teratogens in pregnancy, this data was not consistently 
recorded in all individuals. It did not specify if the mother had longstanding or 
gestational diabetes, or what glycaemic control was like periconceptually. This 
made it difficult to exclude a genetic cause of CHD in most individuals, so a 
decision was made to include them in the study. It would also be extremely 
difficult to include all these environmental factors into the analysis alongside the 
genetic analysis. 
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12,031 control exomes with matched ancestry, were ascertained from the 
parents of probands without CHD from the DDD project (n=7301) and assumed 
healthy blood donors from the INTERVAL study (n=4730) [496, 497].   
 
3.3.2 Defining the High Confidence CHD Gene List 
 
 
For the WES analysis, we produced a list of genes we were confident cause CHD 
in humans for the following purposes: 
 As a test list to see if the analysis picks up common genes such as 
PTPN11 to allow necessary quality control. 
 For comparison of mutational burden between the S-CHD and NS-CHD 
groups. 
 To identify those with mutations in known CHD genes so that the cohort 
could be split into resolved and unresolved CHD. 
 To identify pathogenic mutations in these genes which can be validated 
and fed back to that individual.  
 
The list was derived from three primary sources:   
 A list compiled by M Hitz causing S-CHD and NS-CHD in humans (n=234)  
 Genes causing cardiac phenotypes in the DDG2P genes database produced 
by the DDD project (n=250) https://decipher.sanger.ac.uk/ddd#ddgenes 
[495]. The DDG2P list has been produced by Clinical Geneticists using 
information from OMIM, UniProt, Nature Genetics and American Journal of 
Human Genetics (http://www.ebi.ac.uk/gene2phenotype/) [496, 540, 
544]. These genes are associated with developmental disorders.  
 Genes identified in CHD-Wiki, a freely available site set up and curated by 
J Breckpot https://homes.esat.kuleuven.be/~bioiuser/chdwiki/ [545].  
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Genes causing a cardiovascular phenotype that we would not want to include in 
the study including cardiomyopathy and arrhythmia were removed. Perinatal 
lethal genes were included if they were X-linked or had variable expression that 
might result in milder phenotypes, however there were no antenatal or post 
mortem derived DNA samples in the cohort. Genes that cause a cardiac 
phenotype due to a metabolic process were also not included given that this is a 
different mechanism.  
 
The genes were then split into two tiers based on the evidence available from 
the literature and previous animal models. Tier 1 genes are “confirmed” cardiac 
genes and tier 2 are “probable” and “possible” cardiac genes (Appendix J, 
supplementary table 19). This follows the same model used by the DDD project 
[495]. Each gene was annotated with inheritance pattern, whether it causes S-
CHD or NS-CHD and the disease mechanism e.g. gain or loss of function. 
Evidence of links with the heart was collected from OMIM [540], the MGI mouse 
database [546] and Pubmed (https://pubmed.ncbi.nlm.nih.gov/). Reported 
mutations in association with PDA in a preterm infant were not counted, as this 
could represent normal physiology.  
 
A list of 121 tier 1 genes (95 syndromic CHD, 24 non-syndromic and 2 genes 
that cause both syndromic and non-syndromic CHD) and 70 tier 2 genes (9 non-
syndromic CHD, 61 syndromic CHD) was finalised (appendix K, supplementary 
table 20) [12].  
 
3.3.3 De novo Mutations are an important cause of S-CHD, and NS-
CHD to a lesser extent 
 
The de novo analysis was based on a comparison of the actual rate of de novo 
mutations with the expected number under a null mutational model [494]. This 
considered all trios, as they did not need to be ethnically matched with a control 
population. 
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The number of de novo mutations was compared between S-CHD and NS-CHD 
and across three sets of genes;  
 
 CHD-associated genes. These are genes with good evidence that they 
cause dominant CHD in humans.  
 Non-CHD developmental disorder (DD) genes. These are genes 
known to cause developmental disorders, but not CHD derived from the 
DDDG2P list (see 3.3.2) [522]. 
 All remaining protein coding genes.  
 
The results were as follows. Please also see Figure 1A in appendix F. 
1. Across all trios, there was no difference in the burden of silent mutations 
in S-CHD and NS-CHD. 
 
2. In the S-CHD group, there was a significant excess of de novo protein 
truncating variants (PTVs) (27 variants, OR 81, p=1.21x10-43) and de 
novo missense variants (22 variants, OR 8.6 p=7.35x10-15) in autosomal 
dominant (AD) CHD-associated genes. The difference between S and NS-
CHD was most striking for PTVs, compared with missense variants. The 
observed difference between de novo PTVs in NS-CHD and S-CHD 
confirms the findings of Homsy et al. [14]. This burden additionally 
mirrors that observed in autism between individuals with and without 
intellectual disability [498]. 
 
3. In the NS-CHD group, there was a lower burden of de novo PTVs in AD 
CHD-associated genes (4 variants, OR 7.3, p=2.61x10-4).  
 
4. In the S-CHD group, there was a significant excess of de novo PTVs in 
non-CHD AD developmental disorder genes (12 variants, OR 18.4, 
p=3.49x10-13). This implies that some of the known non-CHD DD genes 
may also cause CHD. 
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5. In both S-CHD and NS-CHD, there was a significant exome wide excess of 
de novo missense mutations, in all other protein coding genes. This 
suggests that there are further AD CHD causing genes to be discovered. 
 
This confirms the findings of Zaidi et al. [16] and Homsy et al. [14], that de 
novo mutations are important in the pathogenesis of CHD. The role of de novo 
deleterious mutations had been predicted because of the low recurrence risk 
seen, and the likelihood that CHD results in reduced reproductive fitness.  
 
The higher rate of de novo PTVs in S-CHD compared to NS-CHD, confirms the 
findings of Homsy et al. where they considered CHD with and without NDD. NDD 
is the most common clinical abnormality seen in combination with CHD. 
Subsequently Jin et al. analysed WES results from a cohort of 2871 probands 
with CHD (2645 trios) and found a relatively low rate of de novo mutations in 
NS-CHD [15]. This cohort includes the individuals analysed in Homsy et al. and 
is published by the same group. They found that 3.1% of NS-CHD is a result of 
de novo mutations. This means that the genetic aetiology of NS-CHD remains 
unexplained in the majority. 
 
3.3.4 Inherited mutations may contribute to the pathogenesis of NS-
CHD. 
 
The inherited mutation analysis considered trios of European ancestry only, 
compared to an ethnically matched control population. The results were as 
follows. Please also see Figure 1C in appendix F. 
 
1. There was no difference in mutational burden of silent mutations across the 
NS and S-CHD groups. 
2. There was no difference in mutational burden of missense mutations across 
NS and S-CHD. 
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3. In the NS-CHD group, there was a significant excess of rare inherited PTVs in 
AD CHD-associated genes (17 variants, OR=2.67 p=1.1x10-4). This excess 
was not present in the S-CHD group (p=0.3). This is a novel finding. 
4. In the NS-CHD group, there was an exome wide excess of rare inherited PTVs 
(3318 variants, OR=1.08, p=1.51x10-5) in the remaining protein coding 
genes (group 3 genes). This was not seen in the S-CHD group and suggests 
that there are other novel genes showing incomplete penetrance to be 
discovered. 
 
For the first time, this study identified that different genetic mechanisms 
contribute to S-CHD and NS-CHD [12]. The inherited burden of reduced 
penetrance variants is a new finding. This could result from differences in 
coverage, ancestry and gender between the cohorts. However, principal 
component analysis (PCA) analysis has shown that both the S-CHD and NS-CHD 
groups have similar ancestry [12]. There was no significant difference in the PTV 
burden analysis between males and females. Variant calling used the same 
pipeline, although there were some differences between the sequencing 
parameters used to analyse all of the cohorts (sequencing depth and exome 
capture platform). If there were differences in the methodology that were 
significant, we should see differences in the burden of synonymous variants 
between the different cohorts. This was not detected.   
 
Another obvious question to consider is whether a parent is labelled as 
unaffected, but does actually have CHD. This was considered to be unlikely as 
many types of CHD would declare themselves before adulthood, and especially 
in pregnant women. However, it is also not uncommon for a milder lesion to be 
diagnosed incidentally or in later life. In the Glenfield cohort, family history was 
discussed as standard and parents were referred for imaging if there was a 
history of CHD in themselves or they have symptoms suggestive of CHD. Within 
the Clinical Genetics clinic, some parents may be referred for echocardiograms. 
However, routinely screening asymptomatic parents raises ethical questions and 
is not done routinely in all settings. 
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Under-phenotyping was not the source of this result and the significant exome 
wide association of rare inherited PTVs remains even after removal of known 
CHD causing genes and developmental disability genes. This suggests that there 
are further novel genes to be discovered and incomplete penetrance is present 
in CHD. 
 
Inherited PTVs were found in genes that cause S-CHD, in the NS-CHD 
population. The individual genes are shown in table 3.2 following a discussion of 
possible reasons that might explain why apparently damaging mutations in S-
CHD genes were identified in individuals with NS-CHD, and inherited from 
apparently normal parents. 
 
 Have the genes been correctly categorised as syndromic or non-
syndromic? 
 
The list of high confidence CHD genes was reviewed. The majority of the genes 
were clearly associated with either NS-CHD or S-CHD. A few could be classified 
as either. Deletions containing ELN cause S-CHD in the form of Williams Beuren 
Syndrome. However isolated mutations in ELN cause NS-CHD. In addition there 
is the possibility that disruption of the gene by abnormalities affecting promoter 
regions and other regulatory elements could also lead to a phenotype as shown 
for other genes [547, 548] and could produce the same syndromic phenotype as 
a deletion. Overall, no changes were made to the classification of genes in the 
list. 
 
 Does this mean that the patients have been incorrectly 
phenotyped, and a syndromic phenotype has been missed? 
 
Possible explanations for this happening include very mild abnormalities, and 
patients being phenotyped at a very young age, when abnormalities such as 
developmental delay or internal structural abnormalities would not necessarily 
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be immediately obvious. A number of these S-CHD genes can produce a mild 
and more subtle phenotype. We went back to the patient notes where possible 
to see if they phenotype was recorded accurately. A few Nottingham patients 
were subsequently found to have S-CHD rather than NS-CHD on review of up to 
date notes, and were moved in to the syndromic group. This did not change the 
results however and inherited damaging variants in S-CHD genes remained 
significant in the NS-CHD individuals. 
 
 Does this represent an expansion of the known clinical spectrum? 
 
As clinical testing has mainly been carried out on a gene by gene basis until 
recently, only patients with a convincing and syndromic phenotype were offered 
genetic testing. As a result, there is an ascertainment bias and fewer 
opportunities for us to discover the atypical, milder or non-syndromic 
phenotypes. Non-targeted sequencing studies like this allow an unbiased 
approach. It is possible that the phenotype is wider than previously thought and 























ABCC9 Cantu Syndrome, a mild phenotype could be missed. Also 
causes isolated atrial fibrillation and cardiomyopathy. 
ACTC1 NS-CHD. Isolated atrial septal defect (ASD), cardiomyopathy 
and left ventricular non-compaction. 
COL1A1 Ehlers Danlos Syndrome, a mild phenotype can be missed. 
Dominant negative mutations cause osteogenesis imperfecta, 
without CHD. 
ELN Mutations are associated with NS-CHD supravalvular aortic 
stenosis and peripheral pulmonary stenosis and cutis laxa. 
Deletion of ELN produces a S-CHD phenotype (Williams 
Syndrome).  
FBN2 Beals Syndrome, phenotype can be mild and contractures can 
be subtle at a young age. 
FGFR2 Phenotype of the craniosynostosis syndromes can be mild, 
and is also usually caused by gain of function mutations. LOF 
mutations cause LADD syndrome which does not include 
CHD. 
MYH6 NS-CHD. ASD and cardiomyopathy. 
NOTCH1 Can cause both S-CHD and NS-CHD. Associated with Adams 
Oliver Syndrome and isolated aortic valve disease.  
NOTCH2 Alagille Syndrome, phenotype can be mild and sometimes 
only isolated CHD is found in members of families with 
confirmed Alagille syndrome. 
SALL4 Okihiro Syndrome, phenotype can be mild. 
SOS1 Gain of function mutations cause Noonan Syndrome. Mild 
phenotype can be missed.  
 
Table 3.2 S-CHD genes identified in individuals with NS-CHD. 
AD S-CHD genes identified in the NS-CHD cohort, with explanation as to why 
they might be found in this population. Variants in recessive genes were not 
considered as they are unlikely to be pathogenic unless homozygous, or unless 
digenic mechanisms are known. 
 
Overall, we ensured that phenotyping was conducted as accurately as possible, 
which suggests that the phenotypic spectrum of some of these genes listed in 
table 3.2, might be wider than previously thought. 
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Another interesting finding was that the S-CHD genes in which we identified 
inherited mutations in the NS-CHD group, do not overlap with the S-CHD 
associated genes where de novo PTVs were detected in the S-CHD group 
(Appendix F: figure 1D in Sifrim et al [12], and table 3.3 below). This could 
result if the S-CHD genes with de novo mutations caused a more severe 
phenotype and led to reduced reproductive fitness to the extent that inheriting a 
deleterious mutation was unlikely to be compatible with life, and in turn the S-
CHD genes with inherited mutations produced a mild phenotype. Reviewing the 
genes and associated syndromes, this does not explain the division between the 
two groups of genes. For example, only de novo mutations were found in NSD1. 
LoF mutations and haploinsufficiency cause Sotos Syndrome which may be 
inherited. This could be a reflection of insufficient sample size. 
 
Other explanations for this finding include both expanded phenotype of known 
syndromes, mild phenotypes and different inheritance patterns, such as biallelic 
mutations in a normally monoallelic condition. Testing in larger cohorts might 
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Genes with de novo PTVs in S-CHD 
NSD1 Sotos Syndrome 
KMT2A (MLL) Wiedemann Steiner Syndrome 
ADNP  Helsmoortel van der Aa Syndrome 
CHD7  CHARGE Syndrome 
KMT2D  Kabuki Syndrome 
ANKRD11 KBG Syndrome 
MED13L Mental retardation and distinctive 
facial features with or without cardiac 
defects 
EHMT1 Kleefstra Syndrome 
CBL Noonan Syndrome-like disorder with 
or without juvenile myelomonocytic 
leukaemia 
KANSL1 Koolen-De Vries Syndrome 
ASXL1 Bohring Opitz Syndrome 
Genes with rare inherited PTVs in NS-CHD 
ELN Cutis Laxa, supravalvular aortic 
stenosis 
FGFR2 Craniosynostosis syndromes, LADD 
syndrome 
ABCC9 Cantu Syndrome 
MYH6 ASD and cardiomyopathy 
ACTC1 Isolated atrial septal defect (ASD), 
cardiomyopathy and left ventricular 
non-compaction. 
COL1A1 Ehlers Danlos Syndrome, 
osteogenesis imperfecta 
SALL4 Okihiro Syndrome 
NOTCH2 Alagille Syndrome 
SOS1 Noonan Syndrome 
FBN2 Beals Syndrome 
NOTCH1 Adams Oliver Syndrome and isolated 
aortic valve disease 
 
Table 3.3 Genes containing rare PTVs. 
Genes and related phenotypes, in which either de novo or inherited rare PTVs 
were identified. None of these genes showed both inherited and de novo rare 
PTVs. 
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3.3.5 Comparison with other disease models 
 
This analysis considered all CHD trios and compared them with other disease 
cohorts without CHD from published autism [498] and developmental disability 
studies [495] [499]. Across all groups there was no difference in the burden of 
de novo silent mutations, and there was no difference between those with NS-
CHD and controls. However, the excess of de novo missense mutations in S and 
NS-CHD, is similar to the excess seen in autism with and without intellectual 
disability [498]. In addition, the excess burden of de novo PTVs in S-CHD is 
similar to that seen in severe developmental disability without CHD. The rate of 
de novo PTVs in autism alone was much lower.  
 
There is a higher mutation burden with more severe phenotypes in NDD and 
autism, similar to S-CHD and NS-CHD. The more severe phenotypes of S-CHD 
and severe developmental disability show similar excess of de novo PTVs. 
Autism which would generally be classed as a milder phenotype than severe 
NDD, shows much lower burden, and NS-CHD and controls showed no excess 
burden. We see a similar higher burden of de novo missense mutations in S-CHD 
and autism with ID, compared with NS-CHD and individuals with autism alone. 
The increased rates of de novo mutations may reflect the reduced reproductive 
fitness associated with a more severe phenotype. 
 
3.3.6 Gene Function and Pathway Analysis 
 
We sought to identify enrichment of specific gene pathways and functions in 
CHD. The STRING PPI database [549] was used to determine where high 
confidence interactions (score > 0.9) existed between genes we had identified as 
potentially linked with CHD (genes with a false discovery rate of less than 50%). 
Genes related to chromatin modification, neural tube development, cardiac 
development and protein phosphorylation were significantly over represented 
(FDR<10%). Signalling pathways of note are the NOTCH-, IGF1-, HDAC Class II-
, ERBB and NFKB- pathways. Many of the top ranking genes could actually be 
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mapped together as shown in figure 3.1 below. This level of network connection 
was greater than that expected due to chance alone (p=5.84x10-3). Central hubs 
included known CHD genes such as PTPN11, NOTCH1, SOS1, SMAD4 and EP300. 
 
 
Figure 3.1 Protein-protein interactions between high confidence genes. 
Reproduced with permission from Sifrim et al. High confidence interactions found 
in the STRING PPI database in top-ranking set of CHD-associated genes (false 
discovery rate <50%) in the integrated de novo and inherited variant analysis. 
Known CHD-associated genes are coloured blue, other nodes are scaled 
according to their association false discovery rate. The size of the nodes is scaled 
by its degree. 
 
This confirms the previous reports of the importance of chromatin modifiers [14, 
16] and also suggested HDAC class II genes are important, which is supported 
by mouse studies [550-552]. Genes related to neural tube development also 
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appear significant, whether this could relate to folate metabolism or not is 
unclear [553-555]. 
 
The highly connected map of genes we have produced can be used to identify 
additional genes that might be significant by exploring other related genes and 
proteins. Priest et al utilised a model previously used in cancer and NDD to 
identify protein networks that were enriched in individuals with AVSD, to identify 
novel loci [353]. 
 
3.3.7 Expanding the phenotype of known genes; wider phenotype 
associated CHD and NDD genes 
 
We have been able to expand the phenotypic consequences of mutations in 
several genes. TAB2 had only been associated with NS-CHD previously, our 
results suggest that it is also associated with S-CHD. In particular it appears that 
a number of genes thought to cause NDD only, also contribute to CHD. DYRK1A 
and DDX3X were associated with developmental disability only previously, but 
may also be associated with CHD. DYRK1A is associated with autism, but plays a 
role in regulation of cardiomyocyte hypertrophy [556] [557]. De novo mutations 
in DDX3X cause X-linked mental retardation, in some cases other additional 
congenital abnormalities are present [495] and individuals with CHD have been 
reported since our publication [558]. 
  
This highlights the usefulness of testing in cohorts without a narrow phenotypic 
spectrum. It is important to report instances where an atypical phenotype is 
found so clinicians can consider testing in individuals who wouldn’t be considered 
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3.3.8 The potential shared genetic aetiology between CHD and NDD 
 
Like NDD, only a small proportion of individuals with CHD have a single mutation 
in a highly penetrant gene. We see a similar complex inheritance patterns and 
simplex cases in both disorders. Homsy et al suggested a shared mechanism 
between NDD and CHD [14] and we know that NDD is the commonest additional 
abnormality found in individuals with S-CHD. We have shown that genes 
associated with NDD also cause CHD. 
 
Previously NDD was thought to be a consequence of haemodynamic compromise 
and hypoxia in individuals with CHD, especially in relation to complex surgery 
and time on bypass. It is common in more severe types of CHD and is thought 
to affect up to 50% of children who have CHD such as TGA, LVOTO and single 
ventricle defects [559-562]. However, this does not seem to account for all NDD 
seen with CHD, as NDD often predates surgical intervention [469, 561]. Homsy 
et al. showed that certain genes are likely to increase the risk of both CHD and 
autism [14]. A further recent study also concluded that the presence of CHD 
increased the odds of autism spectrum disorders by 30% (odds ratio 1.3), with 
the highest risk possibly being linked to ASD and VSDs [563]. These septal 
lesions can have important haemodynamic consequences, but equally are less 
likely to require major surgical intervention that could potentially predispose to 
neurological changes. This study had also adjusted for genetic conditions, 
maternal age and gestational diabetes, prematurity and other risks for NDD and 
CHD. 
 
Jin et al. compared the sequencing results for genes in the top 25% of heart and 
brain expression, in individuals with CHD and a cohort with autism (n=4778) to 
identify genes that play a part in the pathogenesis of CHD and NDD[15]. There 
were 19 genes with damaging de novo LoF mutations common to both cohorts. 
Chromatin modifier genes made up 40% of these genes and were associated 
with a higher chance of NDD at the point of recruitment into the study. 
Chromatin modifying genes like CHD4, are known to play a role in the 
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development of autism spectrum disorders [564, 565], but most of those with 
autism and a mutation in a chromatin modifying gene do not have CHD. 
 
Perhaps not surprisingly, 67% of the individuals with LoF mutations in genes 
common to both brain and heart development had NDD in addition to CHD. This 
was a higher incidence than the cohort as a whole, where only 33% had NDD. It 
is possible that the same genes are required in both the brain and heart, or 
regulate other genes that are required for correct organogenesis of both. Both of 
these organs have high oxygen requirements and could be more severely 
affected than other less dependent organs as a result of an abnormality in a 
more ubiquitously expressed gene. 
 
Identifying genes that can cause both CHD and NDD, may provide additional 
prognostic information for the affected individual. However, it is likely that there 
are contributions to NDD and CHD from both genetics and environment and 
genotype is unlikely to predict the full phenotype. It would seem sensible to 
consider this in selecting individuals who will benefit from surgery in addition to 
genetic results, but also aim to minimise risks to the brain associated with 
treatments as much as possible in all.  
 
3.3.9 Individual Gene Analysis 
 
 
To identify novel CHD genes, we searched for those that were significant at a 
genome wide level. Across the whole CHD cohort (S-CHD and NS-CHD), 11 
genes were significant. Separating the cohort into S-CHD and NS-CHD resulted 
in no genes reaching genome wide significance in the NS-CHD group, but 12 
reaching this threshold in the S-CHD cohort (table 3.4). These included the same 
11 genes found to be significant across the whole cohort and one additional 
gene. 9 of these 12 genes are known NDD genes. 4 had not previously been 
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associated with CHD. Genes such as TAB2 had only been associated with NS-




Known DD Gene 
PTPN11   
ANKRD11   
CDK13   
ADNP   
NSD1   
PACS1   
KMT2A   
TAB2   
DYRK1A   
DDX3X   
CHD4   
CHD7   
 
Table 3.4 Significant S-CHD genes identified. 
Genes identified as significant in the analysis of S-CHD. CDK13, DYRK1A, DDX3X 
and CHD4 are highlighted as they have not previously been linked to CHD. 
 
To look for further novel CHD-associated genes, all individuals whose WES 
results had identified a de novo mutation that could explain their CHD were 
removed from further analysis to leave those with “unresolved CHD”. This led to 
the identification of three genome wide significant and novel S-CHD genes; 
CDK13, CHD4 and PRKD1. There were no genes of genome wide significance in 
the unresolved NS-CHD group. 
 
The TADA (Transmission and De Novo Association) analysis allowed us to 
identify genes that might be CHD genes based on both de novo and inherited 
mutations and both PTV and missense mutations, combined with case control 
data. Candidate genes were stratified by false discovery rate of strong (FDR 
<0.01/1%), intermediate (FDR >=0,01 and <0.05/>=1% and <5%) and weak 
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(>=0.05 and <0.1/ >=5% and <10%). Table 3.5 below shows the results for 
the highest confidence genes. Whilst these results suggests these genes may be 
involved in the aetiology of CHD, this analysis is not thought not to be sufficient 
to claim this definitively, due to the risk of false positives.     
 
 










ANKRD11     
NSD1     
ADNP     
KMT2A     
KMT2D     
NOTCH1     
CHD7     
DYRK1A     
TAB2     
KAT6A     
PTPN11     
PACS1     
MYH6     
CHD4     
CDK13     
DIAPH3     
 
Table 3.5 Likely CHD genes identified. 
Genes identified with strong confidence to be CHD causing genes. CHD4 and 
CDK13 are included again. 
 
These results correctly identify a number of genes that are already known to 
cause CHD. CHD4 was identified as a novel CHD gene as it reached genome wide 
significance and is discussed later in this chapter. CDK13 also reached genome 
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wide significance and is considered further in chapter 6. DYRK1A is found within 
the trisomy 21 critical region and is thought to contribute to NDD. In addition, 
heterozygous mutations in this gene cause DYRK1A intellectual disability 
syndrome. Aortic valve insufficiency and stenosis, pulmonary valve abnormalities 
and VSDs have been reported as part of this syndrome, although this is not a 
common feature.  
 
DIAPH3 may be a novel CHD gene, but the confidence in this gene was not high 
enough to consider it definite. It is associated with autosomal dominant auditory 
neuropathy possibly due to gain of function mutations [566]. Homozygous 
individuals have a more severe phenotype. Transgenic mice overexpressing 
Diaph3 have cardiac defects [566], but no heart abnormalities were seen in the 
family reported.  
 
NOTCH1 and KAT6A were the only two genes enriched for both de novo and 
inherited variants, as shown above in table 3.5. This is perhaps less surprising in 
the case of NOTCH1 as the phenotype can be variable and includes isolated 
heart defects. Frameshift, nonsense and truncating mutations have been 
identified in KAT6A in individuals with AD Mental Retardation [567-569]. ASD, 
VSD and PDA have been reported in these individuals. All mutations were de 
novo. The inherited mutations enriched in this cohort may act by another 
mechanism. 
 
The phenotypes of the individuals with mutations in CDK13, PRKD1 and CHD4 
were reviewed. As all patients were recruited to the DDD study, they had been 
phenotyped by a Clinical Geneticist already, but the uploaded phenotyping is 
sometimes brief. We collected additional information and reviewed the clinical 
phenotypes for similarities including facial features from photographs.  
 
 




7 individuals were identified with S-CHD and missense mutations in CDK13. 
6 of the 7 mutations were known to be de novo, the seventh was of uncertain 
inheritance. All mutations clustered in the kinase domain, and four individuals 
had the same p.Asn842Ser mutation. These mutations are predicted to impair 
ATP or magnesium binding, or interactions with Cyclin K. There is a recognisable 
facial gestalt and other important similarities include significant developmental 
delay, mild to moderate microcephaly and two individuals had agenesis of the 
corpus callosum. Please see Appendix F (Figure 3A and 3C in Sifrim et al [12]) 
and Appendix L (Supplementary table 10 from Sifrim et al). CDK13 is discussed 





Three S-CHD individuals with de novo missense mutations in PRKD1 were 
identified, two individuals had the same mutation. Two individuals have AVSD 
and the third had PS. Other shared features include severe developmental delay, 
ectodermal defects and limb abnormalities. Individuals with photos available and 
mutations in PRKD1 had a broad forehead with frontal bossing, deep set eyes, 
recessed nasal root, infraorbital creases and a pointed and prominent chin. 
Please see appendix M (supplementary figure 3 from Sifrim et al. [12]). PRKD1 
is discussed further in chapters 4 and 5, with the relevant experimental work.  
 
3.3.12 CHD4  
 
Previous studies looking for genetic causes of CHD have identified genes 
involved in chromatin modification as important in the pathogenesis of CHD [14, 
16]. Jin et al. have since also identified a prominence of chromatin modifying 
genes and loss of function mechanism as significant [15]. CHD4 is a chromatin 
remodelling enzyme, and has been identified as a genome wide significant novel 
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gene causing S-CHD, a syndrome now called Sifrim Hitz Weiss Syndrome. A 
detailed review of the individuals reported in Sifrim et al. [12] and further 
publications follows, along with discussion of possible mechanisms by which 
mutations in CHD4 result in CHD. 
 
3.3.12.1 Mutations in CHD4 cause CHD and a recognisable phenotype, which 
overlaps with other disorders of chromatin modification 
We identified five individuals with S-CHD and de novo mutations in CHD4 (4 
missense variants and 1 in-frame deletion). Of the five individuals reported, two 
had TOF, one had an ASD, VSD and PV abnormality, one had a VSD and one had 
CoA. Considering these 5 individuals, it is possible that TOF spectrum 
abnormalities may be a characteristic of this syndrome.  
All had significant early NDD, two had Chiari malformations and three of the four 
males had cryptorchidism or ambiguous genitalia. The individuals with mutations 
in CHD4 share a wide, tall forehead with frontal bossing, distinct arched 
eyebrows, a depressed nasal root, broad nasal tip and low set anteverted ears 
(Figure 3.2). However, photographs are only available for three individuals so it 







Identifying Novel Genes that cause Congenital Heart Disease  162 
 
 
Figure 3.2 Probands with de novo CHD4 mutations. 
A. Clinical synopsis of the observed phenotypes across patients carrying CHD4 
mutations. Columns represent single probands, shades of cells represent the 
number of probands sharing a phenotype in the given phenotypic categories. 
Photographs of affected probands are shown for which consent could be obtained 
for publication.  
B. Protein plot showing CHD4 protein domains and the distribution of de novo 
mutations. 
This is supplementary Figure 2 from Sifrim et al. 
 
Since the publication of Sifrim et al. changes in genome annotation have meant 
that two of the mutations have been reclassified on the Decipher Database [12, 
522]. The mutation p.Cys1012* has changed from deletion causing truncation, 
to an insertion of three amino acids (p.Leu1009_Val1011dup) (IDs:267060). 
This individual has TOF, developmental delay, genital abnormalities and shares 
similar facial features including the arched eyebrows. The clinical phenotype is in 
keeping with the other reported individuals.  
In the second individual, the mutation has changed from p.Val1698Ile to 
p.Val1636Ile (ID:267459). This missense variant is reported in gnomAD [570], 
detected in heterozygous state in Asian and non-Finnish European (allele count 
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0.000027 in non-Finnish European population and 0.000037 over all 
populations). The mutation also falls in a region that is not under high missense 
constraint pressure. The mean allele frequency attached to this variant may still 
be low enough to mean the variant is pathogenic. Unfortunately, photographs 
were not available for this individual so we cannot comment on whether they 
have a similar facial appearance. The clinical phenotype we have does share 
some similarities with the other reported individuals with CHD4 mutations 
including developmental delay and hearing loss.  They are the only individual 
with CoA. It is difficult to assess whether this mutation is definitely pathogenic 
without further information. 
 
The individuals with CHD4 mutations showed overlap with features of CHARGE 
Syndrome and Rubenstein Taybi Syndrome (RTS), caused by heterozygous LoF 
mutations in the paralog CHD7 and EP300, a histone acetyltransferase 
respectively. The overlapping features are shown in table 3.6 below and include 
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Phenotype in CHD4 
 
Seen in RTS 
 
Seen in CHARGE 




Coarctation + + 
ASD + + 
VSD + + 
TOF Rare + 
Impaired balance - + 
Arnold Chiari + +[571] 
Syringomyelia + +[571] 
Hydrocephalus +[572] +[573, 574] 
Ptosis + + 
Hypermetropia +[575] - 
Astigmatism - +[576] 
Abnormality of the 
ear, including low set 
+ + 
Abnormality of the 
ear lobe 
- + 
Bilateral hearing loss Conductive sensorineural 
Omphalocoele - + 
Cryptorchidism + + 
Renal Abnormalities + + 
Syndactyly + + 
Nail hypoplasia - + 




Eyebrows Thick eyebrows, down 
slanting palpebral 
fissures 
Down slanting palpebral 
fissures 
Anteriorly placed anus - - 
Elbow Dislocation of radial 
head 
- 
Broad, short clavicles - - 
Flat acetabular roof - - 




Short femoral neck Slipped upper femoral 
epiphyses 
Bifid femur 
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Table 3.6 Overlapping phenotypes seen in CHARGE, RTS and CHD4 
mutations. 
Known core components of CHARGE and RTS are included, with some less 
common features. This demonstrates an overlap between the individuals with 
mutations in CHD4, with both RTS and CHARGE syndrome. RTS: Rubenstein 
Taybi Syndrome. 
 
3.3.12.2 Additional Individuals Reported with mutations in CHD4 
A further fourteen individuals have now been reported with mutations in CHD4, 
and some consistent features are now apparent (table 3.7) [522, 577]. Shared 
facial features include a wide forehead, telecanthus, dysmorphic ears and arched 
eyebrows. Additional common phenotypes include developmental delay and 
intellectual disability, hearing loss, skeletal, palatal and genitourinary 
abnormalities. Of those where information was available, normal birthweight, 
weight, height and OFC have been reported along with short stature, micro and 
macrocephaly. Only one individual had no information about NDD. All 19 other 
individuals had either developmental delay or ID or both. Where reported this 
ranged from mild to severe. Three individuals are reported to have specific 
language deficiencies. 





Mutation Protein Consequence Inheritance Domain CHD Phenotype 
2674591,3 M 3y c.4822G>A , changed to 
c.4906G>A in latest 
annotation 
p.Val1608Ile in Sifrim et al., 
changed to p.Val1636Ile 
missense variant Exome 
MAF:3.65x10-5,  






2692941,3 M 16y c.3203G>A  missense variant 
p.Arg1068His,  
De novo C Helicase 
domain 
ASD and VSD 
 
2670601,3 M 1y g.6701138delCATTCAGCA  
changed to c.3033-
3034insCTGAATGTG 
p.Cys1012* in Sifrim et al., 
changed to inframe insertion 
p.Leu1009_Val1011dup, 
1012V/LNVV 




2640401,3 F 11y c.2552C>A p.Ser851Tyr, missense 
variant 




ASD, VSD and PV 
abnormality 
 
2591791,3 M 6y c.1400G>A  p.Cys467Tyr missense 
variant 




12 M 10y c.3380G>A p.Arg1127Gln, missense 
variant 
De novo C helicase 
domain 
No CHD 
22 F 16y c.3518G>T p.Arg1173Leu, missense 
variant 
De novo After C helicase 
domain  
No CHD 
32 M 10y c.3380G>A p.Arg1127Gln, missense 
variant 
De novo C helicase 
domain 
No CHD 
42 F 5y c.3443G>T p.Trp1148Leu, missense 
variant 
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52 M 18y c.3008G>A p.Gly1003Asp, missense 
variant 




VSD, BAV, mild 
aortic dilatation 
2627313 M 6y , c.3380G>A missense variant, 
p.Arg1127Gln,  
De novo C helicase 
domain 
No CHD 
2655853 F 11y c.1933C>T missense variant , 
p.Arg645Trp 
De novo Chromo 
domain 
No CHD 




2756973 M 6y c.2860A>G,  missense variant, 
p.Met954Val 




284058 F 10y c.4019G>A missense variant, 
p.Arg1340His 
De novo DUF No CHD 
2925553 M 2y c.3937T>G,  missense variant 
p.Tyr1313Asp 
De novo DUF Perimembranous 
VSD 
3373103 M C.3547C>T,  missense variant, 
p.Arg1183Cys 




3817813 F Age 
Unknown 
c.3395G>A Missense variant 
p.Gly1132Glu (1132G/E) 
De novo C Helicase 
domain 
No CHD 
2589973 F 3y c.329A>G Missense variant 
p.Tyr110Cys (110Y?C) 
Unknown na No CHD 
 
Table 3.7 Clinical features of all the individuals reported with mutations in CHD4. 
DUF: Domain of unknown function, HH: hypothalamic hypogonadism, IUGR: intrauterine growth retardation, PHD: PHD 
finger, SNF2: SNF2 family domain, USPFs: up slanting palpebral fissures, UTI: urinary tract infection, VPI/SMC: 
velopharyngeal insufficiency/submucous cleft, VUR: vesicoureteric reflux, -: no data. References: 1: Sifrim et al. [12], 2: 
Weiss et al. [577], 3: Decipher Database [522]. 














H: 50th,  
OFC SD 2.32 
Delayed 
development 
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H:-1SD 









33.5 cm (SD 
-0.87) at 

















 - Cryptorchidism - 
 
Trigonocephaly VUR, feeding 
difficulties 
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- - Abnormality of 
the male 
genitalia 
- - Abnormal face 
shape, 
plagiocephaly 
2655853 - Intellectual 
disability, 
moderate 














language   










- - - Cleft 
palate 
- Carious teeth, 
hyperactivity 












- - - High 
palate 
- Anteverted 


























3373103 - Globally 
delayed 
development 
- Yes - - - - 
3817813 - - - - - - - - 
3861033 - Intellectual 
disability 
- - - - - Behavioural 
abnormality 
2589973 - Globally 
delayed 
development 




Identifying Novel Genes that cause Congenital Heart Disease  172 
 
3.3.12.3 CHD is seen in almost half of individuals with mutations in CHD4 
The penetrance of CHD is 40% (9/19). The specific types of CHD are outlined 
below in table 3.8. Septal defects, TOF and TOF like defects predominate.   
CHD Number 
ASD and VSD 2 
TOF 2 
ASD, VSD, PV abnormality 1 







Table 3.8 CHD phenotypes reported with mutations in CHD4. 
The two PDAs both required ligation and were found in combination with an ASD 
and VSD in both cases. 
 
3.3.12.4 CHD4 is a chromatin remodelling enzyme  
 
There are four families of chromatin remodelling enzymes; the SWI/SNF, ISWI, 
INO80 and CHD (Chromodomain-Helicase-DNA binding) families. These ATP 
dependant chromatin remodelling enzymes control DNA transcription, replication 
and repair by altering the level of compaction of chromatin. They are important 
in transcription regulation and many developmental processes. CHD4 is a 
member of the CHD gene family. The CHD family comprises three subfamilies. 
Subfamily I includes Chd1 and 2. CHD3 CHD4 and CHD5 form subfamily II, and 
Chd6-Chd9 form the third subfamily. There are two important motifs common to 
the CHD family, tandem chromo domains in the N-terminal region, and a SNF2-
like ATPase domain in the centre of the protein.  
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There is already evidence that these genes play a role in congenital heart 
disease. The SWI/SNF complex has been linked with congenital heart disease 
through its interactions with GATA4, TBX5 and NKX2.5 [578], and loss of 
function mutations in CHD7 cause CHARGE syndrome. 
 
 
3.3.12.5 Structure of CHD4 and other CHD proteins 
 
CHD4 comprises a number of important domains including the central ATPase 
helicase, PHD and tandem chromo domains shown in figure 3.3 below. CHD3 
and CHD4 do not have a DNA binding domain [579] and differ from Chd1 and 2 
as they have paired PHD zinc finger like domains in the N-terminal section. 
These PHD domains bind with histones and may play a role in determining what 
the CHD4-NuRD complex binds with [580]. They also both have tandem 
chromodomains and an ATPase motor [581]. In Chd1, the chromodomains 
regulate the ATPase motor activity in the SNF2 domain [582].  
 
CHD4 also has an HMG-box (high mobility group) like domain in the N-terminal 
domain. HMG boxes are chromatin binding domains, specific for certain nucleic 
acid structures [583].This domain is important in localising CHD4 to sites of DNA 
damage, and can preferentially bind PAR (poly ADP-ribose) over DNA in vitro  
[580]. This results in reduced remodelling function of CHD4. PARylation has an 
important role in DNA repair and nucleosome remodelling.  
 
There are an additional two domains of currently unknown function in the C-
terminal domain.  The Chd6-9 subfamily has additional C-terminal motifs, 
including paired BRK domains, SANT-like, CR and DNA binding domains which 
set them apart from the other CHD genes [584-586].   
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Figure 3.3 Pictorial representation of CHD4 and reported mutations. 
Variants in red text are associated with CHD, those in black do not. Areas of 
missense constraint are a.a. 148-709, 710-1504, 1684-1912 [494] 
Domains: 
CHDNT (orange): Conserved domain found in PHD/RING finger and chromo 
domain-associated helicases. 
PHD1 (turquoise): PHD finger 1 found in class II Chromodomain-Helicase-DNA 
binding (CHD) proteins 
PHD2 (turquoise): PHD finger 2 found in class II Chromodomain-Helicase-DNA 
binding (CHD) proteins 
Chromo Domain 1 (green): A chromatin organization modifier (chromo) domain 
is a conserved region of approximately 50 amino acids. This domain is found in a 
number of chromosomal proteins, which are important for functional 
organization of the nucleus. This domain may be involved in the binding of these 
proteins to methylated histone tails and possibly RNA. A tandem arrangement is 
not uncommon. 
Chromo Domain 2 (green): Chromatin organization modifier domain 
SNF2 family NTD (lime green): SNF2 family N-Terminal Domain. This domain is 
found in proteins involved in transcription regulation (including SNF2), DNA 
repair and recombination and chromatin unwinding. 
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DEXDc (blue): This domain contains the ATP-binding region. It is seen in the 
DEAD-like helicases superfamily, which are proteins involved in ATP-dependent 
RNA or DNA unwinding. Also known as the DEAD/DEAH box helicase 
C Helicase: Helicase conserved C-terminal domain.  This domain family is found 
in a wide variety of helicases and helicase related proteins. It is likely to be an 
important part of the helicase. 
DUF (dark green): Domain of unknown function 
Neuromodulin (pink): Neuromodulin (Axonal membrane protein GAP-43) 
sequences. Often found in conjunction with a Calmodulin-binding motif 
(pfam00612). GAP-43 is a neuronal calmodulin-binding phosphoprotein that is 
important in axon growth. 
CHDCT2 (yellow): This C-terminal domain is found in PHD/RING finger and 
chromo domain-associated CHD-like helicases. 
Black box, dashed outline: ATPase motor Farnung et al. 
Domain interacting with pericentrin (grey): Required for anchoring to 
centrosomes along with CHD3 [587].  
Build 38, domain sites from https://www.ncbi.nlm.nih.gov/gene/1108 last 
updated 12.10.19. Mutations reported by Sifrim et al, Decipher and Weiss et al 
[12, 489, 588].  
 
3.3.12.6 Function of CHD4 
 
The CHD3 and CHD4 subfamily, are mainly associated with transcriptional 
repression [589]. CHD3, CHD4 and CHD5 all attach to the NuRD complex [579, 
590]. The NuRD complex has an important role in chromatin remodelling and 
gene transcription [591]. Specifically, it can perform ATP-dependant nucleosome 
remodelling and deacetylate histones, having these two enzymatic functions sets 
it apart from other similar complexes [580, 592]. NuRD has a role in gene 
repression and activation, progression of the cell cycle, response to DNA 
damage, embryonic development and stem cell renewal and differentiation and 
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progenitor cell fate [593-597]. Given the importance of NuRD in many cellular 
pathways and processes, it is feasible that alterations in CHD4 may have 
deleterious consequences. 
 
The NuRD complex consists of a number of subunits outlined in table 3.9 below; 
Gata2a/2b, MBD2/3, MTA1/2/3, Rbbp7, Rbbp4, HDAC1, HDAC2 and CHD3/4 and 
5 and possibly an additional subunit CDK2AP1 (DOC-1) [598]. Another gene 
involved in this complex, GATAD2B, is associated with intellectual disability but 
not CHD [599]. 
 
Subunit Associated functions 
HDAC1, HDAC2 Histone deactelylases, remove acetyl groups from lysine 
residues on histone tails and proteins, including p53 
[600]. Not specific to the NuRD complex. Important for 




Chromodomain-helicase-DNA-binding proteins – helicase 
and ATPase activity. Repositions nucleosomes on DNA 
using ATP [601].  
MBD2 or MBD3 Methyl-CpG- binding domain proteins, no enzymatic 
function. They bind cytosine-methylated DNA [602]. 
MTA1, MTA2 or 
MTA3 
Metastasis associated proteins allow binding to DNA, 
HDAC1, transcription factors and other substrates of the 
NURD complex [603, 604]. 
Rbbp4, Rbbp7 Histone binding proteins. Bind histone H4 and allow 
formation of larger complexes [605]. Not specific to the 
NURD complex. 
Gata2a, Gata2b Nuclear zinc finger proteins interact with MBD2/3 [594]. 
 
Table 3.9 Components of the NuRD complex. 
 
Different combinations of NuRD subunits mean that the complex can work with 
multiple transcription and regulatory factors in different tissues to produce 
different effects. Methylation and demethylation of the MTA1 subunit allows 
inactivation and activation of genes with CHD4. Methylated MTA1 forms the 
H3K9me2 histone mark with histone H3, which then recruits CHD4 and creates 
an inactive chromatin state [597]. When MTA1 is demethylated, it associates 
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with a different set of factors and CHD4 and the NuRD complex are removed, 
resulting in active gene transcription [606].  
  
CHD4 plays an important role in cell differentiation and acts by repressing 
certain cell lineages [607]. NuRD also interacts with SMAD2/3 and the hippo 
pathway to reduce expression of pluripotency genes and silence mesoendoderm 
differentiation genes [608]. Specifically CHD4 has a role in the haematopoietic 
system, where it drives cells down the lymphoid lineage [609] and conditional 
deletion in the bone marrow leads to lack of lymphoid and myeloid cells  [610]. 
More recently tbx5 has been shown to interact with the NuRD complex [611]. It 
represses specific gene programs to allow normal development of the heart. This 
supports the role of CHD4 as a novel CHD gene. 
 
Despite the similarities between CHD3 and CHD4, there does not appear to be 
redundancy between the two genes. Although human CHD3 and CHD4 are co-
expressed in many tissues, they form separate complexes with NuRD, and act on 
some unique and some shared gene targets [612]. Both CHD3 and CHD4-NuRD 
complexes are found at repair sites of UV-induced DNA damage, but have 
different nuclear localization patterns in undamaged cells. In vitro there is 
evidence of both gene repression and activating functions in shared and specific 
genes of these two CHD proteins.  
 
3.3.12.7 Mouse models suggest CHD4 is required for normal development of 
both cardiac and skeletal muscle  
 
Mouse models can help provide supporting evidence for the effects of a gene in 
humans. The IMPC results for the C57BL/6Ntm1b mouse indicates complete 
embryonic lethality in the homozygotes, prior to E9.5 [214]. They also 
demonstrate hypoactivity and decreased lean body mass. Expression is recorded 
in the embryonic atrium, ventricle, outflow tract and pericardium, Low levels of 
expression were seen in the adult vascular system, heart and aorta (>50-day old 
males). 
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With reference to the heart specifically, the NuRD complex controls 
cardiomyocyte differentiation and therefore may play an important role in heart 
development and CHD. It does this by silencing the programme for skeletal 
muscle lineage in both developing and differentiated cardiomyocytes [613, 614]. 
Complementary to this, Chd4/NuRD silences cardiac genes in skeletal muscle. 
Wilczewski et al. found that CHD4/NuRD complex represses non-cardiac 
myofibril paralogs to allow normal cardiac sarcomere formation [614].  If CHD4 
is lost, an abnormal muscle cell forms in the heart that has components of 
cardiac, skeletal and smooth muscle cells. The resulting abnormal sarcomeres 
mean that cardiac function is impaired and the embryo is lost as a result. This 
team also identified CHD4 binding sites in smooth muscle myosin heavy chain, 
fast skeletal α-actin, and the fast skeletal troponin complex genes.  
 
Loss of Chd4 in skeletal muscle causes myopathy in mice [613]. A mouse model 
with deletion of Chd4 causes cardiovascular malformations (VSDs), 
cardiomyopathy and fibrosis, and arrhythmias as well as abnormal skeletal 
muscle [613]. There is also abnormal mitochondrial function in both cardiac and 
skeletal striated muscle. The mice showed thinner ventricular compact 
myocardium due to reduced cardiomyocyte proliferation, more simple trabeculae 
and abnormal ventricular septum formation at E10.5. Death was seen in almost 
all by E14.5.  
 
A further mouse model has been produced without endothelial Chd4. This results 
in death at mid-gestation due to vascular rupture [615]. A conditional mouse 
model was also produced with deletion of Chd4 in terminally differentiated 
cardiomyocytes [613]. The mice died after 3 months of life. Histology showed 
deterioration from grossly normal hearts at 4 weeks old, to atrial dilatation and 
fibrosis in the interventricular septum and the left ventricle, lower ejection 
fraction, late arrhythmias, but no hypertrophy. This shows that not only is Chd4 
required in embryonic stem cells, but it also had a role in the postnatal heart.  
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These mouse models support the role of CHD4 as an important gene in 
development of the mouse heart. Abnormal muscle could certainly result in heart 
failure and death, but how exactly structural defects occur is not certain. VSDs 
were seen in the mouse and fits nicely with the VSDs and TOF/TOF like 
phenotypes we have seen in affected individuals.  
 
3.3.12.8 Disease Mechanisms with CHD4 variants  
 
The majority of the CHD4 mutations reported are missense. Most, but not all fall 
within characterised domains of CHD4 (figure 3.2 shown previously). Farnung et 
al. mapped a number of these mutations onto the protein structure of CHD4 
bound to a nucleosome and proposed a mechanism of action in most cases 









The de novo variant p.C467Y falls within the zinc finger PHD 
type 2 domain. These small protein motifs are important in 
genes which modify chromatin and control gene transcription 
[616, 617]. They bind a variety of metals including zinc and 
can form salt bridges and are involved in a wide variety of 
processes [618].  Farnung et al. suggest that this mutation 





This falls within the second of the tandem chromo domains 
(CHRomatin Organization Modifier). These domains are 
around 50 amino acids long, and are found in other CHD 
proteins including CHD3. The chromodomain helps mediate 
chromatin interactions by binding directly to DNA, RNA, and 
methylated histone H3, based on functional studies [619]. 
   
 
In the mouse, mutations in the chromodomain of Chd1 
cause nuclear redistribution and impaired association with 
chromatin [620] .   Additionally, in Drosophila abnormal 
nucleosome binding, mobilization, and ATPase functions 
resulted when the chromo domains of CHD2 and CHD4 were 
deleted [619, 621]. This suggests a deleterious effect of this 
variant. 
 




A single individual has the de novo variant p.Q715Ter. They 
do not have any other CNVs or other potentially pathogenic 
mutations. They do not have CHD. This would terminate the 
protein before the ATPase helicase domain. No functional 
evidence is available, but I assume it would result in loss of 




This mutation falls in the ATPase lobe 1, Farnung et al. 
mapped this variant onto their crystal structure, but did not 
propose a specific method of action[581].  This individual 




Falls within the SNF2 family NTD and the ATPase lobe 1. This 
residue is identified as an area of low conservation across 
the chromatin remodellers, and a mechanism has not been 
proposed[581]. This individual has an ASD and PS. 
 
G.1003D G.1003D could result in loss of chromatin remodelling ability 
of CHD4. It falls within the ATPase lobe 2, and Farnung et al. 
showed that this variant is close to H3 alpha helix 1[581]. 
Deletion of this loop in Chd1, resulted in loss of chromatin 
remodelling ability [622]. This individual has ASD, PDA, VSD, 
BAV and aortic dilatation.  
 
P1012V/LNVV P1012V/LNVV falls within the ATPase lobe 2. The effect of 
this variant is unknown, but it is in close proximity to 
residues required for H4 and H3 binding, which are 
important for chromatin remodelling ability (Leu1009) [622]. 
This individual has TOF. 
 
 
p.R1068H p.R1068H is predicted to alter the RecAATPase fold as this 
arginine residue is important in forming a number of 
hydrogen bonds to maintain its structure[581]. It falls within 
the ATPase lobe 2. This individual has an ASD and VSD. 
 
R1127Q R1127Q falls within the ATPase lobe 2, and disrupts the 
interactions with the DNA minor groove[581]. Farnung et al. 
also pointed out that a variant in the equivalent arginine of 
SMARCA4 results in Coffin-Siris Syndrome (which includes 
CHD), supporting its pathogenicity [623].  
Weiss et al showed that the R1127Q mutant protein localised 
and interacted with HDAC1 as normal, and predicted that 
this mutation was likely to disrupt ATPase activity[577]. 
Three individuals carry this mutation, none have CHD.  
 
p.G1132E p.G1132E falls within the ATPase lobe 2, within the highly 
conserved canonical ATPase motif V. The consequence of this 
variant is unknown, but R1127Q variant is in the same motif. 
This individual does not have CHD. 
Identifying Novel Genes that cause Congenital Heart Disease  181 
 
 
p.W1148L p.W1148L prevents ATP hydrolysis and chromatin 
remodelling as this residue is part of the ATPase motif Va 
[624, 625]. This individual has an ASD and VSD, PDA and 
PFO. 
 
p.R1173L p.R1173L inserts into an acidic pocket and is predicted to 
result in abnormal folding of the ATPase lobe 2[581]. Weiss 
et al showed that the p.R1173L mutant protein localised and 
interacted with HDAC1 as normal, and predicted that this 
mutation was likely to disrupt ATPase activity [626]. This 
individual does not have CHD. 
 
 
p.R1183C p.R1183C variant does not fall within a specific domain and 
is in an area that shows only low conservation across the 
CHD proteins. However Farnung et al. show this arginine 
residue as forming a bond with the DNA, which may mean 
that this residue is important for CHD4-DNA binding[581]. 
This individual does not have CHD. 
 
 
p.Y1313D p.Y1313D falls within exon 26, and a domain of unknown 
function, the result of which is not clear. This residue is 
conserved in mouse and rat (UCSC Genome browser 
https://genome.ucsc.edu), and Decipher confirms Tyrosine 
in Chimpanzee, chicken, Xenopus, Zebrafish, Drosophila and 
C. elegans. This variant falls within an area of high missense 




p.R1340H p.R1340H falls within a domain of unknown function, the 
result of which is not clear. Decipher confirms Arginine at 
this position in human, mouse, Chimpanzee, chicken, 
Xenopus, Zebrafish, Drosophila and C. elegans. This variant 
falls within an area of high missense constraint. This 
individual does not have CHD. 
 
 
p.V1636I V1636I falls within an area known to interact with pericentrin 
and the neuromodulin domain. It was initially reported as 
p.V1636I in Sifrim et al. but has since been revised with 
more recent annotation [12]. Valine at this residue is 
present in Chimpanzee and Chicken, but not Mouse or 
Zebrafish. This individual has CoA. 
 
p.Y110C The p.Y110C missense variant is of uncertain pathogenicity. 
It falls within a non-missense constrained section of CHD4, 
with no specific function and it is not known if it is de novo. 
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This individual also has another variant in SLC6A1 which is 
associated with epilepsy. The phenotype is abnormal face 
shape and developmental delay, which is not specific to 
CHD4. This individual does not have CHD. 
 
 
Table 3.10 Proposed mechanism of CHD4 mutations. 
All reported CHD4 mutations and proposed mechanism resulting in 
abnormalities. Mutations reported by Sifrim et al. [12], Decipher [489] and 
Weiss et al [577]. 
 
Proposed mechanisms leading to clinical abnormalities include loss of chromatin 
remodelling ability, disruption of ATPase activity and prevention of ATP 
hydrolysis, altered CHD4-DNA binding and abnormal zinc ion binding leading to 
abnormal function of CHD4 [581, 626]. Farnung et al. suggested that the 
mutations they reported had a plausible mechanism that would result in 
abnormal function [581]. 
 
The single truncating mutation, which is sited before the helicase and SNF2 like 
domain is associated with a milder phenotype. The individual has mild NDD, 
dysmorphic features and palatal abnormalities only.  This suggests that there 
may be a milder phenotype with loss of function mutations, and the more severe 
phenotype seen in association with some missense mutations may represent 
another mechanism, particularly those affecting important domains of the 
protein. CHD4 does have a probability of loss of intolerance (pLI) of 1, indicating 
likely haploinsufficiency [627]. CHD7 also has a pLI of 1, and CHARGE syndrome 
results from loss of function mutations. Variants are reported along the length of 
the CHD7 protein that are stop gain mutations and predicted to result in loss of 
function. However additional missense mutations reported in the chromo 
domains, SNF2 family like N terminal domain and the C-helicase are reported as 
pathogenic [521]. 
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To consider haploinsufficiency further, I reviewed a number of databases for 
CNVs overlapping CHD4. There are no benign CNVs which include CHD4, 
reported in the normal population in the International Standards for 
Cytogenomic Arrays (ISCA) database  [628]. Decipher reports 27 deletions 
considered pathogenic that overlap CHD4 [522]. They are all large deletions 
encompassing multiple genes, and none overlap just CHD4. All encompass the 
12p13.33 deletion syndrome locus. There are four smaller deletions marked as 
being of unspecified pathogenicity. All are 3.18Mb in size, contain 110 genes 
including CHD4, and are of unknown inheritance. Phenotype data is available for 
two individuals. Interestingly one individual has macrotia and protruding ears, 
short stature, intellectual disability and skeletal abnormalities including an 
abnormality of the hip bone and scoliosis. The second individual shares a sacral 
dimple, strabismus, pectus excavatum, a preauricular pit and intellectual 
disability. All of these features have been seen in individuals with mutations in 
CHD4. Additional phenotypes include strabismus, brachycephaly, cutis gyrata, 
seizures, hyperextensible skin, constipation, and nasal and columella differences. 
Given the size of the deletions, it is difficult to attribute the phenotype to CHD4, 
especially given that it includes a number of other morbid and haploinsufficient 
genes such as ATN1 (heterozygous mutations cause congenital hypotonia, 
epilepsy and NDD and C1S (heterozygous mutations cause periodontal ehlers 
danlos).   
 
3.3.12.9 Structural abnormalities are common with mutations in the SNF2 family 
and C helicase domains 
 
All individuals reported so far had either developmental delay or ID. The 
majority of individuals have structural abnormalities, especially those with 
variants in the SNF2 family and C-helicase domain (9/10). No structural 
abnormalities were seen in association with mutations in the chromo domain. 
Brain abnormalities were found in all but one individual in these domains, and 
also in association with the p.R1173L mutation just distal to these domains. 
Ventriculomegaly and Arnold Chiari malformations predominate.  
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Genitourinary malformations were associated with variants in the SNF2 family 
NTD and C-helicase domain (7/10). Half of the individuals with variants here had 
palatal abnormalities (5/10). Palatal abnormalities were only associated with this 
domain and a single truncating mutation (p.Q715ter) sited between the 
chromodomain and SNF2 family NTD.  
 
There does not appear to be any specific genotype phenotype correlation for 
growth, however all three individuals with p.R1127Q exhibit macrocephaly. 
Skeletal features were fairly diverse and there did not appear to be any specific 
genotype phenotype correlation. Hearing loss also did not appear to associate 
with any particular location.  
 
Three individuals have the p.R1127Q variant. All had developmental delay and 
genitourinary abnormalities. 2 of the 3 had ventriculomegaly, hearing loss and 
palatal abnormalities. Interestingly these two individuals were reported by Weiss 
et al, the third individual who does not show all the features is from DDD [522, 
577].  The individual with p.R645W (chromo domain) has a milder phenotype 
than others. As mentioned previously, the individual with the truncating 
p.Q715ter mutation also has a milder phenotype. 
 
There does not appear to be a clear genotype-phenotype correlation with respect 
to CHD. Individuals with CHD have mutations along the length of the protein 
including the PHD type 2 domain, the ATPase lobes, the first domain of unknown 
function and the neuromodulin domain. There also does not appear to be a 
specific region where mutations occur that result is a specific type of CHD. Why 
some mutations result in CHD and others do not remains unclear. There is some 
consistency in that all three individuals with p.R1127Q do not have CHD. 
Overall, there does not appear to be any clear genotype-phenotype correlation, 
with the exception of higher likelihood of structural abnormalities with mutations 
in the SNF2 family and C helicase domains. 
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3.3.12.10 Sifrim Hitz Weiss Syndrome shares some clinical features with 
syndromes caused by variants in the other CHD family genes.  
 
Given the similar functions and structures of the genes within the CHD family, it 
is also helpful to review the clinical phenotypes associated with the other CHD 
genes, especially CHD3 given it is in the same subfamily as CHD4. A number of 
syndromes already associated with the CHD gene family are outlined below in 
table 3.11. Common features include NDD, autism, LD, epilepsy, facial 
dysmorphism, genitourinary abnormalities, hypotonia, micro and macrocephaly. 
NDD is not a surprising feature given that CHD3, CHD4 and CHD5 have non-
redundant functions in the brain during development [629].  
 












No NDD. Some 
similarities 
between facial 
features, but too 
few individuals 






























 Yes - 
CHD5 No associated 
syndrome. 
CHD5 expression 
seems to be mainly 
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confined to the 
central nervous 
system and testes 
[633, 634]. 
 




This genomic region 
overlaps with that 
associated with 
human ataxias. 
   
CHD7 CHARGE Syndrome 
[324] 







CHD8 Autism [564, 636, 
637] 
 









Table 3.11 Clinical phenotypes associated with variants in the CHD gene 
family. 
No clinical syndrome has been described for CHD5 as yet, and it is in a different 
subfamily to CHD3 and CHD4.  
 
Several other genes that interact with the NuRD complex, are linked with 
syndromes with overlapping features. The interaction of the NURD complex and 
SALL4 has also been studied in the context of oncogenesis. Like individuals with 
CHD4 mutations, Okihiro Syndrome (SALL4) and Townes-Brocks Syndrome both 
include ear abnormalities, deafness, CHD, anal and genitourinary abnormalities 
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and skeletal features. Interestingly SALL1 (Townes-Brocks syndrome) [638] is 
thought to interact with the NuRD histone deacetylase complex [638]. This is of 
relevance given that there is some overlap between these two syndromes and 
the presentation of the individuals reported with mutations in CHD4.  
 
CHD4 also forms part of the ChAHP complex, with ADNP [639]. Mutations in 
ADNP are associated with Helsmoortel-Van der Aa syndrome, which includes 
CHD as part of the phenotype. The ChHAP complex is required for correct cell 
fate progression and therefore abnormal function was in keeping with the wide 
range of systems affected in this syndrome. There are a number of similar 
features between the individuals reported with mutations in CHD4 and ADNP, 
including developmental delay, intellectual disability, ear abnormalities and less 
commonly CHD in Helsmoortel-Van der Aa syndrome. 
 
There are other possible routes which may lead to clinical abnormalities when 
CHD4 is not functioning as normal. There is evidence that CHD4 can act 
independently of the NuRD complex, specifically in the transition to adult 
haemoglobin via γ-globin gene silencing [640], repression of proneural genes in 
drosophila [641] and CD4 expression and T cell development [642]. Overall 
there is evidence of shared features of NDD amongst the CHD genes and CHD in 
some of these and other linked genes. 
 
3.3.12.11 Clinical Management 
Suggested clinical management of children with deleterious CHD4 mutations 
might include monitoring of growth parameters, as at least one individual 
required growth hormone. Development should be monitored to allow early 
provision of support if required, along with brain imaging if there is evidence of 
NDD. Particular attention should be paid to speech development and hearing 
should be tested in all cases. Palatal assessment and genital/anal examination 
should be carried out in all newborns as part of the normal baby checks. Further 
examination should be carried out if concerns arise. Additional investigations 
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that might be considered include renal ultrasound and skeletal imaging if 
symptomatic. 
 
Given CHD is present in almost half of individuals with mutations in CHD4, an 
echo seems a sensible investigation to include in all individuals, especially given 
the non-invasive nature. A single individual has aortic dilatation in association 
with BAV. It is unclear if this is part of Sifrim Hitz Weiss syndrome. It may be 
that the dilatation is purely related to the BAV rather than any other process in 
the aorta related to CHD4. 
 
There are no specific details about whether the affected individuals in our study 
had myopathy, but given the role of CHD4 in skeletal as well as cardiac muscle, 
it would be worth observing if any of the affected individuals have any features 
of skeletal myopathy. 
 
3.3.12.12 Cancer  
 
We know that the NuRD complex plays a role in response to DNA damage, 
including double strand break repair [643], and failure to correct this can result 
in cancer developing. Mutations are found commonly in certain cancer types 
[644]. It interacts with both tumour suppressors and oncogenes and so can have 
a variable effect on tumour growth [600, 645]. 
 
CHD4 expression increases in response to UV irradiation [646]. CHD4 binds 
PARPs (poly ADP-ribose polymerase) and NuRD, and mobilises to sites of double 
strand breaks and DNA damage [580, 595]. PAR binding motifs are found in the 
N-terminal domain, upstream of the PHD binding domains [580]. 
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Somatic mutations have been identified in CHD4 in nearly 20% of uterine 
cancers, in the helicase domain and second plant homeodomain which binds 
methylated H3K9 [647-649], along with somatic CNVs involving CHD4 and MBD3  
[650]. The exact role of CHD4 is not clear [643, 651]. Interestingly CHD3 and 
CHD4 are associated with dermatomyositis, and 20-30% of individuals with this 
condition go onto develop cancer [652-654]. CHD3 is also linked with Hodgkin’s 
Lymphoma, and CHD5 with neuroblastoma [633, 655, 656]. 
 
A number of variants in CHD4 have been reported in a variety of cancers, 
spanning the PHD finger domain 2, the tandem chromodomain and the two lobes 
of the ATPase motor. Farnung et al. proposed two routes by which these variants 
can have an effect; changes to ATPase and DNA translocation activity, and 
alterations to protein stability[581].  These mutations are often within a few 
residues of those reported in individuals with Sifrim Hitz Weiss Syndrome.  
 
The significance of already having a CHD4 germline mutation upon the risk of 
developing cancers is unknown currently. It would seem prudent to promptly 
review any concerning signs and symptoms and report any occurrences of 
malignancy to determine if any screening is indicated.  
 
3.3.13 Copy Number Variation Analysis 
 
 
A single patient with Turner syndrome and five classical 22q11.2 deletions were 
identified. A single patient with the reciprocal 22q11.2 duplication was also 
identified, the significance of this is currently unclear. I ascertained the gene 
content of each CNV for inclusion of potentially significant genes identified in this 
study. No CNVs overlapped any of the newly identified genes CHD4, CDK13, 
PRKD1, DYRK1A, DDX3X, or DIAPH3.  
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3.3.14 Finding further novel CHD genes will require much larger 
cohorts 
 
Since the publication of Sifrim et al. a number of other studies have identified 
further novel CHD genes including GDF1 and FLT4 [15, 19] and put forward 
additional candidates including ACVR1, JARID2, PLRG1, RYR1, ZFPM1, CAMTA2, 
DLX6, and PCM1 [19, 657]. This is in keeping with the findings of Jin et al. which 
supported the role of FLT4 in TOF [15].  
 
Whilst our study, and subsequent ones, have increased our knowledge of genes 
that contribute to CHD, it is apparent from both the de novo and inherited PTV 
analysis, that there are more novel genes to be discovered. One method would 
be to explore pathways and protein interactions that we identified as significant 
(section 3.3.10 and figure 3.3 shown previously). An updated protein interaction 
map from STRING is shown below in figure 3.4 using the same 374 genes 
identified as potentially significant in the integrated de novo and inherited 
variant analysis, with a FDR of <50% [12]. 
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Figure 3.4 Updated protein-protein interactions. 
High confidence protein interactions (>0.9) from the STRING PPI database in 
top-ranking set of CHD-associated genes (false discovery rate <50%) in the 
integrated de novo and inherited variant analysis (December 2020) [549]. 
CHD4, CDK13 and PRKD1 are all highlighted with red arrows. Yellow arrows 
indicate proteins encoded by novel CHD genes reported since, in close proximity 
to CHD4.  
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Additional proteins visible in figure 3.4, have since been identified as 
contributing to CHD, supporting the role of network maps to identify CHD gene 
candidates. KAT6A (yellow arrow), which is linked with CHD4, has been 
associated with CHD in some individuals, as part of a neurodevelopemental 
disability syndrome [567-569]. AXIN2 has been identified as a cause of CHD 
[658] and variants in HEY2 (yellow arrow) have now been shown to cause both 
CHD and thoracic aortic aneurysms [659]. It is also interesting that the PRKD1 
protein in the figure above, is linked to both SOS1 and PTPN11, which are 
encoded by two common rasopathy genes. One of the three individuals we 
reported with mutations in PRKD1 had pulmonary valve stenosis, a common 
feature seen in Noonan Syndrome. This could support functional connections 
between these genes in heart development.  
 
Approaching novel gene discovery in CHD using pathway analysis has recently 
been used to propose 23 further novel genes [660]. These genes share biological 
functions and properties, and interact with known CHD genes, and may warrant 
further exploration to determine if they are true CHD genes. Pathway analyses 
such as these do not required such large cohorts as required for gene-level 
discovery and provide an alternative method for gene discovery. 
 
To fully elucidate the genetic aetiology of CHD we will require much larger 
cohorts. We estimated that these may need to be 20 times the size of this 
current cohort (Supplementary Figure 5 in appendix N). For case control aspects 
of the study, much larger control datasets will also be required. Clearly this will 
require collaboration between research teams. 
 
3.4 Challenges, Limitations and Future Work 
 
As with any other large scale WES study, using data collected from different 
sources there were a number of challenges relating to standardising the data.  
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3.4.1. Defining S-CHD and NS-CHD 
 
The definition of S-CHD and NS-CHD presented challenges, particularly in 
relation to neurodevelopmental disability (NDD). Children undergoing multiple 
heart surgeries, those who experience post-operative complications, premature 
babies and those who had additional episodes of illness may exhibit 
developmental delay due to prolonged hypoxia and complications of surgery, or 
just extended time in hospital. This means it is difficult to be sure if an 
individual’s developmental delay is genetic or as a consequence of another 
factor. Recruitment to research at an early stage of life can mean it is difficult to 
accurately assess a child’s development. Whilst additional information can be 
gained from brain scans, it is not always possible to predict disability from 
structural lesions alone.  
 
Even with comprehensive medical records and investigations, it would be difficult 
to determine whether or not NDD was purely genetic or non-genetic. The 
proposed overlap between the genetic aetiology of NDD and CHD complicates 
this matter further. For this reason, all patients with developmental delay were 
considered to have S-CHD. Future studies in larger cohorts may help determine 
the contribution of genetic and non-genetic factors in CHD with NDD.  
 
3.4.2 Parental Phenotyping 
 
Ideally we would screen all parents with an ECG and echo to be sure that they 
are unaffected. It is not uncommon for people to be diagnosed with CHD such as 
haemodynamically insignificant septal defects and BAV in old age. Unfortunately 
this is cost prohibitive and there is the risk of detecting disease such as 
cardiomyopathy in asymptomatic individuals, which would require careful 
counselling prior to imaging. Instead, we assumed all parents did not have CHD 
as the Cardiologists/Clinical Geneticists would review any parent with a history 
of CHD or cardiac symptoms. 
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3.4.3 Sample Size 
 
This study has identified that there are further novel CHD genes to be 
discovered, but that this requires a much larger sample size. This will require 
collaboration between researchers, which brings with it the difficulties of 
standardising platforms and pipelines, and differences in allele frequencies 
across different ethnic groups.  
 
It was not possible to consider different CHD phenotype groups separately. This 
is because the number of individuals in each group were too small and genes 
would not reach genome wide significance. The same applied to analysis for 
enrichment of certain pathways including genes involved in diabetes, folate 
processing and alcohol for example. 
 
Increasing the number of individuals with CHD who are sequenced will also 
identify further individuals with mutations in known CHD genes. This will allow 
us to describe the phenotypic spectrum and correlation with genotype more 
accurately. A total of 33 individuals have now been published with mutations in 
CHD4 [12, 577, 588, 661]. CHD, in combination with developmental delay or 
mild to moderate intellectual disability remains a significant feature. 72% 
(21/29) had CHD, most commonly ASD, followed by VSD and pulmonary 
stenosis. PDA, TOF, mitral valve abnormalities, EA and TA have also been 
reported. Cerebral abnormalities are almost always present (92%, 22/24), most 
commonly ventriculomegaly. A further new feature that has been reported is 
Moya Moya disease (stenosis and or occlusion of carotid arteries and associated 
collateral vessels) [662]. Whilst the majority of mutations fall within the ATPase 
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3.4.4 Reduced Penetrance and Mechanisms other than Monogenic 
Inheritance 
 
Further evidence supporting the role of inherited variants in CHD has been 
produced by Jin et al. who found an enrichment of damaging recessive 
genotypes in individuals with laterality type CHD defects, and conversely no 
excess of damaging de novo mutations[15]. This is thought to be accurate based 
on the high recurrence risk in this type of CHD and its prevalence in 
consanguineous populations [663].  
 
The real challenge is looking for inherited variants with reduced penetrance. Li et 
al. identified inherited LoF mutations as a cause of left sided CHD in 4.4% of 
their cohort using WES [657]. Inherited mutations are likely to be important in 
left sided CHD given the high recurrence risk in children and siblings of up to 
20%, albeit more subtle lesions. To understand this mechanism further, larger 
sample sizes are required. It may also be more successful in types of CHD where 
recurrence appears to be more common. 
 
It is also important to consider compound mutations, even for genes associated 
with AD disease as shown by Jin et al [15]. Individuals with compound 
heterozygosity in known monoallelic CHD genes, presented with a more severe 
phenotype. Further evidence of reduced penetrance has also emerged. Page et 
al. identified mutations in NOTCH1 causing TOF [19]. In two instances, the 
unaffected parents appeared to harbour the same mutation as the proband (1 
maternal and 1 paternally inherited mutation). It is not clear whether the cardiac 
status of the parents was formally assessed. 
 
Priest et al. found that putative inherited and de novo mutations across genes 
that cause human and mouse CHD, could explain the occurrence of AVSD in 
32% of their relatively small cohort which supports an oligogenic model for CHD 
[353]. Given the reduced penetrance and variable expressivity we see in CHD, 
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and likely oligogenic model in most, we could consider using different allele 
frequency thresholds. It is possible that contributing variants are present at a 
higher frequency, or even in control cohorts in an oligogenic model. Searching 
for contributing genes under these conditions is more complex however. We 
have also not accounted for genetic mosaicism and somatic mutations in the 
heart. Going forward, it may be possible to collect paired cardiac tissue and 
blood samples to include analysis for somatic mutations. These approaches could 
help explain some of the reduced penetrance and variable expressivity.  
 
3.4.5 Environmental and Maternal Factors 
 
Evidence from mouse studies suggests that factors that modify CHD risk can 
greatly alter the chance of a predisposed individual developing CHD, such as 
maternal age in mice heterozygous for Nkx2.5 mutations [664]. It is difficult to 
determine the importance of genetic variation, without understanding the 
contribution of additional non-genetic influences to CHD risk. Whilst it would be 
very difficult to take all environmental and maternal influences into account, 
future studies may be able to include maternal diabetes or other well established 
risk factors if prospective recruitment or a CHD registry could be established. 
 
3.4.6 Whole Genome Sequencing 
 
There are relatively few WGS based studies in CHD currently. Bjornsson et al. 
used WGS to identify common variants contributing to CoA in the Icelandic 
population [665]. This is a genetically defined and well characterised population. 
Hauser et al. performed WGS in a small cohort of neonates and children (34 
trios) with CHD in America [537]. In 6% of individuals they identified a definite 
pathogenic variant, 26% had a variant of uncertain significance (VUS). They 
concluded that the diagnostic rate was insufficient to recommend WGS in routine 
practice for this group of individuals. 
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We have used WES in this instance as it is cheaper, was established the Sanger 
Institute and used for the DDD project, which formed part of our cohort [522]. 
Moving forward, WGS is likely to become less expensive. Certainly it seems that 
there is increasing evidence that non-coding and miRNAs could be important in 
CHD for example[666].  
 
3.4.7 Further Functional and Animal work 
 
Proteomics and nucleosome binding assays are ongoing within the Brook lab for 
the CHD4. A Chd4 knockout mouse is being examined by S Loughna and J 
Aparicio within the lab, to study the effects on the heart using High Resolution 




We have shown that there are different mechanisms behind S-CHD and NS-CHD. 
We have identified three novel genome wide significant CHD genes, and have 
begun to describe the characteristic clinical features of, and potential 
mechanisms behind these new syndromes. We intend to complete additional 
functional work to add further support to the role of these genes in the heart.  
 
This type of study also provides clinically useful results for participants, and 
other individuals with CHD.  It allows expansion of the phenotype of known CHD 
genes. Results from large cohorts like this also provide clues as to the 
prevalence of syndromes associated with a particular gene, including a relative 
lack of genes considered important for heart development. 
 
We can use the results generated from studies like this to construct networks of 
genes that are important for correct cardiogenesis, and identify further novel 
CHD genes. Results from studies such as this, and ideally larger cohorts, might 
be useful to guide clinical testing.  
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Moving forward, we require a much larger data set. This requires collaboration 
with other researchers and standardisation of data. Ethical aspects of untargeted 
sequencing and generation of secondary findings must be addressed as part of 
this. Data collection should be standardised and phenotyping should be as 
detailed and as accurate as possible, with consideration for additional maternal 
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Chapter 4 The role of PRKD1 in CHD 
 
 
Following the WES in a cohort with CHD described in chapter 3, de novo 
missense mutations in PRKD1 were identified as causing S-CHD [12]. Three 
individuals were reported, two of whom had an identical mutation.  
 
PRKD1 is a serine/threonine protein kinase, which is involved in a number of 
basic cellular processes and has roles in many pathways including MAPK8/JNK1 
and Ras-Raf-MEK-ERK. In the cardiovascular system, it controls cardiac 
hypertrophy and angiogenesis [667, 668]. 
 
This chapter explores what is known about the function of PRKD1 in relation to 
the heart. The genotypes and phenotypes of the individuals identified with 
mutations in this gene are considered, and novel data is presented on two Prkd1 
mutant mouse lines, providing the first characterisation of their phenotypes. 
 
4.1.1 An introduction to the Structure and Function of PRKD1 
 
The expression of PRKD1 is fairly ubiquitous and its functions are diverse, 
affecting many cellular processes and pathways. It has important roles in cell 
survival, fate, differentiation, proliferation, adhesion, migration and apoptosis 
[669-673] as well as basic cellular processes such as maintaining the Golgi 
apparatus and vesicle trafficking to the plasma membrane [674, 675].  It plays a 
role in cell response to stress and antigen challenges, as part of our innate 
immunity and inflammatory responses [670, 672, 676, 677]. It is also required 
for normal structure of neurones [675, 678-681]. Processes more relevant for 
cardiovascular development are outlined later in this chapter, but research so far 
seems to suggest that PRKD1 has a wide range of functions in many different 
tissues and that there is some functional redundancy within the gene family. 
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PRKD1 is one gene in a highly conserved family of large serine threonine protein 
kinases, consisting of PRKD1, PRKD2 and PRKD3. They share similar functional 
domains and high levels of sequence identity, especially within the kinase 
domain [673, 682, 683]. PRKD1 and PRKD2 are the most similar, sharing 85% 
amino acid sequence [684]. The mouse PRKD1, 2 and 3 proteins all share the 
same catalytic and pleckstrin homology domain sequence [685]. Signalling 
molecules like PRKD1 are required to move within the cell in response to specific 
stimuli. PRKD1/2 and 3 all shuttle within the cell once it has been activated, 
suggesting that all three are important in multiple signalling pathways [686].  
 
There are many mechanisms that regulate the activity of PRKD1, including G 
protein coupled receptors, antigen binding and growth factors [686]. PRKD1 can 
be activated by a number of different molecules and physiological stimuli 
including phorbol esters, DAG, TNF and angiotensin II [673, 687]. Its activity is 
also influenced by phospholipase C and protein kinase C, and this is one of the 
more well described sequences [686, 688].  
 
Within the N-terminal domain of the proteins, there are two cysteine rich (CRD) 
diacylglycerol (DAG) binding domains, and a single Plekstrin homology (PH) 
domain, which are required for auto inhibition [673]. The kinase domain is 
contained within the C-terminal region. The four main domains within PRKD1 are 
shown in Figure 4.1. These domains are all important in controlling the 
movement and activity of PRKD1. 
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`  
Figure 4.1 Structure of PRKD1. 
PRKD1 is 912 amino acids (a.a.) long. Each 100 a.a. division is marked with a 
blue line across the top of the protein. 
AP (lilac): Alanine proline rich region a.a. 17-146, part of the regulatory region. 
C1 (blue): Cysteine rich domain 1. Similar to zinc finger domain, binding domain 
for phorbol esters/DAG a.a. 146/7-196/198. 
C2 (blue): Cysteine rich domain 2. Similar to zinc finger domain, binding domain 
for phorbol esters/DAG a.a. 270/271-320/323. 
PH (green): Pleckstrin Homology domain a.a.  423-541. 
PK (red): Protein kinase domain: a.a. 584-839. 
NBD: Nucleotide binding domain a.a. 589-597. 
ATP: ATP binding site at residue 612. 
PAS: PAS, proton acceptor site at residue 716. 
Yellow asterisk: Serine phosphorylation sites at residue 744 and 748, fall within 
the catalytic domain.  
Other important phosphorylation sites include Ser22 and 23[689], Tyr 95 [690], 
Ser203 [691], Tyr 463 [692], and Ser 916 [691]. 
a.a: amino acid 
 
Identifying Novel Genes that cause Congenital Heart Disease  202 
 
The N-terminal regulatory region of PRKD1 contains the cysteine rich domains 
(CRD), which are tandem repeats similar to zinc-finger motifs. The motif is 
structurally similar to others that bind DAG, and not surprisingly DAG binds to 
PRKD1 at these sites. DAG binding facilitates movement within the cell and the 
CRD are required for localisation to the Golgi compartment [693]. The two CRDs 
also appear to have different functional roles, the second CRD has a high affinity 
for DAG and predominantly binds phorbol esters [694], and is required for 
localisation to the membrane and nucleus of the cell without contribution from 
the first CRD [673]. 
 
The pleckstrin homology (PH) domain resides between the catalytic domain and 
CRDs [695]. This type of domain is seen in many proteins. It binds to membrane 
lipids, other proteins and is common in signal transduction proteins. The PH 
domain is required to maintain auto inhibition of PRKD1 [673, 682, 696]. 
Inhibition is removed when there is phosphorylation of serine residues within the 
activation loop of the kinase domain. This results in activation of PRKD1 [697]. 
The PH domain is also required for nuclear export of PRKD1 through a CRM-1 
nuclear export pathway [698]and influences localisation of PRKD1 within the cell 
[673].  
 
There is an additional PDZ binding motif at the C-terminal end of PRKD1. This 
interacts with proteins and may be important in locating specific proteins to the 
cell surface for correct signalling. It may also contribute to controlling the 
location of PRKD1 within the cell [686, 699]. 
 
4.1.2 Movement of PRKD1 within the cell 
 
PRKD1 shuttles to and from the plasma membrane, and in and out of the 
nucleus, in response to a stimulus acting on the cell [700, 701]. In an 
unstimulated cell, PRKD1 mainly resides in the cytosol [700-703], with smaller 
amounts in intracellular compartments such as the mitochondria, Golgi and 
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transport vesicles. The amount and location varies depending on the cell 
population studied [687, 693, 700-708].  
 
A stimulus, such as a molecule binding to a G protein coupled receptor, activates 
phospholipase C and DAG is produced [673]. Phospholipase C activation causes 
the second cysteine rich motif in PRKD1 to bind to diacylglycerol (DAG) at the 
inner plasma membrane [709]. This triggers recruitment of protein kinase Cs at 
the plasma membrane, and their activation. Movement of PRKD1 to the cell 
plasma membrane and into the nucleus requires DAG binding at the second CRD 
only. It is not required to bind to the first CRD. It also occurs independently of 
both the PH domains and activation by phosphorylation within the catalytic 
domain [700-703] .  
 
Following its localisation to the cell membrane, PRKD1 is activated. Protein 
kinase C phosphorylates Ser744 and Ser748 within the activation loop of the 
catalytic domain [710, 711]. This phosphorylation releases PRKD1 from auto 
inhibition by the PH domain, and stabilises the active protein [673]. In addition, 
this phosphorylation is required for movement of PRKD1 back into the cytosol 
from the plasma membrane [700]. Auto phosphorylation then occurs at Ser 203 
and Ser 916 [712] and afterwards, PRKD1 moves into the nucleus via binding at 
the second CRD [701]. The PH domain is required for subsequent nuclear export 
and deletion of this domain results in accumulation of PRKD1 within the nucleus 
[700, 701, 703]. 
 
In addition to the protein kinase C pathway of activation, other scenarios have 
been described. This includes cleavage of the regulatory domains and 
phosphorylation of Tyr 463 in the PH domain [672, 692]. However, the dominant 
mechanism appears to be activation by protein kinase C. 
 
Usually PRKD1 locates to the cell plasma membrane and enters the nucleus, but 
alternative translocation pathways have been described in response to certain 
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stimuli, such as antigens binding to B cells and mast cells [702, 703]. Another 
slightly different mechanism appears to take place under conditions of oxidative 
stress when phospholipase D1 produces mitochondrial DAG and the CRD 
facilitates PRKD1 localisation to the mitochondrial membrane, rather than the 
cell membrane [713].  
   
4.1.3 PRKD1 expression 
 
Expression of mRNA of PRKD isoforms is fairly ubiquitous. The homology of 
Prkd1 and 2 makes it difficult to distinguish their separate expression patterns, 
but Prkd1 shows fairly widespread expression in the developing mouse (table 
4.1) [714]. This includes the developing cardiovascular system. Prkd1 and Prkd2 
are also expressed in the adult mouse heart [684].  
 
Prkd1 is expressed slightly earlier than Prkd2 (E9.5 to 14.5 in the mouse 
embryo, whereas Prkd2 wasn’t detected until E14.5). Prkd3 was only weakly 





Prkd1 E9.5 Generalised expression, but more highly 
expressed in the brain and mandibular and 
hyoid branchial arches, and the apical 
ectodermal ridge in the limb buds 
 E10.5 Generalised expression, but more highly 
expressed in the brain and mandibular and 
hyoid branchial arches, Now seen in the whole 
limb bud, the heart and nasal processes. 
 E14.5 Strong expression in parts of the brain, 
glomeruli, thymus, atria and ventricles of the 
heart, adrenal cortex and cartilage primordia in 
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the axial skeleton. Weaker expression in a 
number of other tissues including bronchi and 
intestine 
 E18.5 Suggested low level of expression in the heart 
Prkd2 E9.5 Not detected 





E14.5 High expression in sections of the brain, 
whiskers, olfactory epithelium, central region of 
the ventricle of the heart, intestine, thymus, 
lung mesenchyme, genital tubercle 
 E18.5 Strongly expressed in whisker follicles, parts of 
brain, retina, olfactory epithelium, tooth 
primordia, tongue, cochlea, lung mesenchyme, 
kidney, intestine and glans penis 
Prkd3 E9.5 Moderate expression in the brain. Also seen in 
limb buds and branchial arches. 
 E10.5 Clear expression in the nasal processes and the 
heart. Also seen in limb buds and branchial 
arches. 
 E14.5 Fairly ubiquitous, higher in parts of brain, 
olfactory epithelium, neuronal layer in eye, 
cardinal veins 
 E18.5 Fairly ubiquitous, but levels now slightly 
reduced. Expression still stronger in parts of 
the brain olfactory epithelium, thymus, atria of 
heart, kidney capsule, liver, tongue. 
 
Table 4.1 Expression patterns of the Prkd genes. 
The different timings of expression of the different PRKD genes may mean that 
they do not exhibit complete functional redundancy, even when expressed in 
the same tissues [685].  
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Prkd1, 2 and 3 expression is also fairly generalised in the adult, suggesting they 
have important roles postnatally too. Two or more isoforms appear to be co-
expressed in the kidney, liver, lung, skeletal muscle, spleen and uterus. Prkd1, 2 
and 3 are all expressed in the adult heart [684]. Only Prkd2 is expressed in 
lymphoid cells. 
 
4.1.4 Functional redundancy 
 
There is some evidence of functional redundancy within the PRKD family across 
a number of species, but also evidence of different expression patterns and 
unique functions [678, 685].  
 
Knockout mouse studies provide evidence that Prkd1 has an essential role in 
embryogenesis, as the knockout mouse is embryonic lethal in the main [684]. A 
Prkd3 gene trap mutant mouse displayed only mild skeletal defects (direct 
submission to MGI database and MGI30335138 Lexicon Genetics). Prkd2 must 
also exhibit an element of functional redundancy as the homozygous knockout 
mice are phenotypically normal and do not show any evidence of reduced 
survival, fertility or abnormal embryogenesis [684]. This suggests that Prkd1 is 
essential for embryogenesis in the mouse, whereas Prkd2 and Prkd3 are not.  
 
Whilst Prkd1 may be non-redundant in embryogenesis, there is evidence of 
functional redundancy between the different isoforms in certain cellular 
functions. PRDK1, 2 and 3 are all able to phosphorylate class II HDACs to 
facilitate their nuclear export. In vitro experiments in cardiomyocytes have 
shown that knock down of PRKD1 alone is not sufficient to completely abolish 
export of HDAC5 from the nucleus [715]. In vitro analysis of specific B cells that 
express both PRKD1 and PRKD3, has shown that phosphorylation of HDAC5/7 
was unaltered with knockdown of either PRKD isoform, but when both were 
knocked out there was loss of phosphorylation of HDAC5 and its nuclear export 
[716]. Matthews et al. summarised reports of functional redundancy seen 
Identifying Novel Genes that cause Congenital Heart Disease  207 
 
between the PRKD genes in processes such as protein transport, Golgi 
organisation and cell survival response, as well as phosphorylation of certain 
substrates [679, 717-725].  
 
Despite evidence of more than one isoform being able to carry out a specific 
process, the embryonic lethal Prkd1 knockout mouse suggests that the isoforms 
must also have specific essential functions. The CRDs in the different PRKD 
proteins have different affinities for different ligands [697] and within the same 
cell type, phosphorylation of a substrate cannot always be achieved by all PRKD 
proteins [678]. PRKD isoforms also reside in different areas of the cell and 
perform unique functions. This include vesicle trafficking by the Golgi based 
isoform and superoxide dismutase 2 expression by the mitochondrial isoform 
(PRKD1/2) [678, 684, 726]. There are also differences in the movements of the 
three isoforms within the cell. PRKD1 resides mainly in the cytosol and travels to 
the cell membrane and is activated in response to the cell being stimulated. It 
then quickly moves back to the cytosol and organelles [687, 727]. PRKD2 is also 
mainly cytoplasmic, but locates to the nucleus from the membrane [727]. 
PRKD3 is found in both cytoplasm and nucleus, even when not active [728].   
 
Overall, despite evidence of functional redundancy in a number of processes 
including phosphorylation of class II HDACs and the fairly ubiquitous expression 
of the PRKD gene family, Prkd1 is clearly essential for normal embryogenesis. 
PRDK1 may be non-redundant because of its ability to carry out a specific task 
initiated by a specific ligand, further refined by specific temporospatial 
expression patterns [685, 729-732]. 
 
4.1.5 Mechanism of action 
 
Histone deacetlylases (HDACs) are key proteins involved in transcriptional 
regulation of many important developmental programs within the body. PRKD1 
can phosphorylate and inactivate a number of class II HDACs (HDAC4, 5, 7 and 
9) (enhanced by BMP2) [715, 716, 733-735]. Phosphorylation of HDAC4/5 by 
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PRKD1, allows their export from the nucleus into the cytoplasm. This allows 
downstream gene expression, by removing gene repression by MEF2A-D 
transcription factors [736, 737]. This process is outlined in Figure 4.2.  Although 
Calmodulin dependant protein kinase II (CaMKII) and IV (CaMKIV) and PRKD1 
all phosphorylate class II HDACs, it appears that phosphorylation by PRKD1 
rather than the CaMK genes causes nuclear export of HDAC4/5 and relieves 




Figure 4.2 Mechanism of action of PRKD1. 
Unphosphorylated class II HDACs remain in the nucleus and associate with 
MEF2 (red), preventing transcription of its targets. PRKD1 (green) 
phosphorylates the class II HDACS (blue), and they are exported (blue arrow) 
from the nucleus (yellow). MEF2 repression is removed (red arrow) and allows 
downstream gene expression which results in pathological cardiac remodelling.  
 
4.1.5.1 Role of PRKD1 In cardiogenesis 
 
The influence of PRKD1 on class II HDACs and genes repressed by MEF2, is 
important in the heart. The MEF2 genes are transcription factors, which are 
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expressed in cardiogenic precursor cells and differentiated cardiomyocytes 
during cardiac morphogenesis [738].  MEF2C is seen from E7.5 in the mouse 
cardiac mesoderm, which goes on to form the heart tube. mRNA from Mef2a, 2c 
and 2d are found in the myocardium at E8.5. Mef2c-/- mice develop an 
abnormal outflow tract and heart tube looping, and are embryonic lethal by E10 
[739, 740]. Given the role of PRKD1 in alleviating the repression of MEF2C, it is 
likely that it plays an important role in cardiogenesis, supporting its role in the 
pathogenesis of CHD. 
 
4.1.5.2 Role of PRKD1 in Cardiac Hypertrophy and Heart Failure  
 
In addition to formation of the heart, Prkd1 plays an important role in the 
response of the heart to stress and resulting hypertrophic response. Cardiac 
remodelling occurs when the heart is exposed to increased stress from 
abnormalities such as hypertension, valve defects or ischaemia. PRKD1 is 
activated in the failing myocardium of the adult human, rat and rabbit in 
response to stress from long-term neuro-hormonal signalling, hypertension 
and pressure overload [715, 741-744]. The role of Prkd1 in cardiac 
hypertrophy is considered further in chapter 5. 
 
4.1.5.3 Role of PRKD1 in Angiogenesis and ischaemia 
 
In addition to cardiogenesis and responses in the stressed heart, PRKD1 is also 
influential in angiogenesis. PRKD1 activity is increased by VEGF in endothelial 
cells [745], and a number of other stimuli in vascular smooth muscle cells [746-
748]. VEGF is required for both normal and pathological angiogenesis [749]and 
PRKD1 modulates VEGF related ERK1 signalling and endothelial cell proliferation 
[745]. VEGF stimulates PRKD1 to phosphorylate HDAC7 in endothelial cells, 
resulting in its nuclear export, subsequent MEF2 transcriptional activation and 
expression of genes required for angiogenesis, including cell migration and tube 
formation processes [667]. Mef2c-/- mice exhibit generalised vascular 
malformations and reduced expression of Vegf and angiopoietin1 [739, 740].  
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PRKD1 may also be important in cardiac ischaemia. It is activated in response to 
reactive oxidative species produced in the mitochondria. This results in increased 
production of proteins required for cell survival under these conditions [690, 
692, 726]. A number of the genes which show increased expression in this 
situation, including mitochondrial manganese dependant superoxide dismutase 
(SOD2), are thought to play a role in ischaemic preconditioning and myocardial 
protection [750]. PRKD1 is also known to phosphorylate TRPV1 and HSP27 [751, 
752]. Both of these proteins are thought to contribute to limiting the extent of 
ischaemia after a myocardial injury [753, 754].  
 
These studies taken together suggest that PRKD1 has an important role in the 
contractile and hypertrophic response of the heart working against increased 
afterload. Given PRKD1 induces expression of genes important in ischaemic 
preconditioning, it may play an important role in the ischaemic heart too. This 
makes it an interesting target in not just CHD, but also heart failure and 
ischaemia. 
 
4.1.6 Existing Prkd1 Mouse Models 
 
A number of mouse models have already been generated to study the effects of 
abnormal Prkd1 function. Feilitz et al. generated a cre-loxP mouse which deleted 
exons 12-14 and disrupts the catalytic domain of Prkd1 [732]. They showed that 
the PRKD1 product was degraded. This resulted in embryonic lethality with 
incomplete penetrance and around a 1% incidence of Prkd1-/- mice surviving to 
term.  These findings were corroborated by Matthews et al. [684]. They 
produced a Prkd1 mouse without the serine phosphorylation sites required for 
activation. They found that around 1% of live births were Prkd1-/- mice (2/177). 
Lethality of the Prkd1-/- mice appeared to be between E9.5-12.5, normal 
mendelian ratios were produced prior to E9.5. This indicates that catalytic 
activity of Prkd1 is almost universally essential for normal mouse 
embryogenesis.  
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In addition to the heart, the effects of Prkd1 on bone development has been a 
topic of much research. PRKD1 has an important role in osteoblast 
differentiation, mediating BMP2 induced nuclear export of HDAC7 and is also 
required for nuclear export of HDAC5 [715, 735]. A number of additional Prkd1 
knockout mice have been studied to determine the effects of Prkd1 on bone 
density. Ford et al. demonstrated a reduction in bone mineral density [755] and 
another conditional deletion of Prkd1 in osteoprogenitor cells results in young 
mice with reduced bone mass [756, 757]. A further conditional Prkd1 knockout 
mouse has been produced and resulted in abnormal bone development and 
osteoblast differentiation [758]. The mice had craniofacial dysplasia. The 
scapulae and long bones were also affected. 
 
The mouse models produced so far confirm that Prkd1 is non-redundant in 
mouse embryogenesis and is required for cardiac hypertrophic response to 
increased afterload. It is also required for normal skeletal development. Previous 
mouse models confirm that no CHD is seen in mice lacking Prkd2 or Prkd3. The 
mouse models I have studied are novel. The Wellcome Trust Sanger Institute 
generated the Prkd1em1(IMPC)Wtsi mouse, which has a different deletion (exon 2) to 
others reported previously, and the Prkd1em2(IMPC)Wtsi mouse which is the first 
humanised mutation mouse designed to replicate the commonest reported 
mutation causing CHD with ectodermal defects. More details about the mouse 




The aims of this chapter are: 
 To describe the genotype and phenotype of individuals reported by Sifrim 
et al. [12] and to consider the mechanism by which mutations in PRKD1 
cause abnormalities in humans. 
 To assess Prkd1em1(IMPC)Wtsi and Prkd1em2(IMPC)Wtsi mice to determine the 
effects of loss of Prkd1 on embryonic survival and formation of the heart 
using HREM. 
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 To develop an MRI protocol to characterise the cardiac phenotypes of 
adult Prkd1em2(IMPC)Wtsi mice. 
 
4.3 Results and Discussion 
 
4.3.1 Individuals Reported with mutations in PRKD1 
 
Three participants were identified with de novo missense mutations in PRKD1 
[12]. Two individuals had identical mutations which fall within the nucleotide 
binding domain of the protein kinase domain (c.1774G>A, p.Gly592Arg). The 
third mutation falls within the second CRD (c.896T>G p.Leu299Trp). All three 
affected individuals have cardiac defects, two have AVSDs and the third has 
pulmonary stenosis (table 4.2). Because of the prominence of associated 
ectodermal features, the syndrome has been named CHD and Ectodermal 
Defects (https://www.omim.org/entry/617364). 
 
ID Mutation Inheritance Cardiac abnormality 
268276 p.Gly592Arg De novo Pulmonary valve stenosis. 
261674 p.Leu299Trp De novo AVSD 
263568 p.Gly592Arg De novo AVSD 
 
Table 4.2 CHD subtypes in PRKD1. 
Genotypes and associated cardiac malformations identified in the three 
individuals with variants in PRKD1.  
 
All three individuals reported with CHD and Ectodermal Defects are male. They 
had variable birth weights, but postnatal height/length appears to be within 
normal limits. Two exhibit microcephaly, and the other has macrocephaly.  A 
single individual has an Arnold Chiari malformation. Developmental information 
suggests developmental delay in one, and learning disability and ADHD in 
Identifying Novel Genes that cause Congenital Heart Disease  213 
 
another. Two of the three had feeding difficulties, with one individual requiring 
NG feeding. 
 
Ectodermal features appear to be a feature of this condition and one of the three 
individuals reported was initially thought to have an ectodermal dysplasia. Two 
of the three individuals have prominent ectodermal features including sparse 
scalp hair, dry/thin skin, fragile nails, small widely spaced teeth and premature 
loss of primary teeth. The third is noted to have a disorganised eyebrow with 
abnormal flare and widely spaced teeth only.  
 
 
Digital abnormalities are also prominent and are described in two of the three 
individuals. These include a broad thumb, short digit, 2, 3 toe syndactyly and 
finger syndactyly.  Photographs were available for two individuals. They share a 
prominent and wide forehead, with high anterior hair line and a stuck on chin. 
Ears appear anteverted. Other less common features included stridor, scoliosis, 
hypotonia, nystagmus and conductive deafness (n=1).  
 
 
In addition to the three individuals we reported [12], a further individual is 
included on ClinVar with the diagnosis of CHD and Ectodermal Defects (clinical 
testing in Brazil) [521]. Unfortunately consent to include the individuals clinical 
information has not been given. All four mutations fall within important domains 
of the protein as shown in figure 4.3.  
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Figure 4.3 Mutations reported in association with CHD and Ectodermal 
Defects. 
All are missense mutations affecting domains required for normal function of 
PRKD1. P.G592R and p.L299W were reported by Sifrim et al [12]. p.R439Q 
(c.29632945 G/A) is included on ClinVar [521], and reported by Mendelics 
Clinical testing Brazil, Rua Cubatao, 86, cj 1202Vila Mariana Sao Paulo  Sao 
Paulo Brazil - 04013-000. All are reported in build 37. Uniprot does not suggest 
any modification occur at residues 299 and 592 [544]. 
 
PRKD1 as a cause of CHD and Ectodermal defects is supported by the correlation 
between the clinical picture reported in these individuals and its expression 
patterns during embryogenesis. The de novo occurence of mutations also 
supports is pathogenicity, although inheritance is unknown in the individual with 
p.R439Q. The mutations all fall within recognised domains within the protein 
that are required for normal function. The supporting evidence for PRKD1 as a 
cause for CHD and Ectodermal Defects and a discussion of the possible 
mechanisms of action follows. 
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4.3.2 Genotype phenotype correlation 
 
The small number of individuals reported with CHD and Ectodermal defects 
means that it is difficult to assess genotype phenotype correlation. However two 
individuals have been reported with the same variant. The two individuals with 
p.G592R both show ectodermal features and limb abnormalities. Both have 
sparse scalp hair, one has dry skin and the other has thin skin, one had 
premature loss of the primary teeth and the other had small teeth. One 
individual has a short digit and broad thumb, and the other has both toe and 
finger syndactyly. Both had feeding problems. Photographs were available for 
both individuals. They share similar facial characteristics, with a wide forehead 
and high anterior hair line, a stuck on chin and anteverted ears.  
 
The individual with the p.L299W mutation differs as they had no digital 
abnormalities, and were the only individual with nystagmus and structural brain 
malformation (Arnold Chiari malformation). They had some ectodermal features 
(a disorganised eyebrow and widely spaced teeth), but not as convincingly as 
the two individuals with p.G592R mutations.  
 
Features which do not correlate with mutation type include NDD, head 
circumference (occipitofronto circumference/OFC) and CHD type. The individual 
with p.L299W had delayed gross motor development, specific learning disability 
and ADHD. One of the individuals with p.G592R had developmental delay, but 
the second individual with this mutation does not. One individual with p.G592R 
has microcephaly and the other has macrocephaly. AVSDs were seen with both 
p.G592R and p.L299W.  
 
Overall there is some evidence of genotype phenotype correlation with respect 
to digital abnormalities and possibly ectodermal features, but not CHD type or 
OFC. There is evidence of shared facial features between the two individuals we 
have photographs for, but we are limited as to what conclusions we can draw 
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between facial features and other abnormalities given the very small sample 
size. 
4.3.3 Correlation of the clinical features with PRKD1 expression 
 
The core features of CHD with ectodermal dysplasia appear to correlate with 
Prkd1 expression during embryogenesis. This includes expression in the heart, 
integument, brain and limb bud. PRKD1 is fairly widely expressed, so its effects 
are likely to be wide ranging. Defects might not arise in other organs because of 
functional redundancy with PRDK2 and PRKD3 or other genes. The significance 
of other less common clinical features is currently unclear, and only further 
reports of affected individuals will determine whether they are part of the same 
disease process or not. Expression and clinical abnormalities in the limb, brain 
and ectodermal tissues are described here. A more detailed discussion 
considering the heart is included later in section 4.3.4 and 4.9. 
 
4.3.3.1 Limb Abnormalities  
 
Digital abnormalities have been reported in two individuals with CHD and 
Ectodermal defects, suggesting a role for PRKD1 in the limbs. One individual has 
a broad thumb and short digit, and another has syndactyly of the fingers and 2, 
3 toe syndactyly.[12]. A short broad thumb might imply radial ray defects and 
bony involvement. It is not clear if the upper limb syndactyly is bony or just soft 
tissue. 2, 3 toe syndactyly is relatively common and could be coincidental. 
Therefore more reports are required to determine the characteristics of 
associated limb defects.  
 
Mouse models confirm expression in the limb bud of the E10.5 mouse embryo 
[685] and a role in development of normal bone structure [755, 758]. This 
supports limb defects as being a true phenotype of abnormal function of PRKD1. 
Whilst the majority of research involving PRKD1 in the skeleton focusses on bone 
mineral density, there is also evidence that loss of Prkd1 can result in other bony 
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abnormalities. 4 and 10 week old Prkd1 conditional null mice show craniofacial 
dysplasia, abnormal scapulae and short long bones compared to WT mice. This is 
due to reduced osteoblast differentiation [758]. Reduced expression of Prkd1 
was seen in the calvarium and long bones. At 14 days old the mice had 
abnormal bone nodules in the scapulae and an under developed cranial cap, 
seen with delayed suture closure and calvarial defects. No specific comment was 
made upon the limb bones apart from length, and it is not possible to say from 
the data whether any specific deformities were present similar to those reported 
in humans. It is also possible that the phenotype in these mice may be in part 
due to the osterix-Cre transgene used to produce a conditional model, as it can 
induce a skeletal phenotype of its own [759]. This includes hypomineralisation 
around the sutures and in a number of craniofacial bones, so the significance of 
these findings is unclear. Specific craniofacial defects have not been reported in 
the human population as yet and it is not clear if there are any other similar 
abnormalities involving the scapula or long bones. Growth appears to be within 
normal limits in the two individuals we have measurements for, and there are no 
reports of delayed suture fusion although a single individual has brachycephaly 
(sifrim). Growth parameters are normal in Prkd1+/- pubescent mice so short 
stature may not occur [755].  
 
Prkd1 is involved in maintaining bone mineral density. It is required for normal 
osteoblast differentiation and maturation [760]. Prkd1 is activated by BMP2 and 
IGF1. A number of mechanisms have been proposed to explain how PRKD1 
regulates bone formation, and include removing reactive oxygen species, its 
influence on HDAC7, activation and expression of osteoblast markers STAT3 and 
p38, and by influencing β-catenin [756, 758].  No data is available regarding 
bone mineral density in the individuals with CHD and Ectodermal defects. Lower 
bone mineral density in Prkd1 null mice normalises with time suggesting that 
other mechanisms must compensate for the loss of Prkd1 [756]. Prkd2 
influences osteoclast differentiation and Prkd3 knockout mice also display 
changes in bone density and therefore the action of these genes may 
compensate (Direct data submission to MGI 2005 from Lexicon Genetics) [546, 
685, 758].  
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The association of PRKD1 with TBX5 is also important given that upper limb 
defects are seen in Holt Oram. This always includes carpal bone abnormalities 
and variable defects from the thumb, the arm bones, scapula and collar bone. 
The defects can be unilateral or bilateral. Detailed descriptions, or imaging of the 
limb defects seen in individuals with CHD and ectodermal dysplasia are not 
available. It would be interesting to review any imaging for carpal bone 
involvement for example to see if there is any cross over with features of Holt 
Oram or not. Holt Oram Syndrome is caused by loss of function mutations. 
Presumable loss of normal PRKD1 would prevent release of TBX5 from binding 
by HDACs and therefore reduced action of TBX5. However gain of function 
mutations in TBX5 have been associated with atypical presentations [761] and 
as mentioned previously there are likely to be other compensating mechanisms. 
 
Overall, evidence of expression of Prkd1 during embryogenesis in the limb bud 
supports limb abnormalities as a feature of CHD and Ectodermal defects. The full 
phenotypic spectrum is yet to be determined. Prkd2, Prkd3 and TBX5 may all 
contribute to development in the limbs and more information is required about 
how they all interact. The importance of Prkd1 in maintaining bone mineral 
density is uncertain since lower bone mineral density in mice normalises with 
time [756] and it is unclear whether this will be of relevance to individuals with 
heterozygous mutations in PRKD1.  
 
4.3.3.2 Ectodermal Features 
 
A number of ectodermal features have been reported and one individual was 
thought to have an ectodermal defect prior to discovery of their pathogenic 
PRKD1 mutation. Dry skin, and thin skin with pigmented naevi are reported, 
along with fragile nails. Scalp hair has been described as sparse. Dental 
abnormalities reported include premature loss of primary teeth and small widely 
spaced teeth (n=2).  
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There is no specific information about dentition and PRKD1. Prkd1 is expressed 
in the mouse skin at E16-E18 [546] and therefore it is possible that ectodermal 
defects are a result of abnormal PRKD1 function. However, mouse models 
including conditional knockout in keratinocytes reveals that Prkd1 is not required 
for normal skin and hair morphology, and numbers of proliferating epithelial cells 
are normal in conditional knockout models under normal conditions [762]. This 
suggests that Prkd1 is not required for normal skin development and 
maintenance. In contrast, PRKD1 plays a non-redundant role in response of 
keratinocytes to stress [731, 763, 764]. Wound healing was slower in conditional 
Prkd1 knockout mice as a result of reduced proliferation and migration of 
keratinocytes.  
 
It is unclear why PRKD1 might result in ectodermal defects currently, and more 
research is needed. Reporting of further affected individuals will delineate the 
spectrum of associated ectodermal defects. 
 
4.3.3.3 The brain 
 
Prkd1 is strongly expressed in the mouse brain between E9.5-14.5 and has been 
shown to be important in neuronal links in the hippocampus [675, 765]. Two of 
the three individuals with phenotype data have features of central nervous 
system involvement. This includes delayed speech and language (n=1), ID 
(n=1), ADHD (n=1)) and structural abnormalities (microcephaly (n=2) and 
Arnold Chiari malformation (n=1)). Given the apparent shared developmental 
pathways and pathogenesis of NDD and CHD, combined with appropriate 
expression patterns, it is certainly possible that NDD is a result of the SNVs in 
PRKD1. 
  
4.3.3.4 Other Features 
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Additional reported features include bilateral conductive hearing loss, stridor, 
scoliosis, nystagmus and hypotonia, which have all been reported in a single 
individual only. The significance of these features is currently unclear. 
PRKD1 also appears to play an important role in insulin secretion and has been 
shown to promote its release in response to glucose [766].  Inducible Prkd1 
knock out mice developed hyperglycaemia and hyperinsulinaemia [767]. One 
individual born at term had hypoglycaemia along with jaundice and hypothermia, 
and also had a low birthweight which could explain these features. 
 
4.3.4 What is the mechanism causing clinical abnormalities, including 
CHD? 
 
Three different missense mutations have been associated with CHD and 
Ectodermal defects in the four individuals reported so far. Whilst PRKD1 does not 
show at least two specific regions of missense constraint [768], all mutations fall 
within functional domains of the protein. The known functions of these domains 
suggests variants in the PH, second CRD and PK domains may all have a 
significant effect. Inheritance is de novo in all except for the mutation in the PH 
domain where inheritance is unknown. These factors all support pathogenicity of 
the variants, but the mechanism by which they cause clinical abnormalities is 
currently unknown. The possible consequences of the individual mutations and 
evidence for specific mechanisms of action are outlined in the following section. 
 
4.3.4.1 p.G592R in the Protein Kinase Domain 
 
The glycine residue affected by the variant p.G592R is conserved in a number of 
mammals including chimpanzee and mouse, as well as xenopus, c.elegans, 
zebrafish and chicken. The mutation falls within the protein kinase domain, and 
more specifically within the nucleotide binding domain (residues 589-597) 
(Figure 4.3 shown previously). This variant could interfere with ATP binding and 
normal function of the kinase domain. 
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Studies involving alterations in the kinase domain have already been carried out 
to assess the functional consequences [710, 769]. Mutation of both serine 
phosphorylation sites (Ser744 and Ser748 in the activation loop) to alanine 
resulted in an inactive kinase domain. Mutation of both serines to glutamic acid, 
mimics phosphorylation and produces an activated PRKD1 protein. Mutation of 
one serine to glutamic acid produces a partially active kinase. The changes in 
kinase activity is as you would expect, but protein localisation is also altered. 
Loss of function by mutation of the serine residues to alanine in cell models, 
resulted in normal translocation of PRKD1 to the plasma membrane, but delayed 
translocation from the plasma membrane to the cytosol [700]. This suggests 
that normal function and reverse translocation requires normal catalytic activity 
of PRKD1.  
 
p.G592R could potentially result in loss of kinase function if it prevents ATP 
binding. This could result in both loss of kinase activity and potentially abnormal 
distribution of the protein. Alternatively it could result in a change in the 
nucleotide binding domain that allows another substrate to preferentially bind. 
For another substrate to activate the kinase, presumably it would need to act as 
a phosphate donor or induce a conformational change that results in activation. 
It would seem more likely that p.G592R would result in loss of kinase function. 
Functional studies are required to confirm this, but initial work by other 
members of the Brook laboratory suggests that p.G592R may result in reduced 
function of the kinase domain (work by T Ghosh and J Aparicio).  
 
4.3.4.2 p.L299W in the Second CRD 
 
p.L299W falls within the second CRD. Leucine at this position is conserved in a 
number of mammals including chimpanzee, mouse and chicken as well as 
xenopus and zebrafish, reinforcing the importance of this domain. Although 
there are two CRDs in PRKD1, it is this second CRD that has the higher affinity 
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for phorbol esters and the two CRDs are not equivalent in function [693, 694, 
696].  
 
The second CRD binds DAG at the plasma membrane, and is required for 
translocation of PRKD1 into the nucleus [700, 701]. Studies have also shown 
that the two CRDs regulate the activity of PRKD1. Deletion of either CRD, or 
both together resulted in increased activity of PRKD1 in COS-7 cells [696]. 
However, mutations of conserved proline residues which contribute to PRKD1’s 
affinity for phorbol esters within the two CRDs, yielded different results. p.P287G 
in the second CRD resulted in similar kinase activity to the WT PRKD1 protein. 
However, this mutation also severely reduced the bombesin stimulated 
translocation of PRKD1 to the plasma membrane in Swiss 3T3 fibroblasts and 
MDCK cells (Madin-Darby canine kidney cells) [700].  In contrast, p.P155G in the 
first CRD, resulted in significantly increased activity of the mutated protein 
compared to WT. This suggests that the two CRDs do not have the same effect 
on the activity of PRKD1. Given the mutated prolines were chosen specifically, it 
is not possible to predict what effect p.L299W might have on the kinase activity 
of PRKD1.  
 
Based on these results, p.L299W could alter DAG binding, movement to the 
plasma membrane and nucleus, and potentially kinase activity. If any of these 
functions were reduced, we might see reduced phosphorylation of HDAC targets 
and continued repression of MEF2 gene targets.  Functional studies should be 
carried out to confirm if like the p.P287G mutation, kinase activity is unchanged. 
In addition, studies of movement of the mutant protein are needed to determine 
if p.L299W alters translocation to the plasma membrane and the nucleus. 
 
4.3.4.3 p.R439Q in the PH Domain 
 
p.R439Q falls within the PH domain. PH domains are required for binding to 
membrane lipids and other proteins [698] and in PRKD1, this domain is 
responsible for autoregulation [673, 682, 696].  The PH domain is also 
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necessary for formation of stable complexes with certain PKCs, including PKCη 
[770], localisation of PRKD1 [698] and its nuclear export [703]. 
A number of experimental studies have determined the effects of a deleted or 
mutated PH domain. Deletion of the PH domain altered the resting location of 
PRKD1 in lymphocytes [703]. Instead of residing in the cytosol, PRKD1 was 
found in both the nucleus and the cytosol. On activation of the cell, PRKD1 could 
still locate to the plasma membrane, despite the altered PH domain. This 
suggests that the PH domain is important in controlling the localisation of PRKD1 
in inactivated cells. Deletion of the PH domain also affects activity levels of 
PRKD1 in COS-7 cells [695]. Deletion of the whole PH domain resulted in very 
high levels of activity. Partial deletion of the PH domain also increased activity 
levels, as did mutations p.R447C and p.W538A which affect semi conserved and 
conserved residues within the domain respectively. Importantly, p.R447C 
modelled in the COS-7 cells appears to be just two residues from p.R439Q 
reported in the individual on ClinVar.  
 
Based on this evidence, it seems likely that p.R439Q will alter the protein 
function and could result in gain of function. The effect on localisation of the 
protein in unclear. Both kinase studies and localisation studies using a mutated 
protein are required to determine the effect of the mutation reported in this 
individual.  
 
4.3.4.4 Additional information to help determine the pathogenic 
mechanism of PRKD1 mutations 
 
Considering the domains affected by the three missense mutations reported so 
far and the functional evidence available, it would seem most likely that p.G592R 
and p.L299W result in loss of function, but p.R439Q may result in a gain of 
function. Whether normal shuttling of the mutated proteins occurs is unclear. If 
translocation of the protein is altered it could increase or decrease the ability of 
PRKD1 to phosphorylate HDACs based on the resulting levels in the nucleus. To 
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try and determine how aberrations in PRKD1 result in abnormalities, we can also 
consider additional reported variants of unknown significance and 
haploinsufficiency as a mechanism. 
 
Two heterozygous truncating mutations have been reported on public databases, 
one on Decipher and one on ClinVar [496, 521] (figure 4.30). Both are of 
unknown significance. One falls within the protein kinase domain (p.Y760*) and 
was detected during clinical testing in Germany (ClinVar). Unfortunately, despite 
contacting the laboratory, I have been unable to find out any further 
information. The other falls between the two CRD (p.Q143*), and is associated 
with moderate global developmental delay, muscular hypotonia, a depressed 
nasal bridge, protruding tongue and synophrys. Discussion with the clinician 
involved has confirmed there are no cardiovascular, limb or ectodermal features 
and the individual has a primarily neurodevelopmental phenotype. The mutation 
has been designated a class 3 variant. The individual also has two other variants 
of uncertain significance, one of which is in a gene associated with NDD. 
 
Whilst NDD does appear to be part of the phenotype associated with missense 
mutations in PRKD1, it has not been seen in isolation in the individuals we have 
reported. However, the Samocha et al. dataset includes a further mutation in 
PRKD1; p.Phe306Tyr (figure 4.4) [768]. This was found in a cohort of 5620 
individuals with NDD. If this mutation proved to be pathogenic and associated 
with NDD in isolation, we would have to reconsider if p.Q143* might be 
significant. However p.Phe306Tyr falls within the second CRD and is therefore 
more likely to be significant. This variant has a MPC score of 1.1226 and could 
be pathogenic (compare to p.Gly592Arg which has a MPC of 1.2269, and 
p.L299W with an MPC score of 1.442). Unfortunately there is no information 
regarding the phenotype, inheritance or whether they have another potentially 
pathogenic mutation as the data is anonymised. This means we cannot be sure if 
isolated NDD is a feature of PRKD1 mutations and whether either of these 
mutations are pathogenic. 
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Figure 4.4 Additional variants reported in PRKD1. 
Mutations above gene: PTVs of uncertain significance [496, 521] and presumed 
pathogenic missense mutation associated with NDD only [768]. A further 
pathogenic homozygous truncating mutation has been reported as causing NS-
CHD, this is p.R618* [771]. 
Mutations below gene: pathogenic missense mutations [12, 521]. Y760X from 
Clinical testing CeGaT Praxis fuer Humangenetik Tuebingen, PHGT Paul-Ehrlich-
Str. 23.  
 
The pLI of PRKD1 is 0.0 [772], suggesting that this gene is tolerant of LoF 
mutations and therefore these truncating mutations may be benign in the 
heterozygous state. However, a family with truncus arteriosus and homozygous 
PTVs in PRKD1 has also been reported [771]. Two healthy half cousin parents 
from a Saudi Arabian family had two affected daughters with TA, and a further 
six children who were well. The affected daughters had NS-CHD (at the time of 
reporting they were 12 and 16 years old and had recently been evaluated). 
Whole exome sequencing was carried out on DNA from the two affected siblings 
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only and used to identify homozygous variants in coding regions or splice 
variants with a frequency of less than 0.001 in dbSNP. Autozygosity mapping 
was then carried out. They then narrowed candidate SNPs down to those 
identified in autozygous regions between the siblings and removed those that 
were also seen in a sample of 549 Saudi individuals who had had WES. This 
filtering process left only a homozygous nonsense mutation p.R618* in PRKD1 
(NM_002742:c.1852C>T). The authors then went on to look at another 17 
individuals with TA, of which only 20% had consanguineous pedigrees. They 
identified three individuals with 22q11.2 deletion syndrome who were excluded 
and targeted sequencing of PRKD1 in the rest revealed no further mutations. It 
is important to note that the parents were not tested for the presence of the 
mutations. The mutation is recorded on ClinVar as being of uncertain 
significance. 
 
The p.R618* mutation maps to the protein kinase domain. This begins at residue 
595, so truncation occurs relatively near the beginning of the kinase domain. 
The consequences of homozygosity for p.R618* are unknown. If the mutation 
resulted in complete loss of function, then presumably the individuals would not 
have survived (with the obvious caveat that we cannot assume the mouse model 
always translates directly to humans). This suggests that the protein might 
retain some function and could represent a partial loss of function mutation. 
Initial work by T Ghosh and J Aparicio in the Brook laboratory suggests that 
p.R618* may result in reduced function of the kinase domain. Alternatively, 
there could be another explanation for the phenotype and the truncating 
mutations are coincidental.  
 
p.Y760* is also located in the PK domain [521]. Although nearby, more of the 
kinase domain will be intact (if the protein is not degraded) and obviously this 
individual has a normal WT protein to compensate, whereas the siblings with 
p.R618* do not.  It is reported as being of uncertain significance. Phenotypic 
information for the individual carrying p.Y760* is required along with functional 
studies to determine if there is nonsense mediated decay or any function in a 
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residual protein to help determine the pathogenicity of these truncating 
mutations, especially given that the pLI value suggests PRKD1 should tolerate 
LoF mutations.  
 
The haploinsufficiency index of PRKD1 is 2.79%, which suggests that it is more 
likely to exhibit haploinsufficiency [773]. DGV records a number of deletions 
within PRKD1 in the normal population. The majority are small and intronic, and 
therefore possibly benign. This could support haploinsufficiency of PRKD1 as 
being detrimental. There are a number of deletions involving half or the whole of 
PRKD1 in isolation associated with NDD and structural brain abnormalities 
recorded on decipher [496]. The significance of most is unclear as inheritance is 
unknown or the individual has other CNVs in addition. Larger deletions including 
neighbouring FOXG1 have been reported as causing atypical Rett syndrome, 
which shares a NDD phenotype. PRKD1 deletions could affect the function of 
nearby FOXG1. Overall the significance of the deletions including PRKD1 is 
unclear at this time. 
 
It is difficult suggest a unifying mechanism to account for all these mutations. 
Considering the phenotypes it is also difficult to explain why homozygosity for 
p.R618* results in NS-CHD, but heterozygous missense mutations in the same 
domain result in S-CHD and a more severe phenotype if both act via the same 
mechanism. More than one mechanism could account for phenotypic differences. 
I have so far not considered the possibility of a dominant negative process, by 
which PRKD1 might be able to sequester HDAC and other proteins resulting in a 
more severe phenotype. Perhaps homozygosity for p.R618* results in reduced 
function and has fewer detrimental effects than a single heterozygous missense 
mutation where the protein retains more function. Different levels of PRKD1 
function could result in different levels of phosphorylation of HDAC molecules 
and different levels of MEF2 target gene expression.  
 
Considering all the information available currently, the mechanism by which 
aberrations in PRKD1 cause disease is uncertain. The haploinsufficiency index 
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and lack of significant deletions in a normal population suggest 
haploinsufficiency is plausible, but reports of individuals with deletions of PRKD1 
and CHD and Ectodermal defects are lacking. Both gain and loss of function are 
possible. Loss of function as a cause of CHD and ectodermal defects would go 
against the pLI value of 0 however. 
 
It is also possible that simply considering mutations to cause gain or loss of 
function is too simplistic given that translocation of PRKD1 is likely to be affected 
in addition, and that it performs many tasks in many different cellular locations 
under different conditions. Ultimately, further reports of individuals with 
mutations and deletions in PRKD1, paired with functional testing will help 
unravel the mechanisms behind CHD with ectodermal defects and whether the 
clinical spectrum includes isolated CHD and isolated NDD. 
 
4.4 Clinical Recommendations 
 
At this stage it is difficult to make clinical recommendations given the small 
number of individuals reported and the lack of phenotype data about many of 
them. The first step needs to be a more detailed collection of clinical features. 
This should be followed by regular review for any new phenotypes. Identification 
of other affected individuals is also necessary to understand the full spectrum of 
signs and symptoms. Based on the information we have available I would 
suggest the following: 
 
Consider genetic testing in individuals with: 
 CHD with ectodermal defects. 
 CHD with limb abnormalities, after review for features of more well 
described hand heart syndromes (Holt-Oram, Okihiro, Ulnar Mammary, 
Rubenstein Taybi, Smith Lemli Opitz and Oral Facial Digital Syndromes) 
and appropriate testing. 
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Suggestions for investigations at this stage include: 
 Echocardiography 
 
Echocardiography is a low risk and non-invasive investigation that can detect 
most structural lesions. This should happen at diagnosis and is likely to form 
part of the ongoing follow up of individuals with CHD. Given the role of PRKD1 in 
cardiac hypertrophy and contractility [689, 741, 774], it would be worth noting 
any evidence of hypertrophy or conduction abnormalities. This may be 
addressed at cardiac follow up appointments or if symptoms arise.  
 
 Careful review at diagnosis for limb defects and appropriate management. 
 
Currently there is only evidence of mild abnormalities.  
 Review for ectodermal defects and appropriate management. 
 
Currently there is no information on whether there is any involvement of sweat 
glands, which might necessitate additional advice and management. 
 Monitor growth parameters and suture closure. 
 
This should include OFC and imaging if required. There is conflicting evidence as 
to whether Prkd1 in the mouse causes short stature or not. Mouse models 
suggest that Prkd1 function is redundant in maintaining post pubescent bone 
mineral density, but it might be worth considering DEXA scanning if there are 
multiple or low impact fractures. 
 Monitor and support development and learning as required. 
 
Structural brain malformations have been seen, but given the small cohort of 
individuals, it is unclear how common a feature this is. It would be appropriate 
to consider imaging if there are additional neurodevelopmental concerns.  
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The above suggestions should be refined as more information becomes 
available. It would be beneficial to report any abnormalities of glucose 
homeostasis given PRKD1 is involved in control of insulin release [766]. 
 
Much of the research about PRKD1 involves its role in cancer as PRKD1 is part of 
an important pathway regulating cell senescence [775]. A mutation hotspot has 
been identified in PRKD1 in polymorphic low-grade adenocarcinoma of the 
salivary glands. These missense mutations fall within the catalytic loop of the 
kinase domain (p.E710D) [776]. This mutation results in increased kinase 
activity and increased cellular proliferation in a cellular model suggesting this 
mutational hotspot is oncogenic.  Genomic rearrangements of the PRKD genes 
have also been described in carcinoma of the salivary glands [683]. The 
significance of this in individuals with germline mutations in PRKD1 is uncertain. 
Incidences of cancer should be reported to help determine if there is any risk to 
individuals with CHD and Ectodermal defects. 
 
4.5 Results from the Prkd1 Mice 
 
Results from both Prkd1 mouse lines are detailed sequentially here. A discussion 
of the results of both lines together is included afterwards.  
 
4.5.1 Confirming genotype in a Prkd1Em1(IMPC)Wtsi mouse 
 
The Prkd1Em1(IMPC)Wtsi mouse was supplied by the WTSI using Crispr/Cas9, and 
deletes exon 2 and some of the surrounding intronic sequence. Exon 1 is the 
first coding exon. Exon 2 precedes the first cysteine rich domain and overlaps its 
start (CRD residues 123-195, exon 2 residues 87-133).  
 
Results for a wild type mouse are shown in figure 4.5. The 1360bp wild type 
band did not always amplify. This was detailed in the mouse information sheet 
from the WTSI. A LongAmp (NEB LongAmp Taq DNA Polymerase M0323) 
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protocol was used to preferentially amplify this band, following the 
manufacturer’s suggested PCR programme. Gel extraction was then completed 
and the product sent for sequencing. This confirmed the product produced was 




Figure 4.5 Prkd1+/+ mouse genotype. 
PCR results after running primer combinations on Prkd1+/+ mouse DNA shows 
the expected band at 223bp and 1360bp. GAPDH primer set used as a control. 
1% gel, Invitrogen 100bp ladder.  
 
Confirming the genotype in the Prkd1Em1/+ and Prkd1Em1/+ mice proved more 
difficult initially, due a larger than expected deletion. The results are shown 
below. As expected for Prkd1Em1/+ mice, DF1ER1 produced a band at 223bp and 
DF1DR1 produced a band at 1360bp. However, there was no band at 212bp in 
DF1DR1 and instead there was an unidentified 400bp band (Figure 4.6).  
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Figure 4.6 Prkd1Em1/+ genotype. 
PCR products from the two primer pairs in 5 Prkd1Em1/+ mice. 100bp ladder and 
3% gel. Each mouse has a six digit ID, shown at the top of the figure. Results 
for the two primer sets are shown for each mouse in the order of DF1ER1 on the 
left and DF1DR1 on the right. 
 
To ascertain why the DF1DR1 band was 400bp rather than the expected 212bp, 
I performed a gel extraction and sent the product for Sanger sequencing. The 
results for the 200bp (Figure 4.7) and 400bp bands (Figure 4.8) are shown 
below and confirm that the deletion was smaller than originally documented by 
the WTSI. 
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Figure 4.7 Sequence of Prkd1Em1/+ mouse. 
Results of PCR using primers DF1 and ER1 produces 200bp band. Gel extraction 
and sequencing shows that the sequence maps to the correct area, but is slightly 





Figure 4.8 Deleted sequence in the Prkd1Em1/+ mouse. 
Sequence results produced from PCR using primers DF1 and DR1 of the deleted 
allele. The deleted section is smaller than expected, which results in a larger 
band on the gel. The information from the WTSI suggested that both red and 
green sections would be deleted, whereas only the red section had been deleted. 
This still contains exon 2 however. Primers are highlighted in dark blue, DR1at 
the top and DF1 towards the bottom of the sequence. The bases highlighted in 
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pink show the first and last bases of the sequence obtained. Guide RNA sites 
used by the WTSI to generate the mouse are highlighted in purple boxes.  
In light of the discrepancy in the size of the deletion I contacted the WTSI. 
Subsequent correspondence confirmed my findings and confirmed the mouse 
supplied had the smaller deletion. The updated expected band sizes are shown 













The final band sizes for confirmation of genotype in the Prkd1Em1(IMPC)Wtsi mouse 
with the smaller deletion than originally documented. 
 
4.5.2 Ratios of Genotypes Produced in the Prkd1Em1(IMPC)Wtsi Mouse 
 
Genotypes were recorded for all mice processed, as part of normal colony 
maintenance and heterozygous crosses for embryo collections, to observe the 
ratios of each genotype produced.  
 































Table 4.3 Updated PCR for Prkd1Em1(IMPC)Wtsi mouse. 




The results of the embryo genotypes are shown in table 4.4 and figures 4.9 and 
4.10. There is evidence of embryonic lethality in the knockout mice, but deaths 
were also seen in WT Prkd1+/+ and Prkd1Em1/+ embryos. Genotype was confirmed 
twice initially to ensure assays were correct. 
 
Gestation Cross Expected Observed 
E9.5 Prkd1Em1/+ x 
Prkd1Em1/+ 
Em1/Em1:25% 
Em1/+:    50% 
+/+:        25% 
Em1/Em1:    0  
Em1/+:        3 (25%) 
+/+:            4 (33%) 
Unknown:     5 (42%) 
E10.5 Prkd1Em1/+ x 
Prkd1Em1/+ 
Em1/Em1:25% 
Em1/+:    50% 
+/+:        25% 
Em1/Em1:    0  
Em1/+:        4 (50%) 
+/+:            2 (25%) 
Unknown:     2 (25%) 
E10.5 Prkd1Em1/+ x 
Prkd1+/+ 
Em1/Em1: 0% 
Em1/+:    50% 
+/+:        50% 
Em1/Em1:    0  
Em1/+:        2 (20%) 
+/+:            4 (40%) 
Unknown:     3 (30%) 
Failed:          1 
E11.5 Prkd1Em1/+ x 
Prkd1Em1/+ 
Em1/Em1:25% 
Em1/+:    50% 
+/+:        25% 
Em1/Em1:     0  
Em1/+:         8 (80%) 
+/+:             1 (10%) 
Unknown:      2 (20%) 
E12.5 Prkd1Em1/+ x 
Prkd1Em1/+ 
Em1/Em1:25% 
Em1/+:    50% 
+/+:        25% 
Em1/Em1:     0 (0%) 
Em1/+:         8 (89%) 
+/+:             0 (0%) 
Unknown       1 (11%) 
E15.5 Prkd1Em1/+ x 
Prkd1Em1/+ 
Em1/Em1:25% 
Em1/+:    50% 
+/+:        25% 
Em1/Em1:     0 (0%) 
Em1/+:       24 (50%) 
+/+:           15 (31%) 
Unknown:      9 (19%) 
E15.5 Prkd1Em1/+ x 
Prkd1+/+ 
Em1/Em1:0% 
Em1/+:    50% 
+/+:        50% 
Em1/Em1:     0 (0%) 
Em1/+:         4 (29%) 
+/+:             8 (57%) 
Unknown:      2 (14%) 
 
Table 4.4 Prkd1Em1(IMPC)Wtsi embryo genotypes. 
Genotypes of all Prkd1em1(IMPC)Wtsi embryos produced. In some cases the embryo 
had died at an early stage of development and sufficient tissue to allow 
genotyping could not be collected. In this instance, the genotype is recorded as 
unknown. +/+: Prkd1+/+, Em1/+: Prkd1Em1/+, Em1/Em1: Prkd1Em1/Em1.  




Figure 4.9 Genotypes from Prkd1Em1/+ crosses. 
Numbers of each genotype produced from Prkd1Em1/+ x Prkd1Em1/+ matings, 
compared with expected, at each gestation. Prkd1Em1/Em1 embryos are not seen 
at any gestation.  
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Figure 4.10 Genotypes from Prkd1Em1/+ WT crosses. 
Numbers of each genotype produced from Prkd1+/+ x Prkd1Em1/+crosses, 
compared with expected over all gestations at which embryos were collected. 
+/+: Prkd1+/+, Em1/+: Prkd1Em1/+, Em1/Em1: Prkd1Em1/Em1. 
 
No null Prkd1Em1/Em1 embryos were found at any gestation indicating embryonic 
lethality. It is likely that they die at an early gestation. It is possible that some of 
the embryos of unknown genotype where insufficient tissue was available for 
genotyping, were actually Prkd1Em1/Em1. At E9.5, I was unable to locate an 
embryo in five instances. There was no clear evidence of an embryo, 
reabsorption, or necrosis. These are the five embryos with unknown genotypes. 
The significance of this is unclear. 
 
The numbers of Prkd1+/+and Prkd1Em1/+ embryos produced at each gestation are 
variable. The numbers at each gestation are small, with the exception of E15.5. 
In this group, numbers of both Prkd1+/+ and Prkd1Em1/+mice are around the 
expected ratios.  This is probably the most accurate, and supports homozygous 
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lethality with no definite evidence of worsened survival in the heterozygotes.  
However larger numbers are required to confirm this and more data from E9.5 
should be collected. 
 
Live born Mice 
 
Genotype results for live born mice are displayed in table 4.5 below. There were 
no Prkd1Em1/Em1 mice, indicating complete embryonic lethality. 
 
Gestation Cross Expected Observed 
Adult Prkd1Em1/+ x 
Prkd1Em1/+ 
Em1/Em1:25% 
Em1/+:    50% 
+/+:        25% 
Em1/Em1:      0  
Em1/+:         40(62.5%) 
+/+:             17 (26.5%) 
Unknown:      7 (11%) 
Adult Prkd1Em1/+ x 
Prkd1+/+ 
Em1/Em1: 0% 
Em1/+:   50% 
+/+:       50% 
Em1/Em1:     0  
Em1/+:       18 (27.3%) 
+/+:           45 (68.2%) 
Unknown:     3 (4.5%) 
 
Table 4.5 Genotypes of Prkd1Em1(IMPC)Wtsi live born mice. 
The expected ratios depending on parents are indicated. +/+: Prkd1+/+, Em1/+: 
Prkd1Em1/+, Em1/Em1: Prkd1Em1/Em1. 
 
Assuming homozygous lethality, the ratios are not far off expected from the 
Prkd1Em1/+x Prkd1Em1/+ matings. There are more Prkd1+/+ than expected from the 
Prkd1+/+ x Prkd1Em1/+crosses, but these unexpected ratios may just be a result of 
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4.5.3 Forelimb Staging of Prkd1Em1(IMPC)Wtsi Mouse Embryos 
 
The forelimb was used to stage all embryos that were harvested at E15.5 (table 
4.6). This was to ensure that they had all reached a developmental stage where 
heart development was complete. 
An example of staging of an embryo I collected is shown below in figure 4.11. 
 
Figure 4.11 Forelimb staging. 
WT E15.5 mouse paw. In the right image the digits have been spread to 
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Gestation Genotype Litter S22- S22 S22+ S23- S23 S23+ Average 
Stage 
(Mode) 
E15.5 Prkd1+/+ 1  - - - - 3 - S23 
2 - - - - - 1 S23+ 
3 - - - - - 2 S23+ 
4 - - - - - 4 S232+ 
5 - - - - - 2 S23+ 
6 - - - - - - - 
7 - - - - - 3 S23+ 
E15.5 Prkd1Em1/+ 1 - - - 1 3 - S23 
2 - - - - - 3 S23+ 
3 -  - - - 5 S23+ 
4 - - - - - 3 S23+ 
5 - - - - - 5 S23+ 
6 - - - - - 1 S23+ 
7 - - - - - 4 S23+ 
E15.5 Prkd1Em1/Em1 1 - - - - - - NA 
2 - - - - - - NA 
3 - - - - - - NA 
4 - -  - - - NA 
5 - - - - - - NA 
6 - - - - - - NA 
7 - - - - - - NA 
 
Table 4.6 Forelimb stage of all Prkd1Em1(IMPC)Wtsi mouse embryos. 
Forelimb stage is indicated for all the mouse embryos collected at E15.5, by 
genotype.  
 
The results indicate that the majority of embryos were at S23+ and therefore 
heart development should be mainly complete. The developmental stage seemed 
to be comparable within each litter. The only litter showing any variability was 
litter 1.  The numbers are too small to identify any difference in development of 
the Prkd1Em1/+ compared to the Prkd1+/+ group. 
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4.5.4 Crown Rump Length Measurements of Prkd1Em1(IMPC)Wtsi Mouse 
Embryos 
 
Crown rump length (CRL) was measured in all embryos collected at E15.5. The 
results are shown in table 4.7. 
 
 
Gestation Genotype Litter CRL (mm) Average CRL (mm) with 
stage 
E15.5 Prkd1+/+ 1  - - 
2 15 15 at S23+ 
3 - - 
4 15, 15, 14 14.7 at S23+ 
5 16, 17 16.5 at S23+ 
6 - - 
7 - - 
E15.5 Prkd1Em1/+ 1 - - 
2 15, 15, 16 15.3 at S23+ 
3 14, 14, 15, 
15, 15 
16.6 at S 23+ 
4 14, 15, 16 15 at S23+ 
5 16, 16, 16, 
17, 17 
16.4 at S23+ 
6 15 15 at S23+ 
7 - - 
E15.5 Prkd1Em1/Em1 1 - - 
2 - - 
3 - - 
4 - - 
5 - - 
6 - - 
7 - - 
 
Table 4.7 Crown rump length of all E15.5 Prkd1Em1(IMPC)Wtsi embryos. 
 
The majority of embryos have a CRL between 15-16.5mm. Two tailed T test 
assuming unequal variances suggests no significant difference (p=0.97). I 
suspected litter 5 was a bit further on with development than the others as I 
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noted that the ribcages were a little tougher during dissection. This could explain 
higher CRL in this litter.  
 
4.5.4 External Phenotype of Prkd1Em1(IMPC)Wtsi Mouse E15.5 embryos 
 
Phenotypes were evaluated after the forelimb stage of the embryo had been 
ascertained. Normal features such as herniation of the gut into the base of the 
umbilical cord were checked, along with development of key structures such as 
ears and limbs. The embryos had uncovered eyes without eyelids, and the 
external ear could be visualised. Digits were parallel and nails were visible. The 
liver is large and easily removed for use in DNA extraction for genotyping. 
 
The results are shown in table 4.8. Phenotyping was carried out before the 
genotype was known. 
 
Gestation Genotype Alive/Deceased Phenotype 





















Not seen Not seen 
E10.5 PRKD1+/+  
(n=6) 
Alive: 5  All normal  
Deceased: 1 Embryo reabsorbed, 
necrotic tissue 
Prkd1Em1/+  
(n = 6) 
Alive: 4  2 normal  
2 slightly delayed, looks 
like E9.5 
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Deceased: 2 Both looked like recent 






Alive: 1  
 
Looks delayed, approx. 
E9-9.5 
Deceased: 5 All necrotic tissue, small 
placenta and uterine 
sac 
 










(n = 8) 
Alive: 8 6 normal appearing  
1 very small but 
otherwise normal 
appearance  
1 with small body and 













Deceased: 1 reabsorbed embryo, 
necrotic tissue 




















Deceased:1 Necrotic tissue, small 
placenta and uterine 
sac 





1 with haemorrhage on 
lung surface 
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1 thin, small, 
cryptophthalmos left, 
mouth wide open 
Deceased:7 Normal 3 
Reabsorbed 4 
Prkd1Em1/+  




Slightly short snout 1 










Deceased:11 Reabsorbed 11 
 
Table 4.8 Phenotypic analysis of all E15.5 Prkd1Em1(IMPC)Wtsi. 
Phenotypes based on external inspection at the time of collection.  
 
Abnormalities were seen across both Prkd1+/+and Prkd1Em1/+ embryos. In the 
Prkd1+/+ embryos, there is evidence of early demise and abnormal phenotypes 
were seen in two at E15.5. Cryptophthalmos was seen in one individual; 
however, eye abnormalities are known to occur in the C57BL6 mice (see 
Appendix C).  
 
Prkd1Em1/+ mice appeared to show demise from the early stages, prior to E10.5 
through to later stages closer to E15.5. A number of Prkd1Em1/+ embryos were 
felt to have died at E10.5-11.5 in the E12.5 harvest. It is difficult to stage them 
very accurately when there is some element of decomposition and maceration. 
Although the vast majority were grossly normal, abnormalities seen included a 
shorter snout, general smaller size, possible IUGR phenotype with relatively 
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4.5.5 Phenotype of Adult Prkd1Em1(IMPC)Wtsi Mice 
 
126 mice had only general assessment for gross abnormalities as part of routine 
care in the BSU, and did not have detailed internal and external examinations. 
No abnormal phenotypes were identified.  
 
A few Prkd1Em1/+ mice were weighed and their length (crown to anus) measured 
at 3 months of age (table 4.9). Data available on Charles River and Jackson 
Laboratory websites suggest the weights of mice are 25g in a WT male mouse 
and 20g in a WT female. These mice are slightly heavier. However we know that 
this strain is prone to weight gain and there may have been differences in diet 
influencing this. I haven’t been able to find any data for length of WT mice of the 
same strain for comparison. 
 
Genotype Sex Average weight (g) 
Prkd1Em1/+ M (n=5) 26.8  
Prkd1Em1/+ F (n=2) 26.3 
  Length (mm) 
Prkd1Em1/+ M (n=5) 73.6 
Prkd1Em1/+ F (n=1) 68 
 
Table 4.9 Weights and lengths of 7 Prkd1Em1+/- mice at three months 
old. 
Of those who had detailed internal and external phenotyping, only a single 
mouse was identified as having an abnormality (Table 4.10). 
Gestation Genotype Phenotype 
Adult Prkd1+/+         n = 2 All normal 
Prkd1Em1/+       n = 22 1 had absent vibrissae 
Prkd1Em1/Em1      n = 0 NA 
Unknown n = 2 All normal 




Phenotypic analysis of 26 adult Prkd1Em1(IMPC)Wtsi mice by external inspection and 
internal examination.  
 
Overall, there is no clear abnormal external phenotype in surviving Prkd1Em1/+ 
adults compared with Prkd1+/+ mice.  
 
4.5.6 HREM cardiac assessment of Prkd1Em1(IMPC)Wtsi Mouse mice 
 
E15.5 embryos were collected and processed for cardiac phenotyping using 
HREM. 18 hearts were analysed (Prkd1+/+=7, Prkd1Em1/+= 11). No Prkd1Em1/Em1 
embryos were identified. Four hearts were excluded from analysis due to 
damage, leaving 14 for review (2 Prkd1+/+ and 2 Prkd1Em1/+).  
 
All 5 Prkd1+/+ hearts were normal. In the normal hearts there were a number of 
consistent features at E15.5 similar to those described by Geyer et al. [224]. 
This includes the TV sitting slightly inferiorly to the MV and a groove between 
the ventricles externally at the apex. The PV is superior and to the right of the 
AV. The pulmonary arteries arise after a short pulmonary trunk. There were no 
hearts with an immediate bifurcation and no common pulmonary artery, as 
described by Geyer et al. [224]. The ductus lumen was comparable to the 
feeding arteries with a normal insertion point. The RV was larger than the LV, 
with a thinner compact myocardium at the insertion point of the IVS to the 
anterior RV free wall. Examples of normal features in both Prkd1+/+ and 
Prkd1Em1/+ mice, are shown in figure 4.12- 4.15. Results are summarised in table 
4.11 after the figures.  
Table 4.10 Adult Prkd1Em1(IMPC)Wtsi mice phenotypes. 
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Figure 4.12 External view of E15.5 heart. 
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Figure 4.13 Aorta and aortic valve. 
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Figure 4.14 Pulmonary artery and ductus arteriosus. 
 
Figure 4.15 The heart valves. 






Prkd1+/+ Prkd1Em1/+ Prkd1Em1/Em1 
Normal heart 
 























Table 4.11 Summary of phenotypes seen in the Prkd1Em1(IMPC)Wtsi 
E15.5 embryo hearts processed using HREM. 
 
A single Prkd1Em1/+ heart showed an abnormality, which was an interrupted 
aortic arch (IAA) (type B). This is shown in figure 4.16. There was no associated 
VSD or aortopulmonary window. I could not confirm whether the AV in one of 
the other Prkd1Em1+/- mice was definitely tricuspid due to under lysis, but 
there were no other abnormalities in this heart. 
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Figure 4.16 Interrupted aortic arch. 
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The disruption of the aorta seen in the Prkd1Em1/+ embryo with an IAA (Figure 
4.16), was sited between the LCC and LSC arteries. The ductus arteriosus was 
continuous with the descending aorta. IAA is a very rare type of CHD, and is 
usually seen in combination with a VSD or aortopulmonary window, and 
abnormalities of the head and neck vessels [777]. Other associated features 
include BAV, TGA and TA. No other abnormalities were seen in this embryo. It is 
possible that there is a defect that cannot be seen without dynamic imaging, 
such as a VSD, and there is a degree of under lysis which makes image 
interpretation more difficult. However, we should also consider the possibility 
that the IAA seen is iatrogenic given it is at the top of the tissue specimen where 
the tissue would be most prone to damage, and because this is a rare type of 
CHD.  
 
There are three subtypes of IAA depending on the location of the disruption 
(Figure 4.17) [778-780]. Type A, where the disruption is distal to the left 
subclavian artery accounts for around 13% of IAA, Type B where the disruption 
falls between the LCC and the LSC arteries (as described above) accounts for 
around 84% of IAA, and Type C where the disruption is located between the 
brachiocephalic artery and the LCC artery is the rarest type (around 3% of IAA). 
.  
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Figure 4.17. Classification of IAA subtypes. Classification is by anatomical 
location of the disruption. 
Type B IAA results from abnormal development of the fourth pharyngeal arch 
arteries. The left fourth arch artery is required to produce the distal part of the 
aortic arch, and the right is required for formation of both the brachiocephalic 
artery, and the proximal part of the right subclavian artery [781]. Type B IAA is 
associated with 22q11 Deletion Syndrome, and almost 50% of patients with IAA 
are diagnosed with this condition. TBX1 is found within this commonly deleted 
segment, and is required for remodelling and formation of the pharyngeal arch 
arteries [782]. Tbx1 null mice develop defects indicative of abnormal forth 
pharyngeal arch development [783, 784], so it is likely that TBX1 is responsible 
for the cardiac phenotype seen as part of this syndrome. There are currently no 
known interactions between PRKD1 and TBX1 to explain why a type B IAA might 
be seen in this mouse line. 
 
4.6  Results from the Prkd1Em2(IMPC)Wtsi Mouse 
 
4.6.1 Confirming genotypes in the Prkd1Em2(IMPC)Wtsi Mouse 
 
The WTSI produced a mouse with the equivalent mutation of p.Gly592Arg, 
detected previously in two of the three individuals with mutations in PRKD1 
reported by Sifrim et al (p.Gly592Arg) [12].  The Variant Effect Predictor (VEP) 
suggests that the most severe consequence of the base change is a missense 
mutation, G592R [493]. The mutation is c.G598R in the mouse (Chr 12 
50,385,167 G/A -1) and VEP predicts 100% missense mutation with moderate 
impact based on one transcript ENSMUST00000002765. Both the human and 
mouse PRKD1 genes have 19 coding exons and the mutation falls in exon 13 in 
both species. The alignment around the mutated base is shown below in figure 
2.2. The mutation maps to the proximal section of the protein kinase domain. 
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Figure 4.8 Alignment of mouse and human sequence of PRKD1 exon 13 
mutation site. 
Mouse sequence is in blue, and the human sequence is in yellow. Base affected 
by mutation is highlighted in red box. Aligned using EMBOSS water alignment 
tool. https://www.ebi.ac.uk/Tools/psa/emboss_water/nucleotide.html 
 
Example genotype results are shown in figure 4.19 and figure 4.20. 
 
 
Figure 4.9 PCR for the Prkd1Em2(IMPC)Wtsi mouse. 
A 361bp product is produced. The PCR product was cleaned up and sent for 
sequencing.  




Figure 4.20 Sequencing results for the three genotypes seen in 
Prkd1Em2(IMPC)Wtsi mice. 
 




All embryos collected were genotyped and the numbers compared to the ratios 
expected. The results are shown in table 4.12 and figure 4.21. 
Gestation Cross Expected Observed 
E9.5 Prkd1Em2/+  
x Prkd1Em2/+  
Em2/Em2: 25% 
Em2/+:     50% 
+/+:         25% 
Em2/Em2: 1 (11%)        
Em2/+:     3 (33%) 
+/+:         2 (22%) 
Unknown:  3 (33%) 
E10.5 Prkd1Em2/+  
x Prkd1Em2/+  
Em2/Em2: 25% 
Em2/+ :    50% 
+/+:         25% 
Em2/Em2: 6 (21%) 
Em2/+:    15 (54%) 
+/+:          2 (7%) 
Unknown: 5 (18%) 
E11.5 Prkd1Em2/+  
x Prkd1Em2/+  
Em2/Em2: 25% 
Em2/+ :    50% 
+/+:         25% 
Em2/Em2: 1 (10%) 
Em2/+:     5 (50%) 
+/+:         3 (30%) 
Unknown:  1 (10%) 
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E12.5 Prkd1Em2/+  
x Prkd1Em2/+  
Em2/Em2: 25% 
Em2/+ :    50% 
+/+:         25% 
Em2/Em2: 4 (21%) 
Em2/+:    10(52%) 
+/+:         2 (11%) 
Unknown: 3 (16%) 
 
E15.5 Prkd1Em2/+  
x Prkd1Em2/+  
Em2/Em2: 25% 
Em2/+ :    50% 
+/+:         25% 
Em2/Em2: 4 (8%) 
Em2/+:    26 (51%) 
+/+:        13 (25%) 
Unknown   9 (18%) 
 
Table 4.12 Genotypes and expected ratios found in the embryos of 
Prkd1 Em2(IMPC)Wtsi  mice. 




Figure 4.21 Genotypes of Prkd1Em2(IMPC)Wtsi  embryos. 
Graphical representation of numbers of embryos of each genotype identified at 
each gestation, and compared with the expected numbers. The ratios are fairly 
well matched with the exception of Prkd1Em2/Em2 embryos. 
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Prkd1Em2/Em2 embryos were found at all stages of embryonic development 
assessed between E9.5 and E15.5. There were fewer than expected suggesting a 
degree of lethality. The expected number of Prkd1Em2/+ embryos were produced, 
suggesting there is no reduced survival during embryogenesis up to E15.5 of this 
genotype. 
 
Live born mouse genotypes 
 
The ratios of Prkd1+/+ and Prkd1Em2/+ in live born mice are around expected 
values, suggesting no reduced survival of Prkd1Em2/+  mice and that they can 
become healthy adult mice under standard laboratory conditions (table 4.13). 
 
Gestation Cross Expected Observed 
Adult Prkd1Em2/+  x 
Prkd1Em2/+  
Em2/Em2: 25% 
Em2/+:     50% 
+/+:         25% 
Em2/Em2:  2 (6%)    
Em2/+:    15 (45%) 
+/+:        16 (50%) 
Unknown:   0 (0%) 
Adult Prkd1Em2/+  x 
+/+ 
Em2/Em2:  0% 
Em2/+:     50% 
+/+:         50% 
Em2/Em2:  0  (0%) 
Em2/+:    39 (39%) 
+/+:        58 (59%) 
Unknown:  2 (2%) 
Adult Prkd1Em2/+  x 
Em2/Em2  
Em2/Em2 :50% 
Em2/+:     50% 
+/+:           0% 
Em2/Em2: 0  (0%)     
Em2/+:    11  (92%) 
+/+:          0 (0%) 
Unknown:   1 (8%) 
 
Table 4.13 Figure 4.21 Genotypes and expected ratios found in the adult 
Prkd1Em2(IMPC)Wtsi  mice. 
+/+: Prkd1+/+, Em2/+: Prkd1Em2+/-, Em2/Em2: Prkd1Em2/Em2. 
 
Two Prkd1Em2/Em2 mice were born and survived to adulthood. One was male and 
one was female. The male proved to be fertile and was used as a stud mouse. In 
the main homozygosity for this mutation is lethal, with around 1.4% (n=2/144) 
surviving to adulthood.  
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4.6.3 Forelimb Staging of Prkd1Em2(IMPC)Wtsi E15.5 Embryos 
 
There was very little variation in the stage of the E15.5 embryos (table 4.14). All 
reached stage S23- at least, so cardiac development should be mainly complete.  
 
Gestation Genotype Litter S22- S22 S22+ S23- S23 S23+ Average 
Stage 
(Mode) 
E15.5 Prkd1Em2+/+ 1  - - - 1 - 4 S23+ 
2 - - - - - 1 S23+ 
3 - - - - - 3 S23+ 
4 - - - - - 3 S23+ 
5 - - - - - 1 S23+ 
E15.5 Prkd1Em2+/- 1 - - - 1 - 2 S23+ 
2 - - - - - 5 S23+ 
3 -  - - - 5 S23+ 
4 - - - - - 6 S23+ 
5 - - - - - 7 S23+ 
E15.5 Prkd1Em2/Em2 1 - - - - - - - 
2 - - - - - 1 S23+ 
3 - - - - - - - 
4 - - - - - 1 S23+ 
5 - - - - - - - 
 
Table 4.14 Forelimb stage of all E15.5 Prkd1Em2(IMPC)Wtsi embryos and 
their respective genotypes. 
The two homozygotes alive at E15.5 were at the same developmental stage as 
Prkd1Em2+/+ and Prkd1Em2+/- embryos. 
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4.6.4 Crown Rump Length Measurements of Prkd1Em2(IMPC)Wtsi E15.5 
Embryos 
 
CRL appeared to be comparable across all the embryos examined as shown 
below in table 4.15. 
 
Gestation Genotype Litter CRL (mm) Average CRL (mm) with 
stage 
E15.5 Prkd1Em2+/+ 1  - - 
2 - - 
3 - - 
4 14, 16, 16 15.3 at S23+ 
5 15 15 at S23+ 
E15.5 Prkd1Em2+/- 1 - - 
2 - - 
3 - - 
4 14, 14, 15, 
15, 15, 15 
14.7 at S 23+ 
5 9, 14, 14, 15, 
15, 15, 16 
14 at S23+ 
E15.5 Prkd1Em2/Em2 1 - - 
2 - - 
3 - - 
4 16 16 at S23+ 
5 - - 
 
Table 4.15 CRL (mm) for all Prkd1Em2(IMPC)Wtsi embryos collected at E15.5 
and their corresponding genotypes. 
 
Excluding the outlier in the Prkd1Em2+/- embryos (CRL 9mm) brings the mean CRL 
to 14.75. The single Prkd1Em2/Em2 embryo may not be representative. One way 
anova does not suggest any significant difference. 
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4.6.5 External Phenotype of Prkd1Em2(IMPC)Wtsi E15.5 embryos 
 
 
External phenotyping was carried out at the time of embryo collection. The 
phenotypes are recorded in table 4.16. Phenotyping was carried out before the 
genotype was known. 
 
























Unknown (n=3) No embryo found NA 
E10.5 PRKD1EM2+/+ 
(n=2) 
Alive: 2  Normal 
Deceased: 0 NA 
Prkd1Em2+/- 
(n=15) 
Alive: 14 Normal 








1 slight developmental 
delay and small in size 
Unknown (n=5) Alive: 0 
 
 
Deceased: 5 All reabsorbed. Small 
sac, oligohydramnios 






Deceased: 0  NA 





Alive: 5  Normal 





Alive: 1 Small for gestation 
 
Deceased: 0 NA 
 


























Embryo looks about 
E11.5, otherwise 
normal. One looks like 
death in last 2 days, 
embryo not overtly 
necrotic but amniotic 
fluid is discoloured. 





















Splaying of the 3rd and 
4th digits in the right 
upper limb in one. 
Deceased: 2 
 
Normal but small and 
pale placenta in one. 
Identifying Novel Genes that cause Congenital Heart Disease  263 
 
Small amount of 




Alive: 2 Normal: 2 
 
Deceased: 2 1 completely 
reabsorbed. 1 roughly 
staged at E10.5, but 
difficult to assess due 
to maceration. 
Unknown (n=8) Alive: 0 
 
 
Deceased: 8 All reabsorbed.  
 
 
Table 4.16 Phenotype of all Prkd1Em2(IMPC)Wtsi embryos collected. 
The corresponding genotypes and whether the embryo was alive or deceased at 
the time of collection is included.  
 
Prkd1+/+ embryos were all alive at the time of collection. All were normal with 
the exception of one who appeared to have a slightly shorter snout. Prkd1Em2+/- 
embryos were alive, with the exception of 3 out of 59 (5%). One had died early 
in gestation and was necrotic, one had died not long before E10.5 and one had 
died close to E15.5. This later death was associated with a small pale placenta, 
which could indicate placental factors contributing to the death.  
 
The majority of the Prkd1Em2/Em2 embryos appeared normal, although 2 were 
noted to be slightly smaller in size. Prkd1Em2/Em2 embryos were found alive at 
every gestation examined. Death occurred from around E10.5-E12.5, based on 
an embryo found dead at E12.5 which was somewhat macerated and the 
amniotic fluid was discoloured. One was completely reabsorbed and may 
represent an even earlier death. There are a number that we could not genotype 
due to lack of tissue and these could represent early embryonic death of any 
genotype, but given the lower than expected numbers of Prkd1Em2/Em2 embryos, 
this genotype might represent a significant proportion. 
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4.6.6 Phenotype of Adult Prkd1Em2(IMPC)Wtsi Mice 
 
No abnormalities were identified in the 188 mice of all genotypes by external 
assessment during routine care. A single male Prkd1Em2/Em2 mouse was born and 
was still alive at the end of my study time. He was externally normal, fertile and 
produced a number of litters. 20 male Prkd1Em2/+ and 7 male Prkd1+/+ mice were 
collected for MRI studies at 2 months of age. They had detailed external 
phenotyping. All were normal. No internal phenotyping was carried out as they 
were required to be intact for the MRI studies. 
 
17 adult mice were examined both externally and internally by dissection. Two 
Prkd1+/+ and two Prkd1Em2/+ mice were dissected for protein studies. Another 8 
female Prkd1Em2/+ mice were phenotyped after being used for embryo harvests. 
The original four Prkd1Em2/+ mice received from the Sanger Institute were also 
examined. Internal and external examination revealed no abnormalities in all 
cases. A single female Prkd1Em2/Em2 mouse required schedule 1 killing after being 
found with a scratch on her cheek. She appeared normal and her heart was 
explanted for HREM. 
   
4.6.7 HREM cardiac assessment of Prkd1Em2(IMPC)Wtsi mice 
 
E15.5 embryos were collected and processed for cardiac phenotyping using 
HREM (Table 4.18). 21 hearts were analysed (Prkd1+/+ =5, Prkd1Em2/+= 15, 
Prkd1Em2/Em2 = 1). 6 hearts were excluded from analysis due to damage, leaving 
15 for review (Prkd1+/+ = 4, Prkd1Em2/+= 10 and Prkd1Em2/Em2 = 1). All hearts 
appeared normal, and displayed features at E15.5 consistent with those 
described by Geyer et al. [224] with the exception of one Prkd1Em2/+ mouse with 
a muscular VSD (Figure 4.22). Results are summarised in table 4.17.  
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Figure 4.17 Muscular VSD in a Prkd1Em2/+ ouse 
A small area of damage was identified in the wall of the right atrial appendage of 
the Prkd1Em2/+ embryo with the muscular VSD, but nowhere else in the heart. 
The atria are more prone to damage because of their more fragile and thin wall. 
I considered whether the defect in the interventricular septum might be 
mechanical damage. I reviewed the images with Dr B Erhayiem and we think 
this most likely represents a muscular VSD because: 
 There is relatively little damage to the heart. It is not uncommon to see 
more significant atrial damage than this, with an intact septum. 
 Ventricular wall damage, but no septal damage has been observed in 
other hearts. The free walls of the ventricles are much thinner than the 
thick muscular septum and are more likely to rupture.  
 This appearance would be consistent with a muscular VSD in the septum. 
It has a very different appearance to those seen in association with AVCD 
where a very definite gap is seen. This narrower and more winding course 
is more typical of a muscular VSD. 
 
Isolated VSDs are not uncommon, and muscular VSDs make up around 20% 
of all VSDs. They may be multiple and often close without intervention. 
Muscular VSDs frequently close in postnatal life and would be compatible with 
postnatal survival, so it is possible that this defect may have been present in 
other apparently healthy surviving Prkd1Em2/+ mice. VSDs are seen in a 
number of genetic syndromes including Holt Oram Syndrome, caused by 
mutations in TBX5. PRKD1 relieves the repression of TBX5, mediated by 
HDAC4/5 so it is possible that there may be a common mechanism causing 
VSDs in Holt Oram and with loss of Prkd1 [785]. In addition, mice with loss of 
both Hdac5 and Hdac9 have lethal VSDs [550] and knockout of Mef2c in the 
second/anterior heart field results in nearly 60% of embryos affected with 
VSDs, or outflow tract abnormalities in combination with a VSD similar to 
TOF [786]. The possible mechanisms by which loss of Prkd1 might result in 
CHD have been discussed in section 4.3.4, and are also reviewed later in 
section 4.9. 
 





Prkd1+/+ Prkd1Em2/+ Prkd1Em2/Em2 
Normal heart 
 






















Table 4.17 Summary of phenotypes seen in the E15.5 embryo hearts 
processed using HREM. 
 
A single adult female, and single male Prkd1Em2/Em2mouse were born and 
apparently both were healthy. The female mouse had to be culled as a result of 
a scratch. Although HREM is not optimal for adult mouse hearts, I collected the 
heart and processed it in accordance with suggestions from T Mohun. This 
included increasing the length of the infiltration stage to a week. Unfortunately 
the images are suboptimal owing to lack of infiltration of the ventricular septum 
and insufficient lysis. This is evident as a lack of staining in the LV and septum. 
However, some useful information can still be gained (Figure 4.23). The atria, 
atrial connections and atrial septum are normal. The TV, MV and AV can be 
visualised, but the PV is not seen clearly. The PA branches normally and the 
aorta appears to have a normal position. The IVS appears intact. The ventricular 
cavities are small, but appear to have a normal shape and relationship. 
Unfortunately there is no comparison series for this adult heart, as the remaining 
adult hearts I processed have not been sectioned. This is because they are also 
likely to show inadequate lysis and infiltration. 
Identifying Novel Genes that cause Congenital Heart Disease  268 
 
 
Identifying Novel Genes that cause Congenital Heart Disease  269 
 
 
Figure 4.18 HREM of Prkd1Em2/Em2 mouse. 
4.7 Comparison of Embryonic Lethality in the Prkd1Em1(IMPC)Wtsi and 
Prkd1Em2(IMPC)Wtsi lines  
 
Mouse models reported previously have confirmed that Prkd1 is required for 
embryogenesis [684, 732]. Conditional models have shown that absence of 
Prkd1 in cardiomyocytes prevents remodelling in response to stress [732]. These 
results suggest complete embryonic lethality in Prkd1Em1/Em1 embryos prior to 
E10.5, which is consistent with previous reports [684, 732]. No Prkd1Em1/Em1 
embryos were identified in collections from E9.5-15.5. In contrast, the 
Prkd1Em2/Em2 mice were embryonic lethal with reduced penetrance from a later 
gestation (E10.5 onwards). Many survived for much longer and died after E15.5. 
Prkd1Em2/Em2 mice were live born with an incidence of 1%, and appeared healthy 
and fertile.  
 
Given Prkd1 appears to have a wide range of functions, is involved in many 
different signalling pathways, and shows fairly ubiquitous expression in 
embryogenesis, it is not surprising that absence results in embryonic lethality. 
Differing timing of expression and localisation may mitigate any potential 
functional redundancy within this gene family. Prkd1 is the dominant Pkd isoform 
expressed in early mouse embryogenesis, with Prkd2 only becoming obvious 
from E14.5, and Prkd3 being expressed weakly from E10.5 [685]. Embryonic 
lethality in Prkd1Em1/Em1 mice here and previous studies confirm that Prkd1 is 
important in embryogenesis.  
 
Both previously reported null models (deletion of exons 12-14 and substitution 
of serine with alanine at the phosphorylation sites) resulted in a 1% incidence of 
live homozygous null mice [684, 732]. The Prkd1Em1 mouse studied here, has a 
deletion of exon 2. It appears to be universally embryonic lethal in the 
homozygous null state and no Prkd1Em1/Em1 mice were born. One explanation for 
this is that my sample size is too small to detect live born Prkd1Em1/Em1 mice.  
Matthews et al. identified 2 Prkd1SSAA/SSAA homozygous null mice in 177 births. 
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157 mice were genotyped and no live Prkd1Em1/Em1 mice were found. Recent 
communication with Professor Brook’s lab reveals that this is still the case, and 
no Prkd1Em1/Em1 mice have survived despite continued breeding.  
 
If it is not related to sample size, then it is possible that there is a different 
effect from deletion of exon 2, which is more severe. The protein product from 
the mouse without exons 12-14 was degraded [732]. It is not clear what 
happens to the protein product in the Prkd1Em1 mouse and work is ongoing to 
determine if a truncated protein is produced, or if nonsense mediated decay is 
occurring. This may help clarify if the different deletions have different effects. 
The consequences of a deletion preceding and including part of the first CRD is 
unclear, but potentially significant given that the second CRD is required for 
normal movement of PRKD1.  
 
Functional studies might help clarify the effect of the exon 2 deletion. They are 
also necessary to assess why the protein kinase missense mutation in the 
Prkd1Em2 mouse line results in lethality at a later gestation and occasional 
survival of homozygous knockout mice. 
 
A number of empty decidua were detected in both Prkd1Em1 and Em2 cohorts, 
with only necrotic tissue present. This suggests post-implantation death (E5.5 
onwards) or possibly peri-implantation death. It is also possible for embryos 
compromised at an earlier stage (E4.5-5.5, peri-implantation) to create an 
identifiable implantation site, as long as they have been able to shed the zona 
pellucida and form a trophoblast layer [787]. In most of these cases, sufficient 
embryonic tissue could not be collected which meant that the genotype was 
unknown. Given that deaths occur in 5-15% of WT embryos at an early 
gestation, we cannot assume that peri or post implantation deaths were related 
to alterations in Prkd1 [787-789]. No pre-implantation studies were carried out 
so we can only conclude that some deaths may occur peri or post implantation in 
both Prkd1Em1 and Em2 mice. 
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The cause of embryonic lethality has not been determined. Collection of hearts 
for HREM requires swift explantation, and detailed examination of the embryo at 
the time of dissection is not possible. Partial destruction of the embryo also 
makes phenotyping afterwards unreliable. The widespread expression of Prkd1 
makes it difficult to assign a cause of lethality as any number of organ systems 
could be involved.  
 
The earlier deaths in the Prkd1Em1 mice, suggest that placental factors or 
cardiovascular malformations may play a role. Causes of death within the first 
half of gestation include placental failure, cardiovascular insufficiency, abnormal 
haematopoesis and abnormal angiogenesis. Placental insufficiency usually 
results in death before E10-E13 and is usually seen in combination with IUGR 
[790]. Small pale placentas were seen in a few embryos, mainly in combination 
with an empty decidua. A single Prkd1Em1/+ embryo appeared to have a small 
body with relatively preserved head circumference, features that are seen in 
IUGR. PRKD1 is expressed in the human placenta [791], so it is possible that 
placental insufficiency contributed, and further studies should include histology 
of the placenta.  VEGF and other stimuli increase the activity of PRKD1 in 
endothelial and vascular smooth muscle cells [745-748], therefore angiogenesis 
may also be a contributing factor in their early embryonic demise.  
 
Abnormalities of the brain, kidney, liver and lung can result in survival in utero 
and death in the peri or postnatal period [790]. Therefore these are less likely to 
be the cause of lethality in the Prkd1 mice. Deaths after E9.5 can result from 
defects that initially occurred at an earlier stage, and in the majority of cases 
embryos dying after E12 have defects that occurred prior to this [790]. 
Therefore, it is possible that defects occur in the same organs at the same early 
time point in both Prkd1Em1 and Em2 lines, but are more severe in Prkd1Em1 
mice resulting in earlier death. 
 
The variable time of death in the Prkd1Em2 line embryos suggests that there is 
reduced penetrance and variable expressivity for any related defects. For 
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example, an early death might be a result of a severe cardiac defect, later death 
related to a less compromised heart, and survival to term seen in those with a 
normal heart or very mild defect. Common causes of embryonic death after E12 
include haemopoetic defects [792] and abnormalities in the heart related to 
defective septation or cardiac conduction problems [217]. HREM only identified a 
single mouse with a septal defect (Prkd1Em2/+) and one embryo with IAA 
(Prkd1Em1/+). Conduction abnormalities could not be assessed, but could be 
important given the role of Prkd1 in maintaining normal contractility in the heart 
[689, 742, 774].  
 
To determine the cause of death, whole embryo HREM should be carried out at 
multiple gestations. Additional examination for placental abnormalities and for 
signs of cardiac insufficiency such as pooling of blood in the heart and 
hepatomegaly should be included [787].  Ideally ECGs, echos and MRI should 
also be carried out to assess function and conduction.  
 
4.8 Comparison of Extra cardiac Phenotypic Abnormalities in the 
Prkd1Em1(IMPC)Wtsi and Prkd1Em2(IMPC)Wtsi lines  
 
Few abnormalities were noted in the embryos from either Prkd1 line, although as 
discussed in the previous section, time for examination was limited. A few 
Prkd1Em1/+ embryos were smaller in size (not significant), and one had a shorter 
snout.  This might be significant given Li et al. reported smaller size and 
craniofacial abnormalities in a conditional null postnatal mice [758], however a 
slightly shorted snout was also seen in a WT mouse (table 4.8) and the sample 
size is too small to determine if short snouts are a feature of loss of Prkd1 in 
these mouse lines.  
 
No digital abnormalities were noted except for unilateral increased splaying of 
the third and fourth digits of the forelimb in a single Prkd1Em2/+ embryo at E15.5. 
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This could be in line with the digital abnormalities reported in CHD and 
ectodermal defects [12]. It is interesting that the abnormality was seen in a 
Prkd1Em2/+ embryo and not a Prkd1Em2/Em2 embryo, and given that limb 
abnormalities were only seen once I cannot be sure that is related to loss of 
Prkd1.  
 
In addition to Prkd1, Prkd3 is expressed in the limb bud, cartilage and axial 
skeleton. Prkd3 knockout mice have reduced cortical thickness in the femur and 
reduced trabecular bone in the vertebrae, so it is likely that Prkd3 also 
contributes to maintaining a normal skeletal phenotype and may mitigate some 
of the effects of loss of Prkd1 [546]. Bony imaging at this stage would be difficult 
due to an immature cartilaginous skeleton, although MRI may helpful in detect 
abnormalities at this stage. It is not known however, what the underlying bony 
malformations in the individuals with CHD and Ectodermal Defects are, which 
makes it challenging to decide what further investigations might be helpful in a 
mouse model. 
 
A single adult Prkd1Em1/+ mouse had no whiskers. There was no other evidence 
of barbering in this mouse or the cage. This might be significant given the 
ectodermal features seen in humans, but a single report is not enough to say 
anything conclusive and larger numbers of mice will need to be examined. 
Whiskers are visible at E17 (Theiler stage 25), so could not easily be seen at the 
embryonic stages I was examining. Prkd2 is expressed at site of whisker 
development at E14.5 so development is unlikely to be solely dependent on 
Prkd1 [546, 685]. 
 
Two Prkd1Em2/Em2 mice were born and survived to adult age. Both were 
apparently normal and the male mouse was fertile. The male mouse was still 
breeding successfully after 7 months. The female mouse had to be culled at five 
months of age due to a scratch, but appeared normal on external examination 
and internal dissection. This suggests reduced penetrance and variable 
expressivity of the protein kinase missense mutation. Further functional work is 
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required to understand the fate of the abnormal mouse protein and its activity, 
to understand why it can is associated with apparently normal survival in 
homozygous states. 
 
Previously published mouse expression data suggests that Prkd1 is expressed in 
the heart, brain, limb buds and other organ systems during embryogenesis. 
Therefore these organs are of interest. Further work should consider imaging or 
histology of the brain and imaging of the limbs and skeleton. Postnatal 
examinations could include behavioural and intelligence tests in addition. 
 
4.9 Significance of Cardiovascular Abnormalities identified in the 
Prkd1Em1(IMPC)Wtsi and Prkd1Em2(IMPC)Wtsi lines  
  
Only two embryos were identified with cardiac defects (n=2/29). A single 
Prkd1Em1/+ E15.5 embryo out of the 9 examined, had an interrupted aortic arch 
(IAA). A muscular VSD was seen in one of the Prkd1Em2/+ mice. The number of 
embryos analysed is small so results should be interpreted with caution. Further 
Prkd1 embryos from both lines need to be examined to determine if these are 
true findings, and if they are associated with loss of Prkd1. It would also be 
beneficial to carry out whole embryo HREM as this prevents any disruption of the 
outflow tract and great vessels. HREM at earlier gestations should also be carried 
out. We may see CHD in mice at earlier gestations, which would have died by 
E15.5 and be unsuitable for analysis at this later stage.  
 
In the developing heart, there are a number of structures that come together to 
form the AV valves, the semilunar valves and the septae. Correct formation of all 
of these prevents the defects seen in the Prkd1 mice and individuals with CHD 
and Ectodermal Defects. Defective endocardial cushion formation could result in 
an AVSD and potentially abnormalities of the pulmonary valve. The muscular 
VSD implies a problem in the developing ventricular septum. Malalignment of 
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this septum with the infundibular septum could lead to obstruction of the LVOT 
and subsequent IAA. Pulmonary stenosis could also result from altered flow. It is 
possible therefore that the abnormalities we see are linked to septation, and the 
endocardial cushions specifically. 
 
A number of different cell populations contribute to the structures affected by 
the abnormalities we have seen. The muscular septum is formed from 
components of the primary and secondary heart fields, with some contribution 
from the proepicardial precursor cells [38, 39]. The aorticopulmonary septum 
derives from the second heart field also. All valves develop from endocardial 
cushions. Both endocardium and ectoderm contribute to valve formation and in 
addition, neural crest cells (from ectoderm) contribute to valve formation in the 
OFT. Therefor there is not one specific cell population that could be linked to all 
the defects exclusively. 
 
There is also evidence from other mouse models to support PRKD1 as a cause of 
the specific CHD defects we have seen. Mef2c knockout mice die around E10 due 
to cardiac abnormalities [739]. Abnormalities include failure of normal heart tube 
looping, a dilated dorsal aorta, disorganised endocardium, dilated ventricles and 
dilated cardiomyopathy [793]. Knockout of Mef2c in the second/anterior heart 
field results in nearly 60% of embryos affected with VSDs or outflow tract 
abnormalities in combination with a VSD [786]. All had abnormalities of the 
aortic or pulmonary valve. Whilst there are similarities in the phenotypes 
described between Prkd1 and Mef2c, however the VSDs seen in the Mef2c mouse 
were membranous and not muscular.  
 
Loss of Prkd1 could result in a similar picture to loss of Mef2c, given Mef2c would 
be either absent or bound to HDACs and this might be one mechanism by which 
mutations in Prkd1 could result in CHD. Alternatively, gain of function SNVs in 
MEF2C have also been shown to cause outflow tract abnormalities in humans 
[794]. p.A103V, was identified in an individual with pulmonary atresia and VSD. 
However, suggesting that loss of Prkd1 is equivalent to loss of Mef2c is likely to 
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be too simplistic an explanation, given the number of other genes involved and 
up regulation of normal alleles for example. 
 
Mice deficient for both HDAC5 and HDAC9 have lethal VSDs [550]. However, loss 
of HDACs would presumably result in less repression of the MEF2 gene targets, 
whereas loss of Prkd1 should result in more repression of MEF2 genes and 
therefore produce a different effect. It is also likely that alteration of HDAC 
phosphorylation by PRKD1 can be at least partially compensated for given 
evidence that HDACs can be phosphorylated by more than one PRKD isoform 
[715, 716].  
 
TBX5 is also required for normal septal development. Tbx5 knockout mice 
develop VSDs, including muscular VSDs [103]. PRKD1 relieves the repression of 
TBX5, mediated by HDAC4/5 [785]. TBX5 has a well-established role in heart 
development and might be another possible mechanism by which alterations in 
PRKD1 lead to CHD.  
 
IAA is a rare defect, but is seen in 22q11.2 deletion syndrome and 1q21 
deletions (Cx40) [795]. Animal models suggest a link with endothelin signalling 
pathways [796] and genes including Foxc1, Foxc2, Cited2 and TBX1 [76, 797, 
798]. Abnormal apoptosis has also been shown to contribute to cardiac defects 
including IAA and septal defects [799]. PRKD1 is cleaved by caspase-3 at Asp-
378 between the CRD and PH domains under conditions of apoptosis. The result 
of this cleavage is not clear and both activation and loss of function have been 
demonstrated [672, 800, 801]. Although Prkd1 is involved in apoptotic 
processes and could potentially contribute to the formation of IAA in this way, 
the exact mechanism by which IAA results remains to be determined.  
 
Overall, the types of CHD seen in mice and humans could be explained by 
deficient septal formation primarily, and endocardial cushion malformations. 
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More detailed expression studies during the formation of the septae and the 
endocardial cushions are required. 
 
4.10 Limitations and Future Work 
 
The major limitation of the work in this chapter is small sample size. This relates 
to both the number of individuals reported with CHD and Ectodermal defects, 
and the number of mice studied. In addition to this functional evidence is 
currently lacking. Determination of PRKD1 protein levels in these mice is ongoing 
on the brain, liver and heart tissue I collected. Kinase assays are being carried 
out by other members of the Brook Laboratory. More detailed expression studies 
of Prkd1 in embryogenesis, including the endocardial cushions are also required. 
It is unfortunate that the CRISPR work in the Zebrafish was unsuccessful in vivo 
as this might have added further evidence for mutational effect. 
 
Given the mouse models have been generated and colonies successfully 
established it offers the opportunity to gather more comprehensive data. 
Sacrifice and collection of the heart for HREM limits the analysis of other parts of 
the mouse. Whole embryo HREM would allow for better visualisation of the great 
vessels, which is important given the finding of IAA in a single embryo. This 
would also allow us to detect limb and structural brain abnormalities for 
example. It may also show evidence of cardiac insufficiency if hepatomegaly and 
other sequelae were present. The same would apply for whole mouse MRI scans. 
 
I had planned to measure heart weight to tibia length ratios. This would allow 
me to compare heart size between mutants and WT embryos. Phenotyping 
pipelines such as those used in the IMPC project weigh the heart immediately 
after it is removed. This was not possible due to the requirement for immediate 
transfer of the heart to warm PBS for lysis. There was also a variable amount of 
soft tissue attached to the superior aspect of the heart at explantation. In 
retrospect it might have been possible to weight the hearts after removal of all 
blood, fixation and subsequent fine dissection. I was easily able to lyse soft 
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tissue from the tibia using the same mix of lysate and proteinase K as I used for 
DNA extraction.  
 
Other aspects of embryonic phenotyping that could be improved include more 
accurate measurement of CRL and weights in adult heterozygous and WT mice. 
Whilst I did review every placenta for gross abnormalities, additional collection 
of the placenta for histology would provide better evidence for placental 
function. 
 
The mouse models did not have a high incidence of CHD. Larger cohorts are 
required to determine the exact incidence and whether IAA (Prkd1Em1+/-) and 
VSDs (Prkd1Em2+/-) are a true phenotypic associations.  The same applies to the 
low incidence of other possibly associated abnormalities. Only one minor limb 




PRKD1 is a novel CHD gene. Whilst clinical reports are few at this stage, we have 
laid the groundwork for reporting of additional affected individuals and further 
investigation of abnormal function of PRKD1 in the heart. At this stage, the 
emphasis should be on identifying other affected individuals to define the clinical 
phenotype and guide clinical management and investigations. Paired functional 
studies are required to understand the mechanism which causes the clinical 





Identifying Novel Genes that cause Congenital Heart Disease  279 
 




Breeding of Prkd1 mice to maintain the colonies and produce females for timed 
matings, meant that excess male mice were generated. These male mice 
provided an opportunity to collect further phenotype data in post-natal life, when 
there is less chance of missing subtle heart defects that might not be seen in the 
embryo. In addition, a single Prkd1Em2/+ E15.5 embryo was identified with a 
muscular VSD using HREM (described in Chapter 4). This defect would not 
necessarily cause foetal demise or symptoms in early life, and therefore it was 
possible that other apparently normal Prkd1Em2/+adult mice might have CHD. We 
hoped to identify further affected mice by imaging adult mice. Importantly, 
Prkd1 also plays a role in cardiac hypertrophy in response to stress, and 
variations from the normal hypertrophic response in a heart with CHD might be 
apparent in these adult mice. This chapter described the development of an MRI 
imaging protocol to assess two month old Prkd1Em2/+ mice.  
 
5.1.1 Role of Prkd1 in Cardiac Hypertrophy 
 
PRKD1 regulates cardiac hypertrophy through its action on HDACs and MEF2 
signalling [668, 715, 732]. Its actions have been studied in a number of 
mouse models. These and the proposed mechanisms are described below. 
 
Class II HDACS are signal responsive repressors of cardiac hypertrophy, and 
act by supressing myocardial expression of pro-hypertrophic genes via MEF2 
[736, 802, 803].  As described previously in chapter 4, PRKD1 phosphorylates 
HDAC5, leading to its nuclear export via the actions of XPO1/CRM-1. This 
produces subsequent MEF2A transcriptional activation, which results in 
activation of gene targets that cause myocyte hypertrophy and cardiac 
remodelling [715, 742]. Hdac5 knockout mice develop enlarged hearts in 
response to increased afterload or constitutive activation of calcineurin, which 
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forms part of the cardiac stress signalling pathways. Hdac9 knockout mice are 
also more sensitive to signals of cardiac stress. Mice deficient for both Hdac5 
and Hdac9 have a thin myocardium and lethal VSDs [550].  
 
The transcription factor CREB is also phosphorylated at Ser133 by PRKD1 [681]. 
This results in expression of CREB related genes. This includes atrial natriuretic 
factor and brain natriuretic factor [681, 804, 805]. These two molecules are 
secreted by the atria and ventricles respectively, in response to increased 
transmural pressure [806]. C-fos is also regulated by CREB and has been 
associated with cardiac hypertrophy [807, 808]. This suggests that there might 
be more than one possible mechanism by which PRKD1 regulates cardiac 
hypertrophy.  
 
PRKD1 might also influence contractility, as it mediates phosphorylation of 
TNNI3 (cardiac troponin I). This leads to reduced calcium sensitivity of the 
myofilament, and accelerated cross bridge cycling in rat ventricular 
cardiomyocytes, and confirms that PRKD1 plays a role in regulation of the 
function of heart muscle [689, 774]. There is evidence to suggest that 
stimulation of PRKD1 may be important in acute regulation of contractility of the 
heart in cardiac failure, when other proteins such as protein kinase A (a known 
regulator of contractility) are downregulated [741, 809].  
 
5.1.2 Previous relevant Prkd1 mouse models 
 
Feilitz et al. generated a mouse expressing cre-recombinase in cardiomyocytes 
to produce a Prkd1conditional model [732]. The mice were viable and appeared 
entirely normal. They then performed arterial banding to increase the afterload, 
and found that the homozygous conditional knockout mice showed minimal 
fibrosis and hypertrophy, no reduction in contractility, increase in LV end 
diastolic diameter or bradycardia in response. There was no activation of foetal 
or fibrosis genes. The WT mice however showed poor cardiac function, reduced 
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contractility and heart rate, and up regulation of foetal, hypertrophic and fibrosis 
genes. In comparison, cardiac specific expression of activated Prkd1 in mice 
leads to cardiomyopathy and death [742]. Initial cardiac hypertrophy was 
followed by ventricular dilatation and thinning of the ventricular walls and 
reduced contractility. This confirms the role of Prkd1 in controlling hypertrophy, 
contractility and remodelling in stressed hearts. 
 
Further evidence of its role in hypertrophy was shown by Harrison et al. who 
performed Prkd1 knockdown with siRNA and found that this reduces subsequent 
hypertrophy seen in response to stress in both mice and in vitro cardiomyocytes 
[742].  
 
The effect of β adrenergic stimulation on Prkd1 is unclear. In comparison to 
these in vitro studies where Prkd1 was not affected by β adrenergic stimulation 
[742], Prkd1 was required to promote hypertrophy in response to β adrenergic 
stimulation in a conditional mouse model Feilitz et al. Other studies have shown 
that pressure overload and angiotensin II stimulation both require PRKD1 for 
pathological remodelling [732].  
 
5.1.3 Imaging Modalities 
 
Given that HREM was used to analyse the embryonic hearts, this was considered 
as a method for analysing the adult hearts too. Personal communication with 
Tim Mohun revealed that he had had variable success with HREM in adult mouse 
hearts. Limitations included the heart arresting in systole and difficulty removing 
blood from the heart, which obscures morphology and impairs phenotyping. Dr 
Mohun had not found using antiarrhythmics or anticoagulants had helped. I did 
try a modified protocol with extended time for infiltration, but this was only 
partially successful (see chapter 4, section 4.67, figure 4.22) 
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A number of alternative imaging options were considered and are discussed 
below. The major limitations were the size of the adult mouse heart and the 
inability to carry out any intervention on mice prior to death, due to lack of an 
appropriate Home Office licence. Post mortem MRI presented its self as a 
feasible option, with the potential additional benefit of being able to carry out 
downstream work as the tissue would not require fixation. There is an MRI 
facility within the University which allowed easy transport of mice. Ideally I 
would have validated the findings using histology afterwards, but unfortunately 
this was not feasible due to time restrictions.   
 
Traditional methods used to phenotype the mouse heart include paraffin 
embedding and sectioning, along with newer methods such as ultrasound, 
computed tomography (CT), optical projection tomography (OPT), magnetic 
resonance imaging (MRI), episcopic fluorescence image capture (EFIC) and high 
resolution episcopic microscopy (HREM). Some of these methods are non-
invasive and some allow image reconstruction in multiple planes. At the time 
within the lab, we were exploring if there was a method of imaging we could use 
that would also allow us to carry out RNA studies afterwards. Many of these 
techniques rely on the use of fixative, dehydration and embedding, which makes 
downstream work more difficult. Another significant limiting factor was the 
absence of a specific project licence allowing scans under sedation, use of 
contrast or any other intervention on live animals. Possible false positive and 
false negative results led Lui et al. to recommend histological confirmation of 
phenotypes after all other imaging techniques [810].  
 
MRI is one of the more popular techniques for imaging the mouse. However 
most of the published methods either rely on use of contrast and fixation in 
deceased animals with the associated risks of shrinkage, or require specific 
animal licencing to allow injection of contrast and imaging under anaesthesia in 
a live mouse. Given it is extensively used in both animal and human cardiac 
studies, and the University has a well-established MRI facility, I explored this 
option further and ultimately used MRI imaging in post mortem mice. 





 Option for image manipulation and 3D constructions using the data 
collected. 
 No radiation. 
 Good resolution in soft tissues without contrast. 
 Potential for imaging multiple samples at once [811]. 
 A wide variety of scanning options to answer the clinical question posed. 
 
Disadvantages 
 Longer scan times to achieve high resolutions. 
 Technical difficulties such as wrap around artefact.  
 Can be difficult to visualise smaller structures such as valves, papillary 
muscles and small vessels [810]. 
 Many protocols rely on either imaging with contrast in a live animal, or 
fixation and contrast in ex-vivo embryos. 
 
MRI was pursued given the resources at the University Of Nottingham and the 
excellent soft tissue resolution it provides, even without contrast. As the Home 
Office Licence we were working under was for breeding only, any imaging of the 
adult mice would have to be carried out after death. Post mortem imaging does 
have some advantages.  Image acquisition time is not limited by anaesthesia, 
there is no motion artefact, and longer scan times allow higher resolution 
images.  
 
5.1.4 The Basis of MRI  
 
MRI relies on the spin of protons contained within water molecules in cells. The 
direction of spin of protons varies throughout the body, unless it is aligned with 
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a magnetic field. MRI exploits the ability to manipulate proton alignment using a 
magnetic field produced by a superconducting magnet. The aligned protons have 
a net magnetisation that rotates around the direction of the main magnetic field. 
Radiofrequency (RF) pulses (low energy electromagnetic waves) cause the net 
magnetisation to rotate orthogonally to the main magnetic field. This is the 
resonance part of MRI. The rotating net magnetisation gives rise to a detectable 
signal. There are two processes that cause the decay of this detectable signal. 
These processes are known as relaxation and have the time constants T1 and 
T2.  
 
Different tissues exhibit different relaxation times, which are known as T1 and 
T2. T1 is the longitudinal relaxation time and T2 is the transverse relaxation 
time.  T1 is the time constant for the protons to regain their original pattern of 
spin within the magnetic field. The spin relaxes from the transverse plane to the 
longitudinal magnetic vector. Two important settings in MRI are the repetition 
time (TRMRI) and time to echo (TE). The TRMRI is the time between pulses in a 
specific slice, and TE is the time it takes between sending the RF pulse and 
receiving the signal. T1-weighted imaging relies on a short TE and TRMRI. T2 is 
the time constant for the loss of alignment of proton spin in the transverse 
plane. It represents the time taken for the excited protons to go out of phase 
with each other along the line of nuclei spinning perpendicular to the magnetic 
field. T2-weighted imaging relies on a longer TE and TRMRI. In MRI, it is common 
to acquire repeated measurements of the data, which are then added together 
to ensure that enough signal can be generated to be detected and used to form 
an image. This frequency information is translated into intensity information at 
each specific location and used to produce pixels of varying grey scale values. 
 
5.1.5 Previous relevant MRI studies 
 
Whilst planning MRI imaging in the adult mouse, I considered a number of 
published protocols for mouse embryo MRI imaging to see if any could be 
adapted for a post-mortem adult mouse. Embryos are obviously a lot smaller, 
and also show a comparative lack of contrast between tissues making it more 
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difficult to delineate structures adequately in early to mid-gestation [811]. MRI 
in live and dead embryos is possible. In live animals prospective gating can be 
used to combat movement artefact from respiratory and cardiac cycles. 
Gadolinium contrast is used to help delineate the anatomical structures. This can 
be introduced by injection, or by soaking the embryo in contrast solution after 
fixation. 
 
Parasoglou et al. scanned in utero mouse embryos at E10.5 and E12.5 with 
manganese enhancement [812, 813]. Whilst this worked well for the cerebral 
vasculature, limbs, spine and CNS, it worked less well for the heart. Longer 
echo times were required for good contrast between the vasculature and other 
soft tissues in the earlier embryos (E10.5 for example). Use of contrast in this 
situation was not be possible under our current licence. 
  
Schneider et al. have published a number of MRI protocols to image single 
mouse embryos with a resolution of 25 x 25 x 26µm voxels, validated by 
histology. These were fixed embryos and relied on a T1 weighted gradient echo 
sequence, rather than spin echo [814, 815] and fast spoiled 3D gradient echo 
sequence with T1 weighting [816].  They were able to identify ASD, VSD, DORV 
and aortic arch abnormalities. Subsequent to this they developed a protocol that 
allowed imaging of up to 32 embryos in a single scan, reaching a resolution of 
43 x 43 x 36µm [817]. The embryos were fixed with PFA and embedded in 1% 
agarose gel containing Magnevist (gadolinium-DTPA). Similar resolutions were 
obtained by Zouagui et al. [818] using the same methods [817]. I discussed 
their methods with S. Bamforth who is one of the authors involved in pioneering 
the multi embryo MRI imaging using PFA and Magnevist. They had not tried 
using Magnevist in the adult mouse, but felt it would not be suitable given the 
requirement for adequate infiltration by the contrast agent.  
 
Gabbay-Benziz et al. used MRI to characterise the E17.5 mouse embryo heart 
[819]. They removed the embryos and fixed them in 4% paraformaldehyde and 
held them in place using Fomblin (a perfluoropolyether oil). With an eight hour 
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acquisition time in a 17.6T MRI coil they achieved a voxel resolution of 51 x 53 x 
78µm. This method allowed the identification of TGA and VSDs, and did not 
require any other contrast agent. The higher power coil used in this study meant 
that the resolution was adequate for analysis without complex imaging protocols 
or contrast required for the previous MRI studies of the mouse embryo. 
Unfortunately I did not have access to such a powerful magnet. 
 
Post-mortem cardiac MRI also has a role in detecting cardiac lesions in humans 
and has been proposed as a first line assessment for all deceased foetuses and 
neonates. It could replace conventional autopsy and picks up the vast majority 
of CHD [820]. Unfortunately there is a relative lack of post mortem mouse MRI 
studies that concentrate on the heart, and much of the research focusses on the 
brain instead. Von Bohlen Und Halbach et al. used post mortem MRI studies to 
compare scans of anaesthetised live mice, unfixed post mortem in situ and fixed 
ex-situ brains [821]. Post mortem imaging of the unfixed brain provided much 
more detailed images than the scans on the live mice. This was due to the 
longer T2 weighted sequences that could be used, rather than the faster T1 
weighted scans used in live mice. Scans of the fixed brains showed that the 
structures in the brain were much less well preserved and had decomposed 
significantly, compared to the immediate post mortem scans. Long term, but not 
short term fixation was associated with significant shrinkage. Other studies have 
confirmed adverse effects of fixation in the brain and artefacts have been 
reported in almost one third of fixed mouse brains. This was thought to be 
related to flow of perfusates through capillaries and inadequate fixation causing 
unusual appearances on scan [822]. This suggests that post mortem imaging is 
fruitful in the brain, and short term fixation can be considered if immediate 
scanning is not possible. Brain tissue is more fragile and unlikely to be directly 
comparable to cardiac tissue. Immediate post mortem scanning might be a 
viable option to consider. 
 
Crowe et al. performed post mortem imaging in mice who had undergone 
ischaemia reperfusion injuries [823]. They were first scanned under anaesthetic 
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after injection with gadolinium intraperitoneally, and scanned using a 3D flash 
GRE MRI protocol (16 minutes, isotropic resolution of 130µm) post-mortem. The 
post mortem images were higher resolution with no movement artefact, 
although gadolinium would have also been present at post mortem scanning. 
The mice were killed with injection of potassium chloride which causes cardiac 
arrest. Interestingly, in 50% of cases, the heart had contracted between the live 
animal MRI and post-mortem scan. Presumably this would limit what could be 
detected from the images. The authors did not comment on specific structural 
defects, but it suggests that potassium chloride should be avoided if 




Given there are a number of Prkd1 mouse models already reported, I chose to 
concentrate on the Prkd1em2(IMPC)Wtsi humanised mutation mouse. The aims were as 
follows: 
 
 Devise an MRI protocol with adequate resolution to allow detection of CHD 
in E15.5 mouse embryos. 
 Arrange MRI scans of Prkd1+/+, Prkd1Em2/+ and if possible Prkd1Em2/Em2 
adult mice. 
 Determine if there is any evidence of CHD or cardiac hypertrophy in any 
of these mice. 
 
5.3 Results and Discussion 
 
The age of the mice at scan was decided by balancing the cost of keeping mice 
for prolonged periods of time, with the benefit of older mice with a larger heart 
and a longer period of life that might allow decompensation or heart remodelling 
if there was a structural cardiac abnormality. Based on previous studies we 
would not expect any features of hypertrophy without additional workload on the 
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heart [732, 742]. C57BL6 mice do become obese over time, although availability 
of fat suppression meant that body composition of the mice should not matter. 
Considering all these factors, a decision was made to image two month old male 
mice. 
 
Ideally I would have liked to scan three groups of mice; Prkd1+/+, Prkd1Em2/+ and 
Prkd1Em2/Em2 mice, but lethality in the Prkd1Em2/Em2 mice was almost complete, 
therefore it was not possible to include this group. A single surviving female 
Prkd1Em2/Em2 had to be killed by schedule one methods after she scratched her 
cheek, and this heart was used to trial HREM in the adult mouse heart, rather 
than MRI. The results have already been described in Chapter 4 (section 4.6.7, 
Figure 4.22). The surviving male homozygote was used for breeding and was 
therefore not available for study. This was intended to be a preliminary study to 
see if the technique is feasible, so power calculations are not appropriate. 
 
5.3.1 Determining the Required Resolution for MRI Scanning 
 
Review of the previous MRI studies reported in section 5.1.5, helped define the 
requirements for scanning the adult mice. A resolution of 25-50µm is sufficient 
to detect CHD in a mid to late gestation mouse embryo. For an adult mouse, 
equal or lower resolution should be sufficient to detect similar types of CHD. 
Lack of a licence for interventions on live mice, fixation processes that would 
prevent downstream work or not work in larger adult mice and lack of very high 
power magnets meant that the same protocols could not be used. Immediate 
post mortem imaging would have been ideal, but did not prove possible due to 
ongoing requirements of the MRI scanner, and ultimately the length of time 
required for the cardiac scans. 
 
Turnbull et al. recommended a spatial resolution of 50µm isotropic (same 
resolution in all axes) for imaging of mouse embryo between E9.5-12.5, and 
100µm for E13.5-15.5 to assess cardiovascular development [824]. Reaching 
resolutions less than 50 µm proved difficult, but the mice to be scanned would 
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be much bigger. I searched the available literature for the heart dimensions of 
the adult C57BL6 mouse to ensure adequate resolution for phenotyping. The 
results are shown in table 5.1 below. 
 
Reference Age and Mode Landmark Measurement 
Doevendans 
et al. [825] 






LV wall (mm) 1.1 
IVS (mm) 1mm 
Baumann et 
al. [826] 
12-14 week mice  
Echo 
LVEDD (mm) 3.79 (F) 4.05 (M) 
LVESD (mm) 2.59 (F) 2.83 (M) 
DWTA (mm) 0.6 (F) 0.7 (M) 
SWTA (mm) 0.92 (F) 1.04 (M) 
DWTP (mm) 0.56 (F) 0.64 (M)  
SWTP (mm) 0.9 (F) 0.96 (M) 




10 day – 2 month  
Echo 
Aortic valve cusps 
length (µm) 
342-474 





Largest at 10 
days old 
Mitral valve cusps 
length (µm) 
332-931 






Table 5.1 C57BL6 cardiac measurements found in the literature. 
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LVEDD = left ventricular end diastolic dimension, LVESD = left ventricular end 
systolic internal dimension, DWTA = left ventricle anterior end diastolic wall 
thickness, SWTA =left anterior wall end systolic thickness, DWTP = left ventricle 
posterior end diastolic wall thickness, SWTP = left ventricular posterior end 
systolic wall thickness  
Review of the known dimensions for structures in the C57BL6 mouse suggests 
that most structures will be visible, although the valves may not be seen along 
their entire length. It is likely though that in the event of a significant valve 
lesion, other abnormalities would be apparent such as post stenotic dilatation. 
 
5.3.2 Preservation of Mice by freezing 
 
To reach the required image resolution without contrast, long acquisition times 
were required. This meant that initially overnight, and then weekend scanning 
was arranged. Due to ongoing commitments within the MRI department and 
availability of suitable mice, the scan could not always be carried out on the 
same day that the mice were culled. To get round this issue we tried freezing the 
mice after culling, and then thawing them for scans.  
 
I considered whether the freeze thaw process could damage cardiac structures 
at the structural level that I was considering. Studies in canine tissue have 
shown that freezing can cause a range of abnormalities. This includes loss of 
staining, extracellular fluid accumulation and cell shrinkage, fractures, 
haemolysis and haematin formation, prominence of collagen in alveolar septae 
and the meninges, and intracellular vacuoles in epithelial cells [828]. On an 
architectural level bronchial cilia were lost. However the authors felt that the 
tissue could still be adequately examined. In human liver and heart tissue, 
freezing at -12 to -80C and subsequent thawing resulted in larger extracellular 
spaces and cell shrinkage [829]. Longer storage time led to more pronounced 
effects. Repeated freeze thaw cycles (-10, -18C) in buffalo muscle did result in 
some more significant changes including shrinking and tearing of the muscle 
fibres [830].  
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Freezing and then thawing of the mice could lead to abnormalities at the cellular 
architecture level. I reduced the chances of this occurring by freezing for the 
shortest time possible, and only using a single freeze thaw cycle. Given I was 
examining the hearts for much larger supracellular abnormalities, the evidence 
suggests that freezing the mice should not induce artefacts that would alter my 
results. In addition, alternative methods such as formalin fixation and paraffin 
embedding also lead to cell shrinkage but are still used to detect structural 
lesions in embryonic hearts. 
 
A number of possible methods are available to reduce the chances of damage 
induced by the freeze thaw process. Snap freezing to -80c and cryosectioning 
tend to be used. Reduction of ice crystals formation by dehydration and reduced 
freezing time has proved useful in rat hearts and skeletal muscle [831]. Skeletal 
muscle samples can be immersed in isopentane at -150C [832] and thawed and 
re-frozen if there is artefact. These samples were much smaller though (1.5cm 
in maximum diameter). In our protocol we did not immerse the tissue or snap 
freeze the mouse as they were large samples. We could try faster freezing 
protocols with the whole mouse to see if there was any difference in architecture 
in future studies, or if there was any evidence of tissue damage visible on the 
scans.  
 
5.3.3 Test MRI Scans 
 
A protocol to image the whole mouse thorax was produced and initial studies 
were carried out on a deceased mouse to ascertain the image quality and 
contrast between tissue and blood. A standard 50µm scanning procedure was 
used initially, then with zero-filled image and then a shortened TR with twice as 
many iterations. A number of test scans were carried out with different 
resolution, acquisition time and echo chain. It is necessary to use spin-echo for 
scans at higher fields such as this, as there is a high incidence of susceptibility 
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artefacts (artefacts and distortions as a result of local changes in the magnetic 
field). A bright blood protocol was thought to be the best starting point to act as 
a contrast in the heart and great vessels.  
 
Scans were carried out overnight initially to allow plenty of time for image 
acquisition. We then carried out further test scans over the weekend period at 
50um, 60um and 70um resolution isotropic (Figure 5.1). Scanning at a lower 
resolution such as 70um allows for more signal averaging which reduced the 
“noise” in the images. After comparison of these three resolution scans, it was 
felt that it would be best to opt for the highest resolution possible so as to not 
miss any lesions, because the amount of noise was fairly minimal at 50um 
resolution. Multiple scans were then run over a whole weekend period (>60 
hours) which showed that the samples were stable enough to collect data for 
several signal averages over a longer period than just the overnight scan. 
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Figure 5.1 MRI images at differing resolutions. 
Comparison of the same mouse showing the LVOT at 50 (A), 60 (B) and 70µm 
(C) resolution. The signal to noise ratio is improved at 70 µm. The right and left 
ventricles are shown, and the right atrium. The structural details appear the 
same across all images and there does not appear to be any significant 
difference across the heart at different resolutions.  
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Wrap around artefact was present on some of the images, but was sufficiently 
distant from the heart to allow a full analysis of cardiac morphology (figure 5.2 
and 5.3). Triple images occasionally occurred on test scans as a result of an 
extra-long echo chain (number of echoes used in fast spin echo/RARE imaging, 
16 resulted in the triple image artefact) (figure 5.3). Some of the initial images 
were darker towards the posterior parts of the chest, which sometimes impeded 
the view of the heart. This was due to using a coil which allowed a very small 
field of view and was resolved by positioning the embryo so that the heart was 
at the 6 o’clock position.  
 
 
Figure 5.2 Wrap around artefact. 
Artefact indicated by blue arrows. The thorax can be seen reflected at the 
bottom of the image (anterior of the mouse) and the limb on the right side of 
the picture.  
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Figure 5.3 Wrap around artefact and image shadow. 
MRI test image showing wrap around artefact from the anterior of the thorax 
(bottom blue arrows) and the limb (blue arrow on right). In addition there is an 
appearance of blurred boundaries of the tissue, as if multiple images are 
overlaid, thought to be a result of using an extra-long echo chain (16 echoes). 
Cross hairs intersect in the left ventricle. 
 
5.3.4 Structural Cardiac findings in 2 month old Prkd1Em2(IMPC)Wtsi mice  
 
A total of 23 Prkd1Em2 mice were scanned. This included 13 male Prkd1Em2/+ 
mice aged 2 months, and some additional mice that were used for test scans. 
Test scans were carried out on mice which included some at 1 month of age and 
a female mouse. All 23 mice had detailed external phenotyping and all were 
normal. No internal phenotyping by dissection was carried out as they were 
required intact for the MRI studies. An example of the transverse, coronal and 
sagittal images with 50 x 50 x 50µm resolution are shown below (Figure 5.4). 
The ability to reference a structure in three planes simultaneously is helpful 
when identifying cardiovascular anatomy. Normal structures identified on the 
MRI scans are shown in figure 5.5 - 5.9 below.  
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Only two mice of the 23 scanned had structural defects. This included a single 
two month old male Prkd1+/+ mouse with a large right atrial appendage (RAA) 
(figure 5.10 A). The significance of an enlarged RAA is unclear. It is not 
characteristic of, or pathognomonic for anything specific. The right atrium and 
rest of the heart appeared normal. The importance of this in a WT mouse is not 
certain.  
 
The second mouse with a structural abnormality was a Prkd1Em2/+ male mouse. A 
dark mass was identified apparently attached to a leaflet of the tricuspid valve. 
This measured 0.77x0.8487x 0.8003mm (Figure 5.10 B). It could it be 
fibroelastoma, as it looks to be associated with the valve, rather than the 
papillary muscles. The significance of this is uncertain. 
 
 
Figure 5.4 Typical images shown in three planes generated in ITK-Snap. 
A: Transverse, B: Coronal, C: Sagittal sections of a normal Prkd1Em2/+ mouse. 
Crosshairs pinpoint the aortic valve.  Anterior is the bottom of the image and the 
right side of the heart is on the right side of the image in the transverse cut. 
Ao: Aorta, IVS: Interventricular septum, LA: left atrium, LBr: Left main 
bronchus, RA: Right atrium, RBr: Right main bronchus, RVOTO: Right ventricular 
outflow tract, SVC: Superior vena cava. 
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Figure 5.5 Left ventricular outflow tract and aortic valve. 
Images of a normal Prkd1Em2/+ mouse. 
A: Coronal slice through the mouse thorax through the heart showing the 
LVOTO. B: Further coronal slice showing the LVOTO and AV in more detail. The 
valve leaflets (arrow) in cross section, bulbous shape of the sinus of Valsalva 
and the sinotubular junction can be seen. C: Transverse slice. The trileaflet 
structure is just discernible (arrow). Anterior is inferior on this image. 
Ao: Aorta, IVS: Interventricular septum, LA: left atrium, LV: Left ventricle RA: 
Right atrium, RV: Right ventricle, RVOTO: Right ventricular outflow tract. 
 




Figure 5.6 Great Vessels on MRI sections of a Prkd1Em2/+ mouse. 
A: Transverse slice across the top of the heart at the level of the pulmonary 
artery bifurcation (PA and arrows). Both the ascending and descending aorta can 
be seen. Bilateral SVC are present. B: Sagittal slice through the right ventricle 
showing the SVC and IVC. C: Sagittal slice through the left ventricle showing 
both the IVC and descending aorta.  
Ao: Aorta, Dao: Descending aorta, IVC: Inferior vena cava, IVS: Interventricular 
septum, LV: Left ventricle, PA: pulmonary artery, RA: Right atrium, RV: Right 
ventricle, SVC: Superior vena cava 
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Figure 5.7 Right and left outflow tracts in a Prkd1+/+ mouse. 
A. Aortic arch. The ascending, descending and arch portions of the aorta can 
all be seen. The three main branches are also shown (arrows).  
B. B. Coronal sections of a normal Prkd1+/+ mouse displaying the right 
ventricular outflow tract (arrow). 
Ao: Aorta, Dao: Descending aorta, LV: left ventricle, RV: Right ventricle 
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Figure 5.8 Valves and atrial septum in a normal Prkd1+/+ mouse. 
A-D. Mitral valve and papillary muscles. 4 images moving up from the base of 
the papillary muscles (A), following their course up to the mitral valve where the 
leaflets are just visible (image D). E-F: Atrial septum and components of 
atrioventricular valves E: Transverse slice showing the intact atrial septum 
(arrow). Part of the right ventricular outflow tract is seen. F: Transverse image 
through the ventricles to demonstrate the papillary muscles. In the right 
ventricle the papillary muscle can be seen reaching up towards the tricuspid 
valve. Comparison between the thick walled left ventricle and thinner walled 
right ventricle can be seen. 
LA: Left atrium, LV: Left ventricle, MV: Mitral valve, PM: Papillary muscle, RA: 
Right atrium, RV: Right ventricle, RVOT: Right ventricular outflow tract 




Figure 5.9 Atrial septum and components of atrioventricular valves in a 
normal Prkd1+/+ mouse. 
A: Sagittal section through the right atrium and ventricle showing the tricuspid 
valve between them. Part of the atrial septum is also visible  
B: Transverse slice through the heart to illustrate the tricuspid valve. The 
leaflets are marked with arrows. 
IAS: Interatrial septum, LV: Left ventricle, RA: Right atrium, RV: Right ventricle, 
TV: Tricuspid valve 
 




Figure 5.10 Abnormal cardiac phenotypes detected. 
A. Transverse section of a Prkd1+/+ mouse. The right atrial appendage 
appeared much larger than in other mice. Although difficult to appreciate in a 
single section, it took up a significant portion of the right side of the thorax. 
There were no other abnormalities and the significance of this is uncertain. B. 
Dark mass on TV leaflet in a Prkd1Em2/+ mouse. A dark mass is apparent 
(arrow) and is associated with the TV. It measures 0.77x0.8487x 0.8003mm. 
This appearance and its apparent association with the valve rather than the 
papillary muscles, mean that it could it be fibroelastoma. It does not appear to 
be clot and there are no other real differentials. 
 
LV: left ventricle, RA: Right atrium, RAA: Right atrial appendage 
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Overall, no structural abnormalities were identified with the exception of a 
possible fibroelastoma associated with the TV, and an enlarged right atrial 
appendage (RAA) in a wild-type mouse. The significance of these two findings is 
unclear. The fibroelastoma was identified in a Prkd1Em2/+ mouse. Fibroelastomas 
are rare tumours that occur on the heart valves. Whilst histology would have 
been helpful to confirm if this was indeed a fibroelastoma, the MRI appearance is 
typical and there are few other differentials. It is unclear if this has any 
relevance to the genotype of the mouse. The enlarged RAA was identified in a 
Prkd1+/+ mouse. An enlarged RAA is not indicative of any particular condition. 
Ideally real time assessment of the TV is required to rule out severe tricuspid 
regurgitation as a cause, as well as an assessment for pulmonary disease. 
However, I would expect right atrial enlargement too if these pathologies were 
present.  
 
5.3.5 Ventricular Wall and Septal Thickness in 2 month old 
Prkd1Em2(IMPC)Wtsi mice 
 
Measurements of the thickness of the ventricular walls and septum were made in 
a total of 13 mice, 8 male Prkd1Em2/+ and 5 male Prkd1+/+ mice, who were 
exactly 2 months old. Measurements were taken in the short axis, at the mid-
ventricular level where the papillary muscles are present. The average wall 
thickness at each site is shown in table 5.2 below. The site of the measurement 
and corresponding p values are shown in figure 5.11. Box and whisker plots for 
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Site Prkd1+/+ (mm) Prkd1Em2/+(mm) T test 
RV free wall  0.408 0.483 0.012 
IVS  1.203 1.348 0.062 
LV anterior wall 1.116 1.233 1.110 
LV posterior wall 1.106 1.261 0.118 
LV lateral wall 1.162 1.158 0.947 
LV internal 
diameter (AP) 




1.997 1.974 0.865 
 
Table 5.2 Ventricular wall thickness in Prkd1+/+ and Prkd1Em2/+ mice. 
Average measurements of wall thickness at mid ventricular level in two month 
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Figure 5.11 Representation of the measurements of ventricular wall and 
septal thickness in Prkd1+/+ and Prkd1Em2/+ mice. 
The only significant value calculated by two tailed T test with unknown variance 
was the measurements of the right atrial free wall, highlighted in red. 
A: Measurements of the width of the ventricular walls and septum were 
measured at the level of the papillary muscles (mid ventricle). P values at each 
location we measured are shown. B: Internal diameters of the left ventricle were 
taken in both anteroposterior and transverse directions. There was no significant 
difference between the two groups of mice. 
LV: left ventricle, RA: Right atrium, RAA: Right atrial appendage 




Figure 5.12 Box and whisker plots of ventricular wall thickness.  
Although p values were insignificant in all except right ventricular free wall, it is 
evident that there is a trend towards increased wall thickness in the Prkd1Em2/+ 
mice in all measurements except the lateral LV wall, when compared with the 
wild type mice. 
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Figure 5.13 Box and whisker plots LV diameter. 
 
Measurements of the aortic root were taken at the level of the sinus of Valsalva. 
Three measurements were taken across the valve cusps in the short axis and 
averaged. Two further measurements taken in the long axis (coronal and sagittal 
planes) and averaged. The results are shown in table 5.3. Figure 5.14 illustrates 
the sites of these measurements and the associated P values based on a two tail 
T test assuming unequal variances. None reached significance. Box and whisker 













Site Prkd1+/+ (mm) Prkd1Em2/+(mm) T test 
SoV (across the 
cusps) 











Table 5.3 Average measurements of the aortic root at the sinus of 
Valsalva (SoV) and ascending aorta. 
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Figure 5.14 Summary of aortic measurements. 
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Figure 5.15 Box and whisker plots of aortic measurements. 
Whilst only the right ventricular free wall reached significance, it is intriguing 
that all ventricular walls with the exception of the LV lateral wall, trended 
towards being thicker in the Prkd1Em2/+ mouse. Isolated RV hypertrophy is 
usually seen in response to pressure overload as a result of pulmonary 
hypertension or TV disease. To investigate this further, would require either 
echocardiographic or real time MRI imaging, to assess the RV and TV function, 
and to look for evidence of pathology such as emboli in the pulmonary 
circulation for example. Without a larger sample size and possibly additional 
dynamic imaging, we cannot confirm that RV hypertrophy is a feature of 
Prkd1Em2/+ mice. Alternatively, it may be that the whole heart was showing a 
hypertrophic response. and failure to reach significance in the other ventricular 
wall measurements was a result of the small sample size, or potentially short 
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lifespan of the mice not allowing adequate time for a hypertrophic process to 
occur for long enough to detect a difference. 
 
Previous mouse models have shown that loss of Prkd1 in the heart results in 
reduced hypertrophy in response to stress [732]. Therefore, if the mutation in 
the mouse results in loss of function, we would not expect to see any 
hypertrophy under normal conditions, or even under conditions of increased 
work. Given there was no clear evidence of CHD in the mouse hearts, I would 
not expect the heart to be under any increased workload. Therefore there should 
not be any difference in ventricular wall thickness between the groups. We could 
consider if increased hypertrophy might be a result of this mutation causing a 
gain of function, as demonstrated in mice with activated Prkd1 [732]. These 
mice showed dilation of the ventricles, wall thinning and enlarged atria. 
Histological assessment showed myocyte disarray, myocyte hypertrophy, 
increased interstitial but only minimal fibrosis [742]. These effects were seen 
from four weeks of age. Therefore it is likely that if the Prkd1Em2/+ mice had a 
gain of function mutation, we might actually see reduced wall thickness given 
that they were two months old. The consequences of a germline non-conditional 
gain of function mutation is also unknown. If the mutation in the mouse does not 
cause a gain of function, another explanation for hypertrophy occurring would be 
upregulation of the normal Prkd1 allele.  
 
Simple up or down regulation of Prkd1 does not easily explain why we might see 
increased wall thickness in the mouse and the occurrence of hypertrophy might 
instead indicate other compensating mechanisms are at work. There is evidence 
that other genes have a similar functional role to PRKD1. Prkd1, 2 and 3 can all 
phosphorylate class II HDACs and facilitate their nuclear export. Loss of Prkd1 
alone does not result in complete loss of HDAC5 nuclear export, and in B cells 
both Prkd1 and Prkd3 had to be knocked out to prevent phosphorylation and 
nuclear export of HDAC5 [715, 716]. These other mechanisms may maintain 
normal hypertrophic response. It is not clear if this would result in hypertrophy 
under no increased cardiac workload though. 
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To move forward with these results, a number of questions need answering. The 
first is whether this increased wall thickness remains significant in a larger 
population. If increased wall thickness is confirmed to be significant we would 
then need to consider why it is occurring. We would need to exclude other 
causes of hypertrophy. This should include some kind of functional assessment 
and subsequent histology. We should also determine what effect this mutation 
has by performing protein and functional studies. 
 
Aortic measurements were also taken to determine if the root and ascending 
aorta were normal, given that dilated aortae have been seen in Mef2c knockout 
mice [793]. There was no significant difference between the Prkd1Em2/+ and WT 
mice with respect to aortic measurements. 
 
Whilst there is room for improvement and further studies, these results do 
provide some useful information about the incidence of CHD in the Prkd1Em2 
mouse model of the commonest p.G592R mutation. It also suggests that this 
might not be a gain of function mutation based on the appearance of the heart 
alone. It would be interesting to perform scans at later ages and with additional 
afterload on the heart to assess hypertrophic response. These data provides a 
baseline for such further studies.  
 
5.4 Challenges, Limitations and Future Work 
 
The main limitations of MRI work are the small cohort analysed and a lack of 
control method of analysis. Lui et al recommend histological confirmation of 
phenotypes after all other imaging techniques [810]. However, not all agree that 
histology is the best method for cardiac phenotyping [819] and MRI has been 
shown to be superior [816].  
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Whilst every effort was made to ensure measurements were as accurate as 
possible there will be some error. The precision of measurements was partly 
limited by the resolution of the scan, but also the nature of some of the heart 
structures. Because the aortic root can often have a triangular shape, multiple 
measurements were taken and averaged. The presence of the papillary muscles 
also makes some measurements more difficult such as the LV internal diameter 
(transverse) and the lateral LV wall. Real time imaging would also allow us to 
confirm that all measurements are taken in end diastole.  
 
Although the atrial and ventricular septae were relatively well demarcated on 
final scans, ASDs and VSDs are often only diagnosed when flow can be 
demonstrated across the septum, so a static image alone is not sufficient. Real 
time imaging was not possible due to license restrictions, but the scan resolution 
should mean that any significant defects would be apparent. Valve defects were 
the other phenotype we were concerned about visualising, which again ideally 
require dynamic imaging with Doppler flow.  
 
The MRI protocol we developed is convenient because it allows use of the MRI 
scanner overnight and at weekends, making good use of potentially redundant 
scanning time. This is also more cost efficient. It also allows for batch processing 
and storage of the mice until you reach a point where it is convenient to scan 
them. However, the question of whether the freeze thaw process we used would 
distort tissue architecture at a supracellular level to the extent we might produce 
false positives and negatives remains unanswered. The literature suggests 
cellular level changes mainly, and I haven’t been able to find any specific 
literature describing the effect we might see on the structure heart at the level 
of detail I was looking [828-832]. It is likely that changes that do occur, are 
below the 50µm resolution we used. Ideally, we would have imaged each mouse 
immediately after death, but this was not possible. Histological analysis 
afterwards and a control group who were scanned without prior freezing could 
help answer this question.  
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To gain high resolution, the image acquisition periods were very long. Given the 
mice were not preserved in any way, there is likely to be some decomposition 
occurring during this time. However, multiple scans of the same mouse over a 
whole weekend did not result in any differences in cardiac structures on 
sequential scans. This suggests that any decomposition or degradation occurring 
it not sufficient to be seen on the MRI scans. 
 
Injection of contrast via the umbilical vessels is something that could be 
investigated further as a post mortem intervention to potentially improve 
images. I did manage to cannulate the umbilical vessels with the same glass 
capillary needles that I used for zebrafish injections, so potentially this could be 
easily done. Whether this would allow adequate perfusion of the heart and great 
vessels is uncertain. Cannulation of other vessels would be preferable, but we 
would still need to determine whether contrast could adequately reach the heart 
and expel blood, and that the pressures required to do this would not result in 
any damage to cardiac structures. 
 
A number of other interventions would also provide useful information. Given 
Prkd1 conditional knockout mice appear to have normal hearts until stressed 
[732], it would also be interesting to stress the Prkd1Em2 mice to see what 
effect this has and whether this might help inform current clinical 
recommendations. Given Prkd1Em2/+ and live born Prkd1Em2/Em2 mice are 
apparently normal, it would not be necessary to generate an additional 
conditional model. ECG analysis of these mice would also be useful given the 




In addition to its role in CHD and ectodermal dysplasia, PRKD1 is likely to be an 
important gene target in managing pathological hypertrophy in the stressed 
heart, angiogenesis and in preventing ischaemic damage. This is important given 
the prevalence of heart failure within the population and its associated morbidity 
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and mortality, especially given the ageing population. Potential treatment 
strategies may also be informed by monitoring cardiac function in individuals 
with CHD and Ectodermal Defects. These results suggest that there is a low 
incidence of CHD in the Prkd1Em2(IMPC)Wtsi heterozygous mouse, and that it does 
not demonstrate hypertrophy under normal conditions. This may provide a 
useful platform for further research into the mechanisms of this mutation and 
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We identified CDK13 as a novel gene causing S-CHD, and since then, further 
publications have confirmed that individuals with mutations in this gene have a 
recognisable phenotype [12, 489, 833-836]. The syndrome is referred to as 
CHD, dysmorphic facial features and intellectual developmental disorder 
(CHDFIDD), or CDK13-related disorder. Just under 40% of individuals exhibit 
CHD, and exactly how variants in this gene result in aberrant cardiac 
development remains to be understood.  Over 80% of the pathogenic mutations 
lie within the kinase domain. Clinical recommendations for care of these 
individuals is now available, and there is an active social media group for the 
families who are affected. 
 
This chapter focuses on the genotypes and phenotypes of affected individuals, 
and phenotyping of a Cdk13 knockout mouse [12]. 
 
6.1.1 The Structure and Function of CDK13  
 
CDK13 is a member of the cyclin-dependant kinase (CDK) family, which 
comprises of 21 ATP-dependant serine-threonine kinases. The proteins encoded 
by these genes are involved in transcription and cell cycle control and are 
required for the normal function of RNA Polymerase II. 
 
Five human CDKs have been described with a role in control of transcription and 
are listed below. Of these five, only CDK8 and now CDK13 have been shown to 
cause syndromic neurodevelopmental disability in humans. Several have a role 
in cancer, and CDK12 also contributes to the pathogenesis of Myotonic 
Dystrophy [837-839]. 
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 CDK7 and its subunit Cyclin H are important in cell cycle control and 
transcription. It forms part of the general transcription factor TFIIH [840]. 
CDK7 is involved in initiation of transcription and phosphorylates Serine 7 
in RNA polymerase II, and acts as a CDK activating kinase [841]. 
 CDK8 and its subunit Cyclin C form part of the mediator kinase module, 
which regulates RNA polymerase II [842]. De novo missense mutations in 
CDK8 have recently been shown to cause syndromic neurodevelopmental 
disability [843]. 
 CDK9 and its subunits Cyclin T1/T2 form part of the positive transcription 
elongation factor P-TEFb [844]. CDK9 is also needed to prevent promotor 
proximal arrest and is located near the transcription start site [845].  
 CDK12 and its subunit Cyclin K (CCNK) [846, 847].  
 CDK13 and its subunit Cyclin K (CCNK) [846]. 
 
Although CDK13 is the subject of this chapter, it is important to note that it is 
structurally similar to CDK12 and shares the same subunit, Cyclin K (CCNK). 
Despite their similarities, they do not appear to be redundant and instead 
regulate different sets of genes [848]. Both CDK12 and CDK13 are thought to 
exhibit some influence over RNA polymerase II, required for transcription of 
protein coding genes in eukaryotes [849-852].  
 
To understand the effect of CDK13 mutations, we need to understand how the 
protein interacts with CCNK and RNA polymerase II in more detail.  
 
6.1.1.1 RNA Polymerase II and the transcription process 
 
The RNA polymerase II complex is required to transcribe DNA into RNA. This 
process is controlled by modification of the amino acid residues in the heptad 
repeats (Y1S2P3T4S5P6S7) found within the largest subunit of the polymerase, 
Rpb1. A number of the CDKs, including CDK13, are required for phosphorylation 
at these residues. This process is required to facilitate normal elongation of 
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transcripts and production of mature mRNA. An illustration of the CDK13-Cyclin 
K complex is shown in figure 6.1, and RNA polymerase II in figure 6.2. 
 
 
Figure 6.1 CDK13 Cyclin K complex. 
Reproduced with permission from Elsevir [848]. Graphical abstract showing the 
Cdk13 (grey) Cyclin K (lilac) complex and its interaction with RNA polymerase II. 
CDK13 may interact with RNA polymerase II, due to the attraction of the 
negatively charged polymerase C-terminal domain, to the positively charged 
closely associated basic patch and ATP binding site. 
Blue section: Polybasic cluster, Green: DCHEL motif. CTD: C terminal domain. 
Orange and Blue molecular interactions:  Interaction between the C-terminal 
extension helix and the kinase domain and the bound nucleotide. ADP binds here 
with the DCHEL motif.  
Red: Phosphorylated T871 residue in the T-loop of the kinase.  
The hepta-sequence in the CTD of RNA polymerase II subunit Rpb1 is shown, 
and phosphorylation sites are denoted by orange markers. CDK proteins 
including CDK13 are responsible for this phosphorylation process.  
Identifying Novel Genes that cause Congenital Heart Disease  319 
 
The RNA Polymerase II core is made up of ten subunits, with some mobile 
elements (Figure 6.2). It is joined by the sub-complex Rbp4/7, to form the 
complete enzymatic complex and initiate transcription [853]. RPB1 and RPB2 are 
the largest subunits of the complex and the active site of RNA polymerase II lies 
between them in the large central cleft.  
 
 
Figure 6.2 RNA polymerase II subunit composition and assembly. 
Transcription process is shown. The turquoise and blue lines represent the two 
strands of DNA which are unwound. Transcription occurs after the template 
strand is taken into the active site cleft, between the Rpb1 and Rpb2 subunits. 
The RNA strand produced is shown as a red line. 
Red: Rpb3, Mauve: Rpb4, Purple: Rpb5, Turquoise: Rpb6, Dark blue: Rpb7 Dark 
green: Rpb8, Orange:Rpb9, Purple: Rpb10, Yellow: Rpb11, Light green:Rpb12 
 
Open chromatin structures mean that the pre-initiation complex is able to bind 
and allow transcription to take place. This includes unphosphorylated RNA 
polymerase II [848]. The DNA helix is unwound to produce a single strand of 
DNA which acts as the template (Figure 6.2). It is brought into the active site 
cleft, which can be opened and closed. Transcription can then begin at the 
transcription start site [854, 855]. An elongation complex forms after a number 
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of false starts, and a DNA-RNA hybrid is produced which is about eight to nine 
base pairs long. This elongation complex is responsible for the addition of the 
next nucleotide to the RNA strand as the DNA template is ratcheted through the 
machinery [856]. A complimentary RNA transcript is produced, attached to the 
DNA strand. The RNA strand is then stripped away and leaves the complex 
through an exit groove.  
 
A pore that runs from the protein surface to the active site, allows entry of the 
nucleotide triphosphates (NTPs). The initial binding of NTPs requires association 
of a magnesium ion with three conserved aspartate residues in the RNA 
polymerase subunits. The NTP is rotated into position at the catalytic A site, to 
be paired with the strand of DNA. This requires a second magnesium ion, 
associating with three aspartate residues [853]. 
 
6.1.1.2 Structure of the RPB1 subunit and the Heptad Repeats 
 
RPB1 is the largest subunit of RNA polymerase II (Figure 6.2). It acts as a main 
site for binding of a number of factors required during transcription and mRNA 
processing. The ratchet mechanism that moves the DNA-RNA through RNA 
polymerase II is provided by a bridge which originates from RPB1 and crosses 
the cleft near the catalytic site, and bends and straightens with each addition of 
a nucleotide [853].  
 
Elongation of the RNA molecule is dependent on phosphorylation of the C-
terminal domain (CTD) of RPB1 (Figure 6.1), which consists of the heptad 
repeats. This series of repeats is thought to provide a platform for binding of 
transcription factors [857]. Importantly, phosphorylation of serine (Ser) 2, 5 and 
7 is an essential part of the transcription process [848, 858-861]. CDK proteins, 
including CDK13, are required to phosphorylate these residues in the heptad 
repeats.  
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Transcription starts when Ser 7 is phosphorylated. This phosphorylation also 
means that the CTD can be modified further and levels of phosphorylated Ser 7 
are high throughout transcription [862]. The transcription process is paused 
when the polymerase has reached 50bp downstream from the transcription start 
site, but continues when Ser 5 (and possibly Ser 7) are phosphorylated. This 
allows elongation of the transcripts [858]. Levels of phosphorylated Ser 5 and 2 
increase in opposite directions, with phosphorylation of Ser 2 increasing as RNA 
polymerase II progresses towards the transcription termination site as a result 
of the action of RNA processing factors working at the 3’ end [848, 863]. 
Phosphorylation status is reset at the end of the process by phosphatases, which 
remove phosphorylation at these sites. CDK13 plays an important role in 
phosphorylation of these serine residues, allowing transcription to continue. 
 
6.1.1.3 Structure of CDK13 and binding with Cyclin K 
 
CDK13 is a long protein (1512 a.a.) and although it is larger than other CDKs, it 
demonstrates the usual kinase fold confirmation. It is made up of a kinase 
domain, with an N-terminal arm on one side, and a C-terminal arm on the other. 
It is activated when it binds with Cyclin K (CCNK) [848, 864, 865].  Figure 6.3 
shows a number of important domains within the protein. Understanding the 
structure and important sites helps us interpret the effects of mutations found 
within these domains. 
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Figure 6.3 A Schematic of CDK13 structure. 
A. Some important domains and residues in CDK13:  
 Blue box SR: Serine Rich domain a.a. 200-435.  
 Red box: protein kinase domain a.a. 705-998.  
 Purple dashed box: Activation loop a.a. 854-878.  
 Blue line NBD: Nucleotide Binding Domain 711-719. Valine at position 719 
is conserved in human CDKs.  
 Green line ATP: ATP binding site Lysine at residue 734 (conserved in 
human CDKs).  
 Turquoise line R751: Part of the PITAIRE motif, this arginine forms 
electrostatic connections with 105KVEE of Cyclin K.  
 Orange line PAS: Proton acceptor site, Aspartate at residue 837 
(conserved in human CDKs).  
 Pink Line: Phospho-threonine co-ordination. R836 and R860 are canonical 
arginines that form ionic interactions with the phosphate group.  
 Grey box: DCHEL sequence including HE motif (H1018, E1019). H1018 
and E1019 form water mediated contacts with ADP, D1016 forms 
interactions with residues in the N and C terminal kinase lobes. The HE 
region forms water mediated bonds that allow interaction of the complex 
with the ribose of the bound ATP, as seen in the transcription elongation 
kinases [866, 867]. 
 Yellow box: Polybasic Cluster 1023-1029, forms a helix with the 1016DCHEL 
sequence, which lies adjacent to the active kinase centre. 
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B. Corresponding main domains of the protein. N. N-terminal lobe a.a. 695-
794, C-terminal lobe 795-998, C-terminal extension 999-1302 
 
C. Areas of missense constraint [768]. Areas identified as missense 
constrained were between a.a. 1-275 (exhibited 8 missense mutations, 
compared with the expected 109 by chance), and between a.a. 682-966 
(exhibited 27 missense mutations, compared with the expected 96.5).  
 
 
In addition to the important domains outlined in figure 6.1 and 6.3, other 
important features of CKD13 are outlined below [848].  
 
 The 746PITAIRE helix (or αC helix) is involved in binding with Cyclin K. 
 855DFG motif is at the start of the activation segment. Substrates can 
access the active site of CDK13 when this motif and the activation 
segment of CDK13 assume the relevant conformation.  
 L858. This follows the DGF motif. This suggests that CDK13 is likely to use 
a serine phosphoacceptor motif (SP), rather than a threonine 
phosphoacceptor motif for phosphorylation. Many serine-threonine kinases 
show a bias towards either serine or threonine as their phosphoacceptor 
of choice (SP or TP) [868].  
 C-terminal extension unit (aa 999-1032). This associates with the kinase 
domain and follows the canonical cyclin box. 
 The 1016DCHEL sequence. This is found within the C terminal extension. 
There is a histidine (H) at position 1018 and a glutamate (E) at 1019. 
These two amino acids bind CDK13 to the ADP/ribose of the bound 
nucleotide using water mediated contacts. Additional support for this bond 
between the HE motif and the kinase domain are provided by a bond 
between D1016 and L1020, which interact with the N and C-terminal 
lobes of the kinase domain. 
 The 1023KKRRRQK sequence /polybasic cluster. This forms a helix with the 
1016DCHEL sequence, which lies adjacent to the active kinase centre.  




For CDK13 to function, it must bind with Cyclin K (CCNK). Cyclin K is 580 amino 
acids long. Figure 6.4 displays some of the important domains in Cyclin K.  
 
 
Figure 6.4 Representation of Cyclin K. 
Missense constrained areas are found between residues 1-282 (observed 17 
mutations, expected 79) [768]. The KVEE at residue 105-108 is marked by a red 
line, it is important for binding with CDK13. 
 
Greifenberg et al. characterised the binding sites between CDK13 and CCNK 
[848]. All the residues that are involved in this interaction are in the N-terminal 
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CDK13 interaction site Cyclin K interaction site 
αC helix  αH3 helix and adjacent loop formed from 
F101 to K112 
αC helix  α5 helix and adjacent M141-Q156 loop  
D969 and K699 α5 helix and N-terminus of Cyclin K 
I770 and T772 in the 𝜷4 helix α5 helix  
 
 
Table 6.1 CDK13 Cyclin K complex. 
The paired interaction sites between CDK13 and Cyclin K [848]. αC helix of 
CDK13 is amino acids 747-758 and includes part of the PITAIRE motif.  
 
Syndromic intellectual disability has been reported in individuals with deletions 
and a mutation in CCNK. This is thought to be due to haploinsufficiency [869]. 
 
6.1.2 Similarities and differences between members of the CDK family 
 
CDK12 and 13 are much larger proteins than CDK 7, 8 and 9, but there are 
many conserved residues shared between them. These include the PITAIRE 
helix, HE motifs and polybasic regions. Table 6.2 displays some of the 
differences and similarities between these proteins.  
 
Flavopiridol inhibits transcription elongation kinases [867], but interestingly it 
inhibits CDK7 to a higher extent than CDK13.  Greifenberg et al. proposed that 
this was due to competition at the HE site between flavopiridol, and this site 
already being occupied as part of the normal binding processes that occur at this 
motif (steric hindrance) [848] . The C terminal extension domain is much larger 
in CDK12 and 13 compared to CDK7. This suggests that there are likely to be 
differences in function, despite structural similar within the CDK family. 
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The most closely related of the CDKs are CDK12 and CDK13, which share 43% 
sequence identity. They are thought to have arisen from a gene duplication. 
They both bind Cyclin K, but form separate complexes [846]. They both have a 
central kinase domain, but differ from CDK 7, 8 and 9 as they contain expanded 
serine-arginine rich motifs in the N-terminal regions [848]. These serine-arginine 
rich motifs are found in the SR protein kinase family, which are usually involved 
in protein interactions, RNA processing and in regulation of splicing [865, 870]. 
This has been confirmed as CDK13 has been shown to interact with SRSF1, a 
splicing factor in this family [871]. SR proteins may attach to pre-mRNA and 
prevent it from attaching to the coding DNA strand [872]. This is thought to 
have a stabilising effect on the genome. CDK13 tends to be found in areas where 
splicing factors are stored, called speckles, in the nucleus [865]. It interacts with 
another splicing factor SRSF1 in HIV [871] and protein p32 which is required in 
splicing regulation [873]. 
 
CDK12 and 13 form fewer salt bridges than the other CDKs. These salt bridges 
are a marker of activation and stabilise loops within the protein [874].  The 
bridges form between the phosphorylated threonine (pT) of the T loop, and 
arginine residues in other loop sections of the kinase (Figure 6.1). In addition to 
stabilising loops, the bridges produce a twist in the DFGxxR motif, re-orientate 
the αc helix that contains the PITAIRE motif, and allow correct positioning of the 
HRD motif, which contains a catalytic aspartate. CDK12 and 13 form two of the 
three bridges, but lack the bridge between the PITAIRE motif and the 
phosphorylated threonine [848]. Instead it forms between the KVEE motif of 
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Similarities between 





CDK12 and CDK13 have 
43% shared sequence 
identity. 
CDK13 exhibits the 
typical folding pattern 
of CDK proteins. 
CDK13 N terminal lobe 
shares 46.9% 
sequence identity with 
CDK9, 
CDK13 C terminal lobe 
shares 41.4% 
sequence identity with 
CDK2. 
Expanded serine-
arginine (SR) repeats in 
the N terminal domain 
sets CDK12 and 13 
apart from CDK7, 8 and 
9. 
Similar position of the 
cyclin subunit and kinase 
domain relative to each 
other. In CDK12 and 13, 
only 2 of the 3 canonical 
arginines are involved in 
maintaining position, the 
third forms a salt bridge 
with the second 
glutamate of 105KVEE in 
Cyclin K. 
Position of the cyclin 
subunit with respect to 
the kinase domain is 
similar to CDK9/cyclin 
T1 and CDK12/Cyclin 
K. The two subunits 
are “twisted” in 
comparison to 
CDK2/cyclin A. This 
might relate to the 
absence of the third 
salt bridge seen in 
other CDKs.  
Position of the cyclin 
subunit with respect to 
the kinase domain is 
rotated further towards 
an open conformation in 
CDK2/cyclin A. All three 
canonical arginines are 
involved in the link 
between the cyclin 
subunit and the kinase 
domain. These three salt 
bridges stabilise the 
loop portions of the 
kinase, which is 
indicative of CDK 
activation [874]. 
The arginine residue of 
the PITAIRE motif is the 
only intermolecular link 
with CCNK [866] 
  In Cdk9/CyclinT1, the 
arginine of the PITAIRE 
motif forms 
intermolecular links with 
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both part of the T-loop 
and the KVEE motif 
[875]. 
In Cdk2/Cyclin A, all 3 
canonical arginines form 
intermolecular links with 
sites in Cyclin A [876].   
 
Table 6.2 Structure of the CDK family proteins. 
Differences and similarities between the CDKs [848].  
 
6.1.3 Function of CDK13-Cyclin K Complex in transcription  
 
CDK13 plays an important part in transcription and splicing processes.  CDK13 
binds with CCNK and is then able to phosphorylate Ser 2 and Ser 5 in the heptad 
repeats of RPB1, allowing transcription to continue [848, 864, 865]. Greifenberg 
et al. demonstrated this by examining the activity of the CDK13-CCNK complex 
on a synthetic RNA polymerase II CTD, which included three heptad repeats 
[848]. The complex displayed the highest activity with pre-phosphorylated Ser7, 
and much lower activity on pre-phosphorylated Thr4, Ser2 and Tyr1. There was 
no activity with phosphorylated Serine 5 or with a Lysine substitution at position 
7. The same synthetic peptide produced minimal activity if there was no pre-
phosphorylation within the heptad repeats. These results suggest that CDK13-
CCNK phosphorylates Ser 2 and 5, and does so most efficiently when Ser 7 is 
pre-phosphorylated. Phosphorylation mark was preferentially attached to the N-
terminal end of the CTD, to a pre-phosphorylated Ser7 site by CDK13-CCNK 
(14).  
 
Kinase assays revealed that both native and recombinant CDK13-CCNK and 
CDK12-CCNK complexes set Ser2 and Ser5 as the site of phosphorylation, 
showing an overlap of function [848]. No Ser7 phosphorylation marks were set. 
In contrast, Cdk9 strongly phosphorylated Ser5, minimally phosphorylated Ser7 
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and did not phosphorylate Ser2 sites indicating the different CDKs also act on 
different residues. This overlap in function of CDK12 and CDK13 is important 
when considering how variants in one of these two genes might cause 
abnormalities.  
 
6.1.4 Differences in Gene Regulation by CDK12 and CDK13 
 
Given the structural similarities between CDK12 and CDK13 and that they share 
the same cyclin partner, it is important to consider whether there is any further 
evidence of redundancy. Research has shown that CDK12 and CDK13-CCNK 
complexes regulate expression of around 1000 genes, but mainly have an effect 
on distinct gene sets [848]. Comparison between RNA expression profiles in 
Cdk12 and Cdk13 null HCT116 cells showed that CDK12 regulates genes 
involved in DNA repair and CDK13 is involved with processes including growth 
signalling, extracellular pathways, including protein kinase signalling and cell 
growth regulation [848]. These results are supported by Liang et al., who 
showed CDK13 knockdown (also in HCT116 cells) affected expression of snoRNA 
genes, and CDK12 knockdown affected genes linked with DNA damage [877]. 
Given CDK12 regulates genes such as BRCA1, FANC1 and FANC2, it is not 
surprising that much of the research around this gene focuses on its role in 
cancer.  
 
There is some cross over between genes regulated by CDK12 and CDK13 and 62 
genes were downregulated by both. They both appear to play a part in neuronal 
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Changes in gene regulation Genes 
Downregulated genes by depletion of 
both Cdk12 and Cdk13 
62 genes. Enriched for basic 
biological processes 
Downregulated genes with depletion 
of Cdk12 only  
Enriched for DNA replication and 
repair processes 
Downregulated genes with depletion 
of Cdk13 only  
Enriched for extracellular and 
growth signalling pathways 
Upregulated genes by depletion of 
both Cdk12 and Cdk13 
49 genes.  Enriched for different 
biological processes 
Upregulated genes with depletion of 
Cdk12 only  
Enriched for neuron development 
and other biological processes 
(different to Cdk13) 
Upregulated genes with depletion of 
Cdk13 only  
Enriched for neuron development 
and other biological processes 
(different to Cdk12) 
 
Table 6.3 Effect of Cdk12 and Cdk13 on RNA expression. 
Summary of changes in RNA expression in HCT116 cells when Cdk12 and Cdk13 
were downregulated [848]. It appears that Cdk12 is required for DNA damage 
response genes including the PARP1/BRACA pathway [846, 848, 877, 879-883] 
and both are important in neuron development. 
 
The regulation of different genes by Cdk12 and Cdk13 is consistent with 
knockout studies in mice. The Cdk12 null mouse succumbs to early embryonic 
lethality just after implantation [884], whereas demise of Cdk13 null mice is 
much later [885]. This is perhaps not surprising given that there is reduced 
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6.1.5 CDK13 Expression 
 
CDK13 expression is fairly ubiquitous in the human and includes adipose tissue, 
brain, thymus and uterus. There is low expression in the adult human heart 
including the LV, LA, MV, PV and TV [886]. Moderate expression was seen in the 
coronary arteries of human post-mortem samples [887]. Specifically in the 
human embryo, low expression was seen in the liver, with moderate expression 
in the fore/hindbrain, testes, ovary, kidney and heart between 4 and 20 weeks 
post conception (Carnegie stage 10 – fetal stage, Theiler stage 10 – fetal period 
in mouse) [888]. Low to medium expression is seen in the embryonic mouse 
heart E11-18 (Theiler stage 18 to 26, equivalent is Carnegie stage 13 - fetal 
period) [886]. Expression in the developing human heart adds credibility to it 
being a CHD causing gene. 
 
6.1.6 Animal Models 
 
Cdk13 deletion mutant mouse lines are available and there is already some 
information about the cardiac phenotype. A modified Cdk13 mouse line was  
established using an insertion cassette, which can be converted to several 









Figure 6.5 Mouse allele models. 
Generation of different mouse models used in Cdk13 animal studies. Reproduced 







CRE: cre recombinase, FLP: Flippase recombinase, En2SA: engrailed 2 gene 
splice acceptor, hBactP: human beta-actin promoter, IRES: IRES-lacZ sequence 
LacZ: LacZ cassette, Neo: neomycin resistance gene, pA: polyadenylation 
sequence. 
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Novakova et al. examined the CDK13tm1a and tm1d alleles [885]. This is the 
same mouse line I have used, but I have studied the tm1b allele. The tm1a 
allele is the first step in producing the knockout mouse, and the promotor driven 
neo selection cassette is present. The tm1b allele no longer contains the 
selection cassette and the critical exon has been removed. The tm1d allele is the 
deletion allele (post Flp and Cre with no reporter).  
 
Novakova et al. demonstrated that the Cdk13tm1a allele produces a CDK13 
protein that is truncated around exon 2, with no kinase or C-terminal domain. 
Immunoblot detected a minor WT CDK13 protein as well as the truncated protein 
in Cdk13tm1a/tm1a. Despite reduced expression of Cdk13, there was no discernible 
effect on phosphorylation of Ser2 or Ser5 in the CTD of RNA polymerase II. They 
proposed that this represents a hypomorphic allele and suggested that the 
protein may have some residual function. Cdk13tm1d mice were then produced, 
in which exons 3 and 4 were deleted. CDK13 protein levels in Cdk13tm1d/+ 
embryonic brain tissue was greatly reduced, and absent in Cdk13tm1d/tm1d mice. 
There was also no clear downregulation of Ser2 phosphorylation in brain tissue 
in this mouse line.  
 
We might expect to see reduced phosphorylation of Ser 2 and 5 with loss of 
functioning CDK13. However previous experiments had shown that 
downregulation of CDK13 in cell lines also had minimal to no effect on levels of 
Ser 2 phosphorylation [846, 848]. Novakova et al. suggested that CDK13 might 
phosphorylate RNA polymerase II for specific sets of genes, in specific organs at 
specific times in development, so that there was no overall difference in 
phosphorylation levels at Ser2 or Ser5 in the mouse [885]. Serine 5 is known to 
be phosphorylated by other CDKS in addition to CDK13 [846]. 
 
Expression studies confirmed CDK13 expression in the mouse heart. At E14.5, 
CDK13 protein expression was highest in the brain, followed by the lung, kidney 
and heart in the tm1a line. In the adult, CDK13 protein was expressed in the 
retina, testes, ovaries and uterus, the gall bladder, bladder, renal pelvis and 
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thyroid. In the adult heart, expression was greater in the ventricle than the atria 
in tm1a mice [885]. 
 
Embryonic lethality in Cdk13tm1a/tm1a embryos was observed by E16.5, with live 
embryos found at E15.5 [885]. Novakova et al. reported an increasing number 
of absorbed embryos from E13.5-16.5, although the results seem to suggest 
that the numbers are relatively stable and then decrease (13% at E12.5, 14% at 
E13.5, 5% at E14.5 and 7% at E15.5). In contrast, the Cdk13tm1d/tm1d null mice 
appeared to show earlier mortality, with a higher proportion of empty decidua 
seen at E12.5 [885]. 
 
Cdk13tm1a/tm1a mice were on average a day behind with their development than 
the rest of the litter [885]. All Cdk13tm1d/tm1d mice exhibited growth retardation, 
which was more severe than the tm1a line. There is always some variability of 
developmental stage within a litter [889], however the growth retarded 
Cdk13tm1a/tm1a mice also had nuchal oedema. Nuchal oedema can be seen in 
association with a number of abnormalities, including reduced cardiac function, 
suggesting that there may be an organic cause for the delayed development 
[885].  
 
Multiple developmental defects were seen in both the Cdk13tm1a/tm1a and 
Cdk13tm1d/tm1d, including heart, renal and cleft abnormalities. Cdk13tm1a/tm1a mice 
had smaller less well developed lungs and livers, and brain development lagged 
behind the WT embryos. Cleft palate was also seen at E15.5 and renal tissue 
exhibited a reduced number of tubules and glomeruli. Orofacial clefting rates 
were higher in the Cdk13tm1d/tm1d mice, and they exhibited midface hypoplasia. 
Cdk13tm1d/tm1d embryos also had smaller livers and displayed “abrogated liver 
parts arrangement”. Hypervascularisation and pericardial oedema were also 
noted in the null mice. Interestingly the same abnormalities were seen in a few 
Cdk13tm1a/+ mice too.  
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Micro CT was used to examine the mice for cardiovascular abnormalities. 
Ventricular wall thickness was thinner in Cdk13tm1a/tm1a mice compared to WT, 
and the heart wall was less compact with reduction of myocardium. Histological 
examination revealed fewer layers of cardiomyocytes and reduced myosin 
expression in the ventricular myocardium in E14.5 Cdk13tm1a/tm1a mice compared 
to WT.  
 
Haemodynamic studies were performed at E14.5 and E15.5 in WT, heterozygous 
and Cdk13tm1a/tm1a embryos. Doppler imaging of embryos revealed normal flow 
velocity in the dorsal aorta at E14.5. At E15.5 normal flow was seen in only 30% 
of the null embryos. In the other 70%, cardiac function was reported to be 
declined, although the authors comment that “standard measurements were not 
possible due to irregular or spare heart beating (11/16)” and that those with 
preserved blood flow were the result of variability in embryo size. Presumably by 
this, the authors are suggesting that these embryos were larger and therefore 
had higher velocities, but did not necessarily have normal cardiac function.  
 
The Cdk13tm1d/tm1d embryos also exhibited smaller hearts and had what the 
authors described as “severe ventricular deficiency”. It is not clear from the 
images exactly what the defect is. In the Cdk13tm1d/tm1d embryos, pericardial 
oedema was seen in 82% of E13.5 embryos, and 44% of E14.5 embryos. Only 
19% of Cdk13tm1a/tm1a embryos had pericardial oedema at E14.5. 2% of 
heterozygous embryos, but no WT embryos displayed pericardial oedema. They 
did not report any gross structural cardiac defects as part of their study. 
 
These mouse models provide evidence that Cdk13 is required for normal 
embryonic development, including the heart. Defects were more severe in the 
Cdk13tm1d mouse than the hypomorphic Cdk13tm1a mouse, and interestingly 
some abnormalities were seen in a proportion of heterozygous mice. Novakova 
et al. suggested that the primary abnormality may have been failure of normal 
perfusion as a result of heart defects, which then led to the abnormalities seen 
in the other organs, especially those with higher levels of Cdk13 expression 
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[885]. The authors have based their conclusion that the null mice died of heart 
failure based on the thinner myocardium, oedema and reduced velocities. It is 
not clear if the abnormal heart rhythms they describe referred to as “irregular or 
spare heart beating” are the last stages of a failing heart or a primary 
conduction problem. The absence of reports on structural defects in the hearts 




The aims of this chapter are: 
 
 To describe the phenotype and genotype of individuals with mutations in 
CDK13 reported by Sifrim et al. [12], and those reported in the literature 
subsequently. 
 
 To assess Cdk13tm1b(EUCOMM)Hmgu  mice to determine the effects of loss of 
Cdk13 on embryonic survival and formation of the heart. 
 
 To consider the mechanism by which mutations in CDK13 cause 
abnormalities in humans. 
 
 
6.3 Results and Discussion 
 
6.3.1 Individuals reported with mutations in CDK13  
 
Six individuals with S-CHD were found to have de novo missense mutations in 
CDK13 using WES [12]. The mutations clustered together in the serine/threonine 
protein kinase domain. Three individuals had an identical mutation; 
p.Asn842Ser. A seventh individual has this same mutation, but corresponding 
parental samples were not available to determine if this was de novo or 
inherited.  
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These 7 patients have recognisable facial gestalt. This includes a broad forehead, 
arched eyebrows, ptosis, a broad nasal root and bridge (Figure 6.6). All have 
septal defects (VSD n=2, ASD n=5) and two have abnormalities of the 
pulmonary valve. Additional shared clinical features include significant 
developmental delay in all, and intellectual disability. Mild-moderate 
microcephaly and structural brain abnormalities (n=4) including agenesis of the 
corpus callosum (n=2) were seen. Clinodactyly was a common feature (n=6/7). 




Figure 6.6 Clinical features seen with missense mutations in CDK13. 
Reproduced from with permission from Nature Publishing Group [12]. 
Photographs of affected children and phenotype summary of probands carrying 
missense mutations in CDK13. Colours indicate the number of times a certain 
phenotype was observed in individuals carrying a de novo mutation in CDK13. 
We were not able to obtain consent to publish photographs for two probands 
(258830 and 270818).  
 
Based on homology modelling using the CDK12 structure which was available at 
the time, the mutations were predicted to impair ATP and magnesium binding 
which is required for normal enzyme activity, or interaction between CDK13 and 
CCNK. Given the clustering of missense mutations, gain of function is a 
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possibility, but would require functional assessment to confirm this. The crystal 
structure produced by Greifenberg et al., shows that asparagine at 842 is part of 
the β7 helix and just adjacent to the HRD motif, which contains the catalytic 
aspartate [848]. This is the most commonly mutated site. 
 
 
6.3.2 The Phenotypic Spectrum of CHDFIDD/CDK13-related disorder 
 
Since the initial publication of the first seven individuals with CHD and mutations 
in CDK13, a total of 44 individuals have been reported [12, 489, 833-836, 890]. 
The syndrome is referred to as CHDFIDD (CHD, dysmorphic facial features, and 
intellectual developmental disorder), and CDK13-related disorder. All were de 
novo mutations, with the exception of one mosaic (ID: DDD259007) and five 
individuals where inheritance was uncertain. 82% of individuals have missense 
mutations within the protein kinase domain.  
 
The main features are characteristic facies, developmental delay, structural brain 
abnormalities and CHD. Figure 6.7 gives more detail about the clinical 
phenotypes and the frequencies of abnormalities. Structural abnormalities are 
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Figure 6.7 Phenotypes reported in individuals with mutations in CDK13. 
More common features are contained in the red sections, and less common in 
the yellow. All individuals have developmental delay (motor and speech) and all 
have characteristic facial features. 96% have intellectual disability and 48% 
have a structural brain abnormality. Feeding difficulties are seen in 70% [891]. 
Typically there is mild to moderate intellectual disability and characteristic facies. 
Septal defects predominate in the heart. 
ADHD: Attention Deficit Hyperactivity Disorder, IUGR: Intrauterine growth 
retardation, SNHL: Sensorineural hearing loss. 
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The DDD project information about individuals with CDK13 mutations in their 
cohort reveals that average gestation at delivery was 37.7 weeks and the birth 
weights tended to be lower than average (z score -0.48)[522]. The individuals 
remained small with height, weight and head circumference z scores -2.01, -
1.05 and -1.67 respectively [496]. 
 
Cdk13 is expressed in the lungs, kidney, brain and heart of the E14.5 mouse. 
This and the known role of CDK13 in regulating genes in neurone development is 
supportive of CDK13 mutations resulting in NDD, CHD, renal and structural brain 
malformations.  
 
Now that a clinical phenotype and facial gestalt have been defined, we might be 
able to identify further individuals for testing. Genotype rather than phenotype 
driven testing might also identify further individuals who do not fit the current 
phenotypic model and help expand the phenotype further. 
 
6.3.3 CHD in CHDFIDD/CDK13-related Disorder 
 
38.6% of the reported individuals have CHD [12, 489, 833-836]. Septal defects 
predominate, along with abnormalities of the PV and PA. The specific CHD 
phenotypes are recorded in table 6.4. The small number of individuals described 
means that it is difficult to be sure of the full cardiac phenotype at this time. 10 
of the 16 individuals with CHD have an ASD. Abnormalities of the PV and PA are 
seen in four individuals, and two have VSDs. There is a single individual each 
with EA, TOF and BAV with LVNC. TOF is driven by abnormal septation, and 
includes abnormalities of the pulmonary valve and a VSD, and so shares some 
common features with the more commonly reported septal and pulmonary 
abnormalities.  
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Individual ID Sex Mutation Inheritance and 
consequence 





F p.N842S de novo missense 
variant 







de novo missense 
variant 
PK + ASD and PV 
abnormality 







de novo missense 
variant 
PK + VSD and PV 
abnormality 







de novo missense 
variant 







de novo missense 
variant 







Also has de novo 




de novo missense 
variant 




F p.N842S  
c.2525A>G 
de novo missense 
variant 





F p.V719G  
c.2156T>G 
de novo missense 
variant 
PK - DDD 
DDD4K.003812, 
2646133 
F p.R860Q  
c.2579G>A 
de novo missense 
variant 
PK - DDD 




F p.G717R  
c.2149G>A 
(Gly717Arg) 
de novo missense 
variant. Possibly 
mosaic 
PK - DDD 
DDD4K.004082, 
2649613 
F p.K734R  
c.2210A>G 
Lys734Arg 
de novo missense 
variant 
PK - DDD 
DDD4K.020002, 
2717103 
F c.2898-1G>A  
c. 40118318G/A 
de novo splice 
acceptor variant  
Splice site - DDD 
DDD4K.025392, 
2708573 




de novo missense 
variant 
PK - DDD 
113 F p.N842S 
Asn842Ser 
de novo missense 
variant 
PK Secundum ASD Hamilton et al 
3317203 F p. N842D  
c.2524A>G 
Asn842Asp 
de novo missense 
variant 
PK ASD Hamilton et al 
3015093 F p.D896N,  
c.2686G>A 
Asp896Asn 
de novo missense 
variant 
PK - Hamilton et al 
1001 F p.N842D  
c.2524A > G 
de novo missense 
variant 
PK + ASD and 
hypoplastic LPA 





de novo missense 
variant 
PK + ASD Bostwick et al 
1003 M p.N842S  
c.2525A > G 
de novo missense 
variant 
PK - Bostwick et al 
1004 M p.N842S  
c.2525A > G 
de novo missense 
variant 
PK + Hypoplastic LPA, 
dilated PA 
Bostwick et al 
1005 F p.N842S  
c.2525A > G 
de novo missense 
variant 
PK - Bostwick et al 
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1006 F p.N842S  
c.2525A > G 
de novo missense 
variant 
PK + TOF (VSD) Bostwick et al 
1007 M p.N842S  
c.2525A > G 
de novo missense 
variant 
PK - Bostwick et al 
1008 M p.K734E  
c.2200A > G 
de novo missense 
variant 
PK + EA Bostwick et al 
1009 M p.N842S Missense variant, 
inheritance unknown 
PK + BAV, AS, LVNC Bostwick et al 
1 M p.G717R  
c.2525A > G 
 
de novo missense 
variant 
PK - Uehara et al 
2 F p.N842S 
asn842ser 
de novo missense 
variant 
PK - Uehara et al 
3 M p.G717R 
Gly717arg 
de novo missense 
variant 
PK - Uehara et al 
1 M p. N842S asn842ser de novo missense 
variant 
PK - Van den Akker et 
al 
2 F p. N842S asn842ser de novo missense 
variant 
PK - Van den Akker et 
al 
3 F p. N842S asn842ser de novo missense 
variant 
PK - Van den Akker et 
al 
4 F p. N842S asn842ser de novo missense 
variant 
PK - Van den Akker et 
al 
5 M p. N842S asn842ser de novo missense 
variant 
PK - Van den Akker et 
al 
6 F p.G714D, 
Gly714asp 
de novo missense 
variant 
PK + ASD Van den Akker et 
al 
7 F p.R737C 
Arg737cys 
de novo missense 
variant 
PK - Van den Akker et 
al 
8 M p.R880C 
Arg880cys 
de novo missense 
variant 
PK - Van den Akker et 
al 
9 (monozygotic 
twin of 10) 
F c.2601 -2 A>G de novo splice site 
variant 
Splice site + Open ductus of 
Bottali 
Van den Akker et 
al 




twin of 9) 
F c.2601 -2 A>G de novo splice site 
variant 
Splice site - Van den Akker et 
al 
11 F A162fs de novo frameshift 
variant 
 




- Van den Akker et 
al 
12 M A162fs  de novo frameshift 
variant 
 




- Van den Akker et 
al 
13 M A162fs  Frameshift variant 
inheritance unknown 




- Van den Akker et 
al 
14 M p.Arg999* de novo nonsense 
variant 
 
After PK domain 
(a.a.705-998) 
- Van den Akker et 
al 
15 F p.Arg1025* 
 
de novo nonsense 
variant 
 
Polybasic Cluster - Van den Akker et 
al 
8 F p.D855H 
c.2563G>C 
De novo missense 
variant  
 
PK - Carneiro et al 
 
Table 6.4 All reported mutations and CHD phenotype reported up to November 2019. 
The majority are missense variants which fall within the protein kinase domain (PK). Loss of function mutations are 
highlighted. 
Sifrim et al. [5], Bostwick et al. [1], DDD [6], Van den Akker et al. [4] , Uehara et al. [3], Hamilton et al. [2], Carneiro et al. 
[890]  
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Bostwick et al. described an individual with cardiomyopathy and electrical 
disturbance and suggested that this may be an age related consequence of the 
BAV as the individual was 38 years old (individual 1009)  [833]. Given BAV is a 
more common type of CHD in the general population with a reported prevalence 
of 0.5-2% [892, 893], we should consider the possibility that this is an incidental 
finding. No other individuals with variants in CDK13 have been reported with 
BAV. However, a single individual with a 407 Kb duplication, with one breakpoint 
in CDK13, has BAV. They also have another 180kb duplication on chromosome 
18 of uncertain significance. Inheritance of these CNVs is unknown so the 
contribution of both of these CNVs to the individual’s phenotype is unclear. 
Irregular heart rhythms and reduced ventricular myocardium were noted in 
Cdk13-/- mice, although it is not clear if this represents a primary conduction 
problem or could be linked with LVNC [885]. 
 
More detailed expression studies will be required to explore where exactly and 
when in heart development CDK13 is expressed. This may help explain why 
certain defects are more common than others.  
 
6.3.4 Mutational Mechanism causing Clinical Abnormalities 
 
Given CDK13 has relatively ubiquitous expression in development, it is feasible 
that its absence or reduction causes the widespread phenotypes reported. The 
mechanism is currently under discussion and there has been limited functional 
work so far [836]. The mutational spectrum seen in individuals with 
CHDFIDD/CDK13-related Disorder includes both missense and loss of function 
(LoF) mutations. The missense mutations are mainly clustered within the kinase 
domain. Other pathogenic mutations are reported in other domains of the 
protein. Figure 6.8 shows the mutations reported, with and without CHD, and 
table 6.5 lists some of the mutations and the important residues they affect. 
Characteristics of the protein structure and genotype phenotype correlations can 
provide clues as to the mechanism of disease. 




Figure 6.8 Representation of the CDK13 protein and reported mutations. 
The number of individuals with and without CHD at each locus are recorded.  
[12, 489, 833-836]. The majority fall within the kinase domain. Loss of function 
mutations are shown above the protein, and missense mutations are shown 
below. Loss of function frame shift mutations are in blue boxes, splice site in 
green and nonsense in red. Some important domains and residues in CDK13: 
SR: Serine Rich domain, Red box: protein kinase domain, Purple dashed box: 
Activation loop, Blue line NBD: Nucleotide Binding Domain, Green line ATP: ATP 
binding site Lysine, Turquoise line: arginine which binds to Cyclin K, orange line 
PAS: Proton acceptor site, Pink Line: Phospho-threonine co-ordination, Grey 
box: DCHEL sequence including HE motif, yellow box: Polybasic Cluster. 
 
A number of these mutations affect important domains and residues within the 
protein, including clusters in the protein kinase domain, nucleotide binding 
domain and magnesium and ATP binding sites. It is likely that mutations in the 
protein kinase domain disturb the phosphorylation activity of CDK13. CDK13 
contributes to phosphorylation of Ser 2 and Ser 5 in the heptad repeats of RNA 
polymerase II. CDK13 also binds splicing factors and proteins, and associates 
with parts of the splisosome complex (ASF/SF2) and is located in areas of the 
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cell where proteins involved in pre-mRNA processing are found [873, 877, 894]. 
Loss of normal CDK13 function is likely to result in inability of RNA polymerase II 
to form and splice RNA effectively. This would result in abnormalities in the cell 
transcriptome and is likely to involve pathways involved in cell signalling and 






These two variants affect the residue involved in ATP binding, 
lysine 734, which is conserved in human CDKs. This may well 
alter function of CDK13, given that ATP hydrolysis is required for 
CDKs to phosphorylate their targets. 
p.R751Q This variant affects the conserved arginine in the PITAIRE motif, 
R751. This arginine is required for binding Cyclin K. It forms a salt 
bridge with the second glutamate in the 105KVEE motif in CCNK. 
This is likely to be significant given this motif is conserved across 
cyclins K, C, H and T which interact with Cdk 7, 8, 9, 12 and 13. 




The commonest site for mutations is at residue 842, in the kinase 
domain. This is close to proton acceptor site (aspartate at 837) 
and a canonical arginine at 836.  A change from asparagine to 
aspartic acid introduces a negative charge in the active site of the 
protein kinase domain [836]. It is also thought to impair 
magnesium binding, which is required for normal function [12]. 
 
p.R860Q Another of the canonical arginines at residue 860 is affected by a 
further missense mutation. These arginines are required to form 
salt bridges with the phosphate group of T871, which falls within 
the activation segment. Salt bridge formation is one of the hall 
marks of CDK activation [848]. 
 
p.A162fs The frameshift mutations p.A162fs fall near the site of one of the 
salt bridges. The canonical arginines form salt bridges with the 
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phosphate group of T160.  This might produce a protein that is 
degraded by nonsense mediated decay or an alternative 






Seven individuals have missense mutations within the nucleotide 
binding domain (residues 711-719). The effects are unknown but 
tyrosine at residue 716 in CDK13 is known to be phosphorylation 
target [895].  
 
 
Table 6.5 mutations reported in CDK13, with information about their 
possible functional consequences. 
 
Initially gain of function was suggested as the mechanism given that there was 
more clustering of variants than expected by chance, and no loss of function 
mutations [12, 833]. Since then, loss of function mutations have been reported, 
so loss of function should also be considered as a disease mechanism [836].  A 
single splice site mutation was reported initially [489] and then further splice 
site, frame shift and nonsense mutations [836]. This suggests that the initial 
proposed gain of function mechanism might not hold true for all individuals.  
 
The missense constraint score for CDK13 is 3.77, indicating that it is intolerant 
of missense mutations [494]. The pLI value is 0.75 and it has a 
haploinsufficiency index of 11.15%, suggesting that it is not highly intolerant of 
haploinsufficiency [772]. GnomAD records 9 loss of function mutations (4 splice 
site, 2 frame shift and 9 stop gained, accessed Dec19). As suggested by Van den 
Akker et al., it would be interesting to find out more about these individuals 
included in gnomAD to see if they might have a mild phenotype. 
 
The CNV z score for CDK13 is -2.08 which suggests CNVs are not a major cause 
of problems when CDK13 is included [896]. However, the Database of Genomic 
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Variants shows a relative lack of deletions involving CDK13, with the exception 
of a few small deletions, most of which appear to be intronic [897]. There are a 
large number of CNVs overlapping CDK13 on the Decipher database (30 CNVs 
overlapping CDK13, accessed September 2019), which may or may not 
contribute to the individual’s phenotype [522]. Given some are inherited from 
normal parents, it is unlikely to explain the affected individual’s phenotype 
without other contributing factors. Two thirds are losses. There are 10 CNVs that 
are between 100kb and 1 Mb, only one is a deletion, of uncertain inheritance. 
Intellectual disability or neurodevelopmental delay are reported in 4 individuals. 
Together this suggests that while deletions including CDK13 are not seen very 
often in a normal population, there is no conclusive evidence that deletions 
including CDK13 are damaging. 
 
The frameshift and nonsense variants reported could result in haploinsufficiency 
or altered function of the CDK13 protein. Van den Akker et al. reported three 
individuals with the frame-shift variant p.Ala162fs [836]. It is not known if 
nonsense-mediated decay of this transcript occurs, or if there is an alternative 
translational start site. This mutation falls close to the threonine at position 160 
which is involved in forming salt bridges with the canonical arginines in CDK13 
[848]. Two nonsense mutations are reported (c.2995C > T, p.Arg999* and 
c.3073C > T, p.Arg1025*), but both truncate the protein after the protein kinase 
domain, so the effect on the protein function is uncertain. Additionally, one 
variant falls within the polybasic cluster which is important for helix formation 
within CDK13 and might be important for attractions to RNA polymerase II 
[848]. This could result in altered function. Haploinsufficiency might result for all 
of these products, if they are removed by nonsense mediated decay.  
 
The two splice site mutations affect introns 7 and 10, which fall in the middle 
and towards the end of the protein kinase domain. Van den Akker et al. carried 
out some functional work to determine the functional consequence of c.2601-
2A>G [836]. They detected three transcripts; one normal transcript from the WT 
allele, one with an out-of-frame coding sequence from a cryptic splice site in 
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exon 8, and a third transcript with absent exons 8 and 9, but exon 10 was 
present with the correct reading frame. There was no evidence of nonsense-
mediated decay. Interestingly, the other splice site mutation occurs before exon 
11, equivalent to amino acid 966. This is not associated with CHD. Given the 
protein kinase domain ends at 998, it may be that loss or abnormal protein at 
the end of the kinase domain is less significant and does not have such a 
detrimental effect, resulting in a normal heart and milder phenotype. 
 
All of this evidence taken together suggests that haploinsufficiency and loss of 
function is a possible mechanism in some individuals. However, as discussed 
already, the clustering of missense mutations in the protein kinase domain could 
suggest a possible gain of function mechanism. Individuals with frame shift and 
nonsense variants exhibit a milder phenotype, perhaps because they result in 
haploinsufficiency [836, 891].  
 
The commonest missense mutation reported affects residue 842, and are 
associated with more structural abnormalities. Hamilton et al. suggested the 
more severe phenotype may be due to sequestration of Cyclin K by the mutant 
protein resulting in a dominant negative effect, as opposed to just loss of kinase 
action [891].  
 
A syndromic neurodevelopmental disability syndrome has been reported with 
abnormalities in CCNK, which CDK13 and CDK12 form complexes with. Fan et al. 
reported three individuals with intellectual disability and de novo deletions 
including CCNK, and one with a rare de novo missense variant in CCNK [869]. 
The mutation p.Lys111Glu falls within the highly conserved cyclin box and is not 
reported in gnomAD or ExAC [570, 896]. This is also sited close to 105KVEE, 
which is required for binding with CDK13. The authors report that they share 
some features with individuals who have mutations in CDK13 including midface 
defects, hypertelorism, broad nasal tip, thin upper lip and clinodactyly. The 
proposed mechanism was haploinsufficiency based on three individuals having 
deletions of CCNK and structural modelling of the missense mutation leading to 
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partial loss of function. This individual harbouring the mutation had a milder 
phenotype. Rescue experiments in Zebrafish also supported haploinsufficiency as 
a mechanism.  
 
Although there are some similarities between these individuals and those with 
CDK13 mutations, there are also phenotypic distinctions between the two. 
Individuals with mutations in CDK13 show structural abnormalities in the brain, 
heart, palate and kidneys. No such structural defects are reported in individuals 
with deletions or mutations in CCNK. Some of the facial features are different 
and those with abnormalities affecting CCNK exhibit macrocephaly and normal or 
higher than average height and weight. CHDFIDD is more commonly associated 
with microcephaly and lower growth parameters. Posteriorly rotated low set ears 
and clinodactyly were reported in both groups, but these are soft signs and 
clinodactyly was only seen in one individual.  
 
The developmental disability seen with CCNK haploinsufficiency is far more 
severe. All had severe or profound disability, whereas the individuals with CDK13 
mutations had mild-moderate disability, and some had low normal IQ [869]. The 
presence of NDD in both cohorts fits with the known regulation of the genes 
important in neurone development by CDK12 and CDK13 and the resulting lack 
of both CDK12-CCNK and CDK13-CCNK complexes. The zebrafish model 
produced to show the effects of haploinsufficiency in Ccnk produced deformed 
heads, reduced eye size, abnormal spinal cord and features suggestive of neural 
cell death consistent with the role of Cdk12 and Cdk13 in the central nervous 
system. They also showed evidence of DNA strand breaks consistent with the 
role of Cdk12-Ccnk in controlling genes involved in DNA repair [869].  
 
Given that the Ccnk Zebrafish model relied on morpholinos, there is a potential 
for off-target effects. A Ccnk null mouse was embryonic lethal, but heterozygous 
mice were apparently normal [846]. Fan et al. commented that features such as 
facial dysmorphism and neurodevelopmental disability might not be detected in 
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these heterozygous mice without specific testing and therefore could potentially 
replicate the human phenotype [869]. 
 
Haploinsufficiency of CCNK would result in reduced amounts of both CDK13-
Cyclin K and CDK12-Cyclin K complexes, but we do not know what the 
consequences would be for other CDK13-partner complexes including Cyclin L. 
Given that both genes are important in the brain, we would expect 
developmental disability of a greater severity than if CDK13 or CDK12 exhibited 
reduced function alone. The lack of structural abnormalities seen in individuals 
with haploinsufficiency of CCNK correlates with the lack of structural 
malformations seen in individuals with loss of function mutations in CDK13. This 
also suggests that in those individuals with structural malformations and 
mutations in CDK13, the mechanism is something other than loss-of-function or 
haploinsufficiency, and potentially could be gain of function as we suggested, or 
dominant negative effects as proposed by Hamilton et al. Loss of CDK12 is likely 
to be embryonic lethal, even in the heterozygous state given that no individuals 
have been reported with mutations in this gene. Supporting this is the known 
role of CDK12 in regulating genes required for DNA repair. It is likely that 
damage goes unchecked and results in cell death early on in gestation.  
 
Whilst the CCNK reports add weight to the pathogenic nature of CDK13 and the 
genotype-phenotype correlations suggested, only a small number of individuals 
have been reported. It is likely that the full phenotypic spectrum of CDK13 and 
CCNK has not yet been described and there may be more variability in 
neurodevelopmental disability and structural defects. Functional work to clarify 
the mechanism of action should be carried out. 
 
De novo missense mutations in the ATP-binding pocket of the kinase domain of 
CDK8 are also associated with S-CHD [843]. Like CDK13, CDK8 regulates 
transcription as it forms part of the mediator complex [842]. The mediator 
complex is made up of CDK8 or CDK19, together with cyclin C, MED12 or 
MED12L, and MED13 or MED13L. The mediator complex joins gene specific 
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activators and regulatory elements, to RNA polymerase II and general 
transcription factors [898]. 
 
Common phenotypes reported in association with mutations in CDK8 include 
hypotonia, mild to moderate intellectual disability, behavioural problems and 
facial dysmorphism. Additional features included agenesis of the corpus 
callosum, ano-rectal malformations, seizures, and hearing or visual 
impairments. There is significant overlap with the syndromic developmental 
disorders that result from mutations in MED12, MED13, and MED13L. Relevant 
to this thesis is the report that 6 of the 12 individuals with mutations in CDK8 
had CHD. This included VSDs, double orifice mitral valve, HLHS, CoA with mitral 
stenosis, TOF, and ASD and BAV in combination with a hypoplastic aortic arch 
[843]. Mutations in MED13L and MED13 are also associated with CHD [899, 
900]. This further supports the role of genes critical for normal transcription 
processes, in cardiogenesis. 
 
6.3.4 Which Individuals develop CHD 
 
It is not clear why some individuals with CDK13 mutations have developed CHD 
and others have not. Overall, just under 40% of individuals with CDK13 
mutations have CHD. This is predominantly an ASD. Only mutations within the 
protein kinase domain between residues 714 and 842 are associated with CHD. 
However even within this smaller section of the protein, only 16/31 (52%) have 
CHD. The only addition to this is the splice site mutation that occurs just before 
exon 8. However, this is a PDA in a preterm infant so we should be cautious in 
applying blame to CDK13, even if it accounts for the rest of the phenotype. 
 
Within specific domains there is reduced penetrance for CHD. There are 7 
variants in the nucleotide binding domain (a.a711-719), but only 3 are 
associated with CHD. There are two mutations at residue 714, p.G714R and 
p.G714D. Despite the different amino acid substitution, both are associated with 
CHD and the same cardiac phenotype, an ASD.  Glycine is hydrophobic and often 
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found in the protein core, whereas both aspartic acid and arginine are charged 
and have side chains that often form salt bridges. The similarity between these 
two substituted amino acids might result in a similar effect on the protein and 
subsequent CHD. This does not hold true for all mutations though, and even 
substitutions with similar amino acids do not result in CHD. There are two 
variants affecting the ATP binding site at residue 734, p.K734R without CHD and 
p.K734E with CHD. Lysine and the substituted amino acids arginine and glutamic 
acid are all charged amino acids.  
 
The penetrance of CHD in identical mutations is not complete either. 25% (1/4) 
of those with p.G717R have CHD, and 50% (9/18) of those with p.N842S have 
CHD. The majority of individuals with p.N842S have an ASD, but one has an 
additional PV abnormality, one has TOF, one has BAV with LVNC, and one has a 
hypoplastic left PA only.  
 
The chance of CHD is highest with mutations falling within the protein kinase 
domain between residues 714 and 842, but we cannot predict from the mutation 
alone who will develop CHD. Within the same domains and even at the same 
residue, and with the same mutation there is no consistent pattern to determine 
who will develop CHD. A single explanation as to why CHD is found in those 
mutations in the protein kinase domain, before the active site, is not clear. 
Perhaps there is a more significant effect on the kinase domain structure and 
function with mutations in the first half, and less damaging effects with 
mutations in the latter half of the kinase domain where perhaps there is some 
residual function. However fewer mutations are reported in the tail half of the 
protein kinase domain, which could mean they are either selected against or just 
less common. 
 
Most individuals are affected with ASD. Some have additional VSD, PV or PA 
abnormalities. The only unusual occurrences are TOF at residue 842, but this 
shares VSD and PV abnormalities and so could have a similar aetiology. Another 
individual with a mutation at this locus has BAV and LVNC. Given BAV is a more 
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common congenital abnormality there is always the possibility that this is a 
coincidental lesion, although an aortic valve abnormality was seen in one of the 
heterozygous mice I examined. There is a single individual with EA. This is a less 
common form of CHD and is usually accompanied by an ASD. It stands out as 
this individual has a mutation at the ATP binding site (p.K734E). The other 
individual with a different mutation at the same residue (p.K734R) does not 
have CHD. More detailed analysis of possible effects on protein structure and 
ATP binding is required along with functional work to determine the effect of 
these mutations. 
 
The splice site mutation c.2601-2 A/G which is reported to cause CHD is unusual 
as most other mutations are clustered in the kinase domain and are missense 
mutations. This individual is reported as having an open ductus of Bottali (PDA) 
[836]. It should be noted that the individuals with these mutations are 
monozygotic twins. Supplementary data confirms that they were affected by 
twin twin transfusion problems and were born at 35 and 36 weeks. It does not 
clarify the nature of the PDA in any more detail. As described previously, the 
effect of this mutation was production of WT and abnormal transcripts so it is 
unclear what the overall effect would have been. Given that only one of the two 
twins had CHD, and the PDA may well have been associated with prematurity, it 
is difficult to say that it is related to CDK13 function. 
 
One possible explanation for the reduced penetrance and variable expressivity 
for CHD is that CDK13 variants increase your chance of developing CHD, but 
that additional factors may push certain individuals over the threshold for 
developing CHD. This could include placental, other genetic, maternal or 
environmental influences. This is in line with the idea that CHD is an oligogenic 
disease with influences from other environmental and epigenetic factors, which 
are discussed more in the introductory chapter. 
 
Aside from the influence of the CDK13-Cyclin K complex on RNA polymerase II, 
there may be other undiscovered functions and regulators of CDK13 that 
Identifying Novel Genes that cause Congenital Heart Disease  356 
 
contribute to CHD occurring. CCNK expression levels are reasonably stable, as 
seen in other cyclins that interact with transcriptional CDKs, so this does not 
seem to be a major controlling factor of CDK13 function [848]. CDK13 is a very 
large protein and there are numerous domains that allow for multiple 
intermolecular interactions that might contribute to controlling its activity.  
 
Another cyclin that interacts with CDK13 is Cyclin L1. Cyclin L1 interacts with 
CDK11A, CDK12 and CDK13 [901, 902] and may play a role in regulation of RNA 
polymerase II. Expression of Cyclin L1 in the human heart is high [544] and it is 
expressed in the human foetal heart at three and five months post conception 
[903]. There is currently no known clinical syndrome associated with this gene, 
although it may play a role in head and neck cancers. There is no mouse model 
as yet. There are likely to be additional proteins that influence CDK13 that are 
currently unknown and may help explain reduced penetrance and variable 
expressivity of all the clinical features of CHDFIDD/CDK13-related disorder. 
 
6.3.5 Clinical Recommendations 
 
Current clinical recommendations have been provided based on the phenotypes 
seen. As more individuals are reported this may well change. 
 
Core suggestions [833, 836, 891]: 
 ECHO at diagnosis 
 Developmental assessment and support for development and educational 
needs 
 Support with feeding if required 
 
Consider these further investigations based on presentation and balance of risks 
[833, 891]: 
 CNS imaging  
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 Renal ultrasound 
 Ophthalmology review 
 Sacral imaging 
 
Specific factors that might contribute to developmental delay including hypotonia 
and hearing loss. Speech and language therapy should be instigated if required. 
Additional support for neonatal feeding problems may be required. Van den 
Akker et al. suggested that close attention should be paid to risk of seizures 
during neurological examination [836]. Clefts should be considered at all 
newborn checks and those with feeding difficulties. Eye and hearing checks will 
also be part of routine checks/questions for new parents.  
 
Given the relatively high incidence of CHD in this cohort I would agree that a 
baseline echo is wise, even if asymptomatic. Small ASDs can easily go 
unrecognised if the individual is asymptomatic. At this stage I think it is 
impossible to decide whether or not to check an individual’s heart based on 
genotype, and it would seem sensible to scan all individuals given the low risk 
nature of an echocardiogram. The significance of LVNC in the older adult is 
unclear. Bostwick et al. also proposed that the arrhythmias seen in this 
individual may be related to the underlying BAV and not a primary process 
[833]. Only continuing follow up of individuals will give us a clearer insight into 
the risks of complications in later life.  Many individuals with CHD including 
septal defects will have continuing follow up including monitoring for rhythm 
disturbances. 
 
Life expectancy is unknown but two individuals have been reported who are 38y 
and 54y [836, 904]. The role of CDK13 (and CDK7, 8, 9 and 12) in tumour 
oncogenesis is currently being explored and the implications of this for 
individuals with CDK13 mutations is currently unclear [865]. Any concerning 
signs or symptoms should be followed up promptly.  
 
Identifying Novel Genes that cause Congenital Heart Disease  358 
 
Although all individuals have de novo mutations, parents may wish to consider 
prenatal testing if they are planning further children in case of gonadal 
mosaicism. The incidence of this is unknown.  
 
Whilst the phenotypic spectrum is unknown, it makes it difficult to define a 
population who should be offered a genetic test for CDK13.  We should employ a 
genotype first approach in the majority, unless CDK13 is strongly suspected. I 
would propose offering testing in individuals with septal defects and NDD 
currently as a minimum. Bostwick et al. suggested testing those with mutation 
negative Kabuki syndrome due to phenotypic overlap between the two 
conditions [833]. 
 
6.3.6 Results from the Cdk13tm1b(EUCOMM)Hmgu Mouse 
 
This tm1b allele mouse was provided by the WTSI and employs a reporter 
tagged deletion allele (post-cre). Exons 3 and 4 are deleted. There is 95% 
sequence homology between the mouse and human CDK13 (Figure 6.9). The 
protein kinase domain sequence is identical.  
Identifying Novel Genes that cause Congenital Heart Disease  359 
 
 
Figure 6.9 Alignment of mouse and human CDK13 proteins. 
Alignment from https://www.ncbi.nlm.nih.gov/homologene. Query is Homo 
Sapiens, Subject is Mus Muscularis. Grey lowercase letters represent areas of 
low complexity sequence where artefacts might occur. 




6.3.6.1 Embryonic lethality in Cdk13tm1b(EUCOMM)Hmgu  mice 
 
Cdk13tm1b(EUCOMM)Hmgu  null mice exhibit embryonic lethality. Lethality was not 
limited to early gestation, and homozygotes were identified at E15.5 (Tables 6.6 
and 6.7). Stages later than this were not examined. There does not appear to be 
any survival disadvantage in Cdk13tm1b/+ mice. 
 






Tm1b/+:      
50% 
+/+:            
25% 
Tm1b/tm1b:  0 (0%)        
Tm1b/+:       9 (100%) 
+/+:             0 (0%) 






Tm1b/+:      
50% 
+/+:            
25% 
Tm1b/tm1b:  0 (0%) 
Tm1b/+:       1 (17%) 
+/+:             2 (33%) 






Tm1b/+:      
50% 
+/+:            
25% 
Tm1b/tm1b:  1 (11%) 
Tm1b/+:       7 (78%) 
+/+:             1 (11%) 






Tm1b/+:      
50% 
Tm1b/tm1b: 1 (14%) 
Tm1b/+:      4 (57%) 
+/+:            2 (29%) 
Unknown:     0 (0%) 
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Tm1b/+:      
50% 
+/+:            
25% 
Tm1b/tm1b: 1 (16.5%) 
Tm1b/+:      4 (67%) 
+/+:            1 (16.5%) 






Tm1b/+:      
50% 
+/+:           
25% 
Tm1b/tm1b: 2 (5%) 
Tm1b/+:     21 (51%) 
+/+:            6 (15%) 
Unknown:   12 (29%) 
 
Table 6.6 Cdk13tm1b(EUCOMM)Hmgu embryo genotypes. 
Genotypes for all embryos collected between E9.5 and E15.5 from timed matings 
between Cdk13tm1b/+ mouse pairs. Homozygous embryos were collected at most 
stages and were still alive at E15.5.  
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(expected 25%)  
60% (n=46) 
(expected 50%) 

























Table 6.7 Cdk13tm1b(EUCOMM)Hmgu embryo genotypes. 
Row 1: Genotypes of all embryos harvested at E9.5-E15.5, produced from 
heterozygous crosses. Row 2: Live-born mice from Cdk13tm1b/+ crosses. Row 3: 
Live-born mice from Cdk13tm1b/+ x Cdk13+/+ cross. 
 
The small numbers of embryos genotyped (n=78) means it is difficult to be 
completely sure that the ratios of Cdk13+/+/ Cdk13tm1b/+/ Cdk13tm1b/tm1b are as 
expected. This is compounded by empty decidua, which often meant that the 
genotype could not be determined (n=15). It is also possible that the majority of 
the empty decidua represent homozygous embryos that were deceased at an 
early gestation. However, the largest number of embryos were harvested at 
E15.5 and the ratios are not too different to expected results (Table 6.6, Chi 
squared test 0.045 assuming embryonic lethality prior to E15.5).  Considering 
adults as well, there is no clear indication of reduced survival in Cdk13tm1b/+ 
(Table 6.7).  
 
Cdk13tm1b/tm1b mice exhibit complete embryonic lethality over a wide range of 
embryonic stages. The finding of two Cdk13tm1b/tm1b mice at E15.5 suggests that 
lethality can occur after this, but I did not examine any later stages. This is in 
keeping with the results of Novakova et al., who found complete embryonic 
lethality by E16.5 for their hypomorphic tm1a allele, and earlier mortality in the 
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null tm1d allele [885]. A single Cdk13tm1b/tm1b embryo appeared to have died just 
prior to E12.5, and another harvested at E13.5 was necrotic with no clear 
distinguishable features, suggesting early demise. In addition, many empty 
decidua were found that failed the genotyping process. Some of these may 
represent null embryos. Together these results suggest that embryonic lethality 
in the tm1b allele can occur from early stages to after E15.5, but that null mice 
always die prior to birth. This indicates that Cdk13 has an important role in 
embryogenesis. 
 
All nine embryos harvested at E9.5 had the same genotype, Cdk13Tm1b/+. This 
was confirmed by re-genotyping. Unfortunately I did not collect a further litter at 
this stage, but it is unlikely that this is a representative result. This should be 
repeated to determine what the appearance of Cdk13tm1b/tm1b embryos is at this 
stage of gestation. 
 
Despite the structural similarities, CDK12 and CDK13 regulate different genes 
[848]. Further evidence supporting non-redundancy is provided by the Cdk12 
and Cdk13 mouse models, which are both embryonic lethal. Both Cdk12 and 
Ccnk (Cyclin-K) null mice demonstrate embryonic lethality much earlier, at the 
blastocyst stage [846, 884]. This supports non-redundancy between Cdk12 and 
Cdk13 during the early stages of embryogenesis. Cdk12 null embryos showed 
increased apoptosis in the blastocysts and reduced expression of certain DNA 
damage response genes [884]. There is no evidence of mutations CDK12 
causing a disorder in humans even in heterozygous states, suggesting 
embryonic lethality in humans too. 
 
Dia et al. examined murine pluripotent embryonic stem cells and found that 
levels of CDK12, CDK13 and CCNK are highly expressed in mouse embryonic 
pluripotent stem cells, but levels decrease once differentiation has occurred 
[905]. This pattern was mirrored by levels of CCNK. Knockdown of CDK12 or 
CDK13 caused differentiation of the stem cells. They showed that Cyclin K 
associated with CDK12 and CDK13 proteins and that knockdown of these two 
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kinases also resulted in differentiation but via different gene pathways. This was 
replicated by inducing differentiation with CCNK knockdown. Dia et al. suggest 
that these two kinases are important in maintaining the self-renewal properties 
of embryonic stem cells [905]. This supports a role for CDK13 in early 
embryogenesis. Loss of Cdk13 in the null mice could result in early 
differentiation and abnormal embryogenesis. The different stages of embryonic 
lethality between Cdk12 and Cdk13 may be a consequence of the different 
pathways each regulate.  
 
It is not clear why there is such variability in the gestation at which 
Cdk13tm1b/tm1b embryos died. I did not specifically assess for a cause of death, 
however Novakova et al. stated heart failure was the cause in their mice [885]. 
Whilst I did not specifically look for features of cardiac failure, given some 
embryos died early on and others were alive at E15.5, it is unlikely that there is 
a single defect or mechanism to explain the cause of death in all embryos. 
However, variable cardiac malformations could result in a variable time point of 
death depending on the effect on the foetal circulation. A Cdk13tm1b/tm1b embryo 
found deceased at E12.5 appeared to have a looped heart, but further 
development had not occurred. The heart must have been able to provide 
adequate oxygenation up to this point, despite its severe abnormality. This is in 
contrast to the two surviving null embryos harvested at E15.5 that exhibited 
CAVCD, which in comparison had progressed much further with their 
development and must have functioned adequately for longer. The additional 
finding of reduced myocardium reported previously, may have compounded the 
reduced function of the abnormal hearts [885]. This could support the idea that 
more severe cardiac defects cause death earlier in gestation.  In addition, there 
may be other organs affected by loss of Cdk13 function, or other modifiers such 
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6.3.6.2 Forelimb Staging of Cdk13tm1b(EUCOMM)Hmgu  E15.5 Embryos 
 
All the embryos collected at E15.5, were at S23+, or more advanced, with the 
exception of 6 heterozygous and 2 homozygous embryos which were at earlier 
stages of development (Table 6.8).  
 











E15.5 Cdk13+/+ 1  - - - - - 2 23+ 
2 - - - - - 2 23+ 
3 - - - - - 1 23+ 
4 - - - - - - NA 
E15.5 Cdk13tm1b
/+ 
1 - - - - - 3 23+ 
2 - - - 1 - 5 23+ 
3 - 5 - - - - S22 
4 - - - - - 3 S23+ 
E15.5 Cdk13tm1b/t
m1b 
1 - - - - - - NA 
2 - - - - - - NA 
3 - - - - - - NA 
4 - - 2 - - - S22+ 
 
Table 6.8 Forelimb staging of all Cdk13tm1b(EUCOMM)Hmgu embryos collected 
at E15.5, split by litter. 
 
Litter 4 was made up of Cdk13tm1b/+ and Cdk13tm1b/tm1b   mice. The null mice were 
delayed in comparison to the Cdk13tm1b/+ mice. Novakova et al. described 
delayed development in homozygous embryos [885], but we know that there is 
often variation in development of embryos within a single litter, which could 
account for these findings. The numbers are too small to generate reliable 
conclusions.  
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In Cdk13tm1b/+ mice, slightly delayed development compared to Cdk13+/+ 
embryos was seen in litter 3 mainly (Table 6.8). As stated previously, variation 
of developmental stage within a litter is well established, and the numbers 
studied here are too small to suggest whether the delay is related to genotype 
or not. Novakova et al. demonstrated abnormalities in heterozygous embryos, 
which could be a result of abnormal Cdk13 product [885]. The ratios of the 
different genotypes born suggest that there is no survival disadvantage in the 
heterozygote mice and that heterozygosity for a normal Cdk13 product in mice 
does not hamper embryogenesis. 
 
6.3.6.3 Crown Rump Length Measurements of Cdk13tm1b(EUCOMM)Hmgu  
E15.5 Embryos 
 
Crown rump length (CRL) was measured for 26 E15.5 embryos and is shown 
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Gestation Genotype Litter CRL (mm) Average CRL (mm) 
with stage 
E15.5 Cdk13+/+ 1  14, 15 14.5 at S23+ 
2 13, 14 13.5 at S23+ 
3 13 13 at S23+ 
4 - - 
E15.5 Cdk13tm1b/+ 1 14, 15, 15 14.6 at S23+ 
2 10, 13,13, 13, 
13, 13 
10 at S23- 
13 at S23+ 
3 13, 13, 13, 14, 
15, 15, 15 
14 at S22 
14 at S23+ 
4 13, 14, 15 14 at S23+ 
E15.5 Cdk13tm1b/tm1b 1 - NA 
2 - NA 
3 - NA 
4 9, 11 10 at S22+ 
 
Table 6.9 Crown rump length (CRL) of all Cdk13tm1b(EUCOMM)Hmgu embryos. 
Results are split by litter and by genotype. 
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Figure 6.10 Average CRL across all Cdk13tm1b(EUCOMM)Hmgu litters harvested 
at E15.5 by developmental stage. 
We would expect CRL to increase with gestational age and stage of 
development. Reduced CRL can represent retarded growth. Data is only 
available for Cdk13tm1b/+ embryos at more than one stage, and does not follow 
this expected pattern (Figure 6.9). The lower CRL at S23- than S22 would not be 
expected, unless there were specific abnormalities in these heterozygotes not 
common to all Cdk13tm1b/+ mice. The numbers are too small to state anything 
conclusive from these results. 
 
6.3.6.4 External Phenotype of Cdk13tm1b(EUCOMM)Hmgu  E15.5 embryos 
 
I performed a gross assessment for general abnormalities at the time of embryo 
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Gestation Genotype Alive/Deceased Phenotype 
E9.5 Cdk13+/+  
(n=0) 
Alive: 0 NA 
Deceased: 0 NA 
Cdk13tm1b/+  




Abnormal n=2 slight 
developmental delay 
Deceased: 0  NA 
Cdk13tm1b/tm1b 
(n=0) 
Alive: 0 NA 
Deceased: 0  NA 
Unknown  
(n=0) 
Alive: 0 NA 
Deceased: 0  NA 
E10.5 
 
Cdk13+/+   
(n=2) 
Alive: 2 Normal phenotypes 
Deceased: 0 NA 
Cdk13tm1b/+  
(n = 1) 
Alive: 1 Normal phenotype 
Deceased: 0 NA 
Cdk13tm1b/tm1b 
(n=0) 
Alive: 0 NA 
Deceased: 0 NA 
Unknown  
(n=3) 
Alive: 0 NA 
Deceased: 3  Empty Decidua. Small uterus and 
sac, necrotic tissue only, 
oligohydramnios, discoloured 
amniotic fluid 
E11.5 Cdk13+/+   
(n=1) 
Alive: 1 Normal 
Deceased: 0 NA 
Cdk13tm1b/+  
(n=7) 
Alive: 7  Normal 
Deceased: 0 NA 
Cdk13tm1b/tm1b 
(n=1) 
Alive: 1 Normal 
Deceased: 0 NA 
Unknown  
(n=0) 
Alive: 0  NA 
Deceased: 0  NA 
E12.5 Cdk13+/+   
(n=2) 
Alive: 2 Normal phenotype 
Deceased: 0 NA 
Cdk13tm1b/+  
(n =4) 
Alive: 3 Normal 
Deceased: 1 Recent death, small and delayed 
development, smooth paddles and 
some retinal pigmentation 
Cdk13tm1b/tm1b 
(n=1) 
Alive: 0 NA 
Deceased: 1 Recent death, small and  delayed 
development, smooth paddles and 
some retinal pigmentation, heart 
looped but without any subsequent 
development 




Alive: 0 NA 
Deceased: 0 NA 
E13.5 Cdk13+/+   
(n=1) 
Alive: 1 Normal 
Deceased: 0 NA 
Cdk13tm1b/+  
(n=4) 
Alive: 4 Normal 
Deceased: 0 NA 
Cdk13tm1b/tm1b 
(n=1) 
Alive: 0 NA 
Deceased: 1 Necrotic contents within sac. 
Unable to stage embryo as no 
easily distinguishable features. 
Unknown  
(n=0) 
Alive: 0 NA 
Deceased: 0 NA 
E15.5 Cdk13+/+   
(n=6) 
Alive: 5 Normal 
Deceased: 1 Empty Decidua. Necrotic tissue 
only, small placenta, uterine cavity 
and oligohydramnios 
Cdk13tm1b/+  
(n =21 ) 
Alive: 20 
 
18 Normal phenotype. 1 
proportionately small but 
otherwise normal, 1 small and 
anteverted ears 
Deceased: 1 Empty Decidua. Necrotic tissue 




Alive: 2 Normal. CRL 0.9cm, 1.1cm 
Deceased: 0 NA 
Unknown  
(n=12) 
Alive: 0 NA 
Deceased: 12 Empty Decidua. Necrotic tissue 
only, small placenta, uterine cavity 
and oligohydramnios 
 
Table 6.10 Gross external assessment of Cdk13tm1b(EUCOMM)Hmgu embryos 
based on gestation and genotype. 
Homozygous embryos were found alive at E15.5.  
 
Interestingly, the Cdk13tm1b/tm1b embryos that were alive at the time of harvest 
at E11.5 and E15.5 looked apparently normal. It is possible that they lack some 
of the more gross defects that result in earlier demise. A Cdk13tm1b/tm1b embryo 
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found deceased at E12.5 showed a looped heart, but minimal development after 
that. This might explain why the embryo had survived the earlier stages in 
utero, but failed when the heart could no longer provide adequate perfusion. 
 
6.3.6.5 Phenotype of Adult Cdk13tm1b(EUCOMM)Hmgu Mice 
 
As part of routine care of the mice, they were checked for any gross 
abnormalities by external examination (Table 6.11). Compared to the Prkd1 
mouse line I also studied, the Cdk13tm1b/+ mice were subjectively smaller. A 
single Cdk13+/+ and single Cdk13tm1b/+ mouse appeared significantly smaller still. 
Microphthalmia and anophthalmia were recorded in three sibling Cdk13tm1b/+ 
mice. Whilst there are reports of strabismus in the human individuals with 
damaging CDK13 mutations, this type of abnormality is associated with the 
C57Bl6 strain of mouse (https://www.jax.org/news-and-
insights/1995/october/microphthalmia-and-ocular-infections-in-inbred-c57-
black-mice) [891]. The fact that it was seen in three siblings also suggests that 
there may be another mechanism contributing here rather than Cdk13.  
 
The staff in the Bio Support Unit noted that the Cdk13tm1b/+ mice were more 
nervous and “stressed” on arrival. The colony took much longer to settle than 
others I worked with. They were provided with extra environmental stimulation. 
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Gestation Genotype Phenotype 
Adult Cdk13+/+         
n = 47 
Normal 46 
Small 1 
Cdk13tm1b/+            




(renal cyst) 1 
Micro/anophthalmia 3 
Cdk13tm1b/tm1b      
n = 0 
NA 
 
Table 6.11 Abnormalities seen in adult Cdk13tm1b(EUCOMM)Hmgu mice. 
Abnormalities revealed during gross external assessment of adult mice as part of 
routine care. 
 
There was higher than expected neonatal losses of pups with Cdk13tm1b/+ 
mothers. The female mice would give birth normally, but the pups died within 
the first 24 hours. This was thought to be due to maternal neglect, as no milk 
could be seen within the pups’ stomachs. Of the 28 pups born to heterozygous 
mothers, 20 died in the early neonatal period (Cdk13+/+=5, Cdk13tm1b/+ = 9, 
unable to genotype =6). Usually the pups had been cannibalised which made 
phenotyping and genotyping difficult or impossible. This was a fairly consistent 
problem which meant that I had to use female Cdk13+/+ mice and cross them 
with male heterozygous stud mice to continue the colony. The maternal neglect 
of newborn pups by heterozygous females could possibly represent some degree 
of neurodisability, but I did not carry out any assessment to confirm this.  
 
Internal and external examination was carried out on all Cdk13tm1b/+ female mice 
that were sacrificed as part of the procedure to harvest embryos. All were 
normal with the exception of one (n=1/10). I dissected the mouse and found a 
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large multiloculated cyst within the abdominal cavity on the left side (Figure 
6.11). It was adherent to peritoneum, and I was unable to identify the left 
kidney in its normal position. I concluded it was most likely to be a renal based 
cyst and I was able to trace the ureter down into the pelvis as there were a 
number of cysts along it. The transverse colon was very full, probably due to an 
element of obstruction secondary to the mass.  
 
Renal abnormalities have been identified in three human individuals (duplicated 
and dilated collecting systems, fused renal ectopia) and null mice have delayed 
kidney development and reduced numbers of glomeruli [833, 885]. Novakova et 
al. identified Cdk13 expression in the renal pelvis in adult mice; this could be 
relevant given that the cystic mass appeared to continue along the ureter, and 
the renal pelvis and ureter contain similar epithelial cells. Given that this was 
only seen in a single mouse, it is unclear if the cystic abnormality directly is 
related to Cdk13 function. It would be informative to examine all adult 
Cdk13tm1b/+ mice once they have been culled for similar abnormalities. 
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Figure 6.11 Large multiloculated cyst found in Cdk13tm1b/+ female mouse 
abdomen. 
This was presumed to be renal in origin. Further small cysts can be seen along 
the course of what might represent the ureter. 
 
In addition a single adult male mouse had to be culled due to an overgrown 
tooth and was examined internally and externally. No other abnormalities were 
found. 
 




26 E15.5 embryos were collected and processed for cardiac phenotyping using 
HREM (Table 6.12). Two hearts were excluded from further analysis due to 
damage. 
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In the normal hearts there were a number of consistent features at E15.5 similar 
to those described by Geyer et al. [224]. The TV is sited slightly inferiorly to the 
MV, and the septal leaflet is adherent to the septum still. The apex of the heart 
is slightly notched, with a groove between the ventricles. The PV is superior and 
to the right of the AV. The pulmonary arteries arise after a short pulmonary 
trunk. There were no hearts with an immediate bifurcation and no common 
pulmonary artery, as described by Geyer et al. [224]. The ductus lumen was 
comparable to the feeding arteries with a normal insertion point. The RV was 
larger than the LV, with a thinner compact myocardium at the insertion point of 
the IVS to the anterior RV free wall. Examples of normal features are shown in 
chapter 4, section 4.5.6 figures 4.12-4.15. 
No abnormalities were detected in the Cdk13+/+ hearts (0/3). The majority of 
Cdk13tm1b/+ mice were normal (16/19) and both Cdk13tm1b/tm1b hearts were 




Cdk13+/+ Cdk13tm1b/+ Cdk13tm1b/tm1b 
Normal 
heart 





DORV and IAVCD (n=1, 8145C) 
Coronary artery abnormality 
(n=1, 8145B)  








3 19 2 
 
Table 6.12 Summary of abnormalities detected in the 
Cdk13tm1b(EUCOMM)Hmgu  E15.5 embryos by genotype. 
DORV: double outlet right ventricle, IAVCD: Intermediate atrioventricular canal 
defect, CAVCD: complete atrioventricular canal defect. AV: Aortic valve 
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Figures 6.12 -6.20 demonstrate the abnormalities seen in Cdk13tm1b/+ mice. This 
included one mouse with IAVCD and DORV (8145C), one with a single origin of 
the coronary arteries (8145B), and one with an abnormal AV (8145A).  
Identifying Novel Genes that cause Congenital Heart Disease  377 
 
 
Figure 6.12 Abnormal position of outflow tract valves. 
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Figure 6.13 Mitral Valve and VSD 
 
Figure 6.14 Tricuspid valve and VSD. 
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Figure 6.15 VSD and aortic override.  
 a 
Figure 6.16 Relationship of aortic valve and VSD. 
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Figure 6.17 Raw HREM images confirming DORV. 
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One Cdk13tm1b/+ heart shows what appears to be an IAVCD with DORV (8145C, 
Figures 6.12- 6.17). A large VSD is seen with two separate atrioventricular 
valves. The TV looks relatively normal, but the MV has the appearance of a cleft 
valve. There is greater than a 50% override and relatively normal positioning of 
the AV and PV.  
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Figure 6.18 Abnormal origins of the coronary arteries. 
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A single Cdk13tm1b/+ heart demonstrated a common coronary artery trunk that 
appears the divide into left and right branches at the point of exiting the aorta 
(8145B, Figure 6.18). It arises from the right coronary cusp. This is the only 
heart identified with coronary abnormalities, all other hearts had a normal 
insertion of separate left and right arteries. 
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Figure 6.19 BAV in a Cdk13tm1b/+ embryo. 
 
a 
Figure 6.20 Raw HREM images showing BAV in a Cdk13tm1b/+ embryo. 
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An apparent abnormality of the cusps of the AV are seen in a Cdk13tm1b/+ mouse 
embryo (8145A, Figure 6.19 - 6.20). On static imaging it appears to have two 
leaflets, but does not look like a true bicuspid valve (type 0). Due to lack of real 
time imaging it is difficult to define the exact AV abnormality. 
 
Only two homozygous Cdk13tm1b/tm1b were found at E15.5 (8144A, 8144B). Both 
were alive at this gestation, and displayed cardiac abnormalities. Both have a 
common atrioventricular canal defect (Figures 6.21 – 6.28). It is difficult to 
identify 5 valve leaflets even on the raw images in one due to failure to remove 
blood adequately, but the defect does appear to be a common AV valve (mouse 
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Figure 6.21 External view of E15.5 heart. 
 
Figure 6.22 Normal pulmonary and aortic valves in Cdk13tm1b/tm1b heart.  
 
Identifying Novel Genes that cause Congenital Heart Disease  387 
 
Figure 6.23 Common atrioventricular valve in a Cdk13tm1b/tm1b heart. 
a 
Figure 6.24 Common atrioventricular valve and VSD in a Cdk13tm1b/tm1b heart. 
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Figure 6.25 Aortic override in a Cdk13tm1b/tm1b heart. 
a 
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Figure 6.26 Raw HREM images of aortic override. 
 
Cdk13 null mouse 8144A has a CAVCD and likely DORV (Figures 6.21-6.26). The 
fusion of the cusps is difficult to demonstrate on these images, however a 
number of segments can be visualised on video. Papillary muscles are visible on 
both sides of the septum. There is 50% override of the aorta. It is difficult to 
establish if there is any pulmonary stenosis given the static imaging and under-
lysis. 
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Figure 6.27 Raw HREM images of common atrioventricular valve. 
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Figure 6.28 Raw images of aortic override with underlysis. 
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Cdk13 null mouse 8144B also appears to demonstrate a CAVCD (Figures 6.27-
6.28). It is a difficult heart to interpret as there is extensive under-lysis and 
some damage. However, only a single AV valve is seen along with a VSD which 
leads me to suggest this is a CAVCD. 
 
Whilst specific CDK13 expression patterns in the human and mouse foetal heart 
are still unknown, there is low expression in the adult human heart including the 
atrioventricular valves [886]. The BGEE database confirms expression of CDK13 
in the human foetus at three and five months post conception, but the heart is 
formed by this point and earlier expression information is not available [903]. 
From embryonic hearts collected by myself, T Ghosh in the Brook lab has shown 
that CDK13 is expressed in the heart at E11.5, E13.5 and E14.5 using western 
blotting. This provides support for the role of CDK13 in cardiogenesis. 
 
Both of the Cdk13tm1b/tm1b embryos isolated exhibited cardiac abnormalities. Both 
had a complete atrioventricular canal defect and one had DORV, which is not an 
uncommon association. The other heart does not appear to demonstrate any 
over-riding of the aorta, however analysis of this heart was difficult due to 
extreme under-lysis resulting in some additional damage.  Both of these 
embryos were stages S22 and S22+, when it is uncommon to find an 
interventricular communication so these findings are likely to represent a true 
abnormality [224]. 
 
Given AVCDs have been seen in a Cdk13tm1b/+ and Cdk13tm1b/tm1b mice, Cdk13 
may play a role in endocardial cushion development in the mouse. This is a 
different type of abnormality to that seen in the human individuals with 
heterozygous CDK13 mutations. AVCD is not seen, and instead septal defects 
predominate. A single individual has been reported with TOF, which can be seen 
in combination with AVCD [906].  
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From the known protein interactions with CDK13 [549], there are no genes 
known to be specifically linked with endocardial cushion formation in the mouse 
(http://www.informatics.jax.org/go/term/GO:0003272) or AVSD in the human 
https://omim.org/phenotypicSeries/PS606215. CDK13 is thought to interact with 
MMP21, which has a role in left right asymmetry and is thought to be a negative 
regulator of NOTCH[549]. This may be important given the association between 
AVSD and heterotaxy, and the important role of NOTCH signalling in left right 
patterning and the heart [907]. 
 
The range of defects seen in the Cdk13tm1b/+ embryos is more diverse. The first 
mouse had a single coronary artery arising from the aorta, which then bifurcates 
into a left and right coronary artery (8145B). It is difficult to follow the course of 
this to decide if it is likely to have had any haemodynamic impact or not. A 
solitary coronary ostium in the aorta is seen in 6% of C57BL/6N mice so it is 
likely that this is not related to loss of Cdk13 [908].  
 
The second Cdk13tm1b/+ embryo had an intermediate AVCD and DORV. The atrial 
septum appeared deficient anteriorly, and there is a VSD. This embryo was 
stage S23+ indicating a low chance of interventricular connection (2%) [224]. 
The mitral and tricuspid valves appeared to have fused anterior and posterior 
bridging cusps and there was reduced trabeculation in the left atrium. The third 
heart exhibited an abnormality of the aortic valve, possibly related to fused 
commissures (8145A).  
 
There are a few similarities between the CHD seen in the two species, in those 
heterozygous for normal CDK13. One individual with the commonest mutation 
p.N842S has BAV as does one of the mice [833]. However, the reported 
individual has LVNC in addition to BAV. An individual with a duplication with a 
breakpoint in CDK13 has BAV, although the significance of this CNV is 
uncertain [522]. Another Cdk13tm1b/+ mouse has an abnormal origin of the 
coronary arteries and moderate CDK13 expression was seen in the coronary 
arteries of human post-mortem samples [887]. 
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All three of the Cdk13tm1b/+ mice with abnormalities described above were from 
the same litter. Given no abnormalities were seen in other heterozygous mice, 
we should consider whether this may be the result of another genetic or 
environmental factor, in addition to the abnormal Cdk13 product. Novakova et 
al. did find abnormalities in 2-8% of Cdk13tm1a/+ embryos (hypervascularisation, 
nuchal oedema and pericardial oedema) but they did not specifically evaluate for 
structural CHD [885]. Further heterozygous mice should be examined.  
 
One factor that could result in different lesions in the mouse and human heart is 
length of gestation. In the human there is a much longer period between 
completion of heart structure and birth. Despite the differences in CHD types 
seen, there are some shared features between humans and mice including 
palate and renal abnormalities. Submucous clefts have been reported, as have 
renal abnormalities [833, 835]. However there is no evidence of lung or liver 
abnormalities in the human population. Further clinical reporting as more 
individuals are diagnosed may provide more information. 
 
6.3.6.7 Comparison with Cdk13tm1a/d mouse 
 
Whilst the cardiac assessments across the Cdk13tm1a/d and tm1b lines are not 
comparable, there is evidence of cardiac abnormalities in all. Novakova et al. 
considered the tmb1a allele to be hypomorphic, and more severe abnormalities 
were seen in the tm1d allele mouse [885]. The tm1a allele produces a truncated 
protein and they suggested that the milder phenotype could occur for two 
reasons. The first is that the neomycin cassette is in a non-coding region that 
does actually have some influence on the expression of Cdk13. The second is 
that an abnormal but functional protein is produced as a result of post-
transcriptional exon shuffling, which is known to occur at very high frequencies 
in CDK13 [909]. Certainly it is known that the tm1a allele may not be a true 
knockout and can be phenotypically hypomorphic or wild type 





The tm1b allele is considered to be a true knockout so I would expect a more 
severe phenotype than the tm1a mouse, and comparable effects in the tm1d 
mouse. However, I did not study the extra-cardiac parts of the embryo in 
sufficient detail to compare the incidence of palatal or hepatic abnormalities. 
Novakova et al. have used different methods to evaluate the heart, looking at 
histology and function whereas my analysis has focussed on structural 
malformations and myocardial measurements could not be taken [885]. It would 
be interesting to perform histological analysis of the mouse line I have studied to 
see if there is also a reduction in myocardiocytes and to assess function of the 
heart in both null and heterozygous mice. 
 
6.4 Limitations and Future Work 
 
CHDFIDD/CDK13-realted disorder is a newly described syndrome, so it is 
unlikely that we have seen the full mutational and phenotypic spectrum. All 
individuals in Sifrim et al. were recruited through either DDD or the undiagnosed 
diseases network, and therefore we should consider the possibility that there 
may be a degree of ascertainment bias in the phenotypes collected [12]. 
Certainly for recruitment to DDD, developmental delay will be reasonably 
significant or the patient will have multiple congenital abnormalities, so we could 
have missed a milder CDK13 phenotype.  
 
The natural history of CHDFIDD/CDK13-realted disorder is unknown. The 
majority of the cohort with CDK13 mutations is still young, and time will reveal 
the natural history of this condition. Important questions remain such as long 
term prognosis, and whether there is any risk of malignancy. Reporting of 
progress and complications in these individuals will provide clinicians with more 
information to pass onto affected individuals. Van den Akker et al. set up a 
website where any individuals can be reported to help delineate the clinical 
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phenotype (www.humandiseasegenes.com) and there is an active Facebook 
group. 
 
Although some individuals, such as those reported by Bostwick et al. did have 
echocardiograms to exclude structural heart disease, many others will only be 
offered this investigation if there are concerning signs or symptoms [833]. Until 
echocardiography at diagnosis becomes routine, the prevalence of CHD and full 
range of abnormalities may not be apparent. Certainly BAV might not present 
until later life, and it is currently unclear if this is part of the spectrum of CHD 
caused by mutations in CDK13 or not. 
 
One of the main limitations of this work is the lack of expression and protein 
studies in the mouse, including assessments of kinase activity. I have collected a 
number of tissues from embryonic and adult mice for protein and expression 
studies in the heart at various time points by other members of the Brook 
Laboratory. Further functional work is also being carried out in the Brook lab, 
including phosphorylation assays.  
 
The number of mice I have analysed here is small. There are further embryo 
hearts I collected that are embedded, but not yet sectioned. Larger numbers of 
embryos are required for meaningful statistical analysis and to be sure of the 
occurrence of CHD in the mice given several affected embryos were from the 
same litter. Ideally a larger WT cohort would be analysed. Fortunately, Geyer et 
al have already analysed the same strain at the same stage so we can use this 
as control data[224].  
 
The majority of humans with mutations in CDK13 and CHD, have an ASD (60%). 
In the embryonic mouse it is difficult to diagnose ostium secundum defects given 
we expect patency of the foramen ovale. Lack of dynamic imaging means flow, 
the flap and orifice size cannot be assessed. A larger PFO might suggest a 
secundum ASD, but I think it is impossible to tell at this stage, especially when 
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we cannot assess for additional sequelae such as pulmonary hypertension. Lack 
of dynamic imaging also means other lesions including VSD and valve 
abnormalities might be missed. 
 
HREM itself requires use of fixatives and dehydration of the samples. There is 
potential for shrinkage and damage to structures during this process, as there 
would be with histological analysis. Manually transferring delicate embryo hearts 
during the embedding process is also difficult and I have tried to minimise the 
possibility of damage as much as possible. All hearts were assessed for damage 
on HREM imaging and those that had damage making the images 
uninterpretable were removed from further analysis. 
 
Examination of the mouse heart at different time points in embryogenesis and 
correlation with development and evidence of heart failure may help us 
understand why null mice died at different stages. Additional whole embryo 
HREM would allow assessment of the whole mouse to identify extra-cardiac 
abnormalities associated with loss of Cdk13. Ideally dynamic studies such as 
echocardiography would be carried out in addition. Given the irregular 
heartbeats seen in the Cdk13tm1d embryos, and an individual with arrhythmias 
possibly secondary to BAV and LVNC, ECGs in the mice may also be informative. 
 
More detailed Cdk13 expression within the heart may add support to the 
development of CHD in mice and individuals with CDK13 mutations. Expression 
within the endocardial cushions would be especially interesting. I noted any 
gross placental defects in the embryos I harvested, but other additional work 
could include formal histology of the placenta. Abnormal function can result in 
growth restriction and embryo death and might be an important factor in demise 
of the embryos.  
 
In addition to the Cdk13 knockout mouse, the WTSI attempted to produce a 
mouse with a humanised mutation, but unfortunately this was not successful. 
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The mutation pAsn842Ser was chosen as this was the most commonly reported 
mutation (9 individuals with CHD, 9 without). It was thought that the CRISPR 
process was too efficient and this humanised mutation mouse could not be 
produced. An application was submitted to the Genome Editing of Mice for 
Medicine Programme (GEMM, MRC Harwell) for this same mutation and 
p.G717R. This is the second most commonly reported mutation (four individuals, 
one with CHD). We have secured one mouse and have been asked to apply for 
another. 
 
As yet, the mechanism or mechanisms by which CDK13 mutations result in 
abnormalities is unknown. Gain of function, haploinsufficiency and loss of 
function, and dominant negative mechanisms have been suggested. This makes 
it difficult to interpret mutations that have been reported in other areas of the 
gene, and there are a number of mutations reported on Decipher and ClinVar 
that are of uncertain significance. Functional work will help with interpretation.  
 
The role of CDK13 in the context of acute myocardial infarction may also be of 
interest in the future, given its expression in the adult heart and evidence that 
miRNAs that target CDK13 are dysregulated in this situation [910].  Its role in 
progenitor cell differentiation also makes it an interesting candidate for 
regenerative medicine. Potentially it could it play a role in the damaged and 




CHDFIDD/CDK13-related disorder is a recognisable syndrome. The phenotype is 
likely to be delineated further as more individuals are reported. The precise 
mechanism(s) as to how heterozygous mutations cause clinical abnormalities in 
humans is still unclear. Functional studies are required. 
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CHD is reported in around 40% of these individuals. ASDs predominate. 
Mutations in the protein kinase domain before the start of the active site, 
affecting the nucleotide binding domain, the ATP acceptor site and the PITAIRE 
locus are associated with CHD. The risk of CHD with LoF mutations and those 
outside the protein kinase domain is uncertain currently. 
 
Cdk13tm1b/tm1b mice are embryonic lethal, with death occurring up to at least 
E15.5. Given that this mouse and the Cdk12 null mouse are embryonic lethal at 
different time points, it is likely that despite both binding with CCNK and their 
structural similarities these genes are non-redundant in embryogenesis. It is 
likely that homozygous mutations affecting CDK12 and CDK13 function in 
humans results in embryonic lethality as seen in mice. 
 
Endocardial cushion type defects are seen in Cdk13tm1b/tm1b mice. Cdk13+/- mice 
may also exhibit CHD. The large number of apparently healthy heterozygotes 
born suggests that there is no survival disadvantage. Further more detailed 
phenotyping in null and heterozygous mice including assessment for 
neurodevelopmental disability may provide further information. 
 
Genetic testing for CDK13 should be offered to individuals with ASD and NDD, or 
any of the other associated congenital malformations that have been reported or 
similar facial features. Clinical recommendations should be updated with 
continuing follow up of affected individuals and information from newly 
diagnosed families. 
 
The initial individuals reported in Sifrim et al. suggest that pathogenic missense 
mutations in CDK13 result in a recognisable clinical syndrome [12]. Since then, 
further reports have been published allowing us to refine the phenotype. Whilst 
CHD is seen in just less than 40% of affected human individuals, our mouse 
model suggests that CHD is a feature of abnormal function of CDK13. The 
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Chapter 7 Confirmation and Feedback of results to participants and 




WES (whole exome sequencing) studies in cohorts of individuals with CHD has 
proved invaluable for identifying new CHD genes [12, 14, 16]. WES and whole 
genome sequencing (WGS) generate vast amounts of data, much of which will 
not be relevant to CHD. Whilst this approach works well for gene discovery, it 
does leave the researcher to consider which other results should be fed back to 
participants. More specifically, should we feedback results in clinically important 
genes that are separate to the study question? These results are often referred 
to as secondary, or incidental findings. 
 
Participants involved in the WES study described in chapter 3 [12] had been 
recruited over the last 20 years. Participants had the option to opt in or out for 
feedback of pathogenic results relating to the cause of their CHD. At the time 
that participants were consented to join the study, use of WES on a large scale 
was not possible. Therefore, a discussion about secondary findings was not 
included in the consent form. This meant that we had to consider whether in 
addition to pathogenic CHD mutations, we should look for secondary findings. 
This is a complex issue for many reasons, primarily because of the benefits and 
disadvantages of feeding back secondary findings varies depending on the 
clinical consequences of mutations in that specific gene. In this chapter I 
consider the latest guidance regarding secondary findings for clinicians and 
researchers, and illustrate the confirmation of pathogenic results that were fed 
back to the NHS clinician for individuals in our WES study [12].  
 
7.1.1 Duties of Clinicians and Researchers 
 
Historically, genetics research and healthcare have been separate entities.  
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Usually research is driven by the aim of increasing our knowledge about a 
subject. Researchers may have little or no contact with the participants and 
traditionally have not had a duty of care to those individuals. Health care and 
clinicians aim to benefit their individual patient, work closely with them and have 
clear duty of care guidance. More recently, healthcare and research have been 
successfully integrated through large projects such as the DDD Study [522]. 
 
Projects like the DDD study [496], and 100 000 Genomes Project [911] 
incorporate research into healthcare by recruiting participants from, and feeding 
results back through the NHS. In the future it is likely that more and more NHS 
patients will have WES and WGS, and have their genetic data included in 
repositories for use in research [912]. Whilst these projects will benefit 
researchers, clinicians and patients, it is important that each group’s 
responsibilities are clear. Individuals in a study may believe that the researcher 
is specifically working to improve the care of that individual, and not be driven 
by other motives. This is termed therapeutic misconception [913]. In addition, it 
is necessary to make the distinction between healthcare and research clear to 
participants as failure to do this can result in study participants recalling 
research as clinical care [914]. 
 
Clinicians in research are still bound by the General Medical Council guidelines 
and have a duty of care to the patients involved in research (Good practice in 
research and consent to research, 2010 http://www.gmc-
uk.org/guidance/research accessed 21.3.13, and Patients and doctors making 
decisions together 2008 http://www.gmc-
uk.org/static/documents/content/Consent_-_English_0911.pdf accessed 
21.3.13), and it has been suggested that they should be expected to spot and 
deal with incidental findings at a level expected of their training [915].  
Researchers also have professional obligations under the Helsinki and 
Nuremburg Declarations, especially in cases where clinical trials form part of 
medical practice [916, 917] and in some countries they have a legal duty of care 
[918]. With respect to genetic studies, it has been suggested that a researcher’s 
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duty of care will be passing genetic information to the appropriate clinical team 
after consultation with a clinician, and that the principle investigator is ultimately 
responsible for feeding back incidental findings [915]. 
 
7.1.2 Secondary Findings generated by WES 
 
Genetic testing is becoming more complex and single genes tests are no longer 
the norm. Virtual panels of genes, whole exome and whole genome sequencing 
are now more common place and can identify pathogenic mutations for disorders 
including intellectual disability in 20-30% of individuals, and up to 57% of trios 
[919, 920] (and https://www.exeterlaboratory.com/test/exome-sequencing-
services). Whilst this is beneficial in terms of increasing diagnostic rates, it 
means that the possibility of identifying a secondary finding is around 1-7% 
[921].  
 
Secondary findings cannot be considered as a single entity (Figure 7.1). 
Pathogenic variants found will represent a wide spectrum of clinical 
consequences. Examples include a mutation in a tumour suppressor gene or 
being identified as a carrier of a Cystic Fibrosis mutation. Reduced penetrance 
and variable expressivity of genes complicates the matter further. Feeding back 
a result to an individual who is completely asymptomatic and may never develop 
the disease, puts the individual at risk of harm from increased anxiety, 
unnecessary and potentially invasive medical tests, screening and risk 
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Figure 7.1 Examples of secondary findings. 
This might include known pathogenic mutations, or variants of uncertain 
significance (VUS). In a well individual, mutations may be found in genes that 
are associated with disease at a later time in life.  
 
There will also be a number of variants of uncertain significance (VUS) detected. 
Determining the pathogenicity of a VUS is difficult as many genetic conditions 
are rare and there may be limited information about the genetic mechanism 
causing disease. This wide spectrum of results makes it very difficult to devise a 
single guideline to deal all of these possible results, and to discuss them with 
research participants and record their wishes.  On a research basis, sequencing 
has identified pathogenic mutations in 6-14% antenatally and in neonates and 
paediatric individuals with CHD. However, a VUS was also identified in 26 - 80% 
[537, 923]. Whilst this test may be advantageous in terms of making a diagnosis 
(particularly in S-CHD), the significant chance of identifying a VUS should be 
considered and form part of the informed consent process.   
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Discussing the implications of a secondary finding is complicated by variable 
penetrance and expressivity. Even more difficult is the situation when there is no 
proven screening or treatment, such as in conditions such as the cancer 
predisposition Li Fraumeni Syndrome, and certain neurodegenerative conditions. 
Some lower penetrance conditions have suggested screening, although many 
people will remain well and screening may therefore ultimately prove to be 
unnecessary (SDH gene cancer predisposition syndromes). Some genetic 
findings have implications for reproduction, including being identified as a 
carrier. Counselling and testing options will depend on carrier prevalence within 
the population.  In all of these situations, we also need to consider whether 
there might have also been transmission within the family and whether others 
are at risk. 
 
Central to the issue of feeding back secondary findings is informed consent. It is 
a legal requirement for not only the collection of tissue, blood and saliva, but 
also the storage and use of genomic data. Gaining fully informed consent to 
receive secondary findings is difficult because of the number of outcomes that 
must be discussed including carrier status, reduced penetrance, insurance and 
those discussed above. In the relatively short time in a genetics clinic, or during 
consent for research, it is challenging to discuss all of this in sufficient depth to 
gain fully informed consent for all possible findings. It has been suggested that 
this would requires six hours of discussions for consent and 5 hours of direct 
discussion of the results [924, 925]. Clearly this is not feasible.  
 
A number of strategies have been suggested to help minimise the difficulties of 
dealing with secondary findings. This includes lists of important genes where 
mutations should be fed back, and simplifying choices by grouping genes into 
classes or “bins” and making a decision about each group [926]. Some of these 
recommendations for dealing with secondary findings are discussed further here. 
Although mainly directed towards clinicians, they are important for researchers 
too. Whilst there is no UK law regarding the duty to provide secondary findings 
or current test case, it seems prudent for all researchers carrying out untargeted 
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testing to consider their duty to their research participants and how they might 
deal with these results.  
 
7.1.3 Current guidance regarding secondary findings  
7.1.3.1 Guidance for Clinicians 
 
The American College of Medical Genetics and Genomics (ACMG) have 
recommended review of sequencing results, for a specific set of genes that have 
been identified as potentially important. They recommend feeding back class 4 
and 5 variants, in 56 genes [927]. They are cancer predisposition, 
cardiomyopathy, arrhythmia and aortopathy genes in the main, which would 
require increased medical care. However some of these genes exhibit reduced 
penetrance and variable expression. Unless the patient has specifically opted out 
of feedback of these results, the ACMG recommends that these results should be 
passed onto the patient [928].  
 
The European Society for Human Genetics (ESHG) takes a different approach to 
that of the ACMG. Their guidance aims to minimise the production of secondary 
findings. Rather than using all WES and WGS data generated, they suggest 
targeted testing of relevant genes initially. Only if no genetic explanation for the 
individual’s symptoms has been found, should untargeted sequencing be used 
[929]. If the individual concerned has opted in for feedback of secondary 
findings then the health care practitioner should report results that cause serious 
health problems as defined by the ESHG [930]. 
 
7.1.3.2. Guidance for Research 
 
The MRC Framework on the Feedback of Health-related findings in research 
provides useful and practical advice around dealing with secondary findings for 
researchers https://wellcome.ac.uk/sites/default/files/wtp056059.pdf . The 
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guidance suggests that incidental findings should be considered on a case by 
case basis. The cost of feedback, subsequent tests and extra clinical interactions 
in the NHS must be in proportion to the benefits gained by the participant. The 
benefits of feeding back a result should outweigh the disadvantages, and a 
pathway to do this should be factored in to any research plans. The consent 
process must be designed to include information about feedback of secondary 
results. This should include whether they will be available or not, the scope of 
the feedback, whether their primary healthcare provider will be involved, and 
whether they can decide which results they would like.  
 
7.1.3.3 Current Examples: The 100 000 Genomes Project 
 
Recent guidance for feedback of significant results has been developed for the 
100 000 Genomes Project [931]. Participants can opt in or out of receiving 
secondary findings, defined as mutations that cause serious and life threatening 
medical conditions for which there is an option of prevention or treatment 
available within the NHS. A short list of high penetrance cancer predisposition 
genes, and familial hypercholesterolaemia genes has been compiled. CFTR is the 
only gene for which carrier status is offered as an option for feedback. A 
pathway is in place to pass findings through to an NHS clinician who will relay 
the results and organise necessary clinical interventions. With respect to 
children, only childhood onset conditions will be looked at, in line with current 
NHS practice. VUS are withheld, but clinical judgement can be used and 
clinicians can feedback a VUS if more investigation is planned to determine its 
significance. The 100 000 Genomes project experience will be a helpful model 









The aims of this chapter are to: 
 
 Identify and confirm pathogenic mutations identified in individuals with 
CHD recruited locally and feed the results back to the families. 
 Determine how to deal with secondary findings. 
 
7.3 Results and Discussion 
7.3.1 Confirmation of Pathogenic Mutations  
 
De novo and inherited variants in monoallelic tier 1 and tier 2 CHD genes were 
identified by A Sifrim (see section 3.3.2 for description of tier 1 and tier 2). 
Several patients had multiple mutations in a single gene. 4 identical mutations in 
RAI1 were identified in 4 separate individuals. This was an insertion, which was 
thought to be a false call due to difficulty in aligning the reads. These RAI1 
insertions were excluded from further analysis.  
Of the tier 1 and tier 2 de novo variants, seven were VUS and were not 
considered for feedback. 5 individuals were identified with de novo mutations 
that had previously been reported as pathogenic in known monoallelic CHD 
genes. Two individuals with PTPN11 mutations had been diagnosed in the NHS 
since recruitment, so the results did not require reporting. This left three 
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GATA6 Causes AD CHD with or without pancreatic 
aplasia. This mutations has been reported as 
pathogenic [932]. All mutations occur in same 






Causes AD Noonan Syndrome. Reported in the 






Reported as pathogenic [329, 933, 934]   
(rs121918459) 
 
Table 7.1 Review of de novo variants for feedback. 
 
All inherited mutations in tier 1 and tier 2 genes were VUS, and were not 
suitable for reporting. Two individuals were identified with 22q11.2 deletions. 
This diagnosis had also been made in the NHS since recruitment and therefore 
did not require reporting.  
 
7.3.1.1 Confirmation of GATA6 mutation 
 
Sequencing identified the de novo missense mutation c.1367G>A, p.R456H in 
GATA6 based on transcript: ENST00000269216 (rs387906819). Both SIFT and 
Polyphen predicted it to be pathogenic [493].  
 
Mutations in GATA6 are associated with pancreatic agenesis and congenital heart 
defects, as well as isolated ASD, AVSD, persistent TA and TOF [302, 303]. The 
identified p.R456H mutation, has been reported in a single patient with 
pancreatic aplasia, PDA, VSD and a hypoplastic left pulmonary [932]. The 
mutation was identified by targeted sequencing. A further mutation at this 
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codon, p.Arg456Cys, was also found in association with pancreatic agenesis and 
CHD with a congenital diaphragmatic hernia [932]. 
 
Confirmation of the mutation is shown below in figure 7.2. 
 
 
Figure 7.2 PCR was carried out to amplify the region of interest in 
GATA6. 
A 244bp product was confirmed by running the PCR products on a 1% agarose 
gel initially. The PCR was then repeated and sent for Sanger Sequencing. The 
sequencing results for the trio show the G>A mutation in the index (red arrow), 
but neither parent. 
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7.3.1.2 Confirmation of PTPN11 mutation p.Asn308Asp 
 
WES identified the de novo mutation p.Asn308Asp in PTPN11, which has been 
reported as pathogenic previously [329]. Mutations in PTPN11 are associated 
with Noonan Syndrome and related disorders. The individual had pulmonary 
stenosis, the common type of CHD seen in this condition. The result was 
confirmed (Figure 7.3). 
 
Figure 7.3 Sequence results for the PTPN11 mutation. 
Sequence amplifying the region surrounding mutation c.992A>G, p.Asn308Asp 
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7.3.1.3 Confirmation of PTPN11 mutation p.Tyr63Cys 
 
The individual with the p.Tyr63Cys mutation in PTPN11 had pulmonary stenosis. 
The result was confirmed by PCR and subsequent Sanger sequencing (Figure 
7.4). 
 
Figure 7.4 PTPN11 sequence amplifying the region of interest. 
Forward Sequencing results to confirm mutation p.Tyr63Cys. The A to G 
substitution can be seen at position 51 in the index (red arrow), but not in either 
parent. 
 
7.3.2 Consideration of Secondary Findings 
 
Guidance produced by the MRC suggests that investigators consider the chances, 
challenges and consequences of identifying secondary findings. Table 7.2 
outlines the implications for feeding back secondary findings to individuals 
involved in the WES study. 
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Consideration Implications for our study 
Chance of significant 
unexpected result  
3% in WES [935], 1% for Array-CGH [936] 
Severity Variable, could be life threatening in case of certain 
tumour suppressor genes e.g. APC, BRCA, TP53. 
Chance of false 
positive 
Mutations would need to be verified in the lab by a 
second method, before feeding back. A referral to 
NHS Clinical Genetics Services and confirmation in an 
NHS approved laboratory would be required in 
addition. 
Clinical Utility Will vary depending on the gene involved. 
Screening and 
Management options 
Depends on gene, certain such as APC and BRCA 
have definite management plans, others such as 
TP53 are less clear. This screening can vary 
depending on NHS health trust. 
Vulnerable 
populations 
Children: Many participants would have been 
recruited as children, therefore it would not be 
appropriate to feedback information about adult 
onset conditions. Those recruited as children who are 
now adults would need to be re-consented. 
Individuals with NDD: Some individuals were 
recruited with learning difficulties.  
Benefits of feedback For the individual: a mutation may explain other 
pathologies they have, or might identify other organs 
systems that may need surveillance. The option of 
prenatal testing may be available in some cases, and 
lifestyle modifications or treatment options may be 
available for some genetic conditions. 
For the family: screening within the family to identify 
others at risk or reassure them.  
Harms of feedback  Worry and anxiety, especially about later onset 
conditions or those where there is no cure or limited 
treatments. It is very difficult to provide counselling 
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for genes which have variable penetrance and age of 
onset. Implications for insurance would require 
discussion. Communication of results in the family 
may cause upset [937]. 
Logistics and Costs 
of Feedback 
Review of all consent forms to identify those that 
opted to receive results, and a further contact to 
discuss whether they would like to receive secondary 
findings. There was no clinician time allocated for 
additional discussions of secondary findings. Any 
results would require a referral to the local Clinical 
Genetics team and confirmation of the result in a 
NHS approved laboratory. This would require an 
additional blood sample and use of phlebotomy 
services.   
How the results will 
be verified 
In the laboratory initially, PCR and sequencing. 
Mutations would then need confirmation in an NHS 
accredited laboratory as well.   
How and when 
feedback will occur  
Ideally via a clinical geneticist, however there is no 
route other than cardiology in place currently. There 
is currently no guidance on what timeframe these 
results should be identified and verified within. We 
would need to consider the impact on local NHS 
services if all results were passed back to study 
participants at once. 
Who will deliver the 




trained to do this 
Consultant cardiologist but clinical genetics would be 
essential. A new results pathway would need to be 
planned and financed. 
Some participants may no longer be in the area and 
would require feedback from a service more local to 
them or telephone feedback. 
 
Table 7.2 Completed table from the MRC guidance. Consideration of the 
implications of feeding back secondary findings to individuals in this WES study. 
(The MRC Framework on the Feedback of Health-related findings in Research 
https://wellcome.ac.uk/sites/default/files/wtp056059.pdf).  
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This assessment highlights a number of issues. The main difficulties would have 
been the logistical aspect of actually gaining consent retrospectively, and lack of 
involvement of a clinical geneticist. The majority of participants also fell into 
vulnerable categories, given most were very young children when recruited and 
may require careful counselling adapted to their needs.  
 
Professor Brook and I met with the local Clinical Genetics consultants in 2015 to 
discuss feedback of secondary findings further, given that participants would 
have potentially been referred to their service. The consent forms and 
information sheets were available for review. It was decided that it would be 
appropriate to feedback pathogenic mutations in definite CHD causing genes, but 
not secondary findings or VUS. This is because these findings did not form part 
of the original consent process. The option of re-contacting patients to discuss 
secondary findings was considered, but it was not thought practical given the 
number of participants and the amount of time that has passed since they were 
recruited to the study.  
 
We also considered genes that cause CHD and other cardiac phenotypes. A 
number of genes can cause both aortic dilatation and CHD. It was decided that it 
would be appropriate to feed these back. The same applies to genes which cause 
structural CHD and cardiomyopathy later in life. We then discussed genes that 
cause a purely aortic dilatation or cardiomyopathy phenotype. Although these 
processes relate to the heart, we decided that it was a separate issue to 
congenital structural CHD, and would instead fall into the category of secondary 
findings.   
 
Given that the WES data had only been assessed by the WTSI pipeline, the calls 
in genes suggested for reporting of secondary findings had not been analysed in 
sufficient detail to identify pathogenic mutations. It was decided that it would 
not be appropriate to proceed with these any further.  
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Moving forward however, it is necessary to plan for secondary findings. What is 
essential is that consent is informed and should include discussions around what 
feedback is available. It was decided that in the future, new study participants 
should be offered a choice as to whether they would like to receive information 
on secondary findings or not if bioinformatics resources were available to identify 
them, or they would be advised that we would not feedback secondary findings. 
I updated the consent forms accordingly, but this will require a substantial ethics 
amendment to effect the change.  Feedback of secondary findings will require 
careful planning and allocation of resources to set up a MDT to discuss which 
results to feedback, to allow time and laboratory resources to confirm the 




We identified pathogenic mutations in three individuals with no prior genetic 
diagnosis. A MDT to discuss potentially pathogenic results and the possibility of 
functional work for VUS, could also increase this number further. Larger studies 
would increase the chance of identifying more novel CHD genes, and would 
hopefully identify more results for participants. 
 
When considering further patient recruitment, we should think about what 
results might be generated as part of the research. Patient involvement in 
research is being encouraged more and more, and given they provide the data in 
many studies it seems only fair to involve them in decision making, and ask 
which results they feel are important [938]. Close collaboration between 
researchers and clinicians will be required to ensure that important variants are 
identified and that there is an appropriate pathway to return results. 
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Some of the most successful studies seamlessly integrate clinical care with 
research. Most recently the 100 000 Genomes project recruited individuals from 
the NHS and may provide them with a diagnosis, but at the same time the data 
is held securely, strictly anonymised and available to researchers and industry. 
This represents the ideal situation where the individual acts in an altruistic 
fashion to provide information for research and potentially answers for others, 
but may also benefit directly by receiving a diagnosis for themselves too. 
Perhaps as we move towards WES and WGS for patients, this will become the 
normal and all NHS patients will also be research participants. As the boundaries 
between research and clinical care grow ever closer it is likely that it will become 
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Chapter 8 Final Conclusions 
 
CHD is the most common congenital abnormality, and presents significant costs 
to both affected families and health services. Improved survival means that this 
cohort require specialist lifelong care. Understanding the genetic basis of CHD is 
beneficial at the individual and population level. It allows us to provide tailored 
care, prognostic information and prenatal options. It may also help us identify 
therapeutic targets for a wide range of cardiovascular conditions, making it 
relevant to an even wider population. 
 
The majority of individuals with CHD, especially those with NS-CHD, do not 
receive a genetic diagnosis. Previous research has identified a number of genes 
that cause CHD by analysis of families displaying Mendelian inheritance. These 
families are rare however, and CHD is usually a sporadic occurrence. It is likely 
therefore, that these results are not representative of the wider CHD population. 
The WES work carried out as part of this thesis has considered a more 
appropriate CHD cohort, and the results have confirmed the role of de novo 
variants in both S-CHD, and NS-CHD to a lesser extent. It has also strengthened 
the association with genes involved in chromatin modification.  
 
Novel findings in this thesis include the identification of three new genes which 
cause S-CHD: CHD4, PRKD1 and CDK13. We have also identified for the first 
time, that inherited rare PTVs with reduced penetrance, contribute to NS-CHD. 
We have also been able to expand the phenotypes of known CHD genes (TAB2) 
and a number of genes known to cause developmental disability, but not CHD 
previously. 
 
14 individuals have now been reported with mutations in CHD4, in addition to 
the 5 we described, and a consistent phenotype including NDD, hearing loss, 
skeletal, palatal and genitourinary abnormalities and recognisable facial features 
is now apparent. It is now included in NHS genetic testing, on a number of 
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panels. Evidence from mouse models, and the fact that over half of the 
individuals reported with mutations in this gene have CHD, confirms that it is an 
important contributor to CHD. 
 
The case of PRKD1 is less clear. The small numbers of individuals with mutations 
in this gene reported so far, mean that it is difficult to determine the associated 
phenotype and suggest that it is not a common cause of CHD. Studies of 
embryonic survival in the Prkd1Em1(IMPC)Wtsi and Prkd1Em2(IMPC)Wtsi mice, show 
homozygous lethality with no definite evidence of worsened survival in 
heterozygotes. The mouse models did not conclusively support the role of Prkd1 
in CHD, but no Prkd1Em1/Em1 mice, and only a single Prkd1Em2/Em2 mouse (normal 
cardiac phenotype) were available for analysis by HREM. The implications of 
finding an IAA and a muscular VSD in heterozygous mice from the two lines are 
unclear. Despite supporting evidence of CHD in other mouse models with 
knockout of genes known to interact with Prkd1 (Tbx5, Mef2c, Hdac5/9), a larger 
scale analysis including earlier gestations or other functional work are required 
to understand the role of PRKD1 in CHD. 
 
PRKD1 presents an interesting target given its role in hypertrophy. It could be 
an important gene to consider in other cardiac diseases that result in a 
hypertrophic response. Given the Prkd1Em2/+ mice had no evidence of structural 
cardiac disease on MRI, the finding of significant ventricular wall thickening in 
the RV segment and a trend towards an increase wall thickness in the majority 
of ventricular wall segments was surprising. Further work could investigate the 
consequence of the mutation on function of the protein and consider the 
response of the heart in the same line under stress. Careful monitoring of the 
individuals reported with mutations in PRKD1 and CHD will help determine if 
hypertrophy is a feature of the p.Gly592Arg mutation. 
 
After the initial report of seven individuals with mutations in CDK13, a further 37 
individuals have been reported, allowing delineation of the phenotype and 
recommendations for clinical care to be produced. Like CHD4 and PRKD1, it is 
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now included in NHS genetic testing. There is a recognisable facial gestalt and 
key features include developmental delay, structural brain abnormalities and 
CHD. Cdk13tm1b/tm1b mice exhibit complete embryonic lethality, but over a wide 
range of embryonic stages. HREM studies support a role in CHD, with a 
preponderance for endocardial cushion defects. Functional work may help 
ascertain the mechanism by which mutations result in CHD. 
 
The work reported here shows that much larger sample sizes will be required to 
identify the remaining novel CHD genes. The work carried out for this thesis to 
phenotype the cohort and create a list of genes we are highly confident cause 
CHD, has provided a starting point for a larger WES study that is in progress. 
Confirming pathogenic variants and feeding back results to participants is 
possible, but additional resources need to be planned to deal with secondary 

















Identifying Novel Genes that cause Congenital Heart Disease  421 
 
Appendix A. Overview of cardiovascular development in the mouse  
 
The gestational period in the mouse is 19-21 days. Despite the shorter 
timeframe, formation of the mouse heart follows a similar course to that 
described in the human in 1.2.1. The mouse heart is the first organ to form, to 
meet the oxygen requirements of the developing embryo. Oxygenated blood 
flows into the heart through the umbilical veins from the placenta, and 
deoxygenated blood arrives from the systemic circulation via the cardinal veins 
and sinus venosus, and via the vitelline veins from the yolk sac [889]. An 
overview of development is shown in figure A.1 and table A.1 below. Mouse 
embryogenesis is staged by embryonic day (E), and by Theiler stage defined 
by morphological development. 
 
 
Figure A.1 Overview of mouse heart formation including looping. 
Reproduced with permission from Science Direct and Epstein et al [940]. 
Overview of mouse heart formation including looping. E; Embryonic day. 




E7.5 Cardiac crescents form, made up of cells from the first and second 
heart fields [889]. 
E7.5-9.0 Contractions can be seen from E7.5, and a regular sinus rhythm 




Heart tube looping  [942] 
E8.5 – 
E13 
Pharyngeal/aortic arch arteries. There are six bilaterally, and 
they join to the two dorsal aortae [889]. The first and second 
are seen from E8.5, and become the mandibular, stapedial and 
hyoid arteries [943]. Others are seen at a slightly later stage, 
from E9.5 onwards. They eventually become the aortic arch and 
proximal pulmonary arteries and resemble the postnatal 
arrangement by E13 [943].  
E10.5-
E13.5 
Atrial septation [218]. The septum secundum forms from tissue at 
the posterior of the atrium and is present from E11.5. Fusion with 




Ventricular septation occurs between E10.5-13.5 [218]. The 
atrioventricular and outflow tract cushions (ridges) which 
become evident at E9.5, contribute to the valves, ventricular 
septum and division of the outflow tract [944, 945]. Evidence of 
a muscular ventricular septum is seen from E10.5, but this is 
variable, so E11.5 is often considered to be the point at which 
septation truly starts. Closure of the interventricular foramen is 
seen at E13.5. 
E10.5-
E17.5 
Atrioventricular valve formation begins at E10.5 and progresses 
until E17.5. The four endocardial cushions in the atrioventricular 
canal come together at E11.5 to produce the atrioventricular 
septum, and by E12.5 the two atrioventricular valves are 
present [946]. The valves and chordae continue to develop until 
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E17.5, but the tricuspid valve does not delaminate and may not 
separate fully from the septum [218]. 
E11.0  At E11.0 ventricular trabeculations are present [217]. 
E11.5-
E13.5 
Outflow septation. The septum forms from a number of sources. 
The neural crest cells begin septation and the two cushions 
(mesenchymal ridges), which are seen from E9.5, spiral and 




Venous drainage. At E11.5 the IVC, ductus arteriosus and 
coronary sinus (previously left sinus horn) are established. The 
left SVC is developing [889]. The IVC enters the prospective 
right atrium at the sinus venosus [217]. At E12, the left and 
right SVC are present, but the right SVC empties into the IVC at 
this point, rather than the RA [946]. The left SVC and IVC are 
connected by the coronary sinus which does not drain directly 
into the RA until E15.5, and the IVC will maintain its own entry 




The semilunar valves are mainly derived from the endocardial 
cushions and are beginning to form at E11.5. The third valve 
cusps are produced from the walls of the truncus. They thin and 
mature between E12.5 and E18.5.  
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Appendix 2. Cdk13tm1b(EUCOMM)Hmgu Mouse Sequence 
 
The relevant sequences of the Cdk13tm1b(EUCOMM)Hmgu mouse, including the 
cassette, are outlined below in figure 2. The wild type sequence just prior to 
exon 3 with the two relevant primers for identification of the wild type mouse 
are shown in figure 3. 
 
Figure B.1 Sequence of Cdk13 with relevant sites for generating and 
genotyping the Cdk13tm1b(EUCOMM)Hmgu mouse.  
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Frt sites are highlighted in green. The lox P site is highlighted in red. The Exons 
are pink and the introns are turquoise.  The cassette is in yellow. The exon at 
position 9121 is exon 2, and at position 21601 is exon 5. The mouse model 
therefore lacks exons 3 and 4. Primers for genotyping are highlighted in grey: 
CDK13_8441_F primer is at position 14821, Cas-R1Term is at position 15001, 
LacZ small F at 18181 and LacZ_small_R is at 18290. At position 15051, the 




Figure B.2 Wildtype Cdk13 sequence.  
CDK13_84881_F and CDK13_84881_R primers in the wild type mouse sequence 
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Appendix C. Phenotype of the Wildtype C57BL/6N Mouse 
 
The background strain of both the Prkd1 and Cdk13 mice is the commonly used 
C57BL/6N inbred strain. It is a permissive background, with low incidence of 
tumours, they breed well and have a relatively long lifespan 
(https://www.jax.org/strain/000664). This strain is used in the DMDD project 
and is well phenotyped (https:/dmdd.org.uk). Some of the common 
abnormalities that can arise in this strain are outlined in table 2 below. 
Occurrence of any of these features should not be attributed to mutant gene 






Susceptible to diet induced 
obesity, type II diabetes and 
atherosclerosis 
A high fat diet tends to result in 
obesity, mild-moderate 
hyperglycaemia and insulinaemia, and 
atherosclerosis in the aorta. 
Microphthalmia and other eye 
abnormalities 
Affecting 8-20%. Unlikely to be 
relevant in this project, except for 
suitability for breeding [948]. 
Hereditary hydrocephalus Thought to affect 1-4%. Unlikely to be 
relevant in this project, except for 
suitability for breeding. 
Portosystemic shunts Thought to affect 5%. Could be 
relevant in adult studies. 
Hair loss associated with over 
grooming 
Will be monitored and action taken if 
welfare thought to be compromised. 
Severe progressive hearing loss Late onset. Unlikely to be relevant to 
this project 
 
Table C.1 Characteristics of the C57BL/6 mice. 
Information from Jackson Laboratory site https://www.jax.org/strain/000664.  
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To accurately phenotype the mouse heart, it was important to understand the 
expected anatomical development of the heart at E15.5. E14.5 and E15.5 
embryos tend to have reached Theiler Stages 21-23 [224]. There are rapid 
changes in the development of the heart between these stages, and staging 
based on days post coitus and even the Theiler system may not be adequate. 
Geyer et al. produced a more detailed sub stage system to overcome this 
problem and examined the heart at each stage with HREM [518]. The table 
below (table 2) is a summary of the phenotypic information collected. The 
authors noted that the variable anatomy between the stages of development 
mean that there is a risk of incorrect interpretation of normal development as 
pathology. For example, the interventricular foramen may still be open as part of 
normal development, and be incorrectly described as a perimembranous VSD. 
Between these stages, there was huge variation in the diameter of vessels and 
their lumens, meaning that it is hard to comment on vascular stenosis. Another 
specific limitation of this method is the appearance of confined areas of capillary 
dilatation that might be misinterpreted as haemangioma, haemorrhage or 
telangiectasia. The developmental range described was used to inform the HREM 
analysis of E15.5 hearts. 
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Table C.2 Cardiovascular development in mouse embryos. 
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Appendix D Embryonic Mouse Phenotyping Protocol 
 
 
Gross Morphology of E14.5-E15.5 embryos  
1. Measure CRL at time of schedule 1. 
2. External examination. Use Mammalian Phenotype Ontology [949] codes to 
document phenotypes 
3. Remove heart as per HREM protocol 






Heart weight (mg) 
(after fixation) 
 
Tibia length (mm) 
 
 












Sample for DNA  
 
 










Skin haemorrhage Normal/abnormal/unobservable 
 
Head shape Normal/abnormal/unobservable 
 
Facial or palatal cleft Normal/abnormal/unobservable 
 
Body wall morphology Normal/abnormal/unobservable 
 




Vibrissae morphology (whiskers) Normal/abnormal/unobservable 
 






Spina bifida Normal/abnormal/unobservable 
 
Eye morphology Normal/abnormal/unobservable 
 
































Pale placenta Normal/Abnormal/Unobservable 
 
 
Forelimb staging figure reproduced with permission from Geyer et al John Wiley 










Atria Fully septated (except PFO) 
Appendages and pectinate muscles normal 
Coronary sinus Present or absent 
PFO Present or absent 
Tricuspid Valve Cavitations or full cusps seen  
Tricuspid 
Mitral Valve Cavitations or full cusps seen  
Bicuspid 
Ventricular Septum Interventricular foramen should not be present 
(seen in 2% at S23) 
Aortic Valve Cavitations or full cusps seen  
Tri/bicuspid 
Normal position on left, any overriding 
Pulmonary Valve Cavitations or full cusps seen  
Tricuspid 
Normal position on right and more cranial 
Pulmonary artery Normal position and branches 
Aorta Normal position and branches 
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1. Schedule 1 the mouse 
2. Transfer to warm PBS and measure the CRL 
3. Remove heart 
4. Internal and external examinations 
5. Remove tail and freeze for DNA extraction (-20c) 
 






CRL (mm)  








Tissue for DNA taken 








Skin and hair Normal/Abnormal/Unobservable 
Whiskers Normal/Abnormal/Unobservable 
Limbs  Normal/Abnormal/Unobservable 
Digits and nails (number, syndactyly) Normal/Abnormal/Unobservable 
Haemorrhage Normal/Abnormal/Unobservable 






Liver situs Normal/Abnormal/Unobservable 
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Abstract 
We evaluated the burden of high confidence DNMs within S-CHD and NS-CHD trios 
separately (NS-CHD= 518, NNS-CHD= 847). We classified DNMs into three distinct categories: 
PTVs (nonsense, frameshift and splice-site variants); missense variants (including in-frame 
indels); and silent mutations. We compared the observed numbers of DNMs to those 
expected under a null mutational model9, across a set of manually curated CHD-associated 
genes, non-CHD developmental disorder associated genes and all remaining protein coding 
genes (Supplementary Tables 1-3, Figure 1A). S-CHD probands exhibited the largest excess 
in de novo PTVs (27 variants, OR=81, P=1.21x10–43) and de novo missense variants (22 
variants, OR=8.6, P=7.35x10–15) for autosomal dominant CHD genes (Supplementary Table 
4). S-CHD probands also manifested a burden of de novo PTVs in autosomal dominant 
developmental disorder-associated genes not currently associated with CHD (12 variants, 
OR=18.4, p=3.49x10–13). In contrast, NS-CHD probands presented with a much lower burden 
of de novo PTVs in CHD-associated genes (4 variants, OR=7.3, P=2.61x10–4). Finally, we 
found a significant exome-wide excess of de novo missense, but not silent mutations (after 
excluding CHD and developmental disorder genes) in both S-CHD and NS-CHD probands, 
suggesting additional undiscovered dominant CHD-associated genes. The excess of de 
novo PTVs in S-CHD cases reported here is of the same magnitude as that found in cases 
with severe developmental disorders without CHD and considerably higher than that found in 
Autism Spectrum Disorder (Figure 1B, Supplementary Table 5). The observed marked 
difference in DNM burden between NS-CHD and S-CHD confirms findings in a recent study 
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by Homsy et al.8 looking at differences in mutational burden in CHD cases with and without 
neurodevelopmental deficits, which are by far the most common extra-cardiac manifestations. 
This burden additionally mirrors that observed in Autism between individuals with and 




Burden of de novo and inherited variants in NS-CHD compared to S-CHD 
(A) Excess of DNMs compared to null mutation model. Excess of DNMs was computed as the ratio 
of the observed number of DNMs over the expectation given random mutation using a null gene-wise 
mutation rate model. P-values were computed using a Poisson model parameterized by the cumulative 
mutation rate across the gene set for the same number of probands (nS-CHD= 518, nNS-CHD= 847). We 
stratify by variant consequence and within known autosomal dominant CHD genes (n=78), autosomal 
dominant developmental disorder genes excluding autosomal dominant CHD genes (n=203) and all 
autosomal protein coding genes excluding autosomal dominant developmental disorder and CHD 
genes (n=17,404). No data is shown for silent variants in CHD genes for syndromic probands as no 
variants were detected. Error bars represent the 95% confidence interval. (B) Comparison of exome-
wide excess of DNMs across different diseases stratified by variant consequence. (C) Excess of rare 
inherited variants (nS-CHD= 471, nNS-CHD= 663) compared to 12,031 controls of matched ancestry: Excess 
of DNMs was computed as the ratio of the observed number of rare inherited variants over the 
expected numbers as seen in controls. (D) Counts of de novo PTVs in S-CHD probands and rare 
inherited (INH) PTVs in NS-CHD probands in known monoallelic CHD-associated genes. 
To evaluate the contribution of incompletely penetrant inherited variants, we compared the 
burden of rare (Minor allele frequency < 0.1%) inherited variants in the three previously 
described gene sets in the S-CHD and NS-CHD cases of European ancestry, relative to 
population-matched controls (n=12,031, Supplementary Figure 1, Supplementary Table 
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6, Figure 1C). We observed a significant excess of rare inherited PTVs in autosomal 
dominant CHD-associated genes in NS-CHD (17 variants, OR=2.67,p=1.1x10–4), but not in 
S-CHD (p=0.3). The CHD-associated genes with inherited PTVs in NS-CHD 
(Supplementary Table 7) have previously only been linked with non-syndromic or syndromic 
presentations with variable presentations, and were non-overlapping with genes with de 
novo PTVs in S-CHD (Figure 1D). Non-syndromic presentations of inherited PTVs in several 
genes originally associated with S-CHD have previously been described (e.g. JAG111, 
TBX512). Moreover, we also observed an exome-wide excess of rare inherited PTVs (3,318 
variants, OR=1.08, p=1.51x10–5) in NS-CHD probands, even after excluding known CHD-
associated and developmental disorder-associated genes, suggested incomplete penetrance in 
additional, novel CHD-associated genes. We did not observe this exome-wide excess in the 
S-CHD cohort (p=0.8), suggesting a more appreciable role for incomplete penetrance in NS-
CHD than S-CHD. 
Using a previously described null mutation model6,9, we evaluated individual genes for an 
excess of de novo PTVs and de novo missense variants separately, using a high sensitivity set 
of candidate DNMs and defining genome-wide significance as p < 1.3x10–6. When 
considering all CHD trios (S-CHD and NS-CHD), including cases with mutations in known 
developmental disorder or CHD-associated genes, we identified 11 genes, with genome-wide 
significance. When we stratified by syndromic status we found no genes at genome-wide 
significance in the NS-CHD cohort. Conversely, we found the aforementioned 11 genes and 
one additional gene at genome-wide significance in the S-CHD cohort, in line with the 
described increased burden of DNM PTVs in this cohort (Table 1, Supplementary Table 
8, Figure 2A). Nine of the 12 genome-wide significant genes were known to be associated 
with developmental disorders, although not all had previously been implicated in CHD. 
These findings expand the known phenotypic spectrum of several genes (e.g. S-CHD cases 
with de novo mutations in TAB2, a gene previously only described in NS-CHD13), however 
larger genotype-phenotype studies are needed to fully characterise the phenotypic spectrum 
associated with each gene. To maximise power to detect novel causative genes, we focused 
on ‘unresolved’ (i.e. probands without a plausible pathogenic DNM in known developmental 
disorder and CHD-associated genes) S-CHD trios (n=398) and identified three novel 
genes: CDK13, CHD4 and PRKD1, at genome-wide significance (Table 1, Figure 
2B, Supplementary Table 9). All candidate DNMs in these three genes were experimentally 
validated. We found no genes at genome-wide significance when we performed the analysis 
on ‘unresolved’ NS-CHD cases (n=792). 
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Open in a separate window 
Figure 2 
Gene-wise enrichment of de novo mutations 
Gene-wise DNM enrichment was computed for A) the complete S-CHD cohort (n=518), B) 
‘unresolved’ S-CHD trios without a plausible pathogenic DNM in known developmental disorder and 
CHD-associated genes (n=398). The probability of enrichment was computed given a Poisson 
distribution with the rate given by the gene-specific mutation rate multiplied by the number of 
chromosomes considered. This was performed for de novo PTVs and de novo missense variants 
independently. The de novo missense-enrichment probability was further combined with the 
probability of non-random clustering of de novo mutations using Fisher’s method and the minimum 
was taken between the combined and the original p-value. The minimum probability (considering 
either de novo PTVs or de novo missense mutations) was plotted. The dashed horizontal line 
represents genome-wide significance (p<1.31x10–6, Bonferronni corrected P-value of 0.05 corrected 
for 2x19,252 protein coding genes). 
Chapter 9 Table 1 
Genes with genome-wide significant enrichment of de novo mutations in the S-CHD cohort 
(n=518). Probabilities are also given for “unresolved” S-CHD cases (n=398). Missense 






PTPN11D,C 7 (0/7) YES 7.29E–16 NA 







ANKRD11D,C 5 (5/0) NO 8.50E–13 NA 
CDK13 6 (0/6) YES 2.26E–12 4.73E–11 
ADNPD,C 4 (4/0) NO 1.29E–11 NA 
NSD1D,C 6 (4/2) YES 2.77E–11 NA 
PACS1D,C 3 (0/3) YES 2.32E–09 NA 
KMT2AD,C 5 (4/1) NO 2.74E–09 NA 
TAB2C 3 (3/0) NO 4.19E–09 NA 
DYRK1AD 4 (3/1) NO 5.99E–09 NA 
DDX3XD 4 (2/2) NO 1.69E–08 NA 
CHD4 5 (0/5) NO 2.28E–07 6.18E–08 
CHD7D,C 4 (3/1) NO 3.45E–07 NA 







PRKD1 3 (0/3) YES 2.13E–06 9.78E–07 
DAssociated with a developmental disorder 
CAssociated with CHD 
We identified seven S-CHD individuals (Figure 3A) with clustered missense variants, six de 
novo variants and one variant of unknown inheritance, in the highly conserved 
serine/threonine protein kinase domain of cyclin-dependent kinase 13 (CDK13), which shows 
a marked depletion of missense variants in the European population (Figure 3B). Four 
probands carry an identical missense mutation (Asn842Ser). These seven S-CHD cases (6 
trios and 1 singleton) were characterised by septal defects (VSD n= 2, ASD n= 5), with two 
also presenting with pulmonary valve abnormalities. Each had a recognizable facial gestalt, 
significant developmental delay, slight to moderate microcephaly and two had agenesis of the 
corpus callosum (Figure 3A, Supplementary Table 10). Modelling of the kinase domain 
indicates that the observed mutations impair: ATP-binding, binding of the magnesium ion 
that is essential for enzymatic activity, or interactions with Cyclin K, with 
which CDK13 forms a cyclin-dependent kinase complex (Figure 3C). This Cyclin K/CDK13 
complex phosphorylates RNA polymerase II and is necessary for alternative splicing of 
RNA14,15. The knockout mice for Cdk12, the closest paralogue for Cdk13, both of which have 
ubiquitous developmental expression patterns, die at post-implantation (E5.5) suggesting a 
strong developmental effect16. 
 




Overview of CDK13 mutations in S-CHD cases 
A) Phenotype summary of probands carrying missense mutations in CDK13. Colors indicate the 
number of times a certain phenotype was observed in individuals carrying a de novo mutation 
in CDK13. Photographs of affected probands are shown for which consent could be obtained for 
publication. B) clustering of DNMs in Serine-Threonine kinase domain. Density plot displays a 
sliding window (±10 amino acids) missense variant count in the Non-Finnish European population of 
the Exome Aggregation Consortium data, showing a marked reduction of missense variants in the 
kinase domain. C) 3D protein structure of CDK13 by homology modelling adapted from CDK12. 
Mutated residues are marked in bright green. Catalysing Magnesium ion is highlighted in magenta, 
and the co-crystallized AMP ligand is portrayed in orange. 
We observed five S-CHD individuals with DNMs in CHD4 (4 missense variants and 1 in-
frame deletion), which encodes a chromodomain containing protein that catalyses ATP-
dependent chromatin remodelling as a core component of the nucleosome remodeling and 
histone deacetylase (NuRD) repressor complex17. Three patients manifested Tetralogy of 
Fallot or Fallot-like features, while the remaining two had an aortic coarctation and a septal 
defect (Supplementary Figure 2, Supplementary Table 11). All had significant early delay in 
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neurodevelopment, two had Chiari malformations and three of the four males had 
cryptorchidism or ambiguous genitalia. These features suggests an overlap with CHARGE 
syndrome (MIM #214800) caused by heterozygous loss-of-function mutations in the 
paralogous gene, CHD7, which also achieves significance in S-CHD cases (Table 1). 
Haploinsufficiency of another component of the NuRD complex, GATAD2B, has been 
identified as causing a recognisable intellectual disability syndrome, although associated 
CHD has not been reported18. More generally, several components of other ATP-dependent 
chromatin remodelling complexes have been associated with dominant developmental 
syndromes, including CHD in some patients6,7. A recent study showed that mice with 
endothelial knockdown of CHD4, resulting in a dysfunctional NuRD-complex, die of 
vascular rupture during midgestation19. This finding suggests NuRD-complex dysfunction as 
a possible mechanism for the observed human cardiac phenotype. 
We identified three S-CHD individuals with de novo missense mutations in PRKD1, with two 
having identical DNMs, a mutational pattern suggestive of gain of function (Supplementary 
Figure 3, Supplementary Table 12). Two out of the three individuals are affected by 
atrioventricular septal defects, whereas the third is affected by pulmonic stenosis. Other 
features included: severe developmental delay, ectodermal (dry skin, teeth and nail defects) 
and limb abnormalities. A homozygous PTV in PRKD1 has recently been associated with 
truncus arteriosus through autozygosity mapping20. PRKD1 encodes a serine/threonine 
protein kinase that regulates diverse cellular functions, including the transcriptional response 
to cardiac hypertrophy21. Homozygous knockout of Prkd1 in mice is embryonic lethal and 
tissue-specific knockout results in abnormal cardiac remodelling21. 
The burden analyses described above clearly show enrichment for de novo PTVs, de 
novo missense variants and inherited PTVs within our CHD dataset. Therefore we 
hypothesised that some genes might be enriched for both de novo and rare inherited variants 
and that integrating both classes of variation, in trios and in singletons, using a previously 
described hierarchical Bayesian model22 (Online Methods), may improve power to detect 
novel CHD-associated genes. We analysed PTVs and missense variants separately and 
considered candidate CHD-associated genes at strong (FDR < 1%), intermediate (1%< FDR 
< 5%) and weak (5%< FDR < 10%) levels of confidence (Figure 4, Supplementary Tables 
13-14). We found 16 genes at the strongest level of confidence, 12 were known 
developmental disorder-associated genes, 1 gene was only associated with CHD but not with 
developmental disorders (MYH6), and 3 are novel candidate genes 
(CHD4, CDK13, DIAPH3). Most high confidence genes, exhibited enrichment for either 
DNMs or inherited variants, only two genes, NOTCH1 and KAT6A exhibited appreciable 
enrichment for both. NOTCH1 was notable as being the only high confidence gene for which 
the evidence from inherited PTVs exceeds that from DNMs (Figure 4B). Due to the likely 
concentration of false discovery signals in novel gene associations, we believe this analysis 
alone to be insufficient to conclusively assert novel CHD associations. Additional functional 
evidence can prioritise genes for future follow-up studies (Supplementary Table 15). We 
evaluated the over-representation of particular gene functions and pathways among the top 
374 genes with an FDR < 50% (Online Methods). We observed a significant (FDR < 10%) 
over-representation of genes associated with Gene Ontology terms relating to chromatin 
modification, protein phosphorylation, neural tube and cardiac development (Supplementary 
Table 16). Over-represented pathways included: NOTCH1-, IGF1-, HDAC Class II-, ERBB- 
and NFKB- signalling (Supplementary Table 17). In addition, the 374 top-ranking genes 
exhibited considerable functional coherence, with many genes forming a single large inter-
connected subnetwork of high-confidence (STRING Score > 0.9) protein-protein interactions 
Identifying Novel Genes that cause Congenital Heart Disease  443 
 
(Supplementary Figure 4), the degree of interconnection of which was significantly higher 
than expected by chance (p=5.84x10–3). Key hubs in this subnetwork 
were NOTCH1, SOS1, EP300 and SMAD4. 
 
 
Open in a separate window 
Figure 4 
Integrated analysis of de novo and inherited variant enrichment using 
Hierarchical Bayesian modelling 
Scatter plots representing Bayes factors (ratio of the evidence given the alternative model of the gene 
being associated with CHD over the evidence given the null model of the gene not being associated 
with CHD) for the de novo and inherited components of the model for PTVs and missense variants. 
The diagonal solid line represents the identity line, where equal signal is obtained from de 
novo variation compared to inherited variation. Genes at an FDR < 10% are labelled and colors 
represent different confidence thresholds. 
 
Several mechanisms have been proposed to explain the low sibling recurrence risk of CHD, 
ranging from a major role for DNMs7, incomplete penetrance of variants with large effect 
sizes, and a polygenic and/or multifactorial aetiology23. Our analyses (see Supplementary 
Table 18 for an overview) show that the relative contributions of DNMs and incomplete 
penetrance differ markedly between NS-CHD and S-CHD, with a major role for de 
novo mutations in the latter, and inherited high-risk variants in the former. By focusing on 
unresolved S-CHD cases, we discovered three novel S-CHD disorders caused by mutations in 
genes not previously associated with S-CHD (PRKD1, CHD4 and CDK13). CHD is often not 
fully penetrant in syndromic CHD disorders (e.g. KMT2D24, NSD125), and as all patients in 
our study were ascertained for CHD, further studies are necessary to quantify the penetrance 
of CHD in these three new syndromes. These three new genes increase the percentage of S-
CHD probands with a putatively pathogenic DNM from 23% to 26% of patients, effectively 
increasing the diagnostic yield of this class of variation by 13%. 
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Current sample sizes provide limited statistical power to detect novel S-CHD disorders, and 
given the observed burden of de novo PTVs in S-CHD we estimate that data sets at least 20-
fold larger will be needed to discover most dominant CHD-associated genes (Supplementary 
Figure 5). This challenge is likely to be even greater for identifying most genes harbouring 
incompletely penetrant variation in NS-CHD26. Our data motivate different study design 
strategies for S-CHD (trios) and NS-CHD (case/control), nonetheless international 
collaboration and data sharing will be essential to achieve a deeper understanding of the 
genetic architecture of CHD. 
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Appendix G: Syndromic and Non-Syndromic Cohort Composition 
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Table G.1 Cohort composition: Syndromic and non-syndromic 
Supplementary Table 1 from Sifrim et al [12]: Proband counts stratified by 
syndromic status, gender, European ancestry and availability of parental exome 
sequencing data. For probands coming from families with multiple affected 
individuals the numbers represent the number of probands sequenced, whereas 


















Appendix H: Cohort Composition 
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Table H.1 Cohort composition: Participating centres. 
Supplementary Table 2 from Sifrim et al [12]: Samples by cohort: Samples are 
stratified as being part of a parent-child trio or not (i.e. duo or singletons). If the 
dataset was previously published, as part of another study, the respective 













Appendix I: Cardiac Phenotypes 
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HP:0001629 360 190 170 19.04% 31.15% 13.27% 
Abnormality of the 
aortic valve 
HP:0001646 335 59 276 17.72% 9.67% 21.55% 
Defect in the atrial 
septum 
HP:0001631 281 140 141 14.86% 22.95% 11.01% 
Coarctation of aorta HP:0001680 263 39 224 13.91% 6.39% 17.49% 
Tetralogy of Fallot HP:0001636 201 42 159 10.63% 6.89% 12.41% 
Atrioventricular canal 
defect 
HP:0006695 194 21 173 10.26% 3.44% 13.51% 
Abnormality of the 
pulmonary valve 
HP:0001641 169 68 101 8.94% 11.15% 7.88% 
Hypoplastic left heart HP:0004383 155 8 147 8.20% 1.31% 11.48% 
Patent ductus 
arteriosus 
HP:0001643 151 86 65 7.99% 14.10% 5.07% 
Transposition of the 
great arteries with 
ventricular septal 
defect 
HP:0011607 84 17 67 4.44% 2.79% 5.23% 
Abnormal branching 
pattern of the aortic 
arch 
HP:0011587 84 19 65 4.44% 3.11% 5.07% 
Double outlet right 
ventricle 
HP:0001719 68 11 57 3.60% 1.80% 4.45% 
Situs inversus totalis HP:0001696 66 13 53 3.49% 2.13% 4.14% 
Abnormality of the 
mitral valve 
HP:0001633 63 14 49 3.33% 2.30% 3.83% 
Abnormality of the 
vena cava 
HP:0005345 60 3 57 3.17% 0.49% 4.45% 
Hypoplastic aortic arch HP:0012304 59 3 56 3.12% 0.49% 4.37% 
Transposition of the 
great arteries with 
intact ventricular 
septum 
HP:0011606 51 3 48 2.70% 0.49% 3.75% 
Pulmonary valve 
atresia 
HP:0010882 43 1 42 2.27% 0.16% 3.28% 
Abnormality of cardiac 
morphology 
HP:0001627 37 36 1 1.96% 5.90% 0.08% 
Cardiomyopathy HP:0001638 35 28 7 1.85% 4.59% 0.55% 
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Abnormality of the 
coronary arteries 
HP:0006704 35 1 34 1.85% 0.16% 2.65% 
Abnormality of the left 
ventricular outflow 
tract 
HP:0011103 33 5 28 1.75% 0.82% 2.19% 
Tricuspid atresia HP:0011662 29 7 22 1.53% 1.15% 1.72% 
Abnormality of the 
tricuspid valve 
HP:0001702 22 4 18 1.16% 0.66% 1.41% 
Abnormality of the 
pulmonary artery 




HP:0005160 21 7 14 1.11% 1.15% 1.09% 
Mitral atresia HP:0011560 19 0 19 1.00% 0.00% 1.48% 
Hypoplastic right heart HP:0010954 17 0 17 0.90% 0.00% 1.33% 
Double inlet left 
ventricle 




HP:0010773 16 2 14 0.85% 0.33% 1.09% 
Pulmonary artery 
atresia 
HP:0004935 16 6 10 0.85% 0.98% 0.78% 
Ebstein's anomaly of 
the tricuspid valve 
HP:0010316 15 1 14 0.79% 0.16% 1.09% 
Left atrial isomerism HP:0011537 15 0 15 0.79% 0.00% 1.17% 
Congenitally corrected 
transposition of the 
great arteries 
HP:0011540 14 1 13 0.74% 0.16% 1.01% 
Truncus arteriosus HP:0001660 13 6 7 0.69% 0.98% 0.55% 
Right atrial isomerism HP:0011536 12 2 10 0.63% 0.33% 0.78% 
Abnormality of the left 
ventricle 
HP:0001711 10 8 2 0.53% 1.31% 0.16% 
Hypoplasia of right 
ventricle 
HP:0004762 9 2 7 0.48% 0.33% 0.55% 
Arrhythmia HP:0011675 5 5 0 0.26% 0.82% 0.00% 
Abnormality of cardiac 
atrium 
HP:0005120 4 3 1 0.21% 0.49% 0.08% 
Interrupted aortic arch HP:0011611 4 0 4 0.21% 0.00% 0.31% 
Abnormality of the 
right ventricle 
HP:0001707 3 3 0 0.16% 0.49% 0.00% 
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Table I.1 Composition of cohort: CHD phenotype. 
Supplementary Table 3 reproduced from Sifrim et al. [12]: Counts of phenotype 
annotations across all probands (n=1891), the S-CHD cohort (n=610) and the 
NS-CHD cohort (n=1281). Percentages were computed as the number of 
probands annotated with that particular phenotype divided by the number of 



































Appendix J: CHD gene list criteria 
 
 




Table J.1 Criteria for CHD associated genes. 
Supplementary Table 19 from Sifrim et al [12]: Criteria used for manual curation 
of genes associated with CHD. 
* Recurrent de novo mutations convincingly affecting gene function, rare, fully-
penetrant mutations - relevant genotype never seen in controls 
** ORF in protein coding genes, miRNA stem or loop 
*** All structural congenital heart defects (also PDA and ASD), not restricted to 
childhood. Including BAV and abnormalities of large vessels (Aorta root dilation 













Appendix K: High Confidence CHD Gene List 
 




symbol ensg_id description tier inheritance 
GATA4 ENSG00000136574 CHD - Non-syndromic 1 Monoallelic 
GATA6 ENSG00000141448 CHD - Non-syndromic 1 Monoallelic 
GJA1 ENSG00000152661 CHD - Non-syndromic 1 Monoallelic/Biallelic 
ACTA2 ENSG00000107796 CHD - Non-syndromic 1 Monoallelic 
ACVR2B ENSG00000114739 CHD - Non-syndromic 1 Monoallelic 
CCDC103 ENSG00000167131 CHD - Non-syndromic 1 Biallelic 
CCDC114 ENSG00000105479 CHD - Non-syndromic 1 Biallelic 
CCDC151 ENSG00000198003 CHD - Non-syndromic 1 Biallelic 
CCDC39 ENSG00000145075 CHD - Non-syndromic 1 Biallelic 
CCDC40 ENSG00000141519 CHD - Non-syndromic 1 Biallelic 
CFC1 ENSG00000136698 CHD - Non-syndromic 1 Monoallelic 
CITED2 ENSG00000164442 CHD - Non-syndromic 1 Monoallelic 
CRELD1 ENSG00000163703 CHD - Non-syndromic 1 Monoallelic 
DNAAF3 ENSG00000167646 CHD - Non-syndromic 1 Biallelic 
DYX1C1 ENSG00000256061 CHD - Non-syndromic 1 Biallelic 
LEFTY2 ENSG00000143768 CHD - Non-syndromic 1 Monoallelic 
MYH11 ENSG00000133392 CHD - Non-syndromic 1 Monoallelic 
MYH7 ENSG00000092054 CHD - Non-syndromic 1 Monoallelic 
NKX2-5 ENSG00000183072 CHD - Non-syndromic 1 Monoallelic 
NODAL ENSG00000156574 CHD - Non-syndromic 1 Monoallelic 
NR2F2 ENSG00000185551 CHD - Non-syndromic 1 Monoallelic 
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ARID1A ENSG00000117713 CHD - Syndromic 1 Monoallelic 
NOTCH2 ENSG00000134250 CHD - Syndromic 1 Monoallelic 
NSD1 ENSG00000165671 CHD - Syndromic 1 Monoallelic 
ACTB ENSG00000075624 CHD - Syndromic 1 Monoallelic 
ADNP ENSG00000101126 CHD - Syndromic 1 Monoallelic 
AMER1 ENSG00000184675 CHD - Syndromic 1 X-linked 
ASXL1 ENSG00000171456 CHD - Syndromic 1 Monoallelic 
BCOR ENSG00000183337 CHD - Syndromic 1 X-linked 
CCBE1 ENSG00000183287 CHD - Syndromic 1 Biallelic 
CD96 ENSG00000153283 CHD - Syndromic 1 Biallelic 
CHD7 ENSG00000171316 CHD - Syndromic 1 Monoallelic 
CHST14 ENSG00000169105 CHD - Syndromic 1 Biallelic 
CHST3 ENSG00000122863 CHD - Syndromic 1 Biallelic 
COL1A1 ENSG00000108821 CHD - Syndromic 1 Monoallelic 
COL3A1 ENSG00000168542 CHD - Syndromic 1 Monoallelic 
EFTUD2 ENSG00000108883 CHD - Syndromic 1 Monoallelic 
EHMT1 ENSG00000181090 CHD - Syndromic 1 Monoallelic 
ELN ENSG00000262184 CHD - Syndromic 1 Monoallelic 
EVC ENSG00000072840 CHD - Syndromic 1 Biallelic 
EVC2 ENSG00000173040 CHD - Syndromic 1 Biallelic 
FBN2 ENSG00000138829 CHD - Syndromic 1 Monoallelic 
FGFR2 ENSG00000066468 CHD - Syndromic 1 Monoallelic 
FLNB ENSG00000136068 CHD - Syndromic 1 Monoallelic/Biallelic 
FOXC1 ENSG00000054598 CHD - Syndromic 1 Monoallelic 
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GLI3 ENSG00000106571 CHD - Syndromic 1 Monoallelic 
GPC3 ENSG00000147257 CHD - Syndromic 1 X-linked 
HDAC4 ENSG00000068024 CHD - Syndromic 1 Monoallelic 
HRAS ENSG00000174775 CHD - Syndromic 1 Monoallelic 
IRX5 ENSG00000176842 CHD - Syndromic 1 Biallelic 
JAG1 ENSG00000101384 CHD - Syndromic 1 Monoallelic 
KANSL1 ENSG00000120071 CHD - Syndromic 1 Monoallelic 
KDM6A ENSG00000147050 CHD - Syndromic 1 Monoallelic 
KMT2A ENSG00000267910 CHD - Syndromic 1 Monoallelic 
KMT2D ENSG00000167548 CHD - Syndromic 1 Monoallelic 
LTBP3 ENSG00000168056 CHD - Syndromic 1 Biallelic 
MAP2K1 ENSG00000169032 CHD - Syndromic 1 Monoallelic 
MAP2K2 ENSG00000126934 CHD - Syndromic 1 Monoallelic 
MED12 ENSG00000184634 CHD - Syndromic 1 X-linked 
MED13L ENSG00000123066 CHD - Syndromic 1 Monoallelic 
MEGF8 ENSG00000105429 CHD - Syndromic 1 Biallelic 
MGP ENSG00000111341 CHD - Syndromic 1 Biallelic 
MID1 ENSG00000101871 CHD - Syndromic 1 X-linked 
MKKS ENSG00000125863 CHD - Syndromic 1 Biallelic 
NEK1 ENSG00000137601 CHD - Syndromic 1 Biallelic 
NF1 ENSG00000196712 CHD - Syndromic 1 Monoallelic 
NIPBL ENSG00000164190 CHD - Syndromic 1 Monoallelic 
PEX1 ENSG00000127980 CHD - Syndromic 1 Biallelic 
PEX10 ENSG00000157911 CHD - Syndromic 1 Biallelic 
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PEX26 ENSG00000215193 CHD - Syndromic 1 Biallelic 
PEX5 ENSG00000139197 CHD - Syndromic 1 Biallelic 
PTPN11 ENSG00000179295 CHD - Syndromic 1 Monoallelic 
RAB23 ENSG00000112210 CHD - Syndromic 1 Biallelic 
RAI1 ENSG00000108557 CHD - Syndromic 1 Monoallelic 
RBM8A ENSG00000265241 CHD - Syndromic 1 Biallelic 
SALL1 ENSG00000103449 CHD - Syndromic 1 Monoallelic 
SALL4 ENSG00000101115 CHD - Syndromic 1 Monoallelic 
SH3PXD2B ENSG00000174705 CHD - Syndromic 1 Biallelic 
SHOC2 ENSG00000108061 CHD - Syndromic 1 Monoallelic 
SKI ENSG00000157933 CHD - Syndromic 1 Monoallelic 
SLC2A10 ENSG00000197496 CHD - Syndromic 1 Biallelic 
SMAD3 ENSG00000166949 CHD - Syndromic 1 Monoallelic 
SMAD4 ENSG00000141646 CHD - Syndromic 1 Monoallelic 
SMARCA2 ENSG00000080503 CHD - Syndromic 1 Monoallelic 
SMARCA4 ENSG00000127616 CHD - Syndromic 1 Monoallelic 
SMARCB1 ENSG00000099956 CHD - Syndromic 1 Monoallelic 
SMARCE1 ENSG00000073584 CHD - Syndromic 1 Monoallelic 
SMC1A ENSG00000269384 CHD - Syndromic 1 Monoallelic 
SOS1 ENSG00000115904 CHD - Syndromic 1 Monoallelic 
SOX2 ENSG00000181449 CHD - Syndromic 1 Monoallelic 
SOX9 ENSG00000125398 CHD - Syndromic 1 Monoallelic 
STRA6 ENSG00000137868 CHD - Syndromic 1 Biallelic 
TBX1 ENSG00000184058 CHD - Syndromic 1 Monoallelic 
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TBX5 ENSG00000089225 CHD - Syndromic 1 Monoallelic 
TFAP2B ENSG00000008196 CHD - Syndromic 1 Monoallelic 
TGFBR1 ENSG00000106799 CHD - Syndromic 1 Monoallelic 
TGFBR2 ENSG00000163513 CHD - Syndromic 1 Monoallelic 
UBR1 ENSG00000159459 CHD - Syndromic 1 Biallelic 
ZEB2 ENSG00000169554 CHD - Syndromic 1 Monoallelic 
ZIC3 ENSG00000156925 CHD - Syndromic 1 X-linked 
DHCR7 ENSG00000172893 CHD - Syndromic 1 Biallelic 
GDF1 ENSG00000130283 CHD - Non-syndromic 2 Monoallelic/Biallelic 
NAA15 ENSG00000164134 CHD - Non-syndromic 2 
 
NFATC1 ENSG00000131196 CHD - Non-syndromic 2 
 
NKX2-6 ENSG00000180053 CHD - Non-syndromic 2 Biallelic 
PLXND1 ENSG00000004399 CHD - Non-syndromic 2 
 
PQBP1 ENSG00000268142 CHD - Non-syndromic 2 
 
SMAD2 ENSG00000175387 CHD - Non-syndromic 2 
 
TAB2 ENSG00000055208 CHD - Non-syndromic 2 Monoallelic 
ATIC ENSG00000138363 CHD - Syndromic 2 Biallelic 
B3GALT6 ENSG00000176022 CHD - Syndromic 2 Biallelic 
CEP290 ENSG00000198707 CHD - Syndromic 2 Biallelic 
CEP57 ENSG00000166037 CHD - Syndromic 2 Biallelic 
CHRNA1 ENSG00000138435 CHD - Syndromic 2 Monoallelic/Biallelic 
CHUK ENSG00000213341 CHD - Syndromic 2 Biallelic 
COL2A1 ENSG00000139219 CHD - Syndromic 2 Monoallelic 
COX7B ENSG00000269083 CHD - Syndromic 2 
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DDX11 ENSG00000013573 CHD - Syndromic 2 Biallelic 
DDX59 ENSG00000118197 CHD - Syndromic 2 Monoallelic 
DIS3L2 ENSG00000144535 CHD - Syndromic 2 Biallelic 
EOGT ENSG00000163378 CHD - Syndromic 2 Biallelic 
EP300 ENSG00000100393 CHD - Syndromic 2 Monoallelic 
ESCO2 ENSG00000171320 CHD - Syndromic 2 Biallelic 
FBLN5 ENSG00000140092 CHD - Syndromic 2 Biallelic 
FIG4 ENSG00000112367 CHD - Syndromic 2 Biallelic 
FKBP14 ENSG00000106080 CHD - Syndromic 2 Biallelic 
FKTN ENSG00000106692 CHD - Syndromic 2 Biallelic 
GPC6 ENSG00000183098 CHD - Syndromic 2 Biallelic 
IGFBP7 ENSG00000163453 CHD - Syndromic 2 Biallelic 
KAT6B ENSG00000156650 CHD - Syndromic 2 Monoallelic 
KIF7 ENSG00000166813 CHD - Syndromic 2 Biallelic 
LRP2 ENSG00000081479 CHD - Syndromic 2 Biallelic 
LRP5 ENSG00000162337 CHD - Syndromic 2 Monoallelic/Biallelic 
MGAT2 ENSG00000168282 CHD - Syndromic 2 Biallelic 
MKS1 ENSG00000011143 CHD - Syndromic 2 Biallelic 
MPLKIP ENSG00000168303 CHD - Syndromic 2 Biallelic 
NFIX ENSG00000008441 CHD - Syndromic 2 Monoallelic 
NPHP3 ENSG00000113971 CHD - Syndromic 2 Biallelic 
NRXN1 ENSG00000179915 CHD - Syndromic 2 Monoallelic/Biallelic 
NSDHL ENSG00000269336 CHD - Syndromic 2 
 
PHGDH ENSG00000092621 CHD - Syndromic 2 Biallelic 
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PTF1A ENSG00000168267 CHD - Syndromic 2 Biallelic 
RARB ENSG00000077092 CHD - Syndromic 2 Monoallelic/Biallelic 
RBM10 ENSG00000271352 CHD - Syndromic 2 
 
RNF135 ENSG00000181481 CHD - Syndromic 2 Monoallelic 
RNU4ATAC ENSG00000264229 CHD - Syndromic 2 Biallelic 
ROR2 ENSG00000169071 CHD - Syndromic 2 Monoallelic/Biallelic 
RPS19 ENSG00000272852 CHD - Syndromic 2 Monoallelic 
RRAS ENSG00000126458 CHD - Syndromic 2 
 
SETBP1 ENSG00000152217 CHD - Syndromic 2 Monoallelic 
SF3B4 ENSG00000263977 CHD - Syndromic 2 Monoallelic 
SHANK3 ENSG00000251322 CHD - Syndromic 2 Monoallelic 
SNRPB ENSG00000125835 CHD - Syndromic 2 Monoallelic 
SRCAP ENSG00000080603 CHD - Syndromic 2 Monoallelic 
STAMBP ENSG00000124356 CHD - Syndromic 2 Biallelic 
TBC1D24 ENSG00000162065 CHD - Syndromic 2 Biallelic 
TLL1 ENSG00000038295 CHD - Syndromic 2 Monoallelic 
TTC37 ENSG00000198677 CHD - Syndromic 2 Biallelic 
TWIST1 ENSG00000122691 CHD - Syndromic 2 Monoallelic 
WDR60 ENSG00000126870 CHD - Syndromic 2 Biallelic 
WNT5A ENSG00000114251 CHD - Syndromic 2 Monoallelic 
ZFPM2 ENSG00000169946 CHD - Syndromic 2 Monoallelic 
ZMPSTE24 ENSG00000084073 CHD - Syndromic 2 Biallelic 
ACTC1 ENSG00000159251 CHD/CM - Non-
syndromic 
1 Monoallelic 
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BRAF ENSG00000157764 CHD/CM - Syndromic 1 Monoallelic 
CBL ENSG00000110395 CHD/CM - Syndromic 1 Monoallelic 
HCCS ENSG00000004961 CHD/CM - Syndromic 1 X-linked 
KRAS ENSG00000133703 CHD/CM - Syndromic 1 Monoallelic 
BRAF1 NA CHD/CM - Syndromic 1 Monoallelic 
RIT1 ENSG00000143622 CHD/CM - Syndromic 1 Monoallelic 
FTO ENSG00000140718 CHD/CM - Syndromic 2 Biallelic 
ABCC9 ENSG00000069431 CHD/CM - Syndromic 1 Monoallelic 
 
Table K.1 CHD associated genes. 
Supplementary table 20 from Sifrim et al [12]. Tier 1 and tier 2 genes that we 
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Appendix L. Clinical features reported with mutations in CDK13 
 
 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Decipher_ID/Study_ID 265645/DDDP101673 265813/DDDP104368 259460/DDDP111320 262889/DDDP111394 271894/DDDP112485 258830/DDDP102232 270818/DDDP112274
Mutations 
NC_000007.13:g.40085606A>
G;  NM_031267.3:c.2525A>G; 
NP_112557.2:p.Asn842Ser
NC_000007.13:g.40085606A>
G;  NM_031267.3:c.2525A>G; 
NP_112557.2:p.Asn842Ser
NC_000007.13:g.40085606A>














G;  NM_031267.3:c.2525A>G; 
NP_112557.2:p.Asn842Ser
Family history Singleton Singleton Singleton Singleton Singleton Singleton
Unknown, only mother tested 
negative thus far
Sex Female Female Female Male Female Female Male
Age at last assesment 7.18 years 0.19 years 3.21 years 7.83 years 4.98 years 11.87 years 1.25 years
Prenatal or Perinatal 
development 
Gestation 40 weeks 38 weeks 41 weeks 38 weeks 38 weeks 35 weeks 39 weeks
Birth weight 3640 grams (SD 0.51) 3500 grams (SD 1.16) 3310 grams (SD -0.20) 2000 grams (SD -2.65) 2636 grams (SD -0.89) 1700 grams (SD -1.93)
Birth head circumference 
(BHC)
- 34 cm (SD -0.44) 35cm (0.4th - 2nd) 30.8 cm (SD -2.08)
Complications




Social smile 16 weeks - 6 weeks Unknown 6 weeks Unknown Unknown
Sat Independently 3-4 years - 11 months 12 months 12 months 13 months 11 months
Walked Independently
Not yet achieved (walking with 
a frame)
- 23 months 3-4 years 2-2.5 years 3-4 years Unknown
First words 20 months - 14 months 2-2.5 years 2.5-3 years 5 years and over Unknown
Postnatal Growth
Height/length 106.8 cm (SD -3.13) 81 cm (SD -1.05) 82.4 cm (SD -3.84) 108 cm (SD -0.06) 136 cm (SD -1.74)
Weight 22.5 kg (SD -0.41) 4.39 kg (SD -1.16) 10.06 kg (SD -1.34) 11.96 kg (SD -2.08) 18 kg (SD -0.05) 41 kg (SD 0.24) 7.84 kg (SD -3.08)
Occipital Frontal 
Circumference (OFC)




Cardiac Morphology Ventricular septal defect (VSD)
Interatrial communication 
(ASD) and Pulmonary valvar 
abnormality
Interatrial communication 
(ASD) within oval fossa 
(secundum)
Ventricular septal defect 





(ASD) and Ventricular septal 
defect (VSD)
Interatrial communication 





Head and Neck Low posterior hairline
Redundant neck skin, 
Prominent occiput, 
Postnatal microcephaly Postnatal microcephaly Plagiocephaly Microcephaly
Facial
Hypertelorism, Upslanted 
palpebral fissure, Epicanthus, 
Thick eyebrow, Highly arched 
eyebrow, Prominent nasal 
bridge
Hypertelorism, Downturned 
corners of mouth,  Short 
lingual frenulum, Nevus 
flammeus of the forehead, 
Telecanthus
Curly hair, Upslanted 
palpebral fissure, 
Hypertelorism, Narrow mouth, 
Thin upper lip vermilion, Thick 
upper lip vermilion, Bulbous 
nose
Plagiocephaly with mild facial 
assymetry. Epicanthus with 
wide nasal bridge with 
upslanting palpebral fissures, 
thin upper lip, long smooth 
philtrum and small mouth
Hypertelorism, Microdontia, 
Upslanted palpebral fissure, 
Wide nasal bridge, Short 
philtrum
Upslanted palpebral fissure, 
Downturned corners of mouth, 
narrow mouth, 
Blepharophimosis, Ptosis
Thin lips, Abnormality of the 
pinna
Nervous system
Global developmental delay Moderate Yes Yes 'spiky profile' Yes Yes Yes Moderate
Motor delay Yes Yes Yes Yes Yes





Structural Periventricular leukomalacia Spina bifida occulta
Underdevelopment of the front 
part of the brain and corpus 
callosum
Agenesis of corpus callosum
Aplasia of the inferior half of 
the cerebellar vermis, small 
cerebral cortex







Low-set, posteriorly rotated 
ears, Preauricular pit
Dysplastic ears with cupped 




Central sleep apnoea 










Limbs Clinodactyly of the 5th finger
 Second toe clinodactyly, 
Third toe clinodactyly, 
Clinodactyly of the 5th finger
Short fingers and toes with 
2nd toe clinodactyly. 
Symmetrical skin folds like 
Clinodactyly of the 5th finger 
Camptodactyly (2nd-5th 
fingers), Carpal tunnel release
5th finger camptodactyly
Integument Dry skin Hypertrichosis
Skeletal system
Scoliosis, Hyperextensibility of 
the finger joints
Joint hypermobility
Hypotonia with joint 
hypermobility
Hyperlordosis
Musculature Lower limb hypertonia Muscular hypotonia Hypotonia




Blood and Blood-forming 
Tissues
Metabolism/homeostasis
Mucopolysaccharides found on 
synovial biopsy but urine MPS 
screen and lysosomal enzyme 
screen normal, Abnormality of 
lysosomal metabolism
Neoplasm
Intial Clinical diagnosis CHARGE syndrome
Ohdo considred but felt not to 
be typical. Charge also raised 
but did not have typical ear 
anomalies.
Feeding difficulties. PEG fed 
for some years.
Rubinstein-taybi syndrome
Additional Comments Feeding difficulties
Velopharyngeal dysfunction 
causing unsafe swallow
Feeding difficulties reguiring 
PEG insertion
Facially wondered about Ohdo 
but KAT6B negative
Truncal obesity, also has de 
novo TCF12 missense change
Feeding difficulties
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Table L.1 Clinical features reported with mutations in CDK13 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Decipher_ID/Study_ID 265645/DDDP101673 265813/DDDP104368 259460/DDDP111320 262889/DDDP111394 271894/DDDP112485 258830/DDDP102232 270818/DDDP112274
Mutations 
NC_000007.13:g.40085606A>
G;  NM_031267.3:c.2525A>G; 
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G;  NM_031267.3:c.2525A>G; 
NP_112557.2:p.Asn842Ser
NC_000007.13:g.40085606A>














G;  NM_031267.3:c.2525A>G; 
NP_112557.2:p.Asn842Ser
Family history Singleton Singleton Singleton Singleton Singleton Singleton
Unknown, only mother tested 
negative thus far
Sex Female Female Female Male Female Female Male
Age at last assesment 7.18 years 0.19 years 3.21 years 7.83 years 4.98 years 11.87 years 1.25 years
Prenatal or Perinatal 
development 
Gestation 40 weeks 38 weeks 41 weeks 38 weeks 38 weeks 35 weeks 39 weeks
Birth weight 3640 grams (SD 0.51) 3500 grams (SD 1.16) 3310 grams (SD -0.20) 2000 grams (SD -2.65) 2636 grams (SD -0.89) 1700 grams (SD -1.93)
Birth head circumference 
(BHC)
- 34 cm (SD -0.44) 35cm (0.4th - 2nd) 30.8 cm (SD -2.08)
Complications




Social smile 16 weeks - 6 weeks Unknown 6 weeks Unknown Unknown
Sat Independently 3-4 years - 11 months 12 months 12 months 13 months 11 months
Walked Independently
Not yet achieved (walking with 
a frame)
- 23 months 3-4 years 2-2.5 years 3-4 years Unknown
First words 20 months - 14 months 2-2.5 years 2.5-3 years 5 years and over Unknown
Postnatal Growth
Height/length 106.8 cm (SD -3.13) 81 cm (SD -1.05) 82.4 cm (SD -3.84) 108 cm (SD -0.06) 136 cm (SD -1.74)
Weight 22.5 kg (SD -0.41) 4.39 kg (SD -1.16) 10.06 kg (SD -1.34) 11.96 kg (SD -2.08) 18 kg (SD -0.05) 41 kg (SD 0.24) 7.84 kg (SD -3.08)
Occipital Frontal 
Circumference (OFC)




Cardiac Morphology Ventricular septal defect (VSD)
Interatrial communication 
(ASD) and Pulmonary valvar 
abnormality
Interatrial communication 
(ASD) within oval fossa 
(secundum)
Ventricular septal defect 





(ASD) and Ventricular septal 
defect (VSD)
Interatrial communication 





Head and Neck Low posterior hairline
Redundant neck skin, 
Prominent occiput, 
Postnatal microcephaly Postnatal microcephaly Plagiocephaly Microcephaly
Facial
Hypertelorism, Upslanted 
palpebral fissure, Epicanthus, 
Thick eyebrow, Highly arched 
eyebrow, Prominent nasal 
bridge
Hypertelorism, Downturned 
corners of mouth,  Short 
lingual frenulum, Nevus 
flammeus of the forehead, 
Telecanthus
Curly hair, Upslanted 
palpebral fissure, 
Hypertelorism, Narrow mouth, 
Thin upper lip vermilion, Thick 
upper lip vermilion, Bulbous 
nose
Plagiocephaly with mild facial 
assymetry. Epicanthus with 
wide nasal bridge with 
upslanting palpebral fissures, 
thin upper lip, long smooth 
philtrum and small mouth
Hypertelorism, Microdontia, 
Upslanted palpebral fissure, 
Wide nasal bridge, Short 
philtrum
Upslanted palpebral fissure, 
Downturned corners of mouth, 
narrow mouth, 
Blepharophimosis, Ptosis
Thin lips, Abnormality of the 
pinna
Nervous system
Global developmental delay Moderate Yes Yes 'spiky profile' Yes Yes Yes Moderate
Motor delay Yes Yes Yes Yes Yes





Structural Periventricular leukomalacia Spina bifida occulta
Underdevelopment of the front 
part of the brain and corpus 
callosum
Agenesis of corpus callosum
Aplasia of the inferior half of 
the cerebellar vermis, small 
cerebral cortex







Low-set, posteriorly rotated 
ears, Preauricular pit
Dysplastic ears with cupped 




Central sleep apnoea 










Limbs Clinodactyly of the 5th finger
 Second toe clinodactyly, 
Third toe clinodactyly, 
Clinodactyly of the 5th finger
Short fingers and toes with 
2nd toe clinodactyly. 
Symmetrical skin folds like 
Clinodactyly of the 5th finger 
Camptodactyly (2nd-5th 
fingers), Carpal tunnel release
5th finger camptodactyly
Integument Dry skin Hypertrichosis
Skeletal system
Scoliosis, Hyperextensibility of 
the finger joints
Joint hypermobility
Hypotonia with joint 
hypermobility
Hyperlordosis
Musculature Lower limb hypertonia Muscular hypotonia Hypotonia




Blood and Blood-forming 
Tissues
Metabolism/homeostasis
Mucopolysaccharides found on 
synovial biopsy but urine MPS 
screen and lysosomal enzyme 
screen normal, Abnormality of 
lysosomal metabolism
Neoplasm
Intial Clinical diagnosis CHARGE syndrome
Ohdo considred but felt not to 
be typical. Charge also raised 
but did not have typical ear 
anomalies.
Feeding difficulties. PEG fed 
for some years.
Rubinstein-taybi syndrome
Additional Comments Feeding difficulties
Velopharyngeal dysfunction 
causing unsafe swallow
Feeding difficulties reguiring 
PEG insertion
Facially wondered about Ohdo 
but KAT6B negative
Truncal obesity, also has de 
novo TCF12 missense change
Feeding difficulties
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Figure M.1 Clinical phenotypes of probands with de novo PRKD1 
mutations. 
Supplementary Figure 3 from Sifrim et al [12]. 
A. Clinical synopsis of the observed phenotypes across patients carrying 
PRKD1 mutations. Columns represent single probands, shades of cells 
represent the number of probands sharing a phenotype in the given 
phenotypic categories. Photographs of affected probands are shown for 
which consent could be obtained for publication.  
B. Protein plot showing PRKD1 protein domains and the distribution of de 
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Appendix N: Sample size requirements for novel CHD gene detection 
 
 
Figure N.1 Saturation analysis for detecting haploinsufficient S-CHD-
associated genes. 
Figure 5. Supplementary Figure 5 from Sifrim et al [12]. 
A box plot showing the distribution of statistical power to detect a significant 
enrichment of PTV mutations across 19252 genes in the genome, for different 
numbers of trios studied, from 500 trios to 10,000 trios. Line within the box 
shows the median, box corresponds to the first and third quartiles (the 25th and 
75th percentiles) and whiskers correspond to most extreme values within 1.5 
times the interquartile range from the box. 
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